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Abstract 
 
Facioscapulohumeral muscular dystrophy (FSHD) is the third most common form of 
muscular dystrophy in Caucasians. FSHD is caused by contraction of a 3.3kb repeat array, 
D4Z4, to below 11 repeat units. Each of these repeat units contains an ORF encoding the 
DUX4 gene and at the beginning of the work described in this thesis expression of transcripts 
from the most distal repeat of this D4Z4 array had been reported. However, expression data 
from the DUX4 gene was new and most research focussed on contraction of the array having 
a position affect on the expression of neighbouring genes.  
There is a similar Dux array located in the mouse genome. This array also contains an ORF 
in each repeat and transcripts from this gene have been detected in a number of different 
tissues. This array is not present in the same chromosomal location as the D4Z4 array in 
humans so is unlikely to be a true ortholog, however it is the only Dux array in the mouse 
genome and may therefore be functionally equivalent. 
The work described in this thesis provides evidence for transcription from multiple repeats 
of the D4Z4 array in a human embryonal carcinoma cell line and gives information on the 
sequence variation within these transcripts. In addition, this work contributes to an 
understanding of expression from the mouse Dux array. Similar to the human array, 
expression appears to come from multiple repeat units, and analysis of the sequences 
amplified by RT-PCR identifies variants which suggest some of these transcripts are non-
coding. 
The aim of this work is to determine whether human DUX4 and mouse Dux genes have 
equivalent functions with the long-term goal of producing a mouse model for FSHD 
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Chapter 1. Introduction 
1.1 Identification of the causative mutation in FSHD 
With an estimated incidence of 1/20 000 (Padberg, 2004a), facioscapulohumeral muscular 
dystrophy (FSHD) is the third most common muscular dystrophy in Caucasians. While most 
patients begin to show symptoms in the second decade of life, the age of onset is variable and 
early onset cases tend to be more severe (Brouwer et al., 1995; Lunt et al., 1995a; Tawil et al., 
1996; Klinge et al., 2006). FSHD has an estimated penetrance of 95% by the age of 20 (Lunt et 
al., 1989).  
The facial muscles are usually affected first; characteristic weakening of muscles 
associated with the eyes and mouth cause difficulty in forming facial expressions (Padberg, 
2004b). The weakness then usually spreads to the upper arms and shoulder girdle. Scapular 
winging may be seen and patients become unable to raise their arms above shoulder height 
(Padberg, 2004b). In 20% of cases the lower leg muscles are also involved and patients 
become wheelchair dependent (Lunt and Harper, 1991). The more severe, early onset cases 
are sometimes associated with non-muscular symptoms including hearing loss (Padberg et al., 
1995; Miura et al., 1998), mental retardation (Funakoshi et al., 1998; Miura et al., 1998), 
epilepsy (Funakoshi et al., 1998; Miura et al., 1998) and retinal vasculopathy (Padberg et al., 
1995). 
Locating the genetic locus for FSHD initially proved difficult. An international consortium in 
the late 1980s produced an exclusion map for the disease (Sarfarazi et al., 1989).
. 
It was not 
until microsatellite markers were used in 1990 that linkage was established to the long arm of 
chromosome 4 (Wijmenga et al., 1990). Over the next couple of years linkage to chromosome 
4 was confirmed and narrowed to the 4q35 region (Wijmenga et al., 1991; Fischbeck and 
Garbern, 1992; Gilbert et al., 1992; Mathews et al., 1992; Mills et al., 1992; Sarfarazi et al., 
1992; Upadhyaya et al., 1992; Weiffenbach et al., 1992; Wijmenga et al., 1992c).  
 3 
Finally, a breakthrough in the search for the causative mutation came when the probe 
p13E-11 was identified in a search for homeobox genes (Wijmenga et al., 1992b). This probe 
is a subclone of a chromosome 4 cosmid (13E) and identifies a polymorphic EcoRI fragment on 
chromosome 4q35. In familial cases of FSHD, the smallest fragments on Southern blots co-
segregated with the disease (Wijmenga et al., 1992b). In most sporadic cases of FSHD, p13E-
11 was found to identify small, de novo fragments (Wijmenga et al., 1992b; Griggs et al., 
1993; Upadhyaya et al., 1993)
 
and these new mutations were transmitted to affected children 
in the next generation (Wijmenga et al., 1992a; Jardine et al., 1993). 
Restriction mapping of cosmid 13E suggested a repeated DNA structure and cloning of 
several rearranged fragments from patients identified a deletion of an integral number of 
3.3kb repeat units (van Deutekom et al., 1993b). The FSHD mutation had been identified 
(Fischbeck and Garbern, 1992) . 
 
1.2 Molecular analysis of D4Z4 
Cloning of the p13E-11 positive EcoRI fragments revealed a polymorphic array of 3.3kb 
KpnI repeats (van Deutekom et al., 1993b; Hewitt et al., 1994) that has been named D4Z4 
(Figure 1.1). Each repeat is GC rich (71% G+C) and contains two dispersed repetitive motifs, 
LSau and hhspm3 (Hewitt et al., 1994), which are typically associated with heterochromatic 
regions of DNA (Zhang et al., 1987; Meneveri et al., 1993). Each repeat has a large open 
reading frame (ORF) which potentially encodes two homeodomains related to the prd family 
(Hewitt et al., 1994).  
In unaffected individuals, the length of the D4Z4 array varies between 11 and 100 repeats, 
an equivalent EcoRI fragment of 40kb-300kb on southern blots. FSHD patients have arrays of 
10 or fewer repeats, seen as fragments of only 10-40kb (Wijmenga et al., 1992b). Alleles 
containing only 1-3 repeats are typically associated with the most severe early onset cases 
(Zatz et al., 1995; Tawil et al., 1996). However, complete deletion of the array is not 
associated with FSHD (Tupler et al., 1996). 
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Figure 1.1 A schematic representation of the EcoRI fragment identified by p13E-11 
Each arrowhead represents one 3.3kb KpnI repeat, the number of repeats in the EcoRI 
fragment varies between 12 and 150 in unaffected individuals. The sequence motifs that are 
present within each individual repeat are shown and the double homeodomain within the 
open reading frame is highlighted in dark blue. 
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Approximately ten percent of FSHD patients are sporadic (Lunt and Harper, 1991) and 
most of these were shown to have de novo contraction of D4Z4 (Wijmenga et al., 1992b). 
These mutations are thought to occur intrachromosomally, facilitated by the repetitive nature 
of the array (Lemmers et al., 2004a). The most likely mechanism is thought to be gene 
conversion without crossover. However, in some cases reciprocal transfer is seen and a 
synthesis-dependent strand annealing (SDSA) model (Nassif et al., 1994) has been proposed 
which allows for both cases (Lemmers et al., 2004a). In this model, newly synthesised DNA 
does not remain base paired with the homologous template during the repair of double 
strand breaks (DSB). Instead, the DNA is displaced, which allows the two newly synthesised, 
complementary strands to anneal. In repeated sequences alignment of these strands can 
occur out of frame, which can result in either expansion or contraction of the region. In most 
cases the donor template will remain unchanged (Figure 1.2). 
Examination of unaffected parents of de novo cases indicates that 15-20% show somatic 
mosaicism for the deletion (Kohler et al., 1996; van der Maarel et al., 2000), suggesting that 
the rearrangement occurs mitotically during early embryogenesis. The clinical presentation in 
mosaic individuals has been shown to depend on both the number of repeats left on the 
deleted allele and the percentage of peripheral blood lymphocytes (PBL) that carry the short 
D4Z4 array (van der Maarel et al., 2000). A later study showed that the proportion of affected 
PBL and muscle cells were comparable (Tonini et al., 2006). A significant percentage of mosaic 
individuals are asymptomatic, which suggests that there is a critical proportion of mutated 
cells needed for an FSHD phenotype. Consistent with this idea, the proportion of mutated 
cells correlates with the severity of the phenotype (van der Maarel et al., 2000). It has also 
been shown that females need a higher proportion of cells carrying the mutation than males 
for FSHD symptoms to occur (van der Maarel et al., 2000).  
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Figure 1.2  The SDSA model of double strand break repair.  
a) The ends of the broken sequence (blue arrowheads) are degraded prior to invasion. b) The 
ends invade a homologous sequence (purple arrowheads) and DNA synthesis then proceeds 
from each 3 end. c) Newly synthesised DNA is displaced from the template and the two single 
strands align in a region of overlap. If alignment occurs out of frame contractions or 
expansions may be seen. d) DNA synthesis continues (orange arrowheads) with each newly 
made strand serving as a template for the other. See Nassif et al. (1994). 
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1.3 The 3.3kb repeat family 
Initial southern blot data showed p13E-11 to hybridise to more than one locus (Wijmenga 
et al., 1992b); a highly similar tandem array was then identified at chromosome 10q26 
(Bakker et al., 1995). Additionally, the short arms of the acrocentric chromosomes contain a 
high number of dispersed repeats similar to D4Z4 (Wijmenga et al., 1992b; Hewitt et al., 
1994; Winokur et al., 1994). This group of repeat sequences are collectively known as the 
3.3kb repeat family and show two distinct types of organisation (Lyle et al., 1995). On the 
acrocentric chromosomes and on chromosomes, 1, 3, 9 and Y the repeats are interspersed 
with E satellite DNA, whilst on 4q35 and 10q26 the sequences have a very homogenous 
tandemly repeated structure with the E satellite DNA only at the distal end of the array (Lyle 
et al., 1995). Importantly, despite >98% nucleotide identity between the 4q35 and 10q26 
arrays (Cacurri et al., 1998), only contractions of the 4q35 repeat array are associated with 
FSHD (Bakker et al., 1995).  
Initially the presence of this 10q array complicated genetic diagnosis of FSHD, since small 
10q fragments (which do not result in disease) could not be distinguished from those arising 
from 4q35 (Weiffenbach et al., 1993). In 1996 a BlnI recognition sequence was found to be 
specific for the 10q repeats (Deidda et al., 1996). For diagnostic analysis, a double digest 
(EcoRI/BlnI) is now performed so that only the 4q fragment remains intact. The restriction 
enzyme XapI has since been shown to uniquely digest 4q derived repeat units, and in 2001, a 
triple analysis with EcoRI, EcoRI/BlnI and XapI was proposed to optimise the molecular 
diagnosis of FSHD (Lemmers et al., 2001). 
In most cases this double-digestion protocol resolves ambiguity, however, variant alleles 
with both BlnI
+ 
and BlnI
- 
repeats have been identified in 10-30% of individuals (van Deutekom 
et al., 1996a; Lemmers et al., 1998; van Overveld et al., 2000; Rossi et al., 2007). Variant 
alleles are also seen in FSHD patients (van Deutekom et al., 1996a), with BlnI
+
 repeats present 
on the disease allele. Variation in the number of BlnI
+ 
and BlnI
- 
repeats on these alleles is likely 
due to intrachromosomal sequence exchanges, which is discussed in more detail in Section 
1.5. 
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1.4 Association of FSHD with a specific 4q telomere 
There are two distinct allelic variants of the 4q telomere, 4qA and 4qB (van Geel et al., 
2002), which have frequencies of 42% and 58% in the population (Lemmers et al., 2002). 4qA 
and 4qB represent the 25-40kb immediately distal to the D4Z4 array and are closely related to 
each other, sharing 92% nucleotide identity (Dickson, 1998; van Geel et al., 2002). The 4qA 
telomere has 8kb of E-satellite sequence distal to D4Z4 adjacent to a divergent (TTAGGG)n 
array (van Geel et al., 2002). Neither of these sequence elements
 
are present on the 4qB 
telomere (Figure 1.3). The terminal D4Z4 repeat also differs between the variants, in 4qB this 
is only 570bp in length and directly abuts the subtelomeric sequence whilst the 4qA terminal 
repeat is adjacent to the E-satellite array (van Geel et al., 2002). Shortly after the publication 
of this polymorphism (van Geel et al., 2002),
 
it was shown that only 4qA alleles are associated 
with FSHD (Lemmers et al., 2002)
 
and this was subsequently confirmed in a separate patient 
cohort (Thomas et al., 2007). In three families, contraction of D4Z4 on a 4qB allele was shown 
not to segregate with the disease (Lemmers et al., 2004b), arguing that the association with 
4qA is not due to a difference in the frequency of deletions between the two. 
To identify the subtelomere variants, DNA is digested with HindIII, which results in a 
fragment containing p13E-11, the D4Z4 array and the subtelomeric region. Probes specific to 
the 4qA or 4qB alleles are then used for pulsed-field gel electrophoresis (PFGE) analysis 
(Lemmers et al., 2002). An additional rare type of 4qter telomere has been identified in four 
individuals (two with FSHD), which does not hybridise to 4qA or 4qB probes (Buzhov et al., 
2005; Thomas et al., 2007). These variants have been referred to as 4qC telomeres (Lemmers 
et al., 2010b). 
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Figure 1.3 A representation of the relationship between the 4p, 4qA, 4qB and 10q 
telomeres  
Not to Scale. The phylogenetic tree is based on sequences distal to D4Z4. Regions of sequence 
similarity and shared motifs are shown. Adapted from van Geel et al. 2002. 
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1.5 The evolution of the 4qA, 4qB and 10q subtelomeres 
Studies of D4Z4 homologues in great apes (Clark et al., 1996; Winokur et al., 1996) and old 
and new world monkeys (Clapp et al., 2007) suggest that the 4q array is ancestral. The DNA 
sequence and repeat content of the 4qA subtelomeric region is more similar to 10q than to 
4qB (van Geel et al., 2002), while the 4qB allele is more similar to the 4p telomere, lacking 
some of the repetitive sequence elements which 4qA and 10q share. 
Both the 4q and 4p subtelomeres share sequence similarity and van Geel et al. (2002) 
proposed that a duplication event involving 4p created the 4qA telomere, which was 
subsequently duplicated onto 10q. The 4qB variant is likely to be the result of a more recent 
transfer from 4p (van Geel et al., 2002). The relationship between these chromosome ends is 
shown in Figure 1.3. Recently, Lemmers et al. (2010) have produced an evolutionary network 
of 4qter evolution that broadly supports this model. In this network four major 
rearrangements occur at the D4Z4 locus, once introducing the 4qB subtelomere onto a 
chromosome 4qA background, and three times transferring the 4q telomere onto 
chromosome 10 (Lemmers et al., 2010b). 
The different size distribution of the 4qA, 4qB and 10q alleles argues against frequent 
interallelic recombination since these major transfer events. Lemmers and colleagues
 
(2004) 
compared the distribution of the D4Z4 copy number of 4qA and 4qB derived repeats and 
showed that 4qA alleles (136 ± 7kb) were significantly longer than 4qB alleles (93 ± 4 kb). 
Linkage disequilibrium analysis between a PvuII-RFLP within the most proximal D4Z4 repeat 
unit and the 4qB variant also suggests that recombination between the alleles is repressed 
(Lemmers et al., 2004a). A difference in average D4Z4 copy number has also been observed 
between 4q and 10q arrays, van Overveld et al. found the median repeat array on 
chromosome 4 to be 21kb larger than that for chromosome 10
 
(van Overveld et al., 2000), 
while Rossi et al. showed a 16kb increase in chromosome 4 array size compared with 
chromosome 10 (Rossi et al., 2007). These observations suggest that the 4qA, 4qB and 10q 
subtelomere regions are evolving independently and support an intrachromosomal 
mechanism for D4Z4 copy number variation.  
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Lemmers et al. (2010) propose that the BlnI
+ 
D4Z4 unit first arose on a 4qA allele, forming 
a hybrid array of BlnI
- 
and BlnI
+ 
repeats which was then transferred to chromosome 10. 
Variation in the distribution of BlnI
- 
and BlnI
+ 
repeats will then have occurred via 
intrachromosomal sequence exchanges. 
 
1.6 Phenotypic FSHD (FSHD2) 
Some FSHD families do not carry a short EcoRI fragment and represent a genetically 
distinct form of the disease, known as FSHD2. However, FSHD2 patients are clinically 
indistinguishable from FSHD1 patients (de Greef et al., 2010). Linkage studies have failed to 
identify the genetic locus for FSHD2 (Iqbal et al., 1992; Gilbert et al., 1993; Yamaoka et al., 
1995; Bastress et al., 2005). More detailed genetic analysis showed that a small proportion of 
these individuals can be accounted for by 4q35 deletions that also remove the p13E-11 probe 
(Lemmers et al., 2003; Deak et al., 2007).  
 
1.7 The FSHD disease mechanism 
Many groups initially searched for transcripts from the D4Z4 array and although related 
cDNA sequences were identified none originated from the 4q35 locus (Hewitt et al., 1994; 
Altherr et al., 1995; Lyle et al., 1995; Gabriels et al., 1999; van Geel et al., 1999). In addition, 
as monosomy of 4q does not result in FSHD (Tupler et al., 1996),
 
haploinsufficiency of a gene 
within the repeat was considered to be an unlikely mechanism for the disease. Thus, D4Z4 
was generally assumed to be a pseudogene and research efforts were concentrated on 
identifying other candidates. 
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Sequencing of the 4q35 region provided evidence for the involvement of chromatin 
organisation and epigenetic mechanisms in FSHD. The D4Z4 array is likely to reside in a 
heterochromatic environment. The KpnI repeats contain LSau and hhspm3 motifs (Hewitt et 
al., 1994), which are commonly found in heterochromatin (Meneveri et al., 1985; Agresti et 
al., 1987). Furthermore, the 4qA allele associated with the disease has a region of E-satellite 
DNA distal to the array (van Geel et al., 2002); this repeat is also heterochromatic in nature 
(Meneveri et al., 1985; Agresti et al., 1987). D4Z4 has a high frequency of DNA methylation at 
CpG islands (Tsien et al., 2001), which is linked to chromatin compaction (Nguyen et al., 
2001).  
Not only does the D4Z4 array contain sequences associated with heterochromatin but, 
unlike other human subtelomeric regions, it has also been shown to localise to the nuclear 
periphery (Masny et al., 2004; Tam et al., 2004). This area of the nucleus is thought to provide 
a repressive environment and many inactive genes have been shown to localise here (Cockell 
and Gasser, 1999). 
The predicted heterochromatic nature of this region and the failure to identify any mRNA 
from the repeat are the main reasons that research on the disease mechanism originally 
focussed on a model where the D4Z4 deletion has a position effect on neighbouring genes. A 
number of hypotheses have been suggested to explain the mechanism underlying such a 
position effect.  
 
1.7.1 Position Effect  
Position Effect Variegation (PEV) was initially described in Drosophila (Levis et al., 1985) 
and is most evident in the white gene, which is responsible for the eye colour of adult flies. In 
some cases when a gene is moved into a region of heterochromatin it is silenced in some cells 
and expressed in others, in the case of the white gene, this results in red and white-patched 
eyes (Lewis, 1950). Telomeric position effect (TPE) has been identified in yeast (Gottschling et 
al., 1990) and there has also been evidence for a role for position effects in mammalian 
genetic disease (Reviewed in Kleinjan and van Heyningen, 1998). Proteins with histone 
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deacetlylase activity (HDACs) are recruited to heterochromatic regions of DNA, such as the 
centromeres and telomeres. Histone deacetylation is associated with a more condensed, 
repressive chromatin structure; the epigenetic marks act as binding sites for further HDAC 
molecules and facilitate the spreading of heterochromatin along the chromosome. It is 
proposed that this heterochromatinisation spreads into neighbouring genes causing them to 
be silenced (Figure 1.4a). 
It has been suggested that the D4Z4 array acts as an insulator element (Ottaviani et al., 
2006); in this role it would protect the genes at 4q35 against the spread of heterochromatin 
from the 4q telomere. Contractions of the array are proposed to bring the candidate genes 
closer to the telomere thereby increasing the chance of heterochromatinisation and 
inactivation of normally expressed genes. Recently, there has been some evidence that D4Z4 
behaves as a CTCF-dependent insulator; in a yeast model it was shown to protect a reporter 
gene from a telomeric position effect (Ottaviani et al., 2006). 
 
1.7.2 An alternative model: Loss of repression in FSHD 
The reverse situation to heterochromatinisation has also been considered. Silencing of 
genes due to juxtaposition of repetitive DNA has been seen in a number of model organisms 
(Garrick et al., 1998)
 
and so it has been suggested that D4Z4 normally has a heterochromatic 
silencing effect on neighbouring genes (Gabellini et al., 2002). Gabellini and colleagues 
postulated that in FSHD shortening of the array reduces this repressive effect, causing 
inappropriate upregulation of genes in the region. 
In support of this model, a repression complex was identified which binds a 27bp 
sequence found in each repeat of the array (Gabellini et al., 2002). The interaction between 
D4Z4 and nuclear proteins was analysed in an EMSA assay with probes which spanned the 
D4Z4 sequence. Three components of the repression complex were isolated; HMG2B, which 
belongs to a family of non-histone nuclear proteins that modulate chromatin architecture 
(Thomas and Travers, 2001); YY1, which interacts with co-repressors such as histone 
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deacetylases (Thomas and Seto, 1999) and nucleolin, a component of transcription factor 
complexes (Hanakahi et al., 1997).  
This complex has the potential to recruit proteins that can establish a repressive 
chromatin structure in the region. The D4Z4 array is methylated in unaffected individuals and 
so it is possible that a DNA methyltransferase is part of, or is recruited by, the complex. In 
FSHD, contraction of the array could reduce the number of bound proteins resulting in a 
smaller repressive effect and increased expression of the genes nearby (Figure 1.4b) (Gabellini 
et al., 2002). 
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Figure 1.4 Schematic representation of position effect hypotheses for FSHD.  
 
a) Position effect variegation (PEV). There is spreading of complexes containing histone 
deacetylases from the telomere. In healthy individuals D4Z4 prevents this 
heterochromatinisation spreading into neighbouring genes. It is proposed that in FSHD, 
contraction of the array allows the heterochromatin to spread into neighbouring genes and 
silence them. b) Loss-of-PEV. A repression complex binds to D4Z4 repeats and silences the 
neighbouring gene. It is hypothesized that when the repeats are lost there is reduced 
repression complex binding that results in inappropriate expression of the gene. c) 
Chromosomal looping. In healthy individuals D4Z4 and the candidate gene reside in different 
chromosomal loops that are separated by an FRR-MAR. In FSHD the MAR is lost and the 
candidate genes reside in the same loop as the array, in this situation D4Z4 may be able to 
influence the expression of the genes. d) Nuclear localisation. Contraction of the array brings 
the candidate genes into a more active environment, leading to their inappropriate 
expression. 
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In 2003, van Overveld and colleagues showed that the D4Z4 array is hypomethylated on 
FSHD alleles (van Overveld et al., 2003; van Overveld et al., 2005), which seemed to support 
the loss of methylating activity on contraction of the array. Recently, however, de Greef et al. 
have shown that D4Z4 is also hypomethylated in FSHD2 patients; in these cases DNA 
methylation is lost from both 4q alleles as well as the homologous arrays on chromosome 10 
(de Greef et al., 2009) and suggests that a change in chromatin structure in the region unifies 
the two forms of the disease
 
(de Greef et al., 2010). It should be noted that patients with ICF 
(immunodeficiency, centromeric instability and facial abnormalities) syndrome exhibit 
complete hypomethylation of D4Z4 without FSHD symptoms (Kondo et al., 2000). Loss of 
methylation of D4Z4 in FSHD is therefore likely to be a downstream consequence of other 
chromatin changes, rather than a causative event.  
 
1.7.3 Chromosomal Looping 
One of the highest orders of chromatin organisation is the looping of DNA into 
transcriptional units. These loops are anchored to a protein scaffold via Scaffold/Matrix 
Attachment Regions (S/MARs)
 
(Boulikas, 1993, 1995; Davie, 1995; van Driel et al., 1995). 
Genes that reside in the same loop are subjected to the same environment and this 
organisation allows the region to be regulated independently of those in other domains.  
There has been some support for chromosome looping having a role in the FSHD 
pathology (Petrov et al., 2006). In normal myoblasts the region encompassing D4Z4 (and the 
candidate genes FRG1 and FRG2), contains a potential S/MAR called FRR-MAR (FSHD-related 
region S/MAR) (Petrov et al., 2006). The FRR-MAR is reported to be weaker in FSHD myoblasts 
(Petrov et al., 2006), which could result in D4Z4 being more able to influence the expression 
of these candidate genes (Figure 1.4c). In 3C experiments, D4Z4 and the candidate gene 
DUX4C were reported to physically interact with the promoter of the FRG1 gene (Pirozhkova 
et al., 2008; Bodega et al., 2009). A small reduction in loop formation between D4Z4 and 
FRG1 was seen in FSHD myoblasts compared with controls, which is probably attributable to 
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the fewer repeats on the contracted allele (Bodega et al., 2009). However, this group did not 
detect FRG1 misregulation in these cells. 
It has also been suggested that looping of the chromatin may allow D4Z4 to have more 
long-range effects on distant genes (Jiang et al., 2003). There is evidence for long-range 
looping between locus control regions and the distant genes that they regulate (Carter et al., 
2002). If more support for this hypothesis is found the search for candidate genes could be 
extended outside of the 4q35 region.  
 
1.7.4 Nuclear localisation 
There is evidence that the position of a locus within the nucleus is correlated with the 
expression of its genes. Subnuclear positioning has been shown to regulate transcription of 
the IgH and Igkappa loci during lymphocyte development (Kosak et al., 2002), while in human 
fibroblasts, inactive loci (albumin, cMHC and neurotensin) are located at the periphery and 
active loci (actin and collagen) reside in speckles rich in RNA metabolic factors (Xing et al., 
1995). As the nuclear periphery is associated with heterochromatic regions of the genome 
(Marshall et al., 1997), the observation that 4q35 resides here prompted a nuclear 
localisation hypothesis for FSHD (Masny et al., 2004). In this model, disruption of the 
localisation pattern due to contraction of the array might bring the candidate genes to a more 
active environment, leading to their inappropriate expression (Figure 1.4d). 
Localisation of the 4q telomere has been compared between affected and unaffected 
individuals using 3D Immuno-FISH, in both lymphoblasts and myoblasts. No significant change 
in localisation linked to FSHD was observed for either cell type (Masny et al., 2004; Tam et al., 
2004). 
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1.8 Is FSHD due to a position effect? 
1.8.1 Epigenetic status 
In 2003, Jiang et al. compared the acetylation of histone H4 at 4q35 between normal and 
FSHD chromosomes using chromatin immunoprecipitation (ChIP) analysis of somatic cell 
hybrids containing a single human chromosome 4 (Jiang et al., 2003). The levels of histone 
acetylation observed were typical of unexpressed euchromatin rather than constitutive 
heterochromatin, and they found no differences in acetylation levels between FSHD alleles 
and controls. However, while the use of somatic cell hybrids allowed the study of D4Z4 
without interference from homologous sequences, it is possible that these human 
chromosomes behaved differently in the rodent environment. Recently, ChIP analysis of D4Z4 
has identified non-overlapping regions of euchromatin (with H3K4me2 and H3 acetylation) 
and heterochromatin (with H3K9me3, ,W࠹ ? and H3K27me3) within the D4Z4 array. In FSHD 
cells, a specific loss of the heterocŚƌŽŵĂƚŝŶŵĂƌŬĞƌƐ, ?< ?ŵĞ ?ĂŶĚ,Ɖ࠹1 was seen on both 4q 
and 10q alleles, with no compensatory increase in euchromatic modifications (Zeng et al., 
2009). 
These studies suggest that transcriptional repression is not spread uniformly along the 
D4Z4 array, rather that there is a more euchromatic arrangement at the proximal region 
(Zeng et al., 2009). Loss of heterochromatin markers on FSHD alleles provides evidence 
against the spreading of heterochromatin in the region. This loss of heterochromatin markers 
is consistent with the model proposed by Gabellini et al. (2002). However, as the loss is not 
restricted to the contracted allele, it is unclear what role the other 4q35 and 10q26 arrays 
may play. 
 
1.8.2 Candidate genes 
The region of chromosome 4q proximal to D4Z4 is gene-poor, however some candidate 
genes have been identified (see Figure 1.5). 
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Figure 1.5 Candidate genes for FSHD at 4q35.  
The region proximal to the array is gene-poor, however some candidate genes have been 
identified and those most studied are shown schematically here. Adenine Nucleotide 
Translocator 1 (ANT1), FSHD-Region Gene 1 (FRG1), Tubulin, Beta Polypeptide 4, member Q 
(TUBB4Q) and FSHD-Region Gene 2 (FRG2) are represented in orange and their distance from 
D4Z4 shown underneath. The arrow indicates the transcriptional orientation. Each arrowhead 
represents an individual D4Z4 repeat. DUX4C is a single copy of a D4Z4 repeat in the reverse 
orientation.  
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1.8.2.ii FRG1 
The first candidate gene identified at 4q35 was FRG1 (FSHD region gene 1), which is 
located 100kb proximal to D4Z4 (van Deutekom et al., 1996b) and is expressed in most 
human tissues (Bodega et al., 2009). In 2002, Gabellini et al. showed increased expression of 
the gene in patient muscle biopsies compared with controls. Some later studies have also 
reported an increase in FRG1 expression (Alexiadis et al., 2007; Bodega et al., 2009). However 
expression levels in these two later studies were not increased by more than 1.5 fold 
compared with the 30-fold increase reported by Gabellini et al. Many repeat studies have 
been unable to confirm a difference in expression levels for FRG1 (Van Deutekom et al., 
1993a; Dixit et al., 2007; Osborne et al., 2007; Masny et al., 2010) and some have even found 
a decrease in expression levels in patients compared to controls. (Winokur et al., 1993; Jiang 
et al., 2003) 
FRG1 protein has been identified in proteomic analyses of the human spliceosome (Jurica 
et al., 2002; Rappsilber et al., 2002) and stable expression of FRG1 in U2OS cells and in a 
transgenic mouse model has been shown to induce altered splicing of the TNNT3 gene 
(Gabellini et al., 2006; van Koningsbruggen et al., 2007). Gabellini et al. also identified altered 
splicing of the TNNT3 gene in muscle cell cultures from FSHD patients (Gabellini et al., 2006). 
However, Osbourne et al. found no difference in the TNNT3 splicing pattern between FSHD 
patients and controls (Osborne et al., 2007). Therefore, a pathogenic role of differential 
splicing in FSHD remains controversial.  
Several groups have overexpressed FRG1 protein, although at much higher levels than 
ever reported for FSHD patients. Experiments in X. laevis (Hanel et al., 2009) and M. musculus 
(Gabellini et al., 2006) provide evidence consistent with the hypothesis that FRG1 has a role in 
FSHD. However, neither of these models gives an FSHD specific phenotype. Overexpression of 
FRG1 in the skeletal muscle of transgenic mice results in a muscular dystrophy phenotype 
(Gabellini et al., 2006). The severity of the phenotype in these mice is correlated with the 
levels of overexpression, with the most affected mice expressing high levels of human FRG1 
relative to the endogenous protein (Gabellini et al., 2006). As this transgene is under the 
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ĐŽŶƚƌŽůŽĨƚŚĞŚƵŵĂŶƐŬĞůĞƚĂůɲ-actin gene promoter, overexpression occurs specifically in the 
skeletal muscle and so it is possible that the muscle phenotype is an artefact of increased 
protein expression in this tissue. To generate even a mild phenotype in these mice, an 
increase in FRG1 10 fold higher than endogenous levels was required (Gabellini et al., 2006).  
When FRG1 protein levels were reduced by morpholino injection in X. laevis a disruption 
of myotome organisation and growth was observed (Hanel et al., 2009). Abnormal muscle 
formation was also seen when levels of FRG1 were elevated (Hanel et al., 2009), and the 
same group have also observed an effect on angiogenesis when levels of FRG1 expression are 
changed (Wuebbles et al., 2009). As these studies have relied on significant over/under 
expression of the gene, it is possible that the phenotypes are an artefact of the experimental 
conditions. 
 
1.8.2.iii FRG2 
Of the genes studied in detail, the putative gene FRG2 lies closest to D4Z4, located 35kb 
proximal to the array (Gabellini et al., 2002); it has the potential to encode a nuclear protein 
of unknown function (Rijkers et al., 2004). Closely related sequences have also been identified 
on a number of different chromosomes (1, 3, 4, 7, 8, 10, 16, 18, 20, 22 via BLAST searches), 
with FISH analysis showing the strongest hybridisation signal to chromosomes 4 and 10 
(Rijkers et al., 2004). One study showed that FRG2 mRNA could be amplified by RT-PCR from 
differentiating myoblast cultures of FSHD cells but not cells from healthy controls. Transcripts 
were absent in all other tissues tested (Rijkers et al., 2004). The PCR products were 
sequenced to determine their chromosomal origin and came predominantly from 
chromosome 10, although some originated from chromosome 4 (Rijkers et al., 2004). Rijkers 
et al. suggest that pairing of the subtelomeric regions of 4q and 10q could explain how 
transcriptional activation of the 10q array occurs on contraction of D4Z4 on chromosome 4. 
FRG2 transcripts have also been identified by RT-PCR in myoblasts derived from non-FSHD 
myopathies; however, these were derived from chromosomes 3 and 22 (Rijkers et al., 2004). 
As the FRG2 primers used in this study amplify transcripts from multiple chromosomes, it will 
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be important to sequence all RT-PCR products from expression studies in order to confirm the 
origin of transcripts. Overexpression of FRG2 in mouse skeletal muscle shows no phenotype 
(Gabellini et al., 2006)
 
and in FSHD patients with extended deletions the region containing 
FRG2 is lost (Lemmers et al., 2003), arguing against a primary role for this gene in the disease. 
 
1.8.2.iv ANT1 
ANT1 encodes an adenine nucleotide translocator, which facilitates transport of ATP over 
the mitochrondrial membrane (Li et al., 1989; Stepien et al., 1992; Doerner et al., 1997; 
Lemmers et al., 2003). Although it resides over 3.5Mb from the array (Wijmenga et al., 1993), 
it has been studied as a functional candidate because of its high expression in heart and 
skeletal muscle. ANT1 expression is increased on depletion of YY1 or MeCP2 (Forlani et al., 
2010). Since YY1 has been identified as part of the D4Z4 binding complex (Gabellini et al., 
2002), this could provide support for the hypothesis that contraction of the array reduces 
binding of the repression complex, thereby increasing expression of the nearby genes. 
However, this effect was also seen with the murine Ant1 gene, despite it having no equivalent 
D4Z4 array nearby (Forlani et al., 2010). There is some western blot support for changes in 
the levels of expression of the ANT1 protein in FSHD patients (Laoudj-Chenivesse et al., 2005; 
Macaione et al., 2007). However, the association of ANT1 mutations with other disorders 
(Hirano and DiMauro, 2001; Jordens et al., 2002; Drner and Schultheiss, 2007; Forlani et al., 
2010) suggests that the protein may have a role in secondary pathological processes, rather 
than the primary cause, especially since overexpression of ANT1 in the mouse has no 
phenotype (Gabellini et al., 2006). 
 
1.8.2.v DUX4C 
DUX4C is inside an inverted, partial copy of a D4Z4 repeat that maps 42kb proximal to the 
main array (Hewitt et al., 1994). The truncated repeat contains an ORF that is 150bp shorter 
than DUX4 and varies from the DUX4 sequence in the C-terminal domain at 33 of the final 141 
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positions. Ansseau et al. used a rabbit antiserum against a 16-residue peptide from the 
C-terminal domain to identify a protein of the predicted size of DUX4C in differentiating 
muscle cells from FSHD patients and controls using western blot. This study reported a 1.5 
fold increase in DUX4C expression in FSHD samples compared with control or Duchenne 
muscular dystrophy cells (Ansseau et al., 2009). They were also able to identify transcripts by 
RT-PCR in both FSHD and control cells, at proliferation and differentiation stages and 
sequencing showed that the RT-PCR products matched the DUX4c sequence (Ansseau et al., 
2009) (for primer positions see Figure 4.3). However, no other expression studies have 
identified transcripts from this locus and, like FRG2, DUX4C is lost in some patients with 
extended deletions (Lemmers et al., 2003) so a primary involvement in the disease seems 
unlikely. 
 
1.8.2.vi  Expression of 4q35 candidate genes 
Thus, several studies have compared expression of these candidate genes in FSHD and 
control cells (for a summary see Table 1.1). However, they have produced conflicting data 
that does not give a clear, consistant picture of the disease. In 2002 Gabellini et al. used end-
point RT-PCR to examine expression of three genes (FRG1, FRG2 and ANT1) in FSHD muscle 
samples and showed increased expression of all three loci (Gabellini et al., 2002). For FRG2, 
expression was seen only in the three patient samples and not in three controls. The increase 
in expression correlated inversely with distance from the array, and Gabellini et al. suggested 
that D4Z4 has more influence on genes that are closer to it. While this data seemed to 
provide support for a position effect and loss of silencing of these genes in FSHD, a number of 
groups have repeated expression analyses for the genes and the results have generally not 
been in agreement with Gabellini et al. (Chen et al., 2000; Jiang et al., 2003; van Overveld et 
al., 2003; Winokur et al., 2003b; Macaione et al., 2007; Masny et al., 2010). The majority of 
studies that have used quantitative measures such qRT-PCR or microarrays have found no 
difference in expression levels of the candidate genes between FSHD samples and controls 
(van Deutekom et al., 1996b; Jiang et al., 2003; van Overveld et al., 2003; Winokur et al., 
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2003b; Dixit et al., 2007).
 
Although the lack of validation could be due to the different 
methods used, different sites of muscle biopsy or state of cell cultures and/or differences in 
the severity of disease in the patients tested, there is no clear consensus of support for the 
derepression model of Gabellini et al. (Table 1.1).  
As the sample sizes in these studies are generally small, any differences seen may be in 
part due to normal variation in gene expression levels. As FRG1 is a multicopy gene it is also 
possible that transcripts from chromosomes other than 4q were amplified by RT-PCR. In order 
to confirm that any variation in expression in this gene is due to changes at 4q35 it is 
important to determine the chromosomal origin of such transcripts.  
In 2010, Masny et al. examined transcription of nascent RNA in single myonuclei using 
quantitative FISH. This method allowed them to distinguish transcription from the contracted 
and the noncontracted alleles, as well as the chromosome 4 specific expression of multicopy 
genes. None of the 16 genes tested showed a difference in expression from the FSHD alleles 
(Masny et al., 2010). Current data therefore suggests that contraction of D4Z4 does not have 
a significant effect on the expression of the candidate genes outside the array.  
While support for a position effect on neighbouring genes is diminishing, evidence for the 
direct involvement of D4Z4 in FSHD is increasing and it is now appropriate to reconsider the 
role that D4Z4 may play in the pathology of FSHD. 
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Table 1.1 Summary of expression analyses for 4q35 candidate gene 
A summary of published expression analyses for the main candidate genes at 4q35. Up regulation of expression in FSHD samples compared to controls is indicated by a 
green arrow, down regulation is indicated by an orange arrow. no change - no significant difference in expression levels between FSHD samples and control samples. n/a - 
not assessed.* - Only 1 of the 3 samples showed up-regulation, the other two showed no change. 
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1.9 D4Z4 may encode the DUX4 gene 
Two cDNAs, DUX1 and DUX2, were identified during a search for target genes of the 
helicase-like transcription factor (HLTF). Using ChIP, Ding et al. showed that HLTF bound to a 
DNA fragment (HEFT1) with 82-86% nucleotide identity to D4Z4. HEFT1 does not map to the 
FSHD locus but presumably to a dispersed 3.3kb repeat (Ding et al., 1998). This fragment was 
shown to have promoter activity when fused to a luciferase reporter gene and introduced 
into HeLa cells and the rhabdomyosarcoma cell line TE671. A probe from HEFT1 was then 
used to isolate the DUX1 and DUX2 cDNAs by library hybridisation. 
Several cDNAs homologous to D4Z4 had been identified previously (Hewitt et al., 1994; 
Lyle et al., 1995). However, as these transcripts did not contain ORFs through the 
homeoboxes they likely represent expressed pseudogenes. The ORF of DUX2 is truncated 
immediately downstream of the first homeodomain and, as no in vivo expression has yet 
been identified, it is likely that this is also a pseudogene. RT-PCR products have been obtained 
for DUX1, and two further putative DUX genes, DUX3 and DUX5 (Ding et al., 1998; Beckers et 
al., 2001). A protein of the apparent molecular weight of DUX1 was identified in TE671 cells 
by western blotting with antiserum raised against a peptide from the predicted protein (Ding 
et al., 1998).  
The promoter-like region in D4Z4 maps just upstream of the homeobox ORF. This putative 
gene within D4Z4 was named DUX4
 
(Gabriels et al., 1999). Gabriels et al. were able to 
demonstrate promoter activity of this HEFT1 related sequence when inserted upstream of a 
luciferase reporter gene and introduced into TE671 cells.  
Dixit et al. extracted RNA from C2C12 cells transfected with a plasmid containing a 
patient-derived D4Z4 array (two repeats) and used 3-RACE to characterise the DUX4 
transcripts. They identified two different sized fragments, which they suggest is due to 
alternative splicing of a 136bp intron located after the stop codon (Dixit et al., 2007; see 
Figure 1.6). This is an unusual organisation as introns in the 3UTR are rarely found as 
nonsense-mediated decay (NMD) degrades transcripts containing premature stop codons 
(Scofield et al., 2007).  
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In 2007, two papers reported evidence of DUX4 expression in FSHD myoblast cell lines 
(Dixit et al., 2007; Kowaljow et al., 2007). Using RT-PCR, Kowaljow et al. were able to amplify 
a 1477bp fragment from both proliferating and differentiating FSHD myoblasts, while Dixit et 
al. were able to amplify a 1700bp fragment only from differentiating FSHD cells (Figure 1.6). 
However, neither of these groups published sequence data of the PCR products and since 4q 
and 10q arrays are very similar, this data is necessary to confirm the origin of the transcripts. 
By Western blot of FSHD muscle proteins, Dixit and colleagues also detected a protein of 
the predicted mass of DUX4 using a mouse monoclonal antibody raised against the final 250 
residues of the DUX4 ORF (Dixit et al., 2007). Using polyclonal antibodies raised against a 
synthetic peptide corresponding to amino acids 342-356, Kowaljow et al. were unable to 
identify the DUX4 protein in FSHD or control myoblasts, however, they identified expression 
of a DUX4-related protein in two rhabdomyosarcoma cell lines (RD and RMS13) (Kowaljow et 
al., 2007). None of these putative DUX4 proteins have been analysed using proteomic 
approaches, so verification that they represent a bona fide DUX4 protein will be important.  
Transcription, if confirmed, would support the view that DUX4 has a coding function. 
Although the organisation of D4Z4 is unusual for a gene, there are examples of tandemly-
arrayed protein-coding genes in humans. For example, RS447 megasatellites on chromosomes 
4p and 8p encode a functional deubiquitinating enzyme, USP17, (Saitoh et al., 2000) and the 
TSPY gene resides within the repeats of the Y-chromosome specific DYZ5 array (Manz et al., 
1993).  
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Figure 1.6 DUX4 transcripts identified in 2007 
A schematic diagram of the final repeat of D4Z4. The ORF is shown in pale blue with the 
homeodomains highlighted in dark blue. The pLAM sequence adjacent to the array is shown 
in green. The potential polyA signal is indicated with an arrow. The RT-PCR products from 
Kowaljow et al. (2007)
 
and Dixit et al. (2007)
 
are shown underneath in orange. Predicited 
introns are identified by dotted lines. 
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1.10 Evolutionary analysis indicates a protein coding function 
for D4Z4 
1.10.1 D4Z4 homologs 
D4Z4 homologs in great apes and Old (rhesus) and New World (marmoset) monkeys, were 
originally identified by physical mapping studies in 1996 (Clark et al., 1996; Winokur et al., 
1996). More recently, the advent of whole genome sequencing has led to the identification of 
homologues in a number of other species, including the murine and Afrotherian lineages 
(Clapp et al., 2007). 
In the great apes, D4Z4 orthologues align along the whole of the 3.3kb repeat. In addition, 
as in humans these species have numerous dispersed copies distributed throughout the 
genome (Clark et al., 1996; Winokur et al., 1996; Clapp et al., 2007). In other species, 
including Old and New World monkeys, there is little nucleotide identity outside of the ORF, 
however the DUX4 ORF itself has been maintained (Figure 1.7). This conservation since the 
divergence of Afrotherian and Eutherian mammals (>100mya) strongly suggests a protein 
coding function for the gene. Statistical comparison of the primate nucleotide sequences 
suggests that the ORF has been conserved by selection (Clapp et al., 2007). 
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Figure 1.7 Schematic diagram of mammalian D4Z4-related repeats.  
Repeats and sequence elements are drawn to scale. The ORF is conserved among all the 
species identified. Taken from Clapp et al. 2007 
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1.10.2 Intron-containing DUX genes 
In 2007, Booth and Holland identified intron containing DUX genes (DUXA and DUXB) in 
humans (Booth and Holland, 2007). Ten retrotransposed pseudogenes of DUXA were also 
identified, indicating expression of the gene in the germline or early embryo. Orthologues of 
DUXA and DUXB have since been identified in a wide range of mammalian species (Clapp et 
al., 2007; Leidenroth and Hewitt, 2010) and two new classes of intron containing DUX genes, 
DUXC and Duxbl, have been discovered (Clapp et al., 2007). 
In addition to searching publically available genome assemblies, Leidenroth and Hewitt 
used synteny information to catalogue both intact and inactive DUX homologues across 
placental mammals (Figure 1.8). This approach also allowed them to identify a homologue 
containing a single-homeobox gene in the non-mammalian species opossum and chicken, 
which they named sDux. 
The similarity between the homeodomains of the four intron-containing DUX genes, as 
well as their similar gene structures and splice locations (Figure 1.9), suggest that duplication 
of the DUX homeobox occurred only once. As no double-homeoboxes have been identified in 
non-mammalian species, the phylogenetic data supports a model where duplication of the 
sDUX homeobox occurred in the ancestor of all placental mammals, giving rise to the 
ancestral DUX gene from which the others are descended. In a maximum likelihood tree of 
the DUX homeodomains, the first homeodomain of DUXB, DUXC and Duxbl cluster together, 
as do the second, providing further support that the two homeodomains were already 
duplicated and divergent in their common ancestor (Leidenroth and Hewitt, 2010).  
Leidenroth and Hewitt identified a pattern of reciprocal loss and retention of DUXB and 
Duxbl (Figure 1.8), suggesting these genes are paralogues and more closely related to each 
other than to either DUXA or DUXC. The initial functional redundancy present after 
duplication allowed one of these paralogues to decay in each mammalian lineage. The fact 
that DUXA is maintained in addition to DUXB/Duxbl suggests that the genes have diversified 
to fill different roles. 
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DUXC is the only intron-containing DUX gene that is found in a tandem array organisation 
(Leidenroth and Hewitt, 2010) and it clusters with DUX4 in phylogenetic analyses (Clapp et al., 
2007; Leidenroth and Hewitt, 2010). In addition, DUXC shares a conserved C-terminal domain 
with the DUX4 homologs and the mouse Dux genes suggesting that DUX4 probably arose 
from a retrotransposed copy of DUXC, with both genes present in the common ancestor of all 
mammalian orders 105 million years ago. The D4Z4 array then arose from amplification of 
DUX4 in this ancestor. Current data indicates that DUX4 has since been lost from 
Laurasiatheria and DUXC lost in the Afrotherian and Primate lineages (Clapp et al., 2007; 
Leidenroth and Hewitt, 2010). 
The Dux array identified in the rodent is likely to have arisen from an independent 
amplification of a retrotransposed copy of DUXC. Although these sequences are unlikely to be 
true orthologs of the DUX4 arrays in humans, they share both the C-terminal domain and 
their tandem array organisation, and thus may be functionally equivalent.  
 
1.11 Dux genes are expressed in mice 
Gene expression studies in the mouse have been less complicated than in human due to a 
lack of dispersed repeats. In 2007, Clapp et al published evidence for expression of at least 
some copies of the mouse Dux gene. Overlapping primers were used to show that the whole 
ORF is transcribed and this was confirmed using RNA-FISH and in situ hybridisation.  
Clapp and colleagues were also able to amplify both sense and antisense transcripts from 
the Dux array by RT-PCR, a transcription pattern that is also found in the R5447 tandem 
repeat array encoding the deubiquitinating enzyme USP17 (Saito et al., 2000). Antisense 
transcription of Dux was confirmed by RNA-FISH (Clapp et al., 2007). Antisense transcription is 
thought to provide a regulatory mechanism for gene expression (Lapidot and Pilpel, 2006). It 
has been shown that endogenous antisense sequences can down-regulate the expression of 
sense transcripts (Lapidot and Pilpel, 2006) and introduction of artificial complementary 
sequences is now used to knockdown gene expression in model systems (Sugimoto, 2004; 
Spaenkuch and Strebhardt, 2005; Zhou et al., 2006). It is possible that these antisense 
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transcripts provide regulatory control for the expression of the mouse Dux array, although 
this needs to be confirmed experimentally. 
In contrast to the apparently limited expression of DUX4 shown in human cell lines, 
expression in the mouse was identified in a number of different tissues, particularly the CNS 
(Clapp et al., 2007). Since the expression patterns seem to differ between species it will be 
important to establish whether human DUX4 and the mouse Dux genes have equivalent 
functions.  
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Figure 1.8 Mammalian DUX distribution 
Summary of the mammalian DUX catalogue produced by Leidenroth and Hewitt (2011). 
Presumed functional genes (with intact ORF across all four homeobox exons, first exon may 
be unidentified) in green. DUX sequences with stop codons or deleted/missing exons in well 
sequenced regions in orange. Putative DUX homologues with unclear functional status 
(mainly due to gaps in assembly) in yellow. Unless marked with ?, synteny was confirmed with 
anchor genes. 
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Figure 1.9 Schematic diagram of the DUX family 
Structures of the DUX family members. The ORF is shown in light blue and homeboxes 
highlighted in dark blue. The conserved C-terminal domain is shown in orange. For the intron-
containing DUX genes the transcription start and end sites are uncertain and indicated by 
dotted lines. Introns and exons are drawn to different scales. Adapted from Leidenroth and 
Hewitt 2011.  
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1.12 What is the likely function of DUX4 in vivo? 
The double homeobox within DUX4 suggests the protein is likely to be a transcription 
factor, it would therefore be expected to localise to the nucleus and a number of groups have 
shown this to be the case for exogenously expressed protein (Ostlund et al., 2005; Kowaljow 
et al., 2007). The C-terminal fragment of DUX4 has also been shown in vivo to enhance the 
transcriptional activity of CIC, a HMG box transcription factor. Fusions between CIC and DUX4 
have been identified in two patients with Ewing-like sarcomas and their ability to activate CIC 
target genes (Kawamura-Saito et al., 2006) provides evidence that DUX4 can behave as a 
transcriptional activator. 
 
1.13 What are the transcriptional targets of DUX4? 
A number of global expression studies have looked for genes that are mis-regulated in 
FSHD muscles (Tupler et al., 1999; Winokur et al., 2003b; Celegato et al., 2006; Dixit et al., 
2007). In order to identify disease-specific changes in expression, the results of such 
experiments (e.g. microarrays) are compared with other forms of muscular dystrophy. Genes 
that are consistently mis-regulated in the other disorders are likely to be the result of 
secondary pathological processes and can be removed from further analysis. 
Some researchers have suggested that there is a global misregulation of gene expression, 
rather than the effect of the deletion being restricted to chromosome 4q35 genes (Winokur 
et al., 2003b). The set of genes with apparently altered expression levels in FSHD are enriched 
in muscle-specific transcripts (Tupler et al., 1999; Winokur et al., 2003b; Celegato et al., 
2006), and in particular those controlled by the muscle-specific transcription factor MyoD 
(Winokur et al., 2003b; Celegato et al., 2006). The MyoD pathway is necessary for myogenic 
differentiation and is involved in the regeneration of muscle in response to stress and injury. 
This pathway has previously been shown to play a role in the nuclear envelope dystrophies, 
which are thought to be related to FSHD (Chen et al., 2000).  
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It is known that cascades of transcription factors are responsible for the control of 
myogenesis and it is possible that DUX4 has a role in this process. If DUX4 is a strong 
transcriptional activator in vivo, low levels of its expression could potentially affect the 
transcription of a large number of genes. Transfection of mouse C2C12 cells with human 
DUX4 inhibited differentiation (Snider et al., 2009) and overexpression of DUX4 in zebrafish 
(Snider et al., 2009)
 
or Xenopus (Grewal et al., 1999) embryos caused developmental arrest 
and a reduction in muscle markers. However, as observed by Leidenroth and Hewitt, the 
relevance of overexpressing DUX4 in species (such as zebrafish or Xenopus) which do not 
contain any double-homeobox genes is unclear. It is possible that the phenotypes seen in 
these embryos are an artefact of overexpression of a transcription factor which these species 
have not evolved to cope with (Leidenroth and Hewitt, 2010). 
Nuclear factor-kappaB (NF-NB), shown to be activated in Duchenne muscular dystrophy, is 
also thought to be involved in the regulation of myogenesis and muscle repair (Monici et al., 
2003). NF-NB is induced in cells in response to oxidative stress; this activation is thought to be 
mediated by receptor for advanced glycation end products (RAGE). The RAGE-NF-NB pathway 
is involved in muscle regeneration in the limb girdle muscular dystrophies (Haslbeck et al., 
2004) and is stimulated in FSHD muscles (Macaione et al., 2007). A number of studies have 
shown that FSHD cells are more susceptible to oxidative stress than controls (Winokur et al., 
2003a; Laoudj-Chenivesse et al., 2005; Macaione et al., 2007). However, the fact that these 
pathways are also activated in other forms of muscular dystrophy (Moylan and Reid, 2007), 
suggests that they are secondary consequences of muscle disorder rather than a causative 
mechanism for the disease. 
Following microarray experiments it has recently been reported that the paired-like 
homeodomain transcription factor 1 (PITX1) is specifically upregulated in the muscles of 
patients with FSHD (Dixit et al., 2007). A potential DUX4 binding site was identified in the 
PITX1 promoter region and PITX1 expression was seen in some C2C12 cells following 
transfection with a DUX4 construct (Dixit et al., 2007). These results suggest that DUX4 could 
be an upstream regulator of PITX1. There are three PITX1 paralogues in humans (PITX1, PITX2 
and PITX3). All three of the genes are expressed in muscle; PITX3 may contribute to 
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myogenesis (Coulon et al., 2007), while PITX1 has a role in determining hind limb identity 
(DeLaurier et al., 2006). 
 
1.14 Analysis of 4q haplotypes implicates DUX4 in FSHD 
A more detailed analysis of polymorphisms on 4q and 10q identified 9 different 
haplotypes based on sequence variations within and flanking the D4Z4 array (Lemmers et al., 
2007; Figure 1.10a). The haplotypes are defined by the chromosomal location (4q35 or 
10q26), an SSLP proximal to D4Z4, 15 SNPs within the D4F104S1 (p13E-11) sequence, 4 SNPs 
within the most proximal unit of the array that alter restriction enzyme recognition sites, and 
the distal A/B/C variation (Figure 1.10b). FSHD sized alleles on only one of the 4q haplotypes 
(4A161) were found to be associated with FSHD; contractions on 4qB and one 4qA allele 
(4qA166) were shown to be nonpathogenic (Lemmers et al., 2007). The low rate of 
interchromosomal rearrangements has allowed these haplotypes to evolve independently 
and there is strong linkage disequilibrium between sequences immediately flanking the D4Z4 
repeat, this means each subtelomere end is unique and can explain why FSHD is associated 
with only one haplotype. 
Since FSHD is associated with only one of the identified haplotypes, there are likely to be 
some functional elements outside of and/or within the array that are necessary for the 
disease. For example, the 4qA161 haplotype may contain a harmful variant that affects 
regulation of DUX4 or leads to altered expression levels/ratios of functional repeat variants. 
With respect to gene regulation the variant might increase the chance of expression, perhaps 
by creating a binding site for activating proteins, or it may disrupt other repression 
mechanisms in the region. Alternatively this haplotype may be missing an element important 
for repression of the gene. If antisense transcription does prove to be an important regulatory 
mechanism for this gene it may also be affected by variants within or outside the array. 
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Figure 1.10 A schematic representation of the 4q haplotypes 
a) The 9 main haplotypes identified by Lemmers et al. are shown, with their population 
frequencies on the right. The haplotypes are defined by three sequence variations, an SSLP 
proximal to D4Z4 (number of base pairs shown), a G/C SNP within D4Z4 which forms a PvuII 
site (C variant) and the distal qA/qB variation (the qA variant is shown in green, the qB variant 
is shown in orange). b) A schematic representation of the sequence variants used to define 
the D4Z4 haplotypes. The SSLP and P13E-11 regions are identified. The BlnI site in the first 
partial repeat and further restriction sites in the first proximal repeat are shown. At the distal 
end is the A/B/C variation. 
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1.15 Implications for the FSHD disease mechanism 
Although conservation of the DUX4 ORF suggests a protein coding function, expression of 
DUX4 was not identified in any normal cell lines or tissues (Dixit et al., 2007; Kowaljow et al., 
2007). However, unpublished data from Jane Hewitts laboratory, generated by Jannine 
Clapp, had identified DUX4 expression by RT-PCR from fetal skeletal muscle and testis. 
Induction of high levels of DUX4 overexpression in adult cell lines has been shown to be 
toxic (Gabriels et al., 1999; Kowaljow et al., 2007; Wallace et al., 2011). These transfected 
cells show characteristic markers of apoptosis, which raises the possibility that inappropriate 
expression of the gene activates apoptotic pathways. Kowaljow et al. saw an increase in the 
release of cytosolic LDH and increased expression of caspases 3 and 7 at 48 hours after 
overexpression of DUX4 in TE671 cells. Recently, Wallace et al. produced a DUX4 construct 
with a mutation in the first homeodomain; expression of this mutant did not cause apoptosis, 
suggesting that DNA binding is required for the toxic effects (Wallace et al., 2011).  
The tandemly repeated structure of D4Z4 has also been conserved among species (Clapp 
et al., 2007; Leidenroth and Hewitt, 2010), which suggests this organisation plays a functional 
role. One possibility is that the tandem repeats help to maintain a heterochromatic 
environment, silencing expression from the DUX4 gene. Following the deletion, 
heterochromatin may open up resulting in inappropriate expression. This hypothesis could 
explain the observation that fewer repeats tend to correlate with a more severe phenotype 
(Brouwer et al., 1995; Lunt et al., 1995b; Tawil et al., 1996; Klinge et al., 2006); if a decrease in 
repeat number results in a less repressive structure, the chromatin could open to a greater 
extent, increasing the possibility of expression from the remaining repeats. However, as small 
arrays on 10q or 4qB do not result in disease, FSHD cannot result simply from the property of 
array organisation and so there are likely to be functional elements on 4qA alleles that are 
necessary for the disease. This hypothesis would also explain why monosomy for the 4q35 
region does not result in FSHD, a factor that is difficult to account for when considering a 
position effect mechanism. 
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1.16 Future perspectives 
The identification of a D4Z4 homolog in the mouse raises the possibility of manipulating 
the mouse Dux array to mimic FSHD. A model organism for the disorder would enable studies 
of the mechanisms involved in the FSHD pathology, and potentially increase our 
understanding of the pathways involved. Before a mouse model can be created it will be 
important to establish whether transcripts from the mouse Dux array play the same role in 
the mouse that DUX4 does in humans and to determine the relationships between mouse 
Dux genomic variants and transcripts.  
Therefore, the aim of the work described in this thesis was to investigate whether the 
mouse and human arrays are functionally equivalent and initial work was focussed on 
whether PITX1 was a target for Dux in the mouse (Chapter 3), as had been described for 
human DUX4 (Dixit et al., 2007). The second aim of this work was to test for expression of 
human DUX4 in normal cell lines by RT-PCR and confirm expression in FSHD myoblasts. In 
order to map sequence variants within the D4Z4 arrays any expressed transcripts would be 
compared with genomic sequences (Chapter 4). Finally, sequence data would be gathered 
from the mouse repeat by RT-PCR and compared with the genomic sequence data (Chapter 
5), in order to investigate whether sequ3ence variation and expression pattern is similar 
between mouse and human repeats. 
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Chapter 2. Methods and Materials 
2.1 Cell Culture 
2.1.1 Maintenance and passaging of cells 
C2C12 (mouse myoblast), TE671, RD, RMS13 (human rhabdomyosarcoma) and hEC 
(human embryonic carcinoma) cells were cultured in 75cm
2
 flasks containing 12ml media (see 
Table 2.9) and incubated at 37qC with 5% CO2. Growth was checked daily and cells were 
passaged at around 80% confluency. When passaging the cells, all solutions were warmed to 
room temperature and cells were washed with 5ml phosphate buffered saline (PBS). Cells 
were incubated at 37qC for 5 to 10 minutes in 3ml of 0.25% trypsin and then dislodged from 
the bottom of the flask by gentle tapping against the hand. Appropriate media (7ml) was 
added to neutralise the trypsin and the cells were pipetted up and down to break up any 
clumps. Cells were typically split ~1:10 and so 1ml of suspension was added to a new flask 
with 11ml fresh media. 
Primary human myoblast cell lines (GM17731, GM17940 and GM17869, Coriell Institute) 
were cultured in 75cm
2
 flasks coated in 0.7% gelatin containing 12ml media (see Table 2.9) 
and incubated at 37qC with 5% CO2. Growth was checked daily and cells were passaged 
before they reached 80% confluency to prevent them ceasing division in preparation for 
differentiation. Passaging of the cells was performed as above with a weaker concentration of 
trypsin (0.1%). Cells were typically split in a 1:5 ratio. 
For immunocytochemistry, myoblast cell lines were cultured in 6 well plates on coverslips 
coated in poly-L-Lysine at a concentration of 500µg/ml. 
 
2.1.2 Coating flasks in gelatin 
Using a cell scraper, 150µl of 0.7% gelatin was spread evenly over the bottom of each 
75cm
2 
flask. Flasks were left for 30-60 minutes to allow the gelatin to solidify before cells 
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were added. Flasks were stored at 4qC for up to a month and stored flasks were warmed to 
37qC before use. 
 
2.1.3 Coating flasks in Matrigel 
Matrigel was thawed on ice, overnight in the fridge and pipettes, racks and flasks were 
pre-chilled in the freezer overnight. Matrigel was diluted 10 times in differentiation medium 
without horse serum and 3ml added to each flask 75cm
2
. Matrigel was spread evenly over the 
surface of the flask using a cell scraper and excess Matrigel was then removed. Flasks were 
left at room temperature to set then used immediately. 
 
2.1.4 Differentiation of myoblasts 
Myoblasts were grown in 75cm
2
 flasks coated in Matrigel containing 12ml media. When 
cells reach 100% confluency, the growth media was removed and cells were washed in PBS. 
Differentiation media one (12ml) was added for 24 hours and then replaced with 
differentiation media two. Differentiation typically took 5-7 days. 
 
2.1.5 Storage in liquid nitrogen 
Freeze media was prepared in advance and kept on ice. Cells were trypsinized (as 
described in section 2.1.1), resuspended in media and the cell suspension transferred to 15ml 
Falcon tubes. The tubes were centrifuged at 600rcf for 5 minutes, the supernatant removed 
and the cells resuspended in the remaining droplet of media. Freeze media (1ml per 75cm
2 
flask) was added to each tube, mixed by pipetting and then 0.5ml of cell suspension was 
transferred to a cryotube. The tubes were stored at -80qC for 48 hours before being 
transferred to liquid nitrogen. 
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2.1.6 Recovery from liquid nitrogen 
Appropriate media was warmed to room temperature and added to a 75cm
2 
flask. Cells 
were removed from liquid nitrogen and thawed quickly by incubating at 37qC. As soon as the 
cells were defrosted they were transferred to the flask and incubated at 37qC. 
 
2.1.7 Transfections 
Cells were transfected with PITX1 constructs that were cloned during this project (section 
3.2.2.i) or with constructs that had been made previously in this lab (Figures 2.1 to 2.4).  
All transfections were carried out in 6 well plates with a total volume of 3ml per well. 
C2C12 cells were seeded at a density of 2x10
5 
and TE671 at a density of 4x10
5
 and then 
incubated overnight prior to transfection. For immunocytochemistry, coverslips were placed 
at the bottom of each well. Non-transfected controls were treated exactly the same except 
for the addition of DNA. After transfection, cells were incubated at 37qC for 24-48 hours 
before being used for immunocytochemistry (section 2.2).  
If required, proteosome inhibitor (Z-Leu-Leu-Leu-Ăů ? ? Ăƚ Ă ĨŝŶĂů ĐŽŶĐĞŶƚƌĂƚŝŽŶ ŽĨ  ? ? ʅD ?
was added to the wells and the cells left to incubate for 5 hours before immunocytochemistry 
was performed. 
 
2.1.7.i   Preparation of coverslips 
A Duran bottle containing coverslips immersed in 20ml nitric acid (69%) and 10ml HCL 
(100%) was covered in foil and incubated at room temperature for 2 hours. The coverslips 
were washed four times with 75% ethanol, followed by a further two washes with 100% 
ethanol. Treated coverslips were stored in 100% ethanol.  
When used for myoblasts, treated coverslips were placed in a single layer in a petri dish 
and covered with Poly-L-Lysine (500µg/ml) for 1 hour at 37°C. Coverslips were then allowed 
to air dry before use. Coated coverslips were covered with parafilm and stored at 4°C. 
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2.1.7.ii Transfection with Effectene  
Cells were washed with 3ml PBS and 1.6ml media was added to each well. 400ng of 
ƉƵƌŝĨŝĞĚ ƉůĂƐŵŝĚ E ǁĂƐ ĚŝůƵƚĞĚ ƚŽ  ? ? ?ʅů ǁŝƚŚ ďƵĨĨĞƌ  ? ŶŚĂŶĐĞƌ  ? ? ? ?ʅů ? ǁĂƐ ĂĚĚĞĚ ?
ǀŽƌƚĞǆĞĚĨŽƌ ?ƐĞĐŽŶĚĂŶĚƚŚĞŶŝŶĐƵďĂƚĞĚĂƚƌŽŽŵƚĞŵƉĞƌĂƚƵƌĞĨŽƌ ?ŵŝŶƵƚĞƐ ? ? ?ʅůĨĨĞĐƚĞŶĞ
reagent was added and mixed by pipetting before being incubated at room temperature for 
10 minutes. Media (600ml) was mixed with the transfection complexes and then transferred 
the appropriate well. Plates were swirled gently to ensure even dispersion of the transfection 
mixture. Non-transfected cells were treated the same except that no DNA was added. 
 
2.1.7.iii Transfection with FuGene  
Cells were washed in 3ml PBS and 3ml of fresh media was then added to each well. 
WƵƌŝĨŝĞĚ ƉůĂƐŵŝĚ E  ? ?ʅŐ ?ǁĞůů ? ǁĂƐ ŵŝǆĞĚ ǁŝƚŚ  ? ? ?ʅů ƐĞƌƵŵ ĨƌĞĞ ŵĞĚŝĂ ĂŶĚ  ?ʅů &Ƶ'ĞŶĞ
reagent, vortexed and incubated for 15 minutes at room temperature. The transfection 
mixture was then added to the well under the surface of the media. The plate was swirled 
gently to ensure an even distribution of the complexes. 
 
2.1.7.iv Transfection with GeneJuice  
Cells were washed in 3ml PBS and 3ml of fresh media was then added to each well. 
'ĞŶĞ:ƵŝĐĞ ƌĞĂŐĞŶƚ  ? ?ʅů ? ǁĂƐ ĂĚĚĞĚ ƚŽ  ? ? ?ʅů ƐĞƌƵŵ ĨƌĞĞ ŵĞĚŝĂ ? ǀŽƌƚĞǆĞĚ ĂŶĚ ŝŶĐƵďĂƚĞĚ Ăƚ
room temperature for 5 minutes. Purified plasmid DNA  ? ?ʅŐ ?ǁĞůů ?ǁĂƐƚŚĞŶĂĚĚĞĚĂŶĚŵŝǆĞĚ
by pipetting before incubation at room temperature for a further 15 minutes. The 
transfection mixture was then added to the correct well and the plate was swirled gently to 
ensure an even distribution of the transfection complexes. 
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2.1.7.v Transfection with Transpass 
ĞůůƐ ǁĞƌĞ ǁĂƐŚĞĚ ŝŶ  ?ŵů W^ ĂŶĚ  ?ŵů ĨƌĞƐŚ ŵĞĚŝĂ ĂĚĚĞĚ ƚŽ ĞĂĐŚ ǁĞůů ?  ?ʅŐ ƉƵƌŝĨŝĞĚ
ƉůĂƐŵŝĚ E ǁĂƐ ĂĚĚĞĚ ƚŽ  ? ? ?ʅů ƐĞƌƵŵ ĨƌĞĞ ŵĞĚŝĂ ĂŶĚ  ?- ? ?ʅů dƌĂŶƐƉĂƐƐ ƌĞĂŐĞŶƚ ? dŚĞ
mixture was incubated at room temperature for 30 minutes and then added to the cells. The 
plates were swirled gently to ensure an even distribution of the transfection complexes. 
 
2.2 Immunocytochemistry  
Cells to be used for immunocytochemistry were seeded onto coverslips in 6 well plates; 
coverslips for myoblasts were first coated with Poly-L-Lysine. If cells were transfected, 
immunocytochemistry was carried out 24 or 48 hours after transfection.  
A volume of 3ml per well was used for each solution. Cells were washed twice in PBS and 
then fixed at room temperature for 10 minutes with 4% PFA. After three washes in PBS, cells 
were permeablised with 0.5% Triton in PBS for 10 minutes on ice and then washed a further 
three times. Next, ƚŚĞĐĞůůƐǁĞƌĞŝŶĐƵďĂƚĞĚĨŽƌ ? ?ŵŝŶƵƚĞƐĂƚƌŽŽŵƚĞŵƉĞƌĂƚƵƌĞŝŶ ? ?ʅŐ ?ŵů
bovine serum albumin (BSA)/5% goat serum in PBS to block non-specific binding. Coverslips 
ǁĞƌĞƚŚĞŶƉůĂĐĞĚĐĞůůƐĚŽǁŶŽŶƚŽ  ? ? ?ʅůƉƌŝŵĂƌǇĂŶƚŝďŽĚǇĚŝůƵƚĞĚ ŝŶ  ? ?mg/ml BSA/5% goat 
serum in PBS and incubated in the dark for 1h. After washing with PBS 3 times for 5 minutes, 
ƚŚĞ ƉƌŽĐĞƐƐ ǁĂƐ ƌĞƉĞĂƚĞĚ ǁŝƚŚ  ? ? ?ʅů ƐĞĐŽŶĚĂƌǇ ĂŶƚŝďŽĚǇ ĚŝůƵƚĞĚ ŝŶ  ? ?ŵŐ ?ŵů ^ ŝŶ W^ ?
After the 1h incubation the cells were washed 3 times for 5 minutes in PBS then mounted 
ŽŶƚŽƐůŝĚĞƐƵƐŝŶŐ ? ?ʅůǀĞĐƚĂƐŚŝĞůĚǁŝƚŚW/ ?dŚĞĞĚŐĞƐŽĨƚŚĞĐŽǀĞƌƐůŝƉƐǁĞƌĞƐĞĂůĞĚǁŝƚŚŶĂŝů
varnish and slides were stored at 4qC in the dark. Antibody dilutions are provided in Table 2.1. 
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Figure 2.1 Map of the FlmD4Z4 V5 construct 
This construct will produce a full length mouse D4Z4 protein tagged at the carboxy terminus 
with the V5 epitope. This construct was generated by Jonathan Rowlinson. 
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Figure 2.2 Map of the FlhD4Z4 V5 construct 
This construct will produce full length human D4Z4 tagged at the carboxy terminal end with 
the V5 epitope. This construct was generated by Jonathan Rowlinson. 
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Figure 2.3 Map of the FlmD4Z4 GFP construct. 
This construct will produce full length mouse D4Z4 tagged at the carboxy terminus with EGFP. 
This construct was generated by Jannine Clapp. 
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Figure 2.4 Map of GFP NtermD4Z4. 
 
This construct will produce the N-terminus and homeodomain region tagged at the amino 
terminus with EGFP. This construct was generated by Jannine Clapp. 
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a. 
 
 
 
 
 
 
 
 
b. 
 
 
 
 
 
 
Table 2.1  Antibodies used for immunocytochemistry 
Source and antibody dilution used in immunocytochemistry for primary antibodies (a) and 
secondary antibodies (b). 
 
 
2.3 Imaging and Photography 
Cells were viewed using an Axioscope 2 compound microscope (Zeiss) and photographs 
were taken using a MTI 3CCD camera and the OpenLab software package (Improvision). 
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2.4 RNA Purification 
2.4.1 RNA extraction from mammalian cells 
RNA was extracted from cultured cells using TRIzol reagent. Cells were trypsinized as 
described previously (section 2.1.1) and pelleted by centrifugation at 600rcf for 5 minutes in 
15ml Falcon tubes. The supernatant was removed and the cells were washed with PBS. Cells 
were re-pelleted by centrifugation for a further five minutes, the supernatant was removed 
and the cells were kept on ice. The pellets were resuspended in 2ml TRIzol per 75cm
2 
flask 
and mixed by pipetting before incubating at room temperature for 5 minutes. Chloroform 
(0.2ml per 1ml TRIzol) was added and the tubes shaken vigorously before incubating at room 
temperature for 5 minutes. The cells were then centrifuged at 4qC for 15 minutes at 16100rcf. 
The upper aqueous phase was transferred to a new tube and 0.5ml propan-2-ol added per 
1ml TRIzol. Samples were incubated at room temperature for 10 minutes and then again 
centrifuged at 16100rcf for 10 minutes at 4qC. The supernatant was removed and the pellet 
was washed in 75% ethanol, vortexed and then centrifuged at 5900rcf for 5 minutes at 4qC. 
The supernatant was removed and the pellet air-ĚƌŝĞĚ ďĞĨŽƌĞ ƌĞƐƵƐƉĞŶĚŝŶŐ ŝŶ  ? ?ʅů ƐƚĞƌŝůĞ
distilled water. The RNA was stored at -80qC. RNA was examined by gel electrophoresis on 1% 
agarose gel (Figure 2.5a) and the quality of the RNA was checked with a nanodrop (ND-1000 
Spectrophotometer, using software version 3.2.1); RNA with an A260/A280 ration of 1.8-2.0 
was used in further reactions. The integrity of all RNA samples was confirmed by a control RT-
WZƵƐŝŶŐƉƌŝŵĞƌƐĨŽƌɴ-actin (Figure 2.5b). 
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Figure 2.5 Quality analysis of RNA extracted from myoblast cells 
a) Gel electrophoresis of 2µl undiluted and 1:10 diluted RNA isolated from myoblast cell lines. 
RNA ladder from New England Biolabs. b) RT-PCR of myoblast RNA with primers for ɴ-actin 
(see Table 2.5 for sequences). Reverse transcription was carried out with Superscript III and 
the PCR step with Biotaq polymerase. 
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2.4.2 Poly (A)
+
 RNA purification 
Poly (A)+ mRNA was isolated from total RNA using the PolyATract mRNA Isolation system 
(Promega). Total RNA (500µg) was made up to 500µl volume with RNase-free water and 
incubated at 65qC for 10 minutes. After incubation, 150pmol Biotinylated-Oligo(dT) Probe and 
13µl 20x SSC was added and the reaction allowed to cool to room temperature for 10 
minutes. Streptavidin MagneSphere Paramagnetic Particles (SA-PMPs) were rinsed three 
times with 300µl 0.5X SSC while in the magnetic stand and then resuspended in 100µl 0.5X 
SSC.  
The contents of the annealing reaction were then added to the washed particles and 
incubated for 10 minutes at room temperature with gentle inversion every 2 minutes. The 
SA-PMPs were captured using the magnetic stand, the supernatant was removed and the 
particles washed four times in 300µl 0.1X SSC. The final SA-PMP pellet was resuspended in 
100µl for RNase-free water and captured with the magnetic stand. The eluted mRNA 
(supernatant) was transferred to a new tube and the elution step repeated with 150µl RNase-
free water. 
 
2.5 DNase treatment of RNA 
DNase treatment was carried out using TURBO DNA-free  ?ŵďŝŽŶ ? ? ? ?ʅŐZEǁĂƐĂĚĚĞĚ
ƚŽ ?yƌĞĂĐƚŝŽŶďƵĨĨĞƌ ?ƐƚĞƌŝůĞĚŝƐƚŝůůĞĚǁĂƚĞƌĂŶĚ ?hEĂƐĞŝŶĂƚŽƚĂůǀŽůƵŵĞŽĨ ? ?ʅůĂŶĚƚŚĞŶ
incubated at 37qC for 30 minutes. A further 2U DNase was added and the sample incubated 
for another 30 minutes at 37q ?dŽŝŶĂĐƚŝǀĂƚĞƚŚĞĞŶǌǇŵĞ ?ʅůŝŶĂĐƚŝǀĂƚŝŽŶƌĞĂŐĞŶƚǁĂƐĂĚĚĞĚ
to the sample and incubated at room temperature for 2 minutes with occasional gentle 
mixing. The sample was centrifuged at 9300rcf for 90 seconds in an Eppendorf microfuge and 
ƚŚĞƐƵƉĞƌŶĂƚĂŶƚƚƌĂŶƐĨĞƌƌĞĚƚŽĂŶĞǁƚƵďĞ ?ƚŚĞĐŽŶĐĞŶƚƌĂƚŝŽŶŽĨZEǁĂƐƚǇƉŝĐĂůůǇ ? ? ?ʅŐ ?ʅů ? 
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2.6 DNA Purification 
2.6.1 Genomic DNA extraction from mammalian tissues 
Tissues were washed in PBS, cut into small pieces and transferred to sterile tubes. The 
tissue was washed twice in PBS then resuspended in 4.12ml DNA buffer. After the addition of 
100µl of 20mg/ml proteinase K and 480µl of 10% SDS the tissue was incubated at 40qC 
overnight. If there were still visible tissue pieces, the samples were homogenised gently and 
another 100µl proteinase K was added before incubation at 40qC for 4 hours. A 
phenol/chloroform extraction was then performed on the samples. The samples were mixed 
with 4.8ml phenol (pH 7.8) on a rotator for 10 minutes and then centrifuged at 720rcf for 5 
minutes. The supernatant was removed to a new tube and mixed with 2.4ml phenol and 
2.4ml chloroform:isoamyl alcohol (24:1) and the rotator and spin were repeated. Finally, the 
supernatant was removed to a new tube and 4.8ml chloroform:isoamyl alcohol (24:1) was 
mixed to the sample and the rotator and spin repeated. After centrifugation, 100µl 3M NaAc 
and 20ml of 100% ethanol were added and mixed gently to precipitate the DNA. The DNA was 
transferred to a new tube, washed in 70% ethanol and allowed to air dry. DNA was dissolved 
in 1ml sterile distilled water on at rotator at 4qC overnight. 
 
2.6.2 Genomic DNA extraction from mammalian cells 
Cells were trypsinised as described in section 2.1.1 and pelleted by centrifugation at 
600rcf for 5 minutes in 15ml Falcon tubes. The supernatant was removed and the cells were 
washed with PBS. Cells were re-pelleted by centrifugation for a further five minutes, the 
supernatant was removed and the cells were kept on ice. The pellet was resuspended in 
4.12ml DNA buffer then 100µl of 20mg/ml pronase and 480µl 10% SDS were added and the 
sample incubated at 40qC overnight. The following day phenol chloroform extraction was 
performed as described previously (Section 2.6.1) and DNA was dissolved in 1ml SDW at 4qC 
overnight. 
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2.6.3 Plasmid DNA minipreps 
To analyse inserts by restriction enzyme digestion, plasmid minipreps were used to isolate 
E ?  ? ? ?ʅů ŽĨ ĂŶ ŽǀĞƌŶŝŐŚƚ ĐƵůƚƵƌĞ ǁĂƐ ĐĞŶƚƌŝĨƵŐĞĚĂƚ 16100rcf for 1 minute to pellet the 
cells. The supernatant wĂƐ ƌĞŵŽǀĞĚ ĂŶĚ ƚŚĞ ƉĞůůĞƚ ƌĞƐƵƐƉĞŶĚĞĚ ŝŶ  ? ? ?ʅů ŽĨ ƐŽůƵƚŝŽŶ  ? ?
^ŽůƵƚŝŽŶ ? ? ? ? ?ʅů ?ǁĂƐĂĚĚĞĚƚŽůǇƐĞƚŚĞĐĞůůƐĂŶĚŵŝǆĞĚŐĞŶƚůǇďǇƉŝƉĞƚƚŝŶŐ ? Next, solution 3 
 ? ? ? ?ʅů ?ǁĂƐĂĚĚĞĚĂŶĚƚŚĞƐŽůƵƚŝŽŶŵŝǆĞĚŝŶďǇŝŶǀĞƌƐŝŽŶ ?dŚĞƐĂŵƉůĞƐǁĞƌĞĐĞŶƚƌŝĨƵŐĞĚĂƚ
16100rcf for 10 minutes and the supernatant transferred to a fresh tube. To precipitate the 
DNA, 1ml of 100% ethanol was added to each sample and then stored at -20qC for 20 
minutes. The samples were centrifuged at 16100rcf for 10 minutes, washed in 70% ethanol 
and then centrifuged for a further 5 minutes before leaving the pellets to air-dry. The DNA 
was ƌĞƐƵƐƉĞŶĚĞĚŝŶ ? ?ʅůĚŝŐĞƐƚŵŝǆ ? 
 
2.6.4 Plasmid DNA minipreps using columns 
When a higher purity of DNA was required, the GenElute plasmid miniprep kit (Sigma) was 
used according to the manufacturers instructions. The DNA was eluted from the columns 
ƵƐŝŶŐ ? ?ʅůƐƚĞƌŝůĞĚŝƐƚŝůůĞĚǁĂƚĞƌ ? 
 
2.6.5 Purification of PCR and digestion products 
The GenElute PCR Clean-up kit (Sigma) was used to remove contaminants from PCR and 
digestion products. Manufacturers instructions were followed and the DNA was eluted into 
 ? ?ʅůŽĨ ƐƚĞƌŝůĞĚŝƐƚŝůůĞĚǁĂƚĞƌ ?dŽƉƵƌŝĨǇ ĨƌĂŐŵĞŶƚƐAM ? ? ?ďƉ ƚŚĞDŝŶůƵƚĞWZƉƵƌŝĨŝĐĂƚŝŽŶŬŝƚ
 ?YŝĂŐĞŶ ?ǁĂƐƵƐĞĚĂŶĚƚŚĞEĞůƵƚĞĚŝŶƚŽƐŵĂůůĞƌǀŽůƵŵĞƐ ?ƚǇƉŝĐĂůůǇ ? ?ʅů ? 
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2.6.6 Extraction of DNA from agarose gels 
The correct sized bands were excised from the gel using a clean scalpel blade and the 
agarose removed by centrifugation through polymer wool for 10 minutes at 9300rcf. The 
supernatant was transferred to a spin column, the sample centrifuged for a further 5 minutes 
at 16100rcf and any further supernatant recovered was also transferred. The MinElute PCR 
purification kit (Qiagen) was used to purify the DNA as described in Section 2.6.5. 
 
2.7 Digestion of DNA 
2.7.1 Plasmid DNA 
Miniprep ĚŝŐĞƐƚ ƌĞĂĐƚŝŽŶƐ ĐŽŶƚĂŝŶĞĚ  ?ʅů ƌĞƐƚƌŝĐƚŝŽŶ ĞŶǌǇŵĞ ? ?y ƌĞƐƚƌŝĐƚŝŽŶ ďƵĨĨĞƌ ?  ? ? ?ʅů
ZEĂƐĞ ? ?ʅŐEĂŶĚƐƚĞƌŝůĞĚŝƐƚŝůůĞĚǁĂƚĞƌƚŽĂƚŽ ĂůǀŽůƵŵĞŽĨ ? ?ʅů ?EƚŚĂƚǁĂƐƉƵƌŝĨŝĞĚ
using the GenElute plasmid miniprep kit was digested in the same way but without the 
addition of RNase A. The reactions were incubated at 37qC for 2-6 hours. Restriction enzymes 
are shown in Table 2.8. 
 
2.7.2 Genomic DNA 
Typically, 500ng of DNA was digested with 100units of restriction enzyme, 1x restriction 
buffer and 10µg BSA in a total volume of 100µl. Samples were incubated at 37qC overnight. 
Restriction enzymes are listed in Table 2.8. 
 
2.8 Modification of DNA ends 
2.8.1 Pfu treatment 
Treatment with Pfu was used to polish the ends of Taq-generated PCR fragments prior to 
ligation into the pSMART vector. The PCR fragments were added to 3U Pfu polymerase, 
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100µM dNTP, 1X Pfu buffer with MgSO4 in a final volume of 50µl. Reactions were incubated 
at 72qC for 30 minutes and then cleaned using the GenElute PCR Cleanup kit (see Section 
2.6.5). 
 
2.8.2 T4 Polynucleotide Kinase treatment 
T4 Polynucleotide Kinase was used for the addition of 5-phosphates to fragments prior to 
ligation into the pSMART vector. PCR products were added to reactions containing 1X T4 DNA 
ligase buffer and 10U T4 Polynucleotide Kinase to a final volume of 50µl. Reactions were 
incubated at 37qC for 30 minutes followed by 65qC for 20 minutes and then cleaned using the 
GenElute PCR Cleanup kit (see section 2.6.5). 
 
2.8.3 Calf intestinal phosphatase treatment 
Digested vectors were treated with calf intestinal phosphatase to remove 5 phosphate 
groups and reduce self-ligation. 2U CIP contained in 1X NEB buffer 3 was incubated at 37qC 
for 30 minutes. The reactions were then incubated at -20qC to inactivate the CIP and then 
cleaned up with the GenElute PCR Cleanup kit (Section 2.6.5). 
 
2.9 Nucleic Acid Electrophoresis 
2.9.1 Gel electrophoresis 
After electrophoresis all gels were imaged using a Gel Doc XR+ System with Quantity 
One software (version 4.6.5, Build 094) 
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2.9.1.i  DNA 
Agarose gels were prepared in 1X dďƵĨĨĞƌǁŝƚŚ ? ? ?ʅŐ ?ŵůĞƚŚŝĚŝƵŵďƌŽŵŝĚĞ ?'ĞůƐǁĞƌĞ
run in 1X TAE buffer for 1 hour at 50V. Commercial ladders from Bioline (Hyperladder I or IV) 
were used as size standards. 
 
2.9.1.ii RNA 
Agarose gels (1%) ǁĞƌĞ ƉƌĞƉĂƌĞĚ ŝŶ  ?y DKW^ ďƵĨĨĞƌ ?  ?ʅů ZE ƐĂŵƉůĞ ŽƌůĂĚĚĞƌ were 
ŵŝǆĞĚǁŝƚŚ ?ʅůĞƚŚŝĚŝƵŵďƌŽŵŝĚĞĂŶĚ ?ʅůĨŽƌŵĂůĚĞŚǇĚĞůŽĂĚŝŶŐďƵĨĨĞƌ ?ŝŶĐƵďĂƚĞĚĂƚ ? ?qC for 
10 minutes and then put immediately onto ice. Samples were briefly centrifuged before being 
loaded onto the gel. Gels were run in 1X MOPS buffer for 3-4 hours at 50V. 
 
2.9.2 Capillary electrophoresis 
Products of the SSLP genotyping reaction modified from Lemmers et al. (2010) were sized 
by capillary electrophoresis on Applied Biosystems 3130xl Genetic Analyzer. 10µl of a 
16-reaction master mix (2µl ROX Genescan and 170µl Hi-Di Formamide) was added to each 
sample. The plate was covered with a grey rubber lid, heat denatured at 96qC for 3 minutes 
and then transferred to ice for a further minute before being loaded onto the machine. 
Samples of known alleles were run as size standards. 
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2.10 Subcloning 
2.10.1 Ligations 
2.10.1.i pcDNA 
dŽŵĂŬĞĐŽŶƐƚƌƵĐƚƐĨŽƌ ůŝŐĂƚŝŽŶ ?ƌĞĂĐƚŝŽŶƐǁĞƌĞƐĞƚƵƉĂƐĨŽůůŽǁƐ P  ?ʅů/WƚƌĞĂƚĞĚǀĞĐƚŽƌ ?
 ?ʅů ƉƵƌŝĨŝĞĚ ŝŶƐĞƌƚ ?  ?y ůŝŐĂƚŝŽŶ ďƵĨĨĞƌ ĂŶĚ  ?ʅů d ? E ůŝŐĂƐĞ ǁĞƌĞ ŵŝǆĞĚ ĂŶĚ ŝŶĐƵďĂƚĞĚ Ăƚ
room temperature for 15 minutes. 
 
2.10.1.ii pSMART vectors 
In each reaction, 50-100ng of blunt-ended, 5-phosphorylated insert DNA, 2.5µl 4X 
CloneSmart Vector premix and 1µl CloneSmart DNA ligase were added to sterile distilled 
water to a final volume of 10µl. Reactions were incubated at 16qC for 16 hours and then heat 
denatured at 70qC for 15 minutes. 
 
2.10.1.iii pGEM-T Easy vector system 
Typically, reactions were carried out in a 10µl volume containing 50-100ng of PCR product, 
50ng of pGEM-T Easy vector, 3U/µl T4 DNA ligase and 1x rapid ligation buffer. Reactions were 
incubated at 4qC overnight. 
2.10.2 Transformations 
Competent cells (see Table 2.2 ? ǁĞƌĞ ŝŶĐƵďĂƚĞĚ ŽŶ ŝĐĞ ĨŽƌ  ? ? ŵŝŶƵƚĞƐ ǁŝƚŚ  ?ʅů ůŝŐĂƚŝŽŶ
mixture. The cells were then heat shocked at 42qC for 45 seconds before being returned to ice 
for a further 2 ŵŝŶƵƚĞƐ ?  ? ? ? A?ů ŽĨ ^K ŵĞĚŝĂ  ?, ?ɲ ? Žƌ  ? ? ? A?ů ZĞĐŽǀĞƌǇ DĞĚŝƵŵ  ?E.cloni) 
were added to the cells and incubated with shaking at 80rcf for 1hr at 37q ?  ? ? ?ʅůŽĨ ĐĞůůƐ
were then plated onto agar plates containing the appropriate antibiotic (see Table 2.2) and 
incubated overnight at 37qC.  
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Table 2.2 Antibiotic requirements of cloning vectors 
 
2.11 Glycerol Stocks 
Once clones that carried the correct sequence were identified, glycerol stocks were made 
for long-term storage. 1ml of an overnight culture was added to a cryotube with 0.5ml 90% 
glycerol and mixed by inversion. Samples were stored at -80qC. 
 
2.12 PCR 
Typical reactions and cycling conditions are described in Table 2.3. Primers sequences are 
listed in Tables 2.4 and 2.5. 
 
2.13 RT-PCR 
2.13.1 Standard RT-PCR 
RNA was first treated with DNase to remove contaminating DNA (see Section 2.5) First 
strand cDNA was synthesised using either the ImProm-II reverse transcription system 
(Promega) or SuperScript III reverse transcriptase (Invitrogen). The quality of cDNA was 
ĐŚĞĐŬĞĚƵƐŝŶŐĂĐŽŶƚƌŽůWZǁŝƚŚƉƌŝŵĞƌƐĨŽƌɴ-actin (Tables 2.4 and 2.5). 
Typically, 5µl of first strand cDNA was used in a 25µl PCR reaction. For standard PCR 
conditions see Table 2.3. 
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Polymerase 
Reaction Mix Cycling Conditions 
Reagents 
Total 
Volume 
Initial 
Denaturation 
Denaturation Annealing Extension 
Number of 
Cycles 
Final 
Extension 
Pfu 
(Promega) 
Template as required 
2-3U/Pl Pfu 
1X reaction buffer 
10mM dNTP 
1PM each primer 
50Pl 95qC 
1 min 
95qC 
30 sec 
 
30 sec 
72qC 
30 sec 
30 
72qC 
5 min 
Proofstart 
(Qiagen) 
Template as required 
2.5U/Pl Proofstart 
1X reation buffer 
300PM dNTP 
1PM primer 
1X Q-Solution 
10% DMSO 
50Pl 95qC 
5 min 
94qC 
1 min 
 
1 min 
72qC 
1 min 
35 
72qC 
1 min 
LA Taq (Takara) 
Template as required 
5U/Pl LA taq 
1X reaction buffer 
2.5mM dNTP 
1PM each primer 
50Pl 94qC 
1 min 
94qC 
30 sec 
 
30 sec 
72qC 
2 min 
30 
72qC 
5 min 
Primestar 
(Takara) 
Template as required 
2.5U/Pl PrimeSTAR 
1X reaction buffer 
2.5mM dNTP 
0.3PM each primer 
50Pl  98qC 
10 sec 
 
5 sec 
72qC 
1 min 
30  
Taq 
(Abgene) 
Template as required 
5U/Pl Taq 
1X reaction buffer 
0.2mM dNTP 
0.5PM each primer 
1.5mM MgCl2 
25Pl 94qC 
1 min 
94qC 
30 sec 
 
30 sec 
72qC 
1 min 
30  
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KOD 
(Novagen) 
Template as required 
1.5U/Pl KOD 
1X reation buffer 
0.2mM dNTP 
0.4PM each primer 
50Pl 98qC 
5 min 
98qC 
20 sec 
 
30 sec 
72qC 
1 min 
35 
72qC 
5 min 
KAPA HiFi 
(GRI) 
Template as required 
1Pl KAPA HiFi 
1X reaction buffer 
0.2mM dNTP 
0.3PM each primer 
50Pl 95qC 
1 min 
98qC 
20 sec 
 
15 sec 
68qC 
30 sec 
35 
68qC 
5 min 
BioMix Red 
(Bioline) 
Template as required 
1X BioMix 
10pmol each primer 
25µl 
95qC 
2 min 
95qC 
30 sec 
30 sec 
72qC 
30 sec 
30  
Platinum Taq 
(Invitrogen) 
Template as required 
1X PCRx buffer 
0.2mM dNTP 
1.5mM MgSO4 
0.2µM each primer 
2.5U Platinum Taq 
20µl 
 
 
94qC 
30 sec 
 
 
30 sec 
 
68qC 
2.5 min 
 
35 
68qC 
7 min 
Phusion 
(NEB) 
2ng template 
1X Phusion HF buffer 
0.2mM dNTP 
0.5U Phusion enzyme 
0.5µM each primer 
25µl 
98qC 
3 min 
98qC 
15 sec 
 
30 sec 
73qC 
15 sec 
32 
72qC 
30 sec 
Table 2.3 PCR conditions 
Reagents and cycling conditions for PCRs described in this work. Annealing temperature varied with primer pair, see Table 2.4 for details. 
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Table 2.4 Primers for amplification of mouse sequences 
 
 
 
 
 
 
 
 
 
 
Primer Name Sequence Annealing Temp Product Size Reference
MPITX1F CCG GCG GAA TTC ATG GCG CAA GCG GGA GCG GA
MPITXRSfuI TCC CTA TTC GAA GTT CAC GGG TTG AGG CGC TC
mD4Z4_ATG_F2 AGT CGA TTC TCC CAA GGT GA
mD4Z4_TGA_R2 CAC AGC TCT GCA TGA AGC AT
mD4Z4_nested_F CTG TTG GTG GCA GTG GTG T
mD4Z4_nested_R CGG GTC TCT TCA GGA CTT TG
mD4Z4_TGA_F AAC TGC TGA CCG AAG TCC AA
mD4Z4_TGA_R2 CAC AGC TCT GCA TGA AGC AT
m_D4Z4_F2 GCA CTC AAG CAG ACA GCA CA
m_D4Z4_R2 GTG TCC ATT TGC TCC CAT GT
mD4Z4_F8 GCC CAC AGC TCA AGA TCA AG
mD4Z4_10 ATC AAG GAG GGG TTC CAG AG
mD4Z4_ATG_F TTT AAG GGG CAG TGG TCA CA
mD4Z4_ATG_R CCA GCT CCT TCC TCT CCT TG
mB-actin-f GAG AGG TAT CCT GAC GAA G
mbeta-actin-R ACG CGA CCA TCC TCC TCT TA
MspI1-F TCA AGG AAG GGG GTC TGA AA
MspI1-R TGT GAC CAC TGC CCC TTA AA
MspI2-F GTA GTG GGC GGG ACT ACC TG
MspI2-R AGC TCT TCC TGG AGC TGT GG
MspI3-F GGA TCC TAG GGC AAG CCT TT
MspI3-R AAG GAG GGG TTC CAG AGA GC
MspI4-F TAG AAA CCC GAG AGG CCA AA
MspI4-R GAG TCC ACT CTC CCC ATT GC
MspI5-F2 TGG ACT CCT TCC CTG GCT TA
MspI5-R2 CTG GAC ATA GCC CAG CCT TC
PgkI_F CAC GCT TCA AAA GCG CAC GTC T
PgkI_R CTT GAG GGC AGC AGT ACG GAA T
M114 ATT CTG GTT GTG CCG AGT TGC GAG
M115 CGT GGC ACT TTT GAG TTC ATC TCT C
MspI_ctrl_F2 GAA GGT TCG TGG GAG AGC
MspI_ctrl_R2 CCC TGC TCC TCA AGT TGG AC
61.9°C 556bp
Clapp et al. (2007)
59°C 1400bp
Clapp et al. (2007)
Clapp et al. (2007)
Clapp et al. (2007)
Clapp et al. (2007)
57°C 360bp
59°C 271bp
59°C 310bp
59°C 2633bp
64°C
57°C
2071bp
586bp
65.6°C 413bp
65.6°C 451bp
67.1°C 408bp
63.1°C 447bp
56.1°C 170bp
60°C 489bp
Cristina Tufarelli (personal 
communication)
64°C 503bp
55°C 972bp
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Table 2.5 Primers for amplification of human sequences 
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2.13.1.ii ImProm-II reverse transcription system 
Reaction tubeƐ ǁĞƌĞ ĐŽŽůĞĚ ŽŶ ŝĐĞ ?  ?ʅŐ EĂƐĞ-ƚƌĞĂƚĞĚ ZE ǁĂƐ ĐŽŵďŝŶĞĚ ǁŝƚŚ  ? ? ?ʅŐ
Oligo(dT)15 ƉƌŝŵĞƌ ĂŶĚ ƐƚĞƌŝůĞ ĚŝƐƚŝůůĞĚ ǁĂƚĞƌ ŝŶ Ă ĨŝŶĂů ǀŽůƵŵĞ ŽĨ  ?ʅů ? dŚĞ ƐĂŵƉůĞƐ ǁĞƌĞ
incubated at 70qC for 5 minutes and then immediately put on ice for a further 5 minutes. 
Reaction mix containing reaction buffer, 25mM MgCl2, 10mM dNTP mix, 20u RNasin and  ?ʅů
ZĞǀĞƌƐĞdƌĂŶƐĐƌŝƉƚĂƐĞŝŶĂƚŽƚĂůǀŽůƵŵĞŽĨ ? ?ʅů ?ZĞĂĐƚŝŽŶƐǁĞƌĞƚŚĞŶŝŶĐƵďĂƚĞĚĂƚ ? ?qC for 5 
minutes and then at 42qC for one hour. The reverse transcriptase was inactivated by 
incubation at 70qC for 15 minutes.  
 
2.13.1.iii Superscript III reverse transcription 
DNase treated RNA (2µg) was mixed with 0.5µg oligo(dT)15 primer and 10mM dNTP in a 
volume of 24µl. The sample was incubated at 65qC for 5 minutes and then transferred to 
55qC. During the incubation 2X First-Strand buffer, 25mM MgCl2, 0.1M DTT, 200U SuperScript 
III RT were mixed and heated to 55qC. Once both samples were at 55qC, the reactions were 
mixed and incubated at 55qC for 1 hour followed by 85qC for 5 minutes. 
 
2.13.2 OneStep RT -PCR 
OneStep RT-PCR (Qiagen) was carried out according to manufacturers instructions. 1. ?ʅŐ
DNase-ƚƌĞĂƚĞĚ ZE ǁĂƐ ƵƐĞĚ ŝŶ Ă ƌĞĂĐƚŝŽŶ ǀŽůƵŵĞ ŽĨ  ? ?ʅů ĐŽŶƚĂŝŶŝŶŐ  ?y ƌĞĂĐƚŝŽŶ ďƵĨĨĞƌ ?
 ? ? ?ƵDŽĨĞĂĐŚĚEdW ? ? ? ?ƵDƉƌŝŵĞƌ ? ?yYƐŽůƵƚŝŽŶĂŶĚ ?ʅůĞŶǌǇŵĞŵŝǆ ?^ĂŵƉůĞƐǁĞƌĞƚŚĞŶ
incubated at 50qC for 30 minutes followed by 95qC for 15min to inactivate the reverse 
transcriptase and activate the DNA polymerase. 40 cycles of: 94qC for 1 minute 
(denaturation), 59qC for 1 minute (annealing) and 72qC for 1 minute were followed by a final 
extension at 72qC for 10 minutes. For no reverse transcriptase (RT) controls, RNA was added 
at the end of the 15-minute inactivation step. Genomic DNA was added instead of RNA for a 
positive control. 
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2.14  DNA sequencing 
2.14.1 Sequencing reaction 
Sequencing reactions were carried out using Big Dye Terminator V3.1 at a 1/12 dilution, 
with 200ng DNA, 1X sequencing buffer and 2pmol/µl primer in a total volume of 5µl. 
Sequencing primers are shown in Table 2.8. The reaction was then incubated at 95qC for 5 
minutes, followed by 45 cycles of 95qC for 30 seconds, 50qC for 20 seconds and 60qC for 4 
minutes.  
 
2.14.2 Precipitation in individual tubes 
dŚĞ ǀŽůƵŵĞ ǁĂƐ ĂĚũƵƐƚĞĚ ƚŽ  ? ? ?ʅů ǁŝƚŚ ƐƚĞƌŝůĞ ĚŝƐƚŝůůĞĚ ǁĂƚĞƌ ĂŶĚ 1 ʅů of 10mg/ml 
glycogen, 1/10
th
 volume 3M NaAc and 2 volumes 100% ethanol were added. The reactions 
were then stored at -20qC for 20 minutes. The samples were centrifuged at 16100rcf for 10 
minutes, washed with 70% ethanol and then centrifuged at 16100rcf for 5 minutes. Pellets 
were left to air dry and then analysed by the Geneservice DNA sequencing facility in 
Nottingham. 
 
2.14.3 Purification of DNA sequencing products in microtitre plates 
 When sequencing reactions were performed in 96-well plates, the CleanSEQ system was 
used for purification. The CleanSEQ was shaken to resuspend the magnetic particles and 10µl 
was added to each sample and mixed with 42µl of 85% ethanol by pipetting. The reaction 
plate was left on the magnet for 3 minutes to separate the beads from the solution, the 
supernatant was discarded and the beads washed twice with 100µl of 85% ethanol. The plate 
was then allowed to air dry for 10 minutes. The reactions were analysed by the Durham 
Sequencing Service (DBS). Primers used for sequencing are shown in Table 2.8. 
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Table 2.6 Primers used for sequencing 
 
 
2.15 Computer analysis of DNA sequences 
2.15.1 BLAST 
BLAST analysis was carried out using the web interface at NCBI 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). Sequences were copied and pasted into the input 
window and generally, all options were left at the default settings. 
 
2.15.2 Sequencher 
Detailed sequence analysis was carried out using the Sequencher program version 4.10.1 
(GeneCodes, USA). 
 
2.16 Protein analysis 
2.16.1 Protein extraction from mammalian cells 
Protein extraction was carried out on ice. Media was removed from the culture flasks and 
the cells were washed with ice cold PBS. Cells were scraped off the flask into fresh PBS, 
transferred to eppendorf tubes and centrifuged at 720rcf for 3 minutes. The cell pellet was 
resuspended in 100µl RIPA buffer per 75cm3 flask and incubated for 30 minutes on ice. After 
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incubation, cells were centrifuged at 16100rcf for 10 minutes at 4qC. The supernatant was 
transferred to a new tube and stored at -80qC. 
 
2.16.2 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
(SDS-PAGE) 
Polyacrylamide 10% gels (1.5mm thick) were cast using Mini-PROTEAN 3 casting frame 
and stand (Biorad). Resolving gels were made up with 1X lower buffer and polymerised with 
0.05% ammonium persulphate (APS) and 0.13% TEMED. Stacking gels were made up with 1x 
upper buffer and were polymerised with 0.03% APS and 0.05% TEMED.  
Protein samples were mixed with 1X DTT and 4µl of loading buffer in a final volume of 
20µl and heated to 80qC for 5 minutes prior to loading into the wells. Electrophoresis was 
performed in 1X running buffer at 100V until the protein had migrated. Commercially 
available protein markers were used as size standards (section x). 
 
2.16.3 Western blotting 
Hybond-P membrane was activated by soaking in methanol and then soaked in 1X transfer 
buffer along with gels from SDS-PAGE for equilibration. Transfer was carried out in 1X transfer 
buffer in a mini transfer cell at 100V for 1 hour at room temperature. The membrane was 
then used in immunodetection (Section 2.17.4). 
 
2.16.4 Immuno-detection 
The membrane was blocked overnight at 4qC with 5% Marvel in 0.05% PBST. The primary 
antibody (9A12) was diluted 1/1000 in 2% marvel in 0.05% PBST, poured over the membrane 
and incubated at room temperature for 3 hours. The membrane was then washed with PBST 
three times for 15 minutes each wash. The secondary antibody (HRP-conjugated goat anti-
mouse IgG) was diluted 1/5000 and incubated on the membrane for 1 hour before repeating 
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the three washes. Enhanced chemiluminescence (ECL) detection was carried out using the 
ECL-Plus kit (Amersham Biosciences) according to manufacturers instructions. The membrane 
was exposed to X-ray film for 5 minutes and the film developed using an SRX-201 developer 
(Konica Minolta). 
 
2.17 Materials 
2.17.1 General reagents 
All standard laboratory reagents that are not otherwise stated below were from Sigma. 
Glycogen was from Roche. TRIzol was from Gibco. 
 
2.17.2 Kits 
Spin miniprep kits used in purifying DNA and PCR products were from Sigma. The ImProm 
Reverse Transcription kit and the Poly(A)+tract mRNA isolation kit were from Promega. The 
OneStep PCR kit was from Qiagen. The TURBO DNA-free kit was from Ambion. The BigDye 
Terminator sequencing kit was from Perkin Elmer Applied Biosystems. The ECL-Plus kit was 
from Amersham biosciences. The CleanSEQ clen up system was supplied by Agencourt 
Bioscience Corporation.  
 
2.17.3 Bacterial Reagents 
MacConkey agar, tryptone and yeast extract were from Difco Laboratories. All other 
bacteriological agents were purchased from BDH. Antibiotics were from sigma. 
 
2.17.4 Enzymes and sequencing 
Restriction enzymes and buffers are shown in Table 2.8. DNA polymerases and buffers are 
shown in Table 2.3. Rnase A was from sigma. PNK and CIP were from NEB. 
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Table 2.7 Restriction Enzymes 
 
 
2.17.5 Nucleic Acids and Protein Standards 
DNA markers were from Bioline (Hyperladders I and IV). Oligonucleotides were designed 
using Primer3 software (http://frodo.wi.mit.edu/primer3/) and ordered from Sigma or 
Invitrogen. The Precision Plus protein marker was from Biorad. dNTPs were purchased from 
Bioline. 
 
2.17.6 Competent bacterial cells and vectors 
E. coli DH5ɲ cells were purchased from Invitrogen. The pGEM-T Easy Vector System was 
from Promega. pcDNA vectors from Invitrogen. The Clone Smart Blunt Cloning Kit was 
produced by Lucigen. 
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2.17.7 Cell culture 
Media, trypsin EDTS, penicillin/streptomycin solution, L-Glutamine, PBS and Fetal Bovine 
Serum (FBS) were purchased from Lonza. bFGF was from Invitrogen. Dimethyl sulphoxide 
(DMSO), Dexamethasone, proteasome inhibitor and Poly-L-Lysine were from Sigma. 
 
2.17.8 Electrophoresis, transfer membrane and film 
Molecular grade agarose was purchased from Geneflow. Type VII low gelling agarose and 
ethidium bromide were from Sigma. Hybond-P membrane was from Amersham Biosciences. 
Formaldehyde loading buffer was from Ambion and X-ray film was from Kodak. 
 
2.17.9 Solutions 
2.17.9.i General Solutions 
DNA Buffer  0.2M Tris-HCL (pH8.0), 0.1M EDTA 
0.5X TBE  45mM Tris-borate, 1mM EDTA 
1X MOPS 10mM EDTA, 0.2M MOPS, 50mM NaAc, 100mM NaOH 
1X RIPA Buffer  150mM NaCl, 40mM Tris, 5mM EDTA, 1% NP40, 1% deoxycholate, 
0.1% SDS 
1X TAE   40mM Tris-acetate, 1mM EDTA 
10X PBS 135mM NaCl, 2.5mM KCL, 10mM Na2HPO4, 1.8mM KH2PO4 pH7.4 
20X SSC   3M NaCl, 0.3M trisodium citrate 
TE   10mM Tris, 2mM EDTA 
2.17.9.ii Miniprep solutions 
Solution 1 50mM glucose, 25mM Tris-HCL pH8, 10mM EDTA pH8 
Solution 2  0.2M NaOH, 1% SDS 
Solution 3  5M KOAc 
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2.17.9.iii SDS-PAGE and Western Blotting 
Running Buffer  25mM Tris, 2M glycine, 1% SDS 
Resolving Buffer  0.1% SDS, 375mM Tris 
Stacking Buffer  0.1% SDS, 250mM Tris 
Transfer Buffer  25mM Tris, 2M glycine, 20% methanol 
PBST   1X PBS, 0.1% Tween-20 
Block Solution  5% Marvel in PBST 
 
2.17.10 Media 
2.17.10.i Cell Culture 
Media and supplements used for cell culture are listed in Table 2.9. 
Freeze media   5% DMSO in complete media (see Table 2.9) 
Myoblast freeze media  10% DMSO in FBS 
Differentiation Media 1 DMEM without L-Glutamine and sodium pyruvate, 2% 
Horse Serum, 2mM L-Glutamine, 100U/ml of 
penicillin/streptomycin solution 
Differentiation Media 2 DMEM without L-Glutamine and sodium pyruvate, 15% 
Horse Serum, 2mM L-Glutamine, 100U/ml of 
penicillin/streptomycin solution 
 
2.17.10.ii Bacteriological 
LB (per litre)   10g tryptone, 5g yeast extract, 10gNaCl 
MacConkey (per litre)  50g MacConkey agar 
SOC (per litre) 20g tryptone, 5g yeast extract, 0.59g NaCl, 1.86g KCl, 
10mM MgSo4, 10mM MgCl2, 20mM glucose  
YT (per litre)   16g tryptone, 10g yeast extract, 5g NaCl 
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Table 2.8 Growth media requirements for cell lines 
 
  
Cell Line Growth Media Supplements
10% fet al bov ine serum
120U/ ml penic illin
120µg/ ml st rept omyc in
4mM L- Glut amine
10% fet al bov ine serum
120U/ ml penic illin
120µg/ ml st rept omyc in
4mM L- Glut amine
10% fet al bov ine serum
120U/ ml penic illin
120µg/ ml st rept omyc in
4mM L- Glut amine
10% fet al bov ine serum
120U/ ml penic illin
120µg/ ml st rept omyc in
4mM L- Glut amine
10mM Hepes
20% fet al bov ine serum
120U/ ml penic illin
120µg/ ml st rept omyc in
10ng/ ml bFGF
1µM Dexamet hasone
10% fet al bov ine serum
120U/ ml penic illin
120µg/ ml st rept omyc in
4mM L- Glut amine
10% fet al bov ine serum
120U/ ml penic illin
120µg/ ml st rept omyc in
4mM L- Glut amine
hEC
GCT27
DMEM with 4.5g/L Glucose
DMEM with 4.5g/L Glucose
DMEM with 4.5g/L Glucose
RPMI 1640
Hams F-10 with L-Glutamine
DMEM with 4.5g/L Glucose
DMEM with 4.5g/L Glucose
C2C12
TE671
RD
RMS13
Myoblasts
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Chapter 3. Does DUX4 regulate PITX1? 
3.1 Introduction and aims 
The use of immortalised cell lines in the study of human diseases is widespread. These 
uniform populations of proliferative cells are easy to manipulate and tend to have accelerated 
growth rates and a reduction in growth requirements in comparison with primary tissues. The 
cell lines allow investigation of the function of the cells and the factors affecting growth rate 
and differentiation. They can be used to observe the cellular effects of gene manipulation or 
of expressing a protein of interest. While primary cell lines have a limited lifespan, in disease 
research they crucially allow a comparison of disease and control cells. 
In addition to myoblast lines (see chapter four), a number of other commonly used cell 
lines have been utilised in FSHD research. Transfection of D4Z4 constructs into the mouse 
myoblast cell line C2C12 was used to show the localisation of the DUX4 protein to the nucleus 
(Ostlund et al., 2005), investigate proposed promoter or enhancer regions (Kawamura-Saito 
et al., 2006; Petrov et al., 2008), and to observe the effect of D4Z4 copy number on 
expression of reporter genes (Yip and Picketts, 2003; Ottaviani et al., 2009). Cells ectopically 
expressing high levels of DUX4 display characteristic markers of apoptosis (Gabriels et al., 
1999; Kowaljow et al., 2007; Wallace et al., 2011). As most overexpression studies used 
C2C12 or the human rhabdomyosarcoma TE671 cell lines, these were adopted for most of the 
work described in this chapter. 
In 2007, based on microarray experiments, Dixit et al. reported that the paired-like 
homeodomain transcription factor 1 (PITX1) is specifically upregulated in the muscles of 
patients with FSHD and proposed that DUX4 was an upstream regulator of this gene (Dixit et 
al., 2007). Pitx1 is expressed predominantly in the developing hindlimb in mice (GibsonBrown 
et al., 1996; Lanctot et al., 1997; DeLaurier et al., 2006) and has been shown to have a role in 
limb patterning and growth in both the chick (Logan and Tabin, 1999) and mouse (DeLaurier 
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et al., 2006). In one family, a PITX1 mutation has been shown to segregate with clubfoot over 
three generations (Gurnett et al., 2008) and 9% of Pitx1
+/-
 mice show a clubfoot-like 
phenotype (Alvarado et al., 2011). Misexpression of Pitx1 in the developing chick wing bud 
changes the morphology such that it resembles a leg (Logan and Tabin, 1999), whilst 
misexpression of Pitx1 in the mouse causes the forelimb to assume some structures 
characteristic of the hindlimb (DeLaurier et al., 2006). Loss of Pitx1 expression in the mouse 
causes the hindlimb to assume the morphology of the forelimb (Lanctot et al., 1999). 
Alterations in the pattern of Pitx1 expression have been proposed to underlie the 
evolutionary adaptation of vertebrate hindlimb structures (Shapiro et al., 2004; Shapiro et al., 
2006).  
By sequence analysis, Dixit et al. identified a potential DUX4 binding site in the promoter 
region of PITX1 and cloned a 369bp fragment containing this site into a luciferase reporter 
construct. Co-transfection of C2C12 cells with the reporter construct and a DUX4 expression 
vector resulted in a 7.4 fold increase in luciferase activity after 24 hours. A mutation of the 
TAAT sequence in the putative DUX4 binding site reduced the induction of luciferase activity 
4-fold. Electrophoretic mobility shift assays (EMSA) of nuclear extracts from the transfected 
C2C12 cells showed a supershift on incubation with an anti-DUX4 antibody (9A12). However, 
no chromatin immunoprecipitation (ChIP) experiments were performed, so the in vivo binding 
of DUX4 to the PITX1 promoter has not been validated. 
Expression of PITX1 was observed by co-immunofluorescence staining in C2C12 cells 
transiently transfected with constructs encoding DUX4. DUX4 was detected using the 9A12 
antibody, and PITX1 was detected with a rabbit serum raised against a Pitx1 specific peptide. 
Both DUX4 and PITX1 proteins were detected in the same nuclei after 24 hours, however, 
expression was not confirmed by RT-PCR or western blotting.  
This publication therefore identified PITX1 as a possible target for DUX4 and the discovery 
provided an avenue to study its targets and in particular, to establish whether the mouse Dux 
protein has the same function as the human DUX4.  The aims of this part of the study were to 
confirm the finding that overexpression of DUX4 results in activation of the endogenous PITX1 
gene and to investigate whether the mouse Dux gene can also induce PITX1.  
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3.2 Results 
3.2.1 Establishing conditions for the efficient transfection of DUX4 
In initial transfection experiments, C2C12 and TE671 cells grown on coverslips were 
transfected with DUX4 constructs made previously in this laboratory (Figures 2.1 and 2.2) 
using Effectene. Immunocytochemistry was performed using anti-V5 antibodies and the 
transfection efficiency was found to be only 1-2% per coverslip. To try and improve 
transfection of the cell lines a number of different reagents were trialled.  
Firstly, different seeding densities were tested so that the culture would be 50-80% 
confluent at the start of the transfection and near to confluency by the end. In case the 
miniprep reagents were affecting the transfection efficiency, constructs were purified with 
either the Sigma or the Qiagen kits (with and without lyse blue) and transfection efficiencies 
compared using Effectene. For this set of experiments, D4Z4-GFP constructs (Figures 2.3 and 
2.4 and Table 3.2) that had been used by previous members of the group and found to 
transfect efficiently were used. In addition, the use of the GFP tag meant that transfection 
efficiency could be analysed without the need for immunocytochemistry. Four different 
reagents were trialled and cells were incubated for 24 or 48 hours. Transfection efficiency 
was calculated by number of cells expressing GFP/total number of nuclei. For each coverslip, 
cell counts were taken from five separate fields with a good spread of nuclei, the average 
transfection efficiency is shown in Table 3.2. Although the FuGene reagent gave excellent 
results for the TE671 cells, Effectene gave consistently good transfection efficiencies for both 
cell lines and was used for subsequent transfections. DNA that had been purified using the 
Sigma columns gave the best results and this kit was used for all subsequent high-purity 
minipreps. 
Typically, a reduced transfection efficiency of 5-25% was seen when the cell lines were 
transfected with FlmD4Z4 V5 or FlhD4Z4 V5 (Table 3.1) and stained with anti-V5 antibodies 
(Figure 3.1). C2C12 cells had transfection efficiencies at the lower end of the range while 
TE671 cells typically had a higher number of nuclei showing expression. 
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Construct Name Vector Insert 
GFP NtermD4Z4 pEGFP C3 Mouse Dux N-terminal region (homeodomains) 
FlmD4Z4 GFP pEGFP N1 Full length mouse Dux ORF 
FlhD4Z4 V5 pcDNA 3.1 B Full length human DUX4 ORF 
FlmD4Z4 V5 pcDNA 3.1 A Full length mouse Dux ORF 
 
 
Table 3.1 Expression constructs used in this chapter 
Constructs were created in Jane Hewitts laboratory by Jannine Clapp and are shown 
schematically in Figures 2.1 to 2.4.  
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Table 3.2. Transfection efficiency of C2C12 and TE671 cells using different 
transfection reagents. 
Transfection efficiency was calculated by number of cells expressing GFP/total number of 
nuclei. For each coverslip, cell counts were taken from five separate fields with a good spread 
of nuclei. The table shows an average of the five fields. 
Cell 
Type 
Reagent Details Time Efficiency 
C2C12 
Effectene GFP NtermD4Z4 24h 25% 
Effectene pEGFP-N1 purified with Qiagen kit 24h 15% 
Effectene pEGFP-N1 purified with Sigma kit 24h 25% 
Effectene pEGFP-N1 purified with Qiagen kit without lyse blue 24h 20% 
FuGene FlmD4Z4 GFP (3:2 ratio of FuGene:DNA) 24h 0% 
FuGene FlmD4Z4 GFP (5:2 ratio of FuGene:DNA) 24h 0% 
FuGene FlmD4Z4 GFP (7:2 ratio of FuGene:DNA) 24h 0% 
GeneJuice GFP NtermD4Z4 24h 2% 
Transpass FlmD4Z4 GFP (10µl Transpass) 24h 10% 
Transpass FlmD4Z4 GFP (12µl Transpass) 24h 45% 
Transpass FlmD4Z4 GFP (10µl Transpass) 48h 0% 
FuGene FlmD4Z4 GFP (5:2 ratio of FuGene:DNA) 48h 0% 
GeneJuice GFP NtermD4Z4 48h 5% 
Effectene GFP NtermD4Z4 48h 10% 
TE671 
Effectene GFP NtermD4Z4 24h 45% 
Effectene pEGFP-N1 purified with Qiagen kit 24h 40% 
Effectene pEGFP-N1 purified with Sigma kit 24h 50% 
Effectene pEGFP-N1 purified with Qiagen kit without lyse blue 24h 45% 
FuGene FlmD4Z4 GFP (3:2 ratio of FuGene:DNA) 24h 0% 
FuGene FlmD4Z4 GFP (5:2 ratio of FuGene:DNA) 24h 0% 
FuGene FlmD4Z4 GFP (7:2 ratio of FuGene:DNA) 24h 70% 
GeneJuice GFP NtermD4Z4 24h 45% 
GeneJuice GFP NtermD4Z4 48h 55% 
FuGene FlmD4Z4 GFP (5:2 ratio of FuGene:DNA) 48h 2% 
Effectene GFP NtermD4Z4 48h 25% 
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Figure 3.1 Expression of D4Z4 constructs 
Expression of full length mD4Z4 in C2C12 cells (a) and hD4Z4 in TE671 cells (b). Transfections were carried out with Effectene reagent and immunocytochemistry performed 
after 24 hours. Nuclei are stained with DAPI. Expression of D4Z4 constructs was detected with an antibody to the V5 tag (see antibody table) and is shown in green. 
DAPI V5 DAPI and V5 
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3.2.2 Does DUX4 regulate PITX1 expression?  
To confirm the finding that overexpression of DUX4 results in activation of the 
endogenous PITX1 gene, cell lines were transiently transfected with constructs encoding 
DUX4 and the expression of PITX1 was then examined by immunostaining. In order to 
establish whether the mouse Dux protein has the same function, similar experiments were 
performed using expression constructs for mouse Dux.  
 
3.2.2.i Generation of PITX1 expression constructs 
Before testing whether DUX4 overexpression induces PITX1, PITX1 expression constructs 
were generated to confirm the specificity and sensitivity of a PITX1 antibody obtained from Dr 
Yi-Wen Chen, (Childrens Hospital, Boston USA). Constructs encoding V5-tagged human DUX4 
and mouse Dux proteins had been generated previously (Clapp et al., 2007). The myc epitope 
was chosen to tag PITX1 so that co-expression of both proteins could be visualised by 
immunocytochemistry.  
In order to produce a myc tagged expression vector, a myc tag was engineered into 
pcDNA3.1. The myc epitope was first amplified by creating primer dimers with primers 
mycSfuF and MycAgeR (Figure 3.2a), which were engineered to contain SfuI and AgeI 
restriction sites respectively. After digestion with SfuI and AgeI, this myc tag was then cloned 
in-frame into the vectors pcDNA3.1/V5 His A, B and C, replacing their V5 tags (Figure 3.2b). 
Primers for mouse and human PITX1 were engineered to contain restriction sites for EcoRI 
and SfuI (Tables 2.4 and 2.5). The coding region for mouse Pitx1 was amplified by RT-PCR from 
Swiss Webster mouse midterm embryo RNA with primers MPITX1F and MPITX1RSfuI, using 
the Improm reverse-transcription kit and KOD polymerase. The human PITX1 coding region 
was similarly amplified from testis RNA, although Primestar polymerase was used instead of 
KOD. The RT-PCR products were gel purified, digested with EcoRI and SfuI, and cloned into the 
myc tagged vector pcDNA3.1/myc HisA. 
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The mouse PITX1 sequence contains an interrupted polyA tract (A2GA3GA9GA12GA) 
between position 743 and 786; the majority of the clones (9 of the 11) were found to contain 
deletions within this tract. However, two clones contained the correct sequence and one of 
these (pcDNA3.1/mPITX1) was used in subsequent experiments. 
Despite using a proofreading polymerase, 5 of the 7 human clones had a number of 
consistent changes (86 nucleotide positions in 947bp) compared to the reference sequence in 
GenBank (NM_002653.4), it is possible that these represent amplification of a pseudogene. 
No identical matches to this sequence were found in the human genome using BLASTN so 
these variant clones are likely to come from an unsequenced part of the genome. However, 
two of the human PITX1 clones conformed to the GenBank sequence (NM_002653.4) apart 
from a G-C substitution at position 896, changing an glycine to an alanine (Figure 3.3a). A 
BLASTN search using the PITX1 reference sequence against the human EST trace archives 
identified other sequences with the same base change, suggesting that it is likely to be a 
polymorphism (Figure 3.3b). One of these clones (pcDNA3.1/hPITX1) was used in subsequent 
experiments. 
Diagrams of both the mouse and human PITX1 constructs are shown in Figure 3.4. 
 83 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 Engineering a Myc tagged expression vector 
a) A screen shot of the Sequencher alignment of the mycSfuF and mycAgeR primers used to produce the 57bp Myc insert. The amino acid sequence is shown in the bottom 
frame and the box indicates the sequence of the Myc epitope. The SfuI site is boxed in red and the AgeI site is boxed in green. b) Map of the pcDNA3.1/myc His construct. 
Myc and His epitopes are shown in grey. The positions of the restriction sites used for removing the V5 tag and replacing it with the Myc insert are shown in red. Selective 
markers, promoters and tags are identified. 
a. b. 
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Figure 3.3 Human PITX1 sequence variants 
a) A screenshot of the Sequencher alignment of the two correct hPITX1 sequences with the Genbank sequence NM_002653.4. The Sequencher programme indicates base 
ambiguities with a black dot underneath the alignment. The amino acid sequence is shown in the bottom frame. The position of the G-C base variation is highlighted at 
position 896. b) Alignment of NM_002653.4 with ESTs from the trace archives to show additional sequences with the G-C base change (highlighted).  
 
a. 
b. 
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Figure 3.4 Human (a) and mouse (b) PITX1 myc constructs.  
Map of the pcDNA3.1/myc HisA construct, engineered to contain human (a) or mouse (b) PITX1 coding sequences. Myc and His epitopes are shown in grey. PITX1 inserts 
are highlighted in pink. The positions of the restriction enzymes EcoRI and SfuI used for cloning are indicated in red. Selective markers, promoters and tags are identified. 
a. b. 
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3.2.2.ii  Validation of the PITX1 antibody 
The PITX1.N2 polyclonal antibody (which apparently cross-hybridises to the mouse Pitx1 
protein, Y-W Chen, personal communication) was raised against the N-terminal region of the 
human PITX1 sequence. Alignment of the mouse and human PITX1 peptides is shown in 
Figure 3.5. The two proteins are highly conserved with 96% amino acid identity. The antibody 
has been previously described to identify endogenous PITX1 in C2C12 cells (Dixit et al., 2007). 
To validate the antibody, C2C12 myoblast or TE671 rhabdomyosarcoma cells were 
transfected with the PITX1 constructs, and then immunocytochemistry was performed after 
24 hours. 
Dixit et al (2007) identified a PEST motif in PITX1. This motif is known to target proteins 
for degradation so they performed their transfection experiments in the presence of a 
proteosome inhibitor because if PITX1 is being degraded rapidly in C2C12 or TE671 cells 
expression may not be seen (Dixit et al., 2007). Therefore, in the experiments described here, 
24h after transfection the synthetic proteosome inhibitor, Z-Leu-Leu-Leu-al, was added to 
some of the transfections at a concentration of 500µg/ml. The cells were incubated for a 
further 5 hours before immunocytochemistry was performed.  
Following transfection with hPITX1 constructs, hPITX1 expression could be seen in 1% 
cells using the anti-myc antibody after 48h, no expression could be seen after 24h. After 
addition of Z-Leu-Leu-Leu-al, a similar proportion of transfected cells could be seen after 24h. 
Co-staining with the anti-PITX1 polyclonal antibody and a monoclonal antibody against myc 
confirmed that the PITX1.N2 antibody is able to detect the human PITX1 protein (Figure 3.6). 
Following transfection of the mPitx1 construct, the protein ǁĂƐŝĚĞŶƚŝĨŝĞĚ ŝŶAM ?A?of cells 
with the anti-myc antibody (Figure 3.6b). However, no positive nuclei were ever seen using 
the PITX1.N2 antibody. This suggests that, in contrast to the information supplied, PITX1.N2 
does not cross react with mouse Pitx1, at least in immunocytochemistry. Therefore, it was not 
possible to investigate the effect expression of mouse Dux has on the endogenous mouse 
Pitx1 gene. However, it was possible to test whether the mDux gene could activate PITX1 
expression in human cells. 
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Figure 3.5 Alignment of human and mouse PITX1 amino acid sequences 
Identical amino acids are highlighted with an asterisk. Within the first 82 amino acids there 
are 10 differences between the two sequences, : indicate conserved substitutions, and . 
indicate semi-conserved substitutions. There is a single base pair insertion/deletion at 
position 80. The peptides are identical from position 83 onwards. 
 
 
 
 
Human MDAFKGGMSLERLPEGLRPPPPPPHDMGPAFHLARPADPREPLENSASESSDTELPEKER 60  
Mouse MDAFKGGMSLERLPEGLRPPPPPPHDMGPSFHLARAADPREPLENSASESSDADLPDKER 60                                           
----  *****************************:*****.****************::**:***   
 
Human  GGEPKGPEDSGAGGTGCGG-ADDPAKKKKQRRQRTHFTSQQLQELEATFQRNRYPDMSMR 119  
Mouse  GGEAKGPEDGGAGSAGCGGGAEDPAKKKKQRRQRTHFTSQQLQELEATFQRNRYPDMSMR 120                 
------ ***.*****.***.:**** *:**************************************   
 
Human  EEIAVWTNLTEPRVRVWFKNRRAKWRKRERNQQLDLCKGGYVPQFSGLVQPYEDVYAAGY 179  
Mouse  EEIAVWTNLTEPRVRVWFKNRRAKWRKRERNQQLDLCKGGYVPQFSGLVQPYEDVYAAGY 180                 
------ ************************************************************   
 
Human  SYNNWAAKSLAPAPLSTKSFTFFNSMSPLSSQSMFSAPSSISSMTMPSSMGPGAVPGMPN 239  
Mouse  SYNNWAAKSLAPAPLSTKSFTFFNSMSPLSSQSMFSAPSSISSMTMPSSMGPGAVPGMPN 240                 
------ ************************************************************   
 
Human  SGLNNINNLTGSSLNSAMSPGACPYGTPASPYSVYRDTCNSSLASLRLKSKQHSSFGYGG 299  
Mouse  SGLNNINNLTGSSLNSAMSPGACPYGTPASPYSVYRDTCNSSLASLRLKSKQHSSFGYGG 300                           
------ ************************************************************   
 
Human  LQGPASGLNACQYNS 314  
Mouse  LQGPASGLNACQYNS 315  
------*************** 
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3.2.2.iii Does transfection with DUX4 constructs upregulate PITX1 
expression? 
While transfection with the human PITX1 construct was successful at the first attempt, 
transfection with the mouse PITX1 construct was initially unsuccessful. As such, co-
immunofluorescence staining for PITX1 and DUX4 was initially performed on both C2C12 and 
TE671 cell lines after transfection with the FlmD4Z4 V5 (containing the full mouse Dux ORF) or 
FlhD4Z4 V5 (containing the full human DUX4 ORF) constructs (Figures 2.1 and 2.2). Twenty-
four hours after transfection the synthetic proteosome inhibitor, Z-Leu-Leu-Leu-al, was added 
to the transfections. The cells were incubated for a further 5 hours before 
immunocytochemistry was performed.  Once it was established that the PITX.N1 antibody did 
not detect the mouse PITX1 protein, co immunofluorescence experiments were restricted to 
TE671 cells.  
Expression of the DUX constructs (FlmD4Z4 V5 and FlhD4Z4 V5) was seen in 
approximately 5% C2C12 myoblast cells and 25% TE671 cells (Figure 3.1). Co-
immunofluorescence staining for PITX1 and hDUX4 was performed four times using TE671 
cells and once in C2C12 cells. Cells transfected with the human PITX1 construct were used as 
a positive control for the PITX1.N2 antibody. Co-immunofluorescence staining for PITX1 and 
mDUX4 was performed three times using C2C12 cells and twice with TE671 cells. However, no 
expression of PITX1 was identified (Figure 3.7).  
Thus, these experiments did not support the previous study by Dixit et al. proposing 
that overexpression of DUX4 results in expression of endogenous PITX1. In addition, no 
evidence that the PITX1.N1 antibody recognises the mouse protein was seen. Therefore, it 
was decided not to pursue this part of the project further. 
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Figure 3.6 Validation of the PITX1 antibody 
C2C12 cells 24h after transfection with a) Human PITX1 constructs and b) mouse PITX1 constructs. Cells were incubated for 5h with 500µg/ml proteasome inhibitor before 
analysis. Immunocytochemistry was performed with anti-PITX1 at a 1:1000 dilution (red) and anti-Myc at a 1:800 dilution (green) followed by appropriate secondary 
antibodies (see Table 2.1). Nuclei are stained with DAPI (blue). 
DAPI anti-PITX1 anti-Myc DAPI, anti-PITX1 and anti-Myc 
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Figure 3.7 Expression of human or mouse DUX4 did not induce PITX1 expression 
TE671 cell 24h after transfection with a) FlhD4Z4 V5 and b) FlmD4Z4. Cells were incubated for 5h with 500µg/ml proteasome inhibitor before analysis. 
Immunocytochemistry was performed with anti-PITX1 at a 1:1000 dilution (red) and anti-V5 at a 1:200 dilution (green) followed by appropriate secondary antibodies (see 
Table 2.1). Nuclei are stained with DAPI (blue). 
 
DAPI anti-V5 anti-PITX1 DAPI, anti-V5 and anti-PITX1 
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3.3 Discussion 
In 2007 Dixit et al. reported that PITX1 is specifically upregulated in the muscle of FSHD 
patients and proposed that DUX4 was an upstream regulator of this gene (Dixit, et al., 2007). 
In order to confirm this observation, and to see whether it held true for the mouse Dux gene, 
C2C12 and TE671 cells were transfected with the mD4Z4 or hD4Z4 constructs and the 
expression of PITX1 detected by immunocytochemistry. 
Initially the PITX1 antibody obtained from Dr Yi-Wen Chen was tested on PITX1 expression 
vectors. The antibody was able to detect human PITX1 protein but not the mouse. In 
agreement with Dixit et al., PITX1 expression could be detected earlier if a proteasome 
inhibitor was used.  
The data suggesting that the PITX1 antibody did not identify the mouse PITX1 protein was 
unexpected, as it had previously been described to identify endogenous PITX1 in C2C12 cells 
(Dixit et al., 2007). The peptide sequences of the two PITX1 proteins show 96% identity, 
however there are 10 variant positions. If a peptide including variant amino acids was used to 
raise the antibody, it is possible the antibody would not recognise both the human and mouse 
proteins. Dixit et al. did not provide any information about how they tested the antibody on 
the mouse PITX1 protein, more information on the antibody would be required before any 
further experiments were performed. 
In co-immunofluorescence experiments, no PITX1 expression could be identified after 
transfection with mD4Z4 or hD4Z4 vectors. Despite the relatively high proportion of cells 
transfected with DUX4 (25% in TE671 cells), no PITX1 expression was identified in cells 
transfected with DUX4. This is in contrast to data published by Dixit et al. (2007) whose DUX4 
construct activated expression of the endogenous PITX1 in C2C12 cells. The difference 
between these data may be as a result of variation in levels of expression of DUX4 between 
the two studies, in order to compare expression levels, quantitative studies would need to be 
performed.  
It was not possible to make any conclusions about the effect expression of the mouse Dux 
gene has on endogenous mouse PITX1, as the PITX1 antibody supplied by Dr Yi-Wen Chen was 
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not shown to bind to the protein produced from the mouse PITX1 expression vector. Despite 
endogenous PITX1 being identified from C2C12 cells by Dixit and colleagues, no endogenous 
PITX1 expression was identified in this study so this line of work was no longer pursued. 
In support of the data provided in this chapter, Bosnakovski et al. used an inducible 
cassette exchange in C2C12 cells to express DUX4 and studied the effect on gene expression. 
Despite identifying 1011 differentially expressed genes, no changes in PITX1 expression were 
seen. In addition, Tsumagari et al. have recently used exon-based microarrays to determine 
the expression profiles of myoblasts and myotubes derived from FSHD patients and control 
individuals. Differential expression of 295 genes in FSHD myoblasts and 797 genes in FSHD 
myotubes was determined compared with control cells, however no change in PITX1 
expression was observed (Tsumagari et al., 2011). 
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Chapter 4. Analysis of human DUX4 
expression 
4.1 Introduction 
The FSHD phenotype is mostly restricted to the skeletal muscle, although some non-
muscle tissues are involved in a subset of patients (Section 1.1). Muscle cells are therefore an 
obvious choice for study when looking for differences between FSHD patients and control 
individuals. The isolation of myoblasts from muscle biopsies is well established, however, this 
results in a heterogeneous mixture of myoblast and fibroblast cells. These contaminating 
fibroblasts may have an influence on the behaviour of the myoblasts so the proportion of 
each should be determined before studies can be accurately compared. The reported 
appearance of cells derived from muscle biopsies of FSHD patients varies between different 
studies. Winoker et al. (2003a) observed FSHD cells with swollen cytoplasm and large 
vacuoles and a higher percentage of necrotic cells than in control muscle samples. However, 
other groups found no morphological differences in FSHD myoblasts compared with controls 
and observed no necrotic cells (Morosetti et al., 2007; Barro et al., 2010). This variation in 
phenotype between FSHD samples suggests that there is likely to also be natural variation in 
expression levels of genes. Some variation in expression levels of genes between different 
muscle types has also been observed (Winokur et al., 2003b; Dixit et al., 2007; Ansseau et al., 
2009). Thus, the origin of the samples must also be taken into account when comparing 
studies using different patient cohorts. 
 In FSHD studies, myoblast cell lines from patients and controls have been used to search 
for differences in expression levels of genes between affected and unaffected individuals 
(Rijkers et al., 2004; Alexiadis et al., 2007; Ansseau et al., 2009; Bodega et al., 2009; Masny et 
al., 2010), and also between affected and unaffected tissues in an individual patient (Winokur 
et al., 2003b; Laoudj-Chenivesse et al., 2005; Dixit et al., 2007; Ansseau et al., 2009). The 
differentiation of myoblasts into myotubes is well understood and this has enabled 
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observation of differences in how the cells behave upon differentiation into myotubes (Rijkers 
et al., 2004; Bodega et al., 2009; Masny et al., 2010). In order to investigate the expression of 
DUX4 in FSHD, myoblast cell lines from three patients were used in this study. 
At the start of the work described in this chapter transcription from the D4Z4 array in 
FSHD myoblast cell cultures had been published by two groups (Dixit et al., 2007; Kowaljow et 
al., 2007) and previous work in this laboratory by Dr Jannine Clapp had showed by RT-PCR 
that DUX4 is transcribed  in human testis and fetal skeletal muscle (Figure 4.1a). 
 Using RT-PCR, Kowaljow et al. (2007) amplified a 1477bp fragment from RNA of 
proliferating and differentiating myoblast cell lines from five FSHD patients, which was absent 
in three controls. They were unable to identify any DUX4 protein in these cell lines. They did, 
however, report endogenous expression of a 50kDa protein in RD and RMS13 
rhabdomyosarcoma cell lines using a DUX4 antibody on western blot. 
  Dixit et al. (2007) used Rapid Amplification of cDNA ends (RACE) to characterise the 
ends of the DUX4 mRNAs from C2C12 cells transfected with genomic D4Z4 repeats and RT-
PCR products from primary patient myoblast cells. The 3 RACE identified a 136bp intron 
located between the stop codon and the end of the D4Z4 unit, and a second 345bp intron 
located in the pLAM region. Whilst the second intron was removed from all transcripts, they 
reported alternative splicing of the first intron, resulting in two variant transcripts (Figure 1.7). 
A reverse primer 109bp from the end of the second intron was used in RT-PCR to amplify a 
1700bp fragment from FSHD myoblasts but not control myoblasts (Dixit et al., 2007). The 
group also identified a non-canonical polyA signal ATTAAA in the pLAM region, at position 
8046 of the GenBank sequence FJ439133. Both Dixit et al. and Kowaljow et al. reported that 
all the transcripts they amplified showed 100% sequence identity, suggesting that only one of 
the repeats is expressed. However, they did not publish sequence data to confirm this.  
Initially, the aim of the work described in this chapter was to test whether DUX4 mRNA 
was expressed in normal tissues or cells and confirm expression in FSHD myoblast cell lines by 
RT-PCR. Any transcripts identified would be sequenced and compared with genomic sequence 
data from other projects in the laboratory aiming to map sequence variants within D4Z4 
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arrays. If possible, such comparison of variants might show whether FSHD transcripts 
originated from the deleted allele. 
While this work was being carried out further publications reported expression from D4Z4. 
Although Snider et al. had difficulty in amplifying the full length transcripts that had been 
described previously, they were able to identify smaller fragments from the 3 and 5 ends in 
both FSHD and control myoblasts (Snider et al., 2009).  Using strand-specific RT-PCR they 
amplified both sense and antisense transcripts, in agreement with the unpublished data from 
Jannine Clapp. However, they were unable to amplify transcription from the central portion 
of the repeat (positions 2270-2398 of the first ORF in GenBank sequence FJ439133). In most 
cases their transcripts matched the last repeat, however there were some variant bases 
suggestive of transcription from internal D4Z4 repeats. By using 3RACE on RNA isolated from 
FSHD myotubes they also confirmed the two splice forms reported previously (Dixit et al., 
2007).   
As well as variant 3 ends, this group were also able to identify heterogeneous 5 ends. Re-
ƐĞƋƵĞŶĐŝŶŐ ŽĨ Ă ƉŚĂŐĞ ĐůŽŶĞ  ?ڔ-42) representing a patient-derived, deleted EcoRI fragment 
containing two D4Z4 repeats identified a number of potential ORFs which are shown in Figure 
4.1b. Using 5RACE they were able to amplify transcripts originating from an MQG ORF 
(position 7050 to 7280 of GenBank sequence FJ439133) which falls within the previously 
identified MAL ORF (position 6006 to 7280 of GenBank sequence FJ439133) (see Figure 4.1). 
These 5 truncated products were uncapped, suggesting that they are processed from a larger 
transcript. Capped transcripts all originated from the standard MAL ORF. They also reported 
other splice variants which removed the MQG ORF, or which appeared to join internal repeats 
to the last repeat of the array. For a summary of these splice forms see Figure 4.1b. 
 Although amplifying full length transcripts had proved difficult in myoblasts, Snider and 
colleagues were able to amplify across the whole region in embryonic stem cell (ESC) and 
mesenchymal stem cell (MSC) lines. Therefore, analysis of a human embryonal carcinoma 
(hEC) cell line was subsequently included in the work described in this chapter. 
In 2010, as the work described in this chapter was being completed, Snider et al. reported 
successful amplification of two transcripts (DUX4-fl and DUX4-s) from the final D4Z4 repeat in 
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muscle biopsies from FSHD patients and non-affected individuals (Snider et al., 2010)
 
using a 
nested RT-PCR approach (Figure 4.1c).  The transcripts begin at the MAL ORF (position 6006 of 
FJ439133) and end immediately downstream of the poly A signal (position 8077 of FJ439133). 
The DUX4-fl transcript has one or both of the two introns identified by Dixit et al. spliced out, 
and was detected in 5/10 FSHD samples and none of the controls. The DUX4-s transcript uses 
a cryptic splice donor site 19bp downstream of the second homeobox, removing the distal 
end of the ORF (Figure 4.1c). DUX4-s was detected in all of the control samples and some of 
the FSHD samples. The group were also able to amplify the DUX4-fl fragment from human 
testis RNA (Snider et al., 2010). 
Thus, the first aim of the work in this chapter was to grow and characterise FSHD myoblast 
cell lines in order to determine if there was expression from the D4Z4 array. Expression of the 
DUX4 gene was then investigated by RT-PCR on myoblast cell lines, as well as the hEC cell line, 
N-TERA2, the rhabdomyosarcoma cell lines, RD and RMS13, and the germ cell tumour line 
GCT27. The final aim of this chapter was to compare sequence variants identified in any 
expressed transcripts with genomic sequence variants previously identified in the lab. 
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Figure 4.1 Expressed transcripts from D4Z4. 
a) RT-PCR on fetal skeletal muscle (FSK), adult skeletal muscle (ASK), testis (T) and adult brain 
(AB) RNA (Ambion). Primers HDUX_F1 and HDUX_R1 amplify an 812bp fragment within the 
ORF (for sequences see table 2.5). Experiments performed by Dr Jannine Clapp. b) A 
schematic representation of the final repeat of the D4Z4 array with the transcripts identified 
by Dixit et al. (2007), Snider et al. (2009) and Jannine Clapp shown underneath. The DUX4 ORF 
is shown in light blue, with the homeodomains highlighted in dark blue. The pLAM region is 
shown in green and the polyA signal predicted by Dixit et al. is indicated. The start and stop 
sites of the MKG, MAL and MQG ORFs, identified by Snider et al. (2009), are shown 
underneath. For the transcripts, exons are represented by an orange line and introns are 
indicated with dotted lines. c) Representation of the transcripts referred to as DUX4-fl and 
DUX4-s in the Snider et al. (2010) publication. 
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4.2 Results 
4.2.1 Maintenance of human cell lines 
For this study a number of cell lines were grown in the lab. Three primary myoblast cell 
lines (GM17731, GM17869, GM17940) were obtained from the Corriell repository. These lines 
were from muscle biopsies of FSHD patients; GM17731 and GM17940 have three copies of 
the D4Z4 repeat unit on the disease allele whilst GM17869 has 5 repeat units (Table 4.1). For 
GM17869 and GM17940, corresponding lymphoblastoid cell lines were also obtained. These 
were used for haplotype and sequence analysis of the D4Z4 locus by an MRes student in the 
laboratory (see Section 4.2.2i). 
The two rhabdomyosarcoma cell lines identified by Kowaljow and colleagues were also 
obtained from the ATCC. RD is a fetal rhabdomyosarcoma cell line that has been shown to be 
at least parental, if not identical, to TE671 cells (Stratton et al., 1989). The RMS13 cell line was 
established from the bone marrow of a child with rhabdomyosarcoma 
(http://www.lgcstandards-atcc.org); these cells show ultrastructural elements of primitive 
skeletal muscle differentiation.  
 
4.2.2 Analysis of myoblast cell lines  
The myoblast cell lines were grown as detailed in Section 2.1. For verification of the 
GM17731, GM17940 and GM19869 cell lines, RT-PCR was used to confirm expression of the 
myoblast-specific marker desmin (Figure 4.2a).  Myoblast cultures are a mixture of myoblasts 
and fibroblasts, and although myoblasts predominate on recovery from liquid nitrogen the 
fibroblast cells take over with increasing passage. In order to reduce the number of fibroblasts 
present, all myoblasts used for the analyses described in this thesis were limited to 5 
passages. To determine the proportion of myoblasts in the cultures, cells were seeded onto 
coverslips and immunocytochemistry performed using antibodies to the myoblast-specific 
marker desmin. At these passage numbers typically 100% of the cells were stained with 
desmin (Figure 4.2b).  
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Myoblasts were differentiated in flasks coated with matrigel as described in Section 2.1.4. 
On reduction of serum in the media, myoblast cells fuse together to form myotubes. For 
verification that these cells have differentiated, immunocytochemistry was performed using 
the myotube-specific marker MF-20 (Figure 4.2c) and RT-PCR confirmed expression of the 
myosin heavy chain gene, which is specific to differentiating muscle cells
 
(Figure 4.2d). 
The fusion index of the myoblasts was calculated 6 days after differentiation. The index 
was calculated by dividing the number of DAPI-positive nuclei within myotubes (MF-20 
positive cells) by the total number of nuclei in the field. The fusion index was averaged over 
10 fields and was 71% for GM17869 and 83% for GM17940. The fusion index for the 
GM17731 cell line was much lower at 46%. 
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Table 4.1 Myoblast cell lines 
Information on age, sex of the donor and the muscle of origin (where known) of the myoblast 
cell lines from the Corelli institute. Matched lymphoblast lines were available for two of the 
myoblast lines, GM17869 and GM17940. The predicted number of D4Z4 repeats on each 
allele is indicated for both chromosome 4 and 10.  
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Figure 4.2 Characterisation of myoblast cell lines 
a) RT-PCR to show expression of desmin in myoblasts. For primers see table 2.5. b) Immunocytochemistry on myoblasts using an antibody to desmin (Table 2.1), shown in 
red. DAPI staining of the nucleus is shown in blue. c) Immunocytochemistry on myoblasts using the antibody MF20 (Table 2.1), shown in green. DAPI staining of the nucleus 
is shown in blue. d) RT-PCR to show expression of myosin in cell lines GM17731, GM17869 and GM17940 on differentiation into myotubes. For primers see Table 2.5. 
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4.2.2.i Haplotyping of myoblast cell lines 
As the myoblast cell lines were derived from FSHD patients all were expected to contain 
the 4qA161 allele. Each of the cell lines were haplotyped to confirm the presence of the 
permissive allele and to determine the other alleles present. The haplotypes are listed in 
Figure 4.3b. The cell lines GM17869 and GM17940 were haplotyped by Joanne Pollington 
according to Lemmers et al. (2007) using sequence information from the amplification of the 
SSLP and p13E-11 region. DNA from the corresponding lymphoblast cell lines was used for 
these analyses. Haplotypes were assigned according to sequence variants (Lemmers et al. 
2007, 2010), however, some haplotypes may not have been sampled due to PCR and cloning 
bias and so the complete set of haplotypes may not have been identified. As expected, each 
cell line contained at least one 4qA161 allele. 
The GM17731 cell line was haplotyped using a modified version of the SSLP genotyping 
reaction described in Lemmers et al. (2010b). The products of this reaction were analysed by 
capillary gel electrophoresis (Figure 4.3a). This technique is sensitive enough to distinguish 
between single base differences in size. However, as the samples do not run true to size, they 
are compared with samples of known alleles as size standards. This cell line carries only 
4qA161 and 10qA166 alleles and is presumably homozygous for each allele. 
 
 
 
 
 
 
 
 
 
 
 103 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Characterisation of myoblast cell lines 
a) Capillary gel electrophoresis results from the 17731 myoblast cell line. Comparison with 
known size standards showed that samples were running at approximately 2.5 bp smaller 
than their true size so two allele sizes, 161 and 166, are predicted. A similar peak height 
between the two alleles suggests that two of each allele size is present in the cell line. b) 
Table to summarise haplotype and fusion index information. Haplotyping of GM17731 was by 
capillary gel electrophoresis as described in Section 2.9.2. Haplotyping of GM17869 and 
GM17940 were by PCR of lymphoblast cell lines by Joanne Pollington.   
  
161 166 
a. 
b. 
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4.2.3 Initial attempts to amplify DUX4 from myoblast and 
rhabdomyosarcoma cell lines 
Initially, three different primer pairs were used for RT-PCR, their positions and sequences 
are shown in Figure 4.4a and Table 2.5, respectively. HDUX4-F1 and HDUX4-R1 were designed 
previously by Dr Jannine Clapp to amplify an 812bp fragment corresponding to the distal end 
of the ORF and including the final 67bp of the second homeobox (Figure 4.1a). Primers #222 
and #219 were used by Kowaljow et al. (2007) to amplify a 1477bp fragment encompassing 
the full ORF. Primers #222 and #407 were used by Dixit et al. (2007) to amplify a 1700bp 
fragment, with the reverse primer annealing in the pLAM region downstream of the putative 
stop codon. 
As previous work by Dr Jannine Clapp had shown that the OneStep kit (Qiagen) is the most 
reliable reagent for amplifying the mouse Dux array (Clapp et al., 2007), this kit was tested for 
amplification of the human sequences. The kit contains two reverse transcriptases and a 
HotStarTaq DNA polymerase that allows reverse transcription and amplification to take place 
in one reaction. Both reverse transcriptases have a higher affinity for RNA templates than 
other reverse transcriptases and one is optimised for use on small amounts of template which 
makes it useful for amplifying transcripts with low expression levels. Q-solution can also be 
included in the reaction, which helps amplification of difficult transcripts by modifying the 
melting behaviour of the nucleic acids (Qiagen OneStep RT-PCR Kit Handbook). 
Using the OneStep kit with HDUX4 primers, no amplification was seen using RNA from 
either of the rhabdomyosarcoma cell lines (Figure 4.4b), or from the three myoblast cell lines 
in either proliferation or differentiation stages (Figure 4.4c). No amplification was seen from 
the testis or fetal skeletal muscle RNA used previously by Jannine Clapp. However, this 
product was not seen in all of her amplification attempts (Jane Hewitt, personal 
communication) 
 A two-step reaction was then performed with each of the primer pairs 
(HDUX4_F1/HDUX4_R1, #222/#219 and #222/#407). The Improm reverse transcription kit 
was used to make cDNA and the PCR step was performed with KAPAHiFi polymerase using a 
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separate buffer for GC rich templates. The reactions were performed using both the 
manufacturers suggested cycling conditions, and those described in both the Dixit and 
Kowaljow publications (Dixit et al., 2007; Kowaljow et al., 2007). However, amplification was 
not seen from any of the RNA samples. 
Finally, a two-step reaction was performed using the Superscript III reverse transcriptase 
for the initial step, and Platinum taq for the PCR step, as described by Dixit et al. and 
Kowlajow et al. However, no amplification of DUX4 was seen from any of the RNA samples 
used in this study (Figure 4.4d). 
 
4.2.4 Amplification from human embryonal carcinoma cells 
In 2009, Snider et al. showed amplification of full length transcripts (see Figure 4.1c) from 
the D4Z4 array in human embryonal carcinoma cells (hEC) and human mesenchymal stem 
cells (hMSC). Human embryonal carcinoma cells are isolated from teratocarcinomas, a subset 
of germ cell tumours that form in the ovaries or testis. The testicular hEC cell line, NTERA-2, 
was cultured as described in Section 2.1. RT-PCR on RNA extracted from this cell line was 
performed using the OneStep kit and HDUX4 primer pair (Figure 4.5a). In contrast to the 
results with myoblast RNA, an 812bp product was amplified from both total (Figure 4.5b) and 
Poly (A)
+
 RNA (Figure 4.5c). Although this product does not cover the full ORF, it does cover 
the central region that Snider et al. were unable to amplify from myoblasts. Thus, this data 
supports their report that longer transcripts are expressed in the hEC cell line. The RT-PCR 
products were sequenced and analysed as described in Section 4.2.6. 
 As both sense and antisense transcripts are expressed from the mouse Dux locus 
(Clapp et al., 2007) and preliminary data from Dr Jannine Clapp had shown both sense and 
antisense transcripts for DUX4 (Figure 4.1a), the amplification protocol was modified to test 
for antisense RNA. When using the OneStep kit, both primers are present during the RT and 
PCR steps, so the amplified product could originate from either strand. Therefore, the 
reaction was modified so that only one of the primers was present in the RT step. The second 
primer was added after the reverse transcriptase had been inactivated. A product was 
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amplified from hEC RNA when either primer was used in the RT step (Figure 4.5d), indicating 
that transcription from this region occurs from both strands. 
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Figure 4.4 DUX4 RNA could not be detected in myoblast cells by RT-PCR 
a)  Schematic representation of the fragments amplified by primer pairs used in the initial 
amplification attempts. The DUX4 ORF is shown in light blue with the homeodomains 
highlighted in dark blue. The pLAM region is shown in green. Positions of the primer pairs are 
shown underneath. HDUX4_F1 and HDUX4_R1 were designed by Dr Jannine Clapp, primers 
#222 and #219 are from Kowaljow et al. and primers #222 and #407 were used in Dixit et al. 
b) RT-PCR of RNA extracted from the human rhabdomyosarcoma cell lines RD and RMS13 
using the HDUX4 primer pair. c) RT-PCR of RNA extracted from myoblast cell line GM17940, 
using the HDUX4 primer pair. The same results were seen using the #222 and #407 primers 
used in the Dixit et al. publication. d) RT-PCR of RNA extracted from myoblast cell lines 
GM17731 and GM17869 using the #222 and #219 primers from Kowaljow et al.  
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Figure 4.5 DUX4 expression in hEC cells 
a) The DUX4 ORF is shown in pale blue with homeodomains highlighted in dark blue. The 
pLAM region is shown in green. The HDUX4 primers amplify an 812bp fragment, the position 
of this is shown underneath. b, c) RT-PCR of hEC RNA using the HDUX4 primer pair. d) Strand-
specific RT-PCR of hEC RNA using the HDUX4 primer pair. p- indicates that only the primer 
used for the RT reaction was included. The RT-PCR band appears larger than the genomic, 
however, sequencing genomic fragments confirmed that this is an artefact of the 
electrophoresis.  
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4.2.5 Haplotyping of the hEC cell line 
FSHD results from deletions on specific haplotypes only. Therefore, the hEC cell line was 
haplotyped to determine whether the expressed transcripts originated from an FSHD 
permissive allele. The SSLP and p13E-11 regions were amplified and sequenced according to 
Lemmers et al. (2007) (See section 1.14). Haplotypes were assigned based on 15 SNPs within 
the p13E-11 region (Figure 4.6). Of the 10 fragments sequenced, 4 were 10qA166 and the 
remaining 6 all 4qB163. 
To confirm this data, a modified version of the SSLP genotyping reaction described in 
Lemmers et al. was subsequently performed and the products were analysed by capillary gel 
electrophoresis as described previously (section 4.2.2i). Two allele sizes, 163 and 166, were 
identified (Figure 4.7) consistent with the p13E-11 sequence data. The peak heights are 
approximately equal. The most likely constitution for this cell line is homozygous for both 
4qB163 and 10qA166. Therefore, the expressed transcripts do not appear to come from an 
FSHD permissive allele and cannot provide information about variants that may be involved in 
the FSHD phenotype. However, as multiple D4Z4 alleles have been conserved and 
amplification of RT-PCR products from this cell line shows there is transcription from these 
non-permissive alleles, they are likely to have a role in normal development. Thus, data from 
this cell line can provide information on repeat variants that are expressed during normal 
development. 
 
4.2.6 Sequence analysis of hEC transcripts 
From sequence data being produced by others in Jane Hewitts laboratory, it was clear 
that there is substantive nucleotide variation within D4Z4 arrays. Therefore, in order to 
identify sequence variants between D4Z4 repeats, the hDUX4 RT-PCR products were cloned 
into pSMART and 88 clones were sequenced to determine whether all the transcripts were 
the same sequence. These primers cover 812bp of the ORF and include the final 67bp of the 
second homeobox. From the 88 sequences, 17 distinct groups were identified based on 10 
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variant positions and a 6bp indel. Where a variant was present in only one of the 88 
sequences it was not used to define a group as it was not possible to exclude that these were 
due to PCR errors.  The 17 groups were compared to the sequence of the most distal D4Z4 
repeat within GenBank sequence FJ439133 and as all of the clones vary from FJ439133 at 
position 6779 an additional variant was identified. Variants are shown in Table 4.2 and Figure 
4.8. This data indicates that multiple repeats are expressed in the hEC cell line. Although the 
data are consistent with the sequences coming from chromosome 4, it is not possible to rule 
out that they come from chromosome 10. Two RT-PCR products from the poly(A)
+
 RNA were 
also sequenced, these matched the variant groups 6 and 15. 
Some of the sequences appear to be more common (for example 19 clones contained the 
same variants in group 6), but this could be due to biases in amplification and/or cloning 
rather than transcript abundance. All the clones contain a silent C-G change at position 6779 
and therefore none of the sequences are 100% identical to the repeat in FJ439133. This is not 
unexpected, as the cell line does not contain a 4qA161 allele from which the FJ439133 allele 
originates and it is likely that this distal repeat varies between haplotypes. For 19 of the 
sequences this C-G change is the only difference to FJ439133. Importantly, no nonsense or 
frameshift mutations were seen and 6/11 of the base changes are silent. There is a 50% indel 
in 50% of the clones, alignment with sequence from the chimp suggests that a single copy is 
ancestral (Jane Hewitt, personal communication). 
None of these variants fall within the 67bp of homeobox sequence at the start of the 
product. The remaining 744bp sequence cover the C-terminal domain which may be less 
constrained than the homeodomains and could account for the high number of variants in 
this stretch. Previous work in Jane Hewitts laboratory had identified highly conserved 
positions in this region (Figure 4.9). The C-T variation at position 7122 falls within a highly 
conserved leucine residue, however this base change is silent. At position 7147, the C-T 
variation identified in 6 sequences results in a proline to leucine change. This proline residue 
is conserved between human, chimp, orangutan, macaque, marmoset, elephant and 
treeshrew (Figure 4.9). 
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4qB168    1 AGCCAGACTTCATCAAATTTCTGCAGCAATGAAAAAAAAATTTACAAGAGAAAAACAAAA 
10qA166   1 AGCCAGACTTCATCAAATTTCTGCAGCAATGAAAAAAAAATTTACAAGAGAAAAACAAAA 
4qA166    1 AGCCAGACTTCATCAAATTTCTGCAGCAATGAAAAAAAAATTTACAAGAGAAAAACAAAA 
4qA161    1 AGCCAGACTTCATCAAATTTCTGCACCAATGAAAAAAAAATTTACAAGAGAAAAACAAAA 
4qB163    1 AGCCAGACTTCATCAAATTTCTGCACCAATGAAAAAAAAATTTACAAGAGAAAAACAAAA 
 
hEC 1     1 AGCCAGACTTCATCAAATTTCTGCACCAATGAAAAAAAAATTTACAAGAGAAAAACAAAA 
hEC 2     1 AGCCAGACTTCATCAAATTTCTGCAGCAATGAAAAAAAAATTTACAAGAGAAAAACAAAA 
                                     *                                   
 
4qB168   61 AACCCTATTAAACGTCACGGACAAGGCCAGAGTTTGAATATACTGTGGTCATCTCCGCTC 
10qA166  61 AACCCTATTAAACGTCACGGACAAGGCCAGAGTTTGAATATACTGTGGTCATCTCCGCTC 
4qA166   61 AACCCTATTAAACGTCACGGACAAGGCCAGAGTTTGAATATACTGTGGTCATCTCCGCTC 
4qA161   61 AACCCTATTAAACGTCACGGACAAGGCCAGAGTTTGAATATACTGTGGTCATCTCTGCTC 
4qB163   61 AACCCTATTAAACGTCACGGACAAGGCCAGAGTTTGAATATACTGTGGTCATCTCTGCTC                   
 
hEC 1    61 AACCCTATTAAACGTCACGGACAAGGCCAGAGTTTGAATATACTGTGGTCATCTCTGCTC 
hEC 2    61 AACCCTATTAAACGTCACGGACAAGGCCAGAGTTTGAATATACTGTGGTCATCTCCGCTC 
                                                                   * 
 
4qB168  121 CAGTGCAAACTGTTTTCAGAAAGCCTGCTTTTATTTTCCTTGCTGTAACAGAGGAACATT 
10qA166 121 CAGTGCAAACTGTTTTCAGAAAGCCTGCTTTTATTTTCCTTGCTGTAACAGAGGAACATT 
4qA166  121 CAGTGCAAACTGTTTTCAGAAAGCCTGCTTTTATTTTCCTTGCTGTAACAGAGGAACATT 
4qA161  121 CAGTGCAAACTGTTTCCAGAAAGCCTACTTCTATTTTCCTTGCTGTAACAGAGGAACATT 
4qB163  121 CAGTGCAAACTGTTTTCAGAAAGCCTACTTCTATTTTCCTTGCTGTAACAGAGGAACATT 
 
hEC 1   121 CAGTGCAAACTGTTTTCAGAAAGCCTACTTCTATTTTCCTTGCTGTAACAGAGGAACATT 
hEC 2   121 CAGTGCAAACTGTTTTCAGAAAGCCTGCTTTTATTTTCCTTGCTGTAACAGAGGAACATT 
                           *          *   *                              
 
4qB168  181 TCCTGTCTTATGCTTATTCTACTCTGCAGTCCCCTAAGGCTTTTTCTCTCCCTCCCAGAA 
10qA166 181 TCCTGTCTTATGCTTATTCTACTCTGCAGTCCCCTAAGGCTTTTTCTCTCCCTCCCAGAA 
4qA166  181 TCCTGTCTTATGCTTATTCTACTCTGCAGTCCCCTAAGGCTTTTTCTCTCCCTCCCAGAA 
4qA161  181 TCCTGTCTTATGTTTATTCTACTCTGCAATCCCCTAAGGCTTTTTCTCTCCCTCCCAGAA 
4qB163  181 TCCTGTCTTATGCTTATTCTACTCTGCAATCCCCTAAGGCTTTTTCTCTCCCTCCCAGAA 
 
hEC 1   181 TCCTGTCTTATGCTTATTCTACTCTGCAATCCCCTAAGGCTTTTTCTCTCCCTCCCAGAA 
hEC 2   181 TCCTGTCTTATGCTTATTCTACTCTGCAGTCCCCTAAGGCTTTTTCTCTCCCTCCCAGAA 
                        *               *                                
 
4qB168  241 TCTTAAAGTGCATTCGAACGCACAGGCAAAATCCTCCCAGAAACTTGTGAAAACATAAAT 
10qA166 241 TCTTAAAGTGCATTCGAACGCACAGGCAAAATCCTCCCAGAAACTTGTGAAAACATAAAT 
4qA166  241 TCTTAAAGTGCATTCGAACGCACAGGCAAAATCCTCCCAGAAACTTGTGAAAACATAAAT 
4qA161  241 TCTTAAAGTGCATTCGAACTCACAGGCAAAATCCTCCCAGAATCTTGTGAGAACATAAAT 
4qB163  241 TCTTAAAGTGCATTCGAACTCACAGGCAAAATCCTCCCAGAATCTTGTGAGAACATAAAT 
 
hEC 1   241 TCTTAAAGTGCATTCGAACTCACAGGCAAAATCCTCCCAGAATCTTGTGAGAACATAAAT 
hEC 2   241 TCTTAAAGTGCATTCGAACGCACAGGCAAAATCCTCCCAGAAACTTGTGAAAACATAAAT 
                               *                      *       *          
 
4qB168  301 GATCTGACTAGTTTGGCATTGCTTTTGGGGATCTGGGAAAATCTGTGCACACTTCTGGAG 
10qA166 301 GATCTGACTAGTTTGGCATTGCTTTTGGGGATCTGGGAAAATCTGTGCACACTTCTGGAG 
4qA166  301 GATCTGACTAGTTTGGCATTGCTTTTGGGGATCTGGGAAAATCTGTGCACACTTCTGGAG 
4qA161  301 GATCTGACTAGTTTGGCATTGCTTTTGGGGATCTGGGAAAATCTGTGCACACTTCTGGAG 
4qB163  301 GATCTGACTAGTTTGGCATTGCTTTTGGGGATCTGGGAAAATCTGTGCACACTTCTGGAG 
 
hEC 1   301 GATCTGACTAGTTTGGCATTGCTTTTGGGGATCTGGGAAAATCTGTGCACACTTCTGGAG 
hEC 2   301 GATCTGACTAGTTTGGCATTGCTTTTGGGGATCTGGGAAAATCTGTGCACACTTCTGGAG 
       
 
 
4qB168  361 ACCCTTGTCAGGCCATTTTTTATAAATCTATTGTGCCTCAAGTCAGAAGTGTCTGAGGGG 
10qA166 361 ACCCTTGTCAGGCCATTTTTTATAAATCTATTGTGCCTCAAGTCAGCAGTGTGTGAGGGG 
4qA166  361 ACCCTTGTCAGGCCATTTTTTATAAATCTATTGTGCCTCAAGTCAGAAGTGTGTGAGGGG 
4qA161  361 ACCCTTGTCATGCCATTTTTTATAAATCTATTGTGCCTCAAGTCAGAAGTGTGTGAGGGG 
4qB163  361 ACCCTTGTCATGCCATTATTTATAAATCTATTGTGCCTCAAGTCAGAAGTGTGTGAGGGG 
 
hEC 1   361 ACCCTTGTCATGCCATTATTTATAAATCTATTGTGCCTCAAGTCAGAAGTGTGTGAGGGG 
hEC 2   361 ACCCTTGTCAGGCCATTTTTTATAAATCTATTGTGCCTCAAGTCAGCAGTGTGTGAGGGG 
                      *      *                            *     *        
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4qB168  421 AGATGGGGAGACATTGGGATGTGCGCGCCTGGGGCTCTCCCACAGGGGGCTTTC 
10qA166 421 AGATGGGGAGACATTGGGATGCGCGCGCCTGGGGCTCTCCCACAGGGGGCTTTC 
4qA166  421 AGATGGGGAGACATTGGGATGCGCGCGCCTGGGGCTCTCCCACAGGGGGCTTTC 
4qA161  421 AGATGGGGAGACATTGGGATGCGCGCGCCTGGGGCTCTCCCACAGGGGGCTTTC 
4qB163  421 AGATGGGGAGACATTGGGATGCGCGCGCCTGGGGCTCTCCCACAGGGGGCTTTC 
 
hEC 1   421 AGATGGGGAGACATTGGGATGCGCGCGCCTGGGGCTCTCCCACAGGGGGCTTTC 
hEC 2   421 AGATGGGGAGACATTGGGATGCGCGCGCCTGGGGCTCTCCCACAGGGGGCTTTC 
                              *        
 
Figure 4.6 Assignment of p13E11 sequences from the hEC cell line 
Alignment of the p13E-11 sequences from Lemmers et al. (2007) used to assign haplotypes to 
the hEC cell line. The 15 variant positions are highlighted with an asterisk. The sequences of 
two clones corresponding to the 4qB163 and 10qA166 alleles are shown. 
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Figure 4.7 Haplotyping of the hEC cell line. 
Capillary gel electrophoresis results from the hEC cell line. Comparison with known size 
standards showed that samples were running at approximately 2.5 bp smaller than their true 
size so two allele sizes, 163 and 166, are predicted. A similar peak height between the two 
alleles suggests that two of each allele size is present in the cell line. 
 
163 166 
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Group 1           GGGCCTCCCGGAGTCCAGGATTCAGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGG 
Group 2           GGGCCTCCCGGAGTCCAGGATTCAGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGG 
Group 3           GGGCCTCCCGGAGTCCAGGATTCAGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGG 
Group 4           GGGCCTCCCGGAGTCCAGGATTCAGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGG 
Group 5           GGGCCTCCCGGAGTCCAGGATTCAGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGG 
Group 6           GGGCCTCCCGGAGTCCAGGATTCAGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGG 
Group 7           GGGCCTCCCGGAGTCCAGGATTCAGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGG 
Group 8           GGGCCTCCCGGAGTCCAGGATTCAGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGG 
Group 9           GGGCCTCCCGGAGTCCAGGATTCAGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGG 
Group 10          GGGCCTCCCGGAGTCCAGGATTCAGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGG 
Group 11 
Group 12          GGGCCTCCCGGAGTCCAGGATTCAGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGG 
Group 13          GGGCCTCCCGGAGTCCAGGATTCAGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGG 
Group 14          GGGCCTCCCGGAGTCCAGGATTCAGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGG 
Group 15          GGGCTTCCCGGAGTCCAGGATTCAGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGG 
Group 16          GGGCCTCCCGGAGTCCAGGATTCGGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGG 
Group 17          GGGCCTCCCGGAGTCCAGGATTCAGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGG 
 
FJ439133    6398  GGGCCTCCCGGAGTCCAGGATTCAGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGG 
                   G  L  P  E  S  R  I  Q  I  W  F  Q  N  R  R  A  R  H  P  G  
                      *                  *                                     
 
Group 1           ACAGGGTGGCAGGGCGCCCGCGCAGGCAGGCGGCCTGTGCAGCGCGGCCCCCGGCGGGGG 
Group 2           ACAGGGTGGCAGGGCGCCCGCGCAGGCAGGCGGCCTGTGCAGCGCGGCCCCCGGCGGGGG 
Group 3           ACAGGGTGGCAGGGCGCCCGCGCAGGCAGGCGGCCTGTGCAGCGCGGCCCCCGGCGGGGG 
Group 4           ACAGGGTGGCAGGGCGCCCGCGCAGGCAGGCGGCCTGTGCAGCGCGGCCCCCGGCGGGGG 
Group 5           ACAGGGTGGCAGGGCGCCCGCGCAGGCAGGCGGCCTGTGCAGCGCGGCCCCCGGCGGGGG 
Group 6           ACAGGGTGGCAGGGCGCCCGCGCAGGCAGGCGGCCTGTGCAGCGCGGCCCCCGGCGGGGG 
Group 7           ACAGGGTGGCAGGGCGCCCGCGCAGGCAGGCGGCCTGTGCAGCGCGGCCCCCGGCGGGGG 
Group 8           ACAGGGTGGCAGGGCGCCCGCGCAGGCAGGCGGCCTGTGCAGCGCGGCCCCCGGCGGGGG 
Group 9           ACAGGGTGGCAGGGCGCCCGCGCAGGCAGGCGGCCTGTGCAGCGCGGCCCCCGGCGGGGG 
Group 10          ACAGGGTGGCAGGGCGCCCGCGCAGGCAGGCGGCCTGTGCAGCGCGGCCCCCGGCGGGGG 
Group 11 
Group 12          ACAGGGTGGCAGGGCGCCCGCGCAGGCAGGCGGCCTGTGCAGCGCGGCCCCCGGCGGGGG 
Group 13          ACAGGGTGGCAGGGCGCCCGCGCAGGCAGGCGGCCTGTGCAGCGCGGCCCCCGGCGGGGG 
Group 14          ACAGGGTGGCAGGGCGCCCGCGCAGGCAGGCGGCCTGTGCAGCGCGGCCCCCGGCGGGGG 
Group 15          ACAGGGTGGCAGGGCGCCCGCGCAGGCAGGCGGCCTGTGCAGCGCGGCCCCCGGCGGGGG 
Group 16          ACAGGGTGGCAGGGCGCCCGCGCAGGCAGGCGGCCTGTGCAGCGCGGCCCCCGGCGGGGG 
Group 17          ACAGGGTGGCAGGGCGCCCGCGCAGGCAGGCGGCCTGTGCAGCGCGGCCCCCGGCGGGGG 
 
FJ439133    6458  ACAGGGTGGCAGGGCGCCCGCGCAGGCAGGCGGCCTGTGCAGCGCGGCCCCCGGCGGGGG 
                   Q  G  G  R  A  P  A  Q  A  G  G  L  C  S  A  A  P  G  G  G  
                                                                                         
 
Group 1           TCACCCTGCTCCCTCGTGGGTCGCCTTCGCCCACACCGGCGGGTGGGGAACGGGGCTTCC 
Group 2           TCACCCTGCTCCCTCGTGGGTCGCCTTCGCCCACACCGGCGGGTGGGGAACGGGGCTTCC 
Group 3           TCACCCTGCTCCCTCGTGGGTCGCCTTCGCCCACACCGGCGCGTGGGGAACGGGGCTTCC 
Group 4           TCACCCTGCTCCCTCGTGGGTCGCCTTCGCCCACACCGGCGCGTGGGGAACGGGGCTTCC 
Group 5           TCACCCTGCTCCCTCGTGGGTCGCCTTCGCCCACACCGGCGCGTGGGGAACGGGGCTTCC 
Group 6           TCACCCTGCTCCCTCGTGGGTCGCCTTCGCCCACACCGGCGCGTGGGGAACGGGGCTTCC 
Group 7           TCACCCTGCTCCCTCGTGGGTCGCCTTCGCCCACACCGGCGCGTGGGGAACGGGGCTTCC 
Group 8           TCACCCTGCTCCCTCGTGGGTCGCCTTCGCCCACACCGGCGAGTGGGGAACGGGGCTTCC 
Group 9           TCACCCTGCTCCCTCGTGGGTCGCCTTCGCCCACACCGGCGCGTGGGGAACGGGGCTTCC 
Group 10          TCACCCTGCTCCCTCGTGGGTCGCCTTCGCCCACACCGGCGCGTGGGGAACGGGGCTTCC 
Group 11 
Group 12          TCACCCTGCTCCCTCGTGGGTCGCCTTCGCCCACACCGGCGCGTGGGGAACGGGGCTTCC 
Group 13          TCACCCTGCTCCCTCGTGGGTCGCCTTCGCCCACACCGGCGCGTGGGGAACGGGGCTTCC 
Group 14          TCACCCTGCTCCCTCGTGGGTCGCCTTCGCCCACACCGGCGAGTGGGGAACGGGGCTTCC 
Group 15          TCACCCTGCTCCCTCGTGGGTCGCCTTCGCCCACACCGGCGAGTGGGGAACGGGGCTTCC 
Group 16          TCACCCTGCTCCCTCGTGGGTCGCCTTCGCCCACACCGGCGCGTGGGGAACGGGGCTTCC 
Group 17          TCACCCTGCTCCCTCGTGGGTCGCCTTCGCCCACACCGGCGAGTGGGGAACGGGGCTTCC 
 
FJ439133    6518  TCACCCTGCTCCCTCGTGGGTCGCCTTCGCCCACACCGGCGCGTGGGGAACGGGGCTTCC 
                   H  P  A  P  S  W  V  A  F  A  H  T  G  A  W  G  T  G  L  P  
                                                           *                   
 
 
 
 
 
 
 
 
 
 
 
 115 
Group 1           CGCACCGCACGTGCCCTGCGCGCCTGGGGCTCTCCCACAGGGGGCTTTCGTGAGCCAGGC 
Group 2           CGCACCGCACGTGCCCTGCGCGCCTGGGGCTCTCCCACAGGGGGCTTTCGTGAGCCAGGC 
Group 3           CGCACCGCACGTGCCCTGCGCGCCTGGGGCTCTCCCACAGGGGGCTTTCGTGAGCCAGGC 
Group 4           CGCACCGCACGTGCCCTGCGCGCCTGGGGCTCTCCCACAGGGGGCTTTCGTGAGCCAGGC 
Group 5           CGCACCCCACGTGCCCTGCGCGCCTGGGGCTCTCCCACAGGGGGCTTTCGTGAGCCAGGC 
Group 6           CGCACCCCACGTGCCCTGCGCGCCTGGGGCTCTCCCACAGGGGGCTTTCGTGAGCCAGGC 
Group 7           CGCACCCCACGTGCCCTGCGCGCCTGGGGCTCTCCCACAGGGGGCTTTCGTGAGCCAGGC 
Group 8           CGCGCCGCACGTGCCCTGCGCGCCTGGGGCTCTCCCACAGGGGGCTTTCGTGAGCCAGGC 
Group 9           CGCACCCCACGTGCCCTGCGCGCCTGGGGCTCTCCCACAGGGGGCTTTCGTGAGCCAGGC 
Group 10          CGCACCCCACGTGCCCTGCGCGCCTGGGGCTCCCCCACAGGGGGCTTTCGTGAGCCAGGC 
Group 11                                    GGGCTCTCCCACAGGGGGCTTTCGTGAGCCAGGC 
Group 12          CGCACCCCACGTGCCCTGCGCGCCTGGGGCTCTCCCACAGGGGGCTTTCGTGAGCCAGGC 
Group 13          CGCACCCCACGTGCCCTGCGCGCCTGGGGCTCTCCCACAGGGGGCTTTCGTGAGCCAGGC 
Group 14          CGCACCGCACGTGCCCTGCGCGCCTGGGGCTCTCCCACAGGGGGCTTTCGTGAGCCAGGC 
Group 15          CGCACCGCACGTGCCCTGCGCGCCTGGGGCTCTCCCACAGGGGGCTTTCGTGAGCCAGGC 
Group 16          CGCACCCCACGTGCCCTGCGCGCCTGGGGCTCTCCCACAGGGGGCTTTCGTGAGCCAGGC 
Group 17          CGCACCCCACGTGCCCTGCGCGCCTGGGGCTCTCCCACAGGGGGCTTTCGTGAGCCAGGC 
 
FJ439133    6578  CGCACCCCACGTGCCCTGCGCGCCTGGGGCTCTCCCACAGGGGGCTTTCGTGAGCCAGGC 
                   A  P  H  V  P  C  A  P  G  A  L  P  Q  G  A  F  V  S  Q  A  
                     *  *                         *                            
 
Group 1           AGCGAGGGCCGCCCCCGCGCTGCAGCCCAGCCAGGCCGCGACGGCAGAGGGGGTCTCCCA 
Group 2           AGCGAGGGCCGCCCCCGCGCTGCAGCCCAGCCAGGCCGCGACGGCAGAGGGGGTCTCCCA 
Group 3           AGCGAGGGCCGCCCCCGCGCTGCAGCCCAGCCAGGCCGCGACGGCAGAGGGGGTCTCCCA 
Group 4           AGCGAGGGCCGCCCCCGCGCTGCAGCCCAGCCAGGCCGCGACGGCAGAGGGGGTCTCCCA 
Group 5           AGCGAGGGCCGCCCCCGCGCTGCAGCCCAGCCAGGCCGCGCCGGCAGAGGGGATCTCCCA 
Group 6           AGCAAGGGCCGCCCCCGCGCTGCAGCCCAGCCAGGCCGCGCCGGCAGAGGGGATCTCCCA 
Group 7           AGCGAGGGCCGCCCCCGCGCTGCAGCCCAGCCAGGCCGCGCCGGCAGAGGGGATCTCCCA 
Group 8           AGCGAGGGCCGCCCCCGCGCTGCAGCCCAGCCAGGCCGCGACGGCAGAGGGGGTCTCCCA 
Group 9           AGCGAGGGCCGCCCCCGCGCTGCAGCCCAGCCAGGCCGCGCCGGCAGAGGGGATCTCCCA 
Group 10          AGCGAGGGCCGCCCCCGCGCTGCAGCCCAGCCAGGCCGCGACGGCAGAGGGGGTCTCCCA 
Group 11          AGCGAGGGCCGCCCCCGCGCTGCAGCCCAGCCAGGCCGCGCCGGCAGAGGGGATCTCCCA 
Group 12          AGCGAGGGCCGCCCCCGCGCTGCAGCCCAGCCAGGCCGCGCCGGCAGAGGGGGTCTCCCA 
Group 13          AGCGAGGGCCGCCCCCGCGCTGCAGCCCAGCCAGGCCGCGCCGGCAGAGGGGGTCTCCCA 
Group 14          AGCGAGGGCCGCCCCCGCGCTGCAGCCCAGCCAGGCCGCGACGGCAGAGGGGGTCTCCCA 
Group 15          AGCGAGGGCCGCCCCCGCGCTGCAGCCCAGCCAGGCCGCGACGGCAGAGGGGGTCTCCCA 
Group 16          AGCGAGGGCCGCCCCCGCGCTGCAGCCCAGCCAGGCCGCGCCGGCAGAGGGGATCTCCCA 
Group 17          AGCGAGGGCCGCCCCCGCGCTGCAGCCCAGCCAGGCCGCGACGGCAGAGGGGGTCTCCCA 
 
FJ439133    6638  AGCGAGGGCCGCCCCCGCGCTGCAGCCCAGCCAGGCCGCGCCGGCAGAGGGGATCTCCCA 
                   A  R  A  A  P  A  L  Q  P  S  Q  A  A  P  A  E  G  I  S  Q  
                     *                                    *           *        
 
Group 1           ACCTGCCCCGGCGCGCCGGGATTTCGCCTACGCCGCCCCGGCTCCTCCGGACGGGGCGCT 
Group 2           ACCTGCCCCGGCGCGCCGGGATTTCGCCTACGCCGCCCCGGCTCCTCCGGACGGGGCGCT 
Group 3           ACCTGCCCCGGCGCGCGGGGATTTCGCCTACGCCGCCCCGGCTCCTCCGGACGGGGCGCT 
Group 4           ACCTGCCCCGGCGCGCGGGGATTTCGCCTACGCCGCCCCGGCTCCTCCGGACGGGGCGCT 
Group 5           ACCTGCCCCGGCGCGCGGGGATTTCGCCTACGCCGCCCCGGCTCCTCCGGACGGGGCGCT 
Group 6           ACCTGCCCCGGCGCGCGGGGATTTCGCCTACGCCGCCCCGGCTCCTCCGGACGGGGCGCT 
Group 7           ACCTGCCCCGGCGCGCGGGGATTTCGCCTACGCCGCCCCGGCTCCTCCGGACGGGGCGCT 
Group 8           ACCTGCCCCGGCGCGCCGGGATTTCGCCTACGCCGCCCCGGCTCCTCCGGGCGGGGCGCT 
Group 9           ACCTGCACCGGCGCGCGGGGATTTCGCCTACGCCGCCCCGGCTCCTCCGGACGGGGCGCT 
Group 10          ACCTGCCCCGGCGCGCCGGGATTTCGCCTACGCCGCCCCGGCTCCTCCGGACGGGGCGCT 
Group 11          ACCTGCCCCGGCGCGCGGGGATTTCGCCTACGCCGCCCCGGCTCCTCCGGACGGGGCGCT 
Group 12          ACCTGCCCCGGCGCGCGGGGATTTCGCCTACGCCGCCCCGGCTCCTCCGGACGGGGCGCT 
Group 13          ACCTGCCCCGGCGCGCGGGGATTTCGCCTACGCCGCCCCGGCTCCTCCGGACGGGGCGCT 
Group 14          ACCTGCCCCGGCGCGCCGGGATTTCGCCTACGCCGCCCCGGCTCCTCCGGACGGGGCGCT 
Group 15          ACCTGCCCCGGCGCGCCGGGATTTCGCCTACGCCGCCCCGGCTCCTCCGGACGGGGCGCT 
Group 16          ACCTGCACCGGCGCGCGGGGATTTCGCCTACGCCGCCCCGGCTCCTCCGGACGGGGCGCT 
Group 17          ACCTGCCCCGGCGCGCGGGGATTTCGCCTACGCCGCCCCGGCTCCTCCGGACGGGGCGCT 
 
FJ439133    6698  ACCTGCCCCGGCGCGCGGGGATTTCGCCTACGCCGCCCCGGCTCCTCCGGACGGGGCGCT 
                   P  A  P  A  R  G  D  F  A  Y  A  A  P  A  P  P  D  G  A  L  
                        *         *                                 *          
 
 
 
 
 
 
 
 
 
 
 
 116 
Group 1           CTCCCACCCTCAGGCTCCTCGGTGGCCTCCGCACCCGGGCAAAAGCCGGGAGGACCGGGA 
Group 2           CTCCCACCCTCAGGCTCCTCGGTGGCCTCCGCACCCGGGCAAAAGCCGGGAGGACCGGGA 
Group 3           CTCCCACCCTCAGGCTCCTCGGTGGCCTCCGCACCCGGGCAAAAGCCGGGAGGACCGGGA 
Group 4           CTCCCACCCTCAGGCTCCTCGGTGGCCTCCGCACCCGGGCAAAAGCCGGGAGGACCGGGA 
Group 5           CTCCCACCCTCAGGCTCCTCGGTGGCCTCCGCACCCGGGCAAAAGTCGGGAGGACCGGGA 
Group 6           CTCCCACCCTCAGGCTCCTCGGTGGCCTCCGCACCCGGGCAAAAGCCGGGAGGACCGGGA 
Group 7           CTCCCACCCTCAGGCTCCTCGGTGGCCTCCGCACCCGGGCAAAAGCCGGGAGGACCGGGA 
Group 8           CTCCCACCCTCAGGCTCCTCGGTGGCCTCCGCACCCGGGCAAAAGCCGGGAGGACCGGGA 
Group 9           CTCCCACCCTCAGGCTCCTCGGTGGCCTCCGCACCCGGGCAAAAGCCGGGAGGACCGGGA 
Group 10          CTCCCACCCTCAGGCTCCTCGGTGGCCTCCGCACCCGGGCAAAAGCCGGGAGGACCGGGA 
Group 11          CTCCCACCCTCAGGCTCCTCGGTGGCCTCCGCACCCGGGCAAAAGCCGGGAGGACCGGGA 
Group 12          CTCCCACCCTCAGGCTCCTCGGTGGCCTCCGCACCCGGGCAAAAGCCGGGAGGACCGGGA 
Group 13          CTCCCACCCTCAGGCTCCTCGGTGGCCTCCGCACCCGGGCAAAAGCCGGGAGGACCGGGA 
Group 14          CTCCCACCCTCAGGCTCCTCGGTGGCCTCCGCACCCGGGCAAAAGCCGGGAGGACCGGGA 
Group 15          CTCCCACCCTCAGGCTCCTCGGTGGCCTCCGCACCCGGGCAAAAGCCGGGAGGACCGGGA 
Group 16          CTCCCACCCTCAGGCTCCTCGGTGGCCTCCGCACCCGGGCAAAAGCCGGGAGGACCGGGA 
Group 17          CTCCCACCCTCAGGCTCCTCGGTGGCCTCCGCACCCGGGCAAAAGCCGGGAGGACCGGGA 
 
FJ439133    6758  CTCCCACCCTCAGGCTCCTCGCTGGCCTCCGCACCCGGGCAAAAGCCGGGAGGACCGGGA 
                   S  H  P  Q  A  P  R  W  P  P  H  P  G  K  S  R  E  D  R  D  
                                       *                       *               
 
Group 1           CCCGCAGCGCGACGGCCTGCCGGGCCCCTGCGCGGTGGCACAGCCTGGGCCCGCTCAAGC 
Group 2           CCCGCAGCGCGACGGCCTGCCGGGCCCCTGCGCGGTGGCACAGCCTGGGCCCGCTCAAGC 
Group 3           CCCGCAGCGCGACGGCCTGCCGGGCCCCTGCGCGGTGGCACAGCCTGGGCCCGCTCAAGC 
Group 4           CCCGCAGCGCGACGGCCTGCCGGGCCCCTGCGCGGTGGCACAGCCTGGGCCCGCTCAAGC 
Group 5           CCCGCAGCGCGACGGCCTGCCGGGCCCCTGCGCGGTGGCACAGCCTGGGCCCGCTCAAGC 
Group 6           CCCGCAGCGCGACGGCCTGCCGGGCCCCTGCGCGGTGGCACAGCCTGGGCCCGCTCAAGC 
Group 7           CCCGCAGCGCGACGGCCTGCCGGGCCCCTGCGCGGTGGCACAGCCTGGGCCCGCTCAAGC 
Group 8           CCCGCAGCGCGACGGCCTGCCGGGCCCCTGCGCGGTGGCACAGCCTGGGCCCGCTCAAGC 
Group 9           CCCGCAGCGCGACGGCCTGCCGGGCCCCTGCGCGGTGGCACAGCCTGGGCCCGCTCAAGC 
Group 10          CCCGCAGCGCGACGGCCTGCCGGGCCCCTGCGCGGTG:CACAGCCTGGGCCCGCTCAAGC 
Group 11          CCCGCAGCGCGACGGCCTGCCGGGCCCCTGCGCGGTGGCACAGCCTGGGCCCGCTCAAGC 
Group 12          CCCGCAGCGCGACGGCCTGCCGGGCCCCTGCGCGGTGGCACAGCCTGGGCCCGCTCAAGC 
Group 13          CCCGCAGCGCGACGGCCTGCCGGGCCCCTGCGCGGTGGCACAGCCTGGGCCCGCTCAAGC 
Group 14          CCCGCAGCGCGACGGCCTGCCGGGCCCCTGCGCGGTGGCACAGCCTGGGCCCGCTCAAGC 
Group 15          CCCGCAGCGCGACGGCCTGCCGGGCCCCTGCGCGGTGGCACAGCCTGGGCCCGCTCAAGC 
Group 16          CCCGCAGCGCGACGGCCTGCCGGGCCCCTGCGCGGTGGCACAGCCTGGGCCCGCTCAAGC 
Group 17          CCCGCAGCGCGACGGCCTGCCGGGCCCCTGCGCGGTGGCACAGCCTGGGCCCGCTCAAGC 
                               
FJ439133    6818  CCCGCAGCGCGACGGCCTGCCGGGCCCCTGCGCGGTGGCACAGCCTGGGCCCGCTCAAGC 
                   P  Q  R  D  G  L  P  G  P  C  A  V  A  Q  P  G  P  A  Q  A  
                                                       *                       
 
Group 1           GGGGCCGCAGGGCCAAGGGGTGCTTGCGCCACCCACGTCCCAGGGGAGTCCGTGGTGGGG 
Group 2           GGGGCCGCAGGGCCAAGGGGTGCTTGCGCCACCCACGTCCCAGGGGAGTCCGTGGTGGGG 
Group 3           GGGGCCGCAGGGCCAAGGGGTGCTTGCGCCACCCGCGTCCCAGGGGAGTCCGTGGTGGGG 
Group 4           GGGGCCGCAGGGCCAAGGGGTGCTTGCGCCACCCGCGTCCCAGGGGAGTCCGTGGTGGGG 
Group 5           GGGGCCGCAGGGCCAAGGGGTGCTTGCGCCACCCACGTCCCAGGGGAGTCCGTGGTGGGG 
Group 6           GGGGCCGCAGGGCCAAGGGGTGCTTGCGCCACCCACGTCCCAGGGGAGTCCGTGGTGGGG 
Group 7           GGGGCCGCAGGGCCAAGGGGTGCTTGCGCCACCCACGTCCCAGGGGAGTCCGTGGTGGGG 
Group 8           GGGGCCGCAGGGCCAAGGGGTGCTTGCGCCACCCACGTCCCAGGGGAGTCCGTGGTGGGG 
Group 9           GGGGCCGCAGGGCCAAGGGGTGCTTGCGCCACCCACGTCCCAGGGGAGTCCGTGGTGGGG 
Group 10          GGGGCCGCAGGGCCAAGGGGTGCTTGCGCCACCCACGTCCCAGGGGAGTCCGTGGTGGGG 
Group 11          GGGGCCGCAGGGCCAAGGGGTGCTTGCGCCACCCACGTCCCAGGGGAGTCCGTGGTGGGG 
Group 12          GGGGCCGCAGGGCCAAGGGGTGCTTGCGCCACCCACGTCCCAGGGGAGTCCGTGGTGGG: 
Group 13          GGGGCCGCAGGGCCAAGGGGTGCTTGCGCCACCCACGTCCCAGGGGAGTCCGTGGTGGGG 
Group 14          GGGGCCGCAGGGCCAAGGGGTGCTTGCGCCACCCACGTCCCAGGGGAGTCCGTGGTGGGG 
Group 15          GGGGCCGCAGGGCCAAGGGGTGCTTGCGCCACCCACGTCCCAGGGGAGTCCGTGGTGGGG 
Group 16          GGGGCCGCAGGGCCAAGGGGTGCTTGCGCCACCCACGTCCCAGGGGAGTCCGTGGTGGGG 
Group 17          GGGGCCGCAGGGCCAAGGGGTGCTTGCGCCACCCACGTCCCAGGGGAGTCCGTGGTGGGG 
 
FJ439133    6878  GGGGCCGCAGGGCCAAGGGGTGCTTGCGCCACCCACGTCCCAGGGGAGTCCGTGGTGGGG 
                   G  P  Q  G  Q  G  V  L  A  P  P  T  S  Q  G  S  P  W  W  G  
                                                    *                        * 
 
 
 
 
 
 
 
 
 
 
 
 117 
Group 1           CTGGGGCCGGGGTCCGCAGGTCGCTGGGGCGGCGTGGGAACCCCAAGCCGGGGCAGCTCC 
Group 2           CTGGGGCCGGGGTCCGCAGGTCGCTGGGGCGGCGTGGGAACCCCAAGCCGGGGCAGCTCC 
Group 3           CTGGGGCCGGGGTCCGCAGGTCGCTGGGGCGGCGTGGGAACCCCAAGCCGGGGCAGCTCC 
Group 4           CTGGGGCCGGGGTCCGCAGGTCGCTGGGGCGGCGTGGGAACCCCAAGCCGGGGCAGCTCC 
Group 5           CTGGGGCCGGGGTCCGCAGGTCGCTGGGGCGGCGTGGGAACCCCAAGCCGGGGCAGCTCC 
Group 6           CTGGGGCCGGGGTCCCCAGGTCGCCGGGGCGGCGTGGGAACCCCAAGCCGGGGCAGCTCC 
Group 7           CTGGGGCCGGGGTCCTCAGGTCGCTGGGGCGGCGTGGGAACCCCAAGCCGGGGCAGCTCC 
Group 8           CTGGGGCCGGGGTCCCCAGGTCGCCGGGGCGGCGTGGGAACCCCAAGCCGGGGCAGCTCC 
Group 9           CTGGGGCCGGGGTCCCCAGGTCGCCGGGGCGGCGTGGGAACCCCAAGCCGGGGCAGCTCC 
Group 10          CTGGGGCCGGGGTCCCCAGGTCGCCGGGGCGGCGTGGGAACCCCAAGCCGGGGCAGCTCC 
Group 11          CTGGGGCCGGGGTCCCCAGGTCGCCGGGGCGGCGTGGGAACCCCAAGCCGGGGCAGCTCC 
Group 12          CTGGGGCCGGGGTCCCCAGGTCGCCGGGGCGGCGTGGGAACCCCAAGCCGGGGCAGCTCC 
Group 13          CTGGGGCCGGGGTCCCCAGGTCGCCGGGGCGGCGTGGGAACCCCAAGCCGGGGCAGCTCC 
Group 14          CTGGGGCCGGGGTCCCCAGGTCGCCGGGGCGGCGTGGGAACCCCAAGCCGGGGCAGCTCC 
Group 15          CTGGGGCCGGGGTCCGCAGGTCGCTGGGGCGGCGTGGGAACCCCAAGCCGGGGCAGCTCC 
Group 16          CTGGGGCCGGGGTCCCCAGGTCGCCGGGGCGGCGTGGGAACCCCAAGCCGGGGCAGCTCC 
Group 17          CTGGGGCCGGGGTCCCCAGGTCGCCGGGGCGGCGTGGGAACCCCAAGCCGGGGCAGCTCC 
 
FJ439133    6938  CTGGGGCCGGGGTCCCCAGGTCGCCGGGGCGGCGTGGGAACCCCAAGCCGGGGCAGCTCC 
                   W  G  R  G  P  Q  V  A  G  A  A  W  E  P  Q  A  G  A  A  P  
                                 *        *                                    
 
 
 
 
Group 1           ACCTCCCCAGCCCGCGCCCCCGGACGCCTCC::::::GCGCGGCAGGGGCAGATGCAAGG 
Group 2           ACCTCCCCAGCCCGCGCCCCCGGACGCCTCC::::::GCGCGGCAGGGGCAGATGCAAGG 
Group 3           ACCTCCCCAGCCCGCGCCCCCGGACGCCTCC::::::GCGCGGCAGGGGCAGATGCAAGG 
Group 4           ACCTCCCCAGCCCGCGCCCCCGGACGCCTCC::::::GCGCGGCAGGGGCAGATGCAAGG 
Group 5           ACCTCCCCAGCCCGCGCCCCCGGACGCCTCC::::::GCGCGGCAGGGGCAGATGCAAGG 
Group 6           ACCCCCCCAGCCCGCGCCCCCGGACGCCTCC::::::GCGCGGCAGGGGCAGATGCAAGG 
Group 7           ACCTCCCCAGCCCGCGCCCCCGGACGCCTCC::::::GCGCGGCAGGGGCAGATGCAAGG 
Group 8           ACCTCCCCAGCCCGCGCCCCCGGACGCCTCCGCCTCCGCGCGGCAGGGGCAGATGCAAGG 
Group 9           ACCTCCCCAGCCCGCGCCCCCGGACGCCTCCGCCTCCGCGCGGCAGGGGCAGATGCAAGG 
Group 10          ACCTCCCCAGCCCGCGCCCCCGGACGCCTCCACCTCCGCGCGGCAGGGGCAGATGCAAGG 
Group 11          ACCTCCCCAGCCCGCGCCCCCGGACGCCTCCGCCTCCGCGCGGCAGGGGCAGATGCAAGG 
Group 12          ACCTCCCCAGCCCGCGCCCCCGGACGCCTCCGCCTCCGCGCGGCAGGGGCAGATGCAAGG 
Group 13          ACCTCCCCAGCCCGCGCCCCCGGACGCCTCCGCCTCCGCGCGGCAGGGGCAGATGCAAGG 
Group 14          ACCTCCCCAGCCCGCGCCCCCGGACGCCTCC::::::GCGCGGCAGGGGCAGATGCAAGG 
Group 15          ACCTCCCCAGCCCGCGCCCCCGGACGCCTCC::::::GCGCGGCAGGGGCAGATGCAAGG 
Group 16          ACCTCCCCAGCCCGCGCCCCCGGACGCCTCC::::::GCGCGGCAGGGGCAGATGCAAGG 
Group 17          ACCTCCCCAGCCCGCGCCCCCGGACGCCTCCGCCTCCGCGCGGCAGGGGCAGATGCAAGG 
 
FJ439133    6998  ACCTCCCCAGCCCGCGCCCCCGGACGCCTCCGCCTCCGCGCGGCAGGGGCAGATGCAAGG 
                   P  P  Q  P  A  P  P  D  A  S  A  S  A  R  Q  G  Q  M  Q  G  
                     *                           ******                      
 
Group 1           CATCCCGGCGCCCTCCCAGGCGCTCCAGGAGCCGGCGCCCTGGTCTGCACTCCCCTGCGG 
Group 2           CATCCCGGCGCCCTCCCAGGCGCTCCAGGAGCCGGCGCCCTGGTCTGCACTCCCCTGCGG 
Group 3           CATCCCGGCGCCCTCCCAGGCGCTCCAGGAGCCGGCGCCCTGGTCTGCACTCCCCTGCGG 
Group 4           CATCCCGGCGCCCTCCCAGGCGCTCCAGGAGCCGGCGCCCTGGTCTGCACTCCCCTGCGG 
Group 5           CATCCCGGCGCCCTCCCAGGCGCTCCAGGAGCCGGCGCCCTGGTCTGCACTCCCCTGCGG 
Group 6           CATCCCGGCGCCCTCCCAGGCGCTCCAGGAGCCGGCGCCCTGGTCTGCACTCCCCTGCGG 
Group 7           CATCCCGGCGCCCTCCCAGGCGCTCCAGGAGCCGGCGCCCTGGTCTGCACTCCCCTGCGG 
Group 8           CATCCCGGCGCCCTCCCAGGCGCTCCGGGAGCCGGCGCCCTGGTCTGCACTCCCCTGCGG 
Group 9           CATCCCGGCGCCCTCCCAGGCGCTCCAGGAGCCGGCGCCCTGGTCTGCACTCCCCTGCGG 
Group 10          CATCCCGGCGCCCTCCCAGGCGCTCCAGGAGCCGGCGCCCTGGTCTGCACTCCCCTGCGG 
Group 11          CATCCCGGCGCCCTCCCAGGCGCTCCAGGAGCCGGCGCCCTGGTCTGCACTCCCCTGCGG 
Group 12          CATCCCGGCGCCCTCCCAGGCGCTCCAGGAGCCGGCGCCCTGGTCTGCACTCCCCTGCGG 
Group 13          CATCCCGGCGCCCTCCCAGGCGCTCCAGGAGCCGGCGCCCTGGTCTGCACTCCCCTGCGG 
Group 14          CATCCCGGCGCCCTCCCAGGCGCTCCAGGAGCCGGCGCCCTGGTCTGCACTCCCCTGCGG 
Group 15          CATCCCGGCGCCCTCCCAGGCGCTCCAGGAGCCGGCGCCCTGGTCTGCACCCCCCTGCGG 
Group 16          CATCCCGGCGCCCTCCCAGGCGCTCCAGGAGCCGGCGCCCTGGTCTGCACTCCCCTGCGG 
Group 17          CATCCCGGCGCCCTCCCAGGCGCTCCAGGAGCCGGCGCCCTGGTCTGCACTCCCCTGCGG 
 
FJ439133    7058  CATCCCGGCGCCCTCCCAGGCGCTCCAGGAGCCGGCGCCCTGGTCTGCACTCCCCTGCGG 
                   I  P  A  P  S  Q  A  L  Q  E  P  A  P  W  S  A  L  P  C  G  
                                            *                       *          
 
 
 
 
 
 
 
 
 118 
Group 1           CCTGCTGCTGGATGAGCTCCTGGCGAGCCCGGAGTTTCTGCAGCAGGCG 
Group 2           CCTGCTGCTGGATGAGCTCCTGGCGAGCCCGGAGTTTCTGCAGCAGGCG 
Group 3           CCTGCTGCTGGATGAGCTCCTGGCGAGCCCGGAGTTTCTGCAGCAGGCG 
Group 4           CCTGCTGCTGGATGAGCTCCTGGCGAGCCCGGAGTTTCTGCAGCAGGCG 
Group 5           CCTGCTGCTGGATGAGCTCCTGGCGAGCCCGGAGTTTCTGCAGCAGGCG 
Group 6           CCTGCTGCTGGATGAGCTCCTGGCGAGCCCGGAGTTTCTGCAGCAGGCG 
Group 7           CCTGCTGCTGGATGAGCTCCTGGCGAGCCCGGAGTTTCTGCAGCAGGCG 
Group 8           CCTGCTGCTGGATGAGCTCCTGGCGAGCCCGGAGTTTCTGCAGCAGGCG 
Group 9           CCTGCTGCTGGATGAGCTCCTGGCGAGCCCGGAGTTTCTGCAGCAGGCG 
Group 10          CCTGCTGCTGGATGAGCTCCTGGCGAGCCCGGAGTTTCTGCAGCAGGCG 
Group 11          CCTGTTGCTGGATGAGCTCCTGGCGAGCCCGGAGTTTCTGCAGCAGGCG 
Group 12          CCTGTTGCTGGATGAGCTCCTGGCGAGCCTGGAGTTTCTGCAGCAGGCG 
Group 13          CCTGCTGCTGGATGAGCTCCTGGCGAGCCCGGAGTTTCTGCAGCAGGCG 
Group 14          CCTGCTGCTGGATGAGCTCCTGGCGAGCCCGGAGTTTCTGCAGCAGGCG 
Group 15          CCTGCTGCTGGATGAGCTCCTGGCGAGCCCGGAGTTTCTGCAGCAGGCG 
Group 16          CCTGCTGCTGGATGAGCTCCTGGCGAGCCCGGAGTTTCTGCAGCAGGCG 
Group 17          CCTGCTGCTGGATGAGCTCCTGGCGAGCCCGGAGTTTCTGCAGCAGGCG 
 
FJ439133    7118  CCTGCTGCTGGATGAGCTCCTGGCGAGCCCGGAGTTTCTGCAGCAGGCG 
                   L  L  L  D  E  L  L  A  S  P  E  F  L  Q  Q  A   
                      *                        *                    
 
 
 
Figure 4.8 Alignment of the 17 distinct groups of expressed sequences 
 
Alignment of the 17 distinct groups identified in the expressed RT-PCR products. DNA 
sequences were edited manually to correct base-calling errors. Primer sequences were 
trimmed and sequences aligned using ClustalW. Sequences are compared to the equivalent 
region of the most distal D4Z4 repeat unit in the FJ439133 (GenBank) reference sequence. 
Group 11 is represented by a single clone that failed to sequence from the 5 end. The 
translation is shown underneath and base changes from the consensus are highlighted with 
an asterisk. For an overview of the variants see Table 4.2. 
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Position 6559 6584 6678 6690 6704 6714 6779 6953 6963 7031 7122 7147 
Variant 
Group 
Number 
of 
Clones 
C C C A C G C C C (GCCTCC)n C C 
1 4 G G A G C C G G T 1 C C 
2 1 A G A G C C G C T 1 C C 
15 2 A G A G C C G G T 1 C C 
14 1 A G A G C C G C C 1 C C 
3 2 C G A G C G G G T 1 C C 
8 11 A G A G C G G C C 2 C C 
17 3 A C A G C G G C C 2 C C 
10 1 C C A G C C G C C 2 C C 
4 3 C C C G C G G C C 1 C C 
5 1 C C C A C G G G T 1 C C 
6 19 C C C A C G G C C 1 C C 
7 11 C C C A C G G C T 1 C C 
9 7 C C C A A G G C C 2 C C 
11 1 nd nd C A C G G C C 2 T C 
12 6 C C C G C G G C C 2 T T 
13 14 C C C G C G G C C 2 C C 
16 1 C C C A A G G C C 1 C C 
Coding change 
* 
 
* * 
 
* 
     
* 
A - E       
A - G  
P - T I - V 
 
G - R 
     
P - L 
 
 
Table 4.2 Summary of variant groups identified from hEC RT-PCR products 
The FJ439133 sequence is shown at the top with sequence position identified. Sequence 
variants for each of the 17 haplotypes are shown, blue blocks are the same base as the 
FJ439133 sequence, orange blocks indicate a change. All variants fall within the ORF, 
however, none are within the homeobox region. Coding changes are highlighted with an 
asterisk and the amino acid change is shown underneath. There is a 6bp indel in 50% of 
clones, 1 indicates a single copy of the GCCTCC sequence, 2 indicates there are two copies 
present in the variant.  
 
 
 
 
 
 120 
 
 
 
                                                  
 
 
 
 
 
Figure 4.9 Clustal alignment of the conserved C-terminal domain 
Taken from Clapp et al. (2007). Clustal alignments of the C-terminal regions of DUXc, DUX4 
and the mouse and rat DUX proteins. Residues that are invariant in all species are highlighted 
in black. Residues that are conserved in at least 60% sequences are highlighted in dark grey, 
with conservation substitutions in light grey. The proline residue which is changed in 6 of the 
hEC RT-PCR products is indicated with an asterisk. 
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4.2.6.i Comparison of expressed variant groups with genomic sequence 
data 
As described in Section 4.2.5, it is likely that both of the chromosome 4 alleles in the hEC 
cell line are 4qB163 alleles. The HHW416 somatic cell hybrid (donated by Dr. Sara Winokur) 
was haplotyped by an MRes student in the laboratory using sequence variants identified by 
Lemmers et al. (2007), and was shown to contain a 4qB163 allele. Amplification of 
overlapping fragments that covered the repeat unit had been carried out on genomic DNA 
from the cell line. 89 PCR products had been cloned and sequenced. As both cell lines contain 
the 4qB163 allele, the expressed hEC sequences were compared with the genomic HHW416 
sequences, to determine whether they shared variants and might provide information about 
which repeats in the array are expressed. 
Like the expressed sequences, the HHW416 sequences were compared with the GenBank 
sequence FJ439133. The 104 genomic sequences were split into 26 distinct groups which 
were identified by 20 variant positions (Table 4.3). Of the 14 variant positions identified in the 
hEC sequences, 10 of these were also seen in the HHW416 sequences.  However, of the 17 
expressed hEC groups, only 4 were identical to a HHW416 genomic group (Table 4.4). The 
genomic sequences are longer than the expressed hEC transcripts, as such they contain more 
variant positions and based on this extra information they could be separated into more 
distinct groups than the hEC transcripts. This has resulted in more than one of the genomic 
sequences being a potential match for the expressed hEC groups, 13 and 17 (see Table 4.4). 
Work in Jane Hewitts laboratory has also identified variant positions in 4qA161 and 
10qA166 genomic sequences, the number of genomic clones containing each of the variants 
identified in this work have been included in Table 4.3. All 31 of the 10qA166 clones 
contained the C-G variant at position 6779, this variant was not seen in any of the 4qA161 
clones. In addition, 4 4qA161 and 1 10qA166 alleles contained the GCCTCC duplication, and a 
further 3 variants were seen in single 4qA161 sequences. 
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4.2.6.ii Comparison of sense and antisense data 
In order to establish whether any of the expressed haplotypes were specific to sense or 
antisense expression, sequences were grouped according to the strand from which they were 
transcribed. Where both primers were present during the reverse transcription reaction, 
sequences were recorded as unknown. The data is summarised in Table 4.5 and although 
there are some haplotypes that contain only one type of transcript, there are no large 
preferences for one or the other strand in any of the haplotypes.  
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Table 4.3 Distinct sequence groups amplified from the HHW416 cell line 
The FJ439133 sequence is shown on the top line. Sequence variants for each of the groups are shown, blue blocks are the same base as the FJ439133 sequence, orange 
blocks indicate a change from the consensus. Coding changes are highlighted with an asterisk. The in-frame duplication at position 7031 in 50% of the groups, 1 indicates a 
single copy of the GCCTCC sequence, 2 indicates two copies present. Variants that are also present in the hEC RT-PCR products (see Table 4.1) are indicated with a ݱ. Work 
in Jane Hewitts laboratory has also identified variant positions in 4qA161 and 10qA166 genomic sequences; the number of genomic clones containing each base change is 
indicated for each of these alleles. 
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Table 4.4 Comparison of RT-PCR products and genomic sequence 
Sequences of transcripts amplified from hEC RNA were compared with genomic sequence 
data from the HHW416 cell line. Genomic haplotypes which potentially match the expressed 
groups are shown in the right hand column. 
 
Expressed group 
Genomic Variant 
Group 
1 No match 
2 No match 
3 No match 
4 No match 
5 No match 
6 No match 
7 20 
8 11 
9 No match 
10 No match 
11 No match 
12 No match 
13 1,2,4,7 
14 No match 
15 No match 
16 No match 
17 8,9,10 
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Group Sense Antisense Unknown Total 
1   1 3 4 
2   1   1 
3 1 1   2 
4 3     3 
5     1 1 
6 3   16 19 
7 5 4 2 11 
8 2 7 2 11 
9 3   4 7 
10 1     1 
11 1     1 
12   5 1 6 
13 7 4 3 14 
14   1   1 
15   1 1 2 
16 1     1 
17 2 1   3 
 
 
 
Table 4.5 Comparison of group between sense and antisense transcripts 
The distribution of sense and antisense transcripts across the 17 expressed groups identified 
from the hEC cell RNA. Where both primers were present during the reverse transcription 
reaction the orientation of transcripts is listed as unknown. 
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4.2.7 Expression at the 3and 5 ends of the ORF 
In their 2009 publication, Snider et al. also had difficulty amplifying full length transcripts 
from D4Z4 however they were able to amplify smaller transcripts from the 3 and 5 ends of 
the ORF. The RT-PCRs they describe in the paper (Figure 4.10a) were repeated on RNA 
extracted from the myoblast cell lines established in this lab. However, no amplification was 
seen from either proliferating or differentiating stages (Figure 4.10d). 
It was possible to amplify transcripts at the 5 end of the ORF (primer pairs 1797/1906 and 
1797/2235) from hEC cell RNA (Figure 4.10c); although attempts to amplify products from the 
3 end of the ORF (2672/2952) were unsuccessful (Figure 4.10c). The fragments from primers 
1797-2235 were cloned and 11 were sequenced, 8 of which were identical (Figure 4.11). In 
addition, the final 3 sequences had only a single base pair change from FJ439133, this was in a 
different position in each sequence so could not be excluded as a PCR error. As this PCR 
product covers the homeobox sequences it would be expected to be highly constrained and 
so a lack of variant positions in this region is expected. 
This fragment overlaps with the first 96bp of the HDUX4 transcript to cover the whole of 
the ORF (Figure 4.10b). However, the overlap does not contain sufficient variants to link 
unambiguously these RT-PCR products to those amplified with the HDUX4 primers. 
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Figure 4.10 Attempts to amplify fragments from the ORF using primers from Snider 
et al. (2009) 
a) Location of the primer pairs used by Snider et al. (2009). The ORF is shown in pale blue with 
homeodomains highlighted in dark blue. The pLAM region is shown in green. Predicted 
transcripts are shown underneath in orange. b) Schematic representation of the overlap 
between the HDUX4 and 1797/2235. c) RT-PCR on RNA extracted from hEC cells using 
Tapscott primer pairs shown in a. d) RT-PCR on RNA extracted from GM17731 cells using 
primer pairs 1797/1906 and 1797/2235. The integrity of all RNA samples was checked using 
an RT-PCR for ɴ-actin, as described in Section 2.4.1 and Figure 2.5. 
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FJ439133 6001   CCGCGATGGCCCTCCCGACACCCTCGGACAGCACCCTCCCCGCGGAAGCCCGGGGACGAG 
hEC 3                ATGGCCCTCCCGACACCCTCGGACAGCACCCTCCCCGCGGAAGCCCGGGGACGGG 
hEC 4                ATGGCCCTCCCGACACCCTCGGACAGCACCCTCCCCGCGGAAGCCCGGGGACGAG 
hEC 7                ATGGCCCTCCCGACACCCTCGGACAGCACCCTCCCCGCGGAAGCCCGGGGACGAG 
hEC 13               ATGGCCCTCCCGACACCCTCGGACAGCACCCTCCCCGCGGAAGCCCGGGGACGAG 
hEC 12               ATGGCCCTCCCGACACCCTCGGACAGCACCCTCCCCGCGGAAGCCCGGGGACGAG 
hEC 11               ATGGCCCTCCCGACACCCTCGGACAGCACCCTCCCCGCGGAAGCCCGGGGACGAG 
hEC 8                ATGGCCCTCCCGACACCCTCGGACAGCACCCTCCCCGCGGAAGCCCGGGGACGAG 
hEC 6                ATGGCCCTCCCGACACCCTCGGACAGCACCCTCCCCGCGGAAGCCCGGGGACGAG 
hEC 9                ATGGCCCTCCCGACACCCTCGGACAGCACCCTCCCCGCGGAAGCCCGGGGACGAG 
hEC 10               ATGGCCCTCCCGACACCCTCGGACAGCACCCTCCCCGCGGAAGCCCGGGGACGAG 
hEC 5                ATGGCCCTCCCGACACCCTCGGACAGCACCCTCCCCGCGGAAGCCCGGGGACGAG 
                  A  M  A  L  P  T  P  S  D  S  T  L  P  A  E  A  R  G  R  G 
                                                                          *  
 
FJ439133 6061   GACGGCGACGGAGACTCGTTTGGACCCCGAGCCAAAGCGAGGCCCTGCGAGCCTGCTTTG 
hEC 3           GACGGCGACGGAGACTCGTTTGGACCCCGAGCCAAAGCGAGGCCCTGCGAGCCTGCTTTG 
hEC 4           GACGGCGACGGAGACTCGTTTGGACCCCGAGCCAAAGCGAGGCCCTGCGAGCCTGCTTTG 
hEC 7           GACGGCGACGGAGACTCGTTTGGACCCCGAGCCAAAGCGAGGCCCTGCGAGCCTGCTTTG 
hEC 13          GACGGCGACGGAGACTCGTTTGGACCCCGAGCCAAAGCGAGGCCCTGCGAGCCTGCTTTG 
hEC 12          GACGGCGACGGAGACTCGTTTGGACCCCGAGCCAAAGCGAGGCCCTGCGAGCCTGCTTTG 
hEC 11          GACGGCGACGGAGACTCGTTTGGACCCCGAGCCAAAGCGAGGCCCTGCGAGCCTGCTTTG 
hEC 8           GACGGCGACGGAGACTCGTTTGGACCCCGAGCCAAAGCGAGGCCCTGCGAGCCTGCTTTG 
hEC 6           GACGGCGACGGAGACTCGTTTGGACCCCGAGCCAAAGCGAGGCCCTGCGAGCCTGCTTTG 
hEC 9           GACGGCGACGGAGACTCGTTTGGACCCCGAGCCAAAGCGAGGCCCTGCGAGCCTGCTTTG 
hEC 10          GACGGCGACGGAGACTCGTTTGGACCCCGAGCCAAAGCGAGGCCCTGCGAGCCTGCTTTG 
hEC 5           GACGGCGACGGAGACTCGTTTGGACCCCGAGCCAAAGCGAGGCCCTGCGAGCCTGCTTTG 
                  R  R  R  R  L  V  W  T  P  S  Q  S  E  A  L  R  A  C  F  E 
                             
 
FJ439133 6121   AGCGGAACCCGTACCCGGGCATCGCCACCAGAGAACGGCTGGCCCAGGCCATCGGCATTC 
hEC 3           AGCGGAACCCGTACCCGGGCATCGCCACCAGAGAACGGCTGGCCCAGGCCATCGGCATTC 
hEC 4           AGCGGAACCCGTACCCGGGCATCGCCACCAGAGAACGGCTGGCCCAGGCCATCGGCATTC 
hEC 7           AGCGGAACCCGTACCCGGGCATCGCCACCAGAGAACGGCTGGCCCAGGCCATCGGCATTC 
hEC 13          AGCGGAACCCGTACCCGGGCATCGCCACCAGAGAACGGCTGGCCCAGGCCATCGGCATTC 
hEC 12          AGCGGAACCCGTACCCGGGCATCGCCACCAGAGAACGGCTGGCCCAGGCCATCGGCATTC 
hEC 11          AGCGGAACCCGTACCCGGGCATCGCCACCAGAGAACGGCTGGCCCAGGCCATCGGCATTC 
hEC 8           AGCGGAACCCGTACCCGGGCATCGCCACCAGAGAACGGCTGGCCCAGGCCATCGGCATTC 
hEC 6           AGCGGAACCCGTACCCGGGCATCGCCACCAGAGAACGGCTGGCCCAGGCCATCGGCATTC 
hEC 9           AGCGGAACCCGTACCCGGGCATCGCCACCAGAGAACGGCTGGCCCAGGCCATCGGCATTC 
hEC 10          AGCGGAACCCGTACCCGGGCATCGCCACCAGAGAACGGCTGGCCCAGGCCATCGGCATTC 
hEC 5           AGCGGAACCCGTACCCGGGCATCGCCACCAGAGAACGGCTGGCCCAGGCCATCGGCATTC 
                  R  N  P  Y  P  G  I  A  T  R  E  R  L  A  Q  A  I  G  I  P 
                             
 
FJ439133 6181   CGGAGCCCAGGGTCCAGATTTGGTTTCAGAATGAGAGGTCACGCCAGCTGAGGCAGCACC 
hEC 3           CGGAGCCCAGGGTCCAGATTTGGTTTCAGAATGAGAGGTCACGCCAGCTGAGGCAGCACC 
hEC 4           CGGAGCCCAGGGTCCAGATTTGGTTTCAGAATGAGAGGTCACGCCAGCTGAGGCAGCACC 
hEC 7           CGGAGCCCAGGGTCCAGATTTGGTTTCAGAATGAGAGGTCACGCCAGCTGAGGCAGCACC 
hEC 13          CGGAGCCCAGGGTCCAGATTTGGTTTCAGAATGAGAGGTCACGCCAGCTGAGGCAGCACC 
hEC 12          CGGAGCCCAGGGTCCAGATTTGGTTTCAGAATGAGAGGTCACGCCAGCTGAGGCAGCACC 
hEC 11          CGGAGCCCAGGGTCCAGATTTGGTTTCAGAATGAGAGGTCACGCCAGCTGAGGCAGCACC 
hEC 8           CGGAGCCCAGGGTCCAGATTTGGTTTCAGAATGAGAGGTCACGCCAGCTGAGGCAGCACC 
hEC 6           CGGAGCCCAGGGTCCAGATTTGGTTTCAGAATGAGAGGTCACGCCAGCTGAGGCAGCACC 
hEC 9           CGGAGCCCAGGGTCCAGATTTGGTTTCAGAATGAGAGGTCACGCCAGCTGAGGCAGCACC 
hEC 10          CGGAGCCCAGGGTCCAGATTTGGTTTCAGAATGAGAGGTCACGCCAGCTGAGGCAGCACC 
hEC 5           CGGAGCCCAGGGTCCAGATTTGGTTTCAGAATGAGAGGTCACGCCAGCTGAGGCAGCACC 
                  E  P  R  V  Q  I  W  F  Q  N  E  R  S  R  Q  L  R  Q  H  R 
  
 
 
FJ439133 6241   GGCGGGAATCTCGGCCCTGGCCCGGGAGACGCGGCCCGCCAGAAGGCCGGCGAAAGCGGA 
hEC 3           GGCGGGAATCTCGGCCCTGGCCCGGGAGACGCGGCCCGCCAGAAGGCCGGCGAAAGCGGA 
hEC 4           GGCGGGAATCTCGGCCCTGGCCCGGGAGACGCGGCCCGCCAGAAGGCCGGCGAAAGCGGA 
hEC 7           GGCGGGAATCTCGGCCCTGGCCCGGGAGACGCGGCCCGCCAGAAGGCCGGCGAAAGCGGA 
hEC 13          GGCGGGAATCTCGGCCCTGGCCCGGGAGACGCGGCCCGCCAGAAGGCCGGCGAAAGCGGA 
hEC 12          GGCGGGAATCTCGGCCCTGGCCCGGGAGACGCGGCCCGCCAGAAGGCCGGCGAAAGCGGA 
hEC 11          GGCGGGAATCTCGGCCCTGGCCCGGGAGACGCGGCCCGCCAGAAGGCCGGCGAAAGCGGA 
hEC 8           GGCGGGAATCTCGGCCCTGGCCCGGGAGACGCGGCCCGCCAGAAGGCCGGCGAAAGCGGA 
hEC 6           GGCGGGAATCTCGGCCCTGGCCCGGGAGACACGGCCCGCCAGAAGGCCGGCGAAAGCGGA 
hEC 9           GGCGGGAATCTCGGCCCTGGCCCGGGAGACGCGGCCCGCCAGAAGGCCGGCGAAAGCGGA 
hEC 10          GGCGGGAATCTCGGCCCTGGCCCGGGAGACGCGGCCCGCCAGAAGGCCGGCGAAAGCGGA 
hEC 5           GGCGGGAATCTCGGCCCTGGCCCGGGAGACGCGGCCCGCCAGAAGGCCGGCGAAAGCGGA 
                   R  E  S  R  P  W  P  G  R  R  G  P  P  E  G  R  R  K  R  T 
                                              *                  
 
FJ439133 6301   CCGCCGTCACCGGATCCCAGACCGCCCTGCTCCTCCGAGCCTTTGAGAAGGATCGCTTTC 
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hEC 3           CCGCCGTCACCGGATCCCAGACCGCCCTGCTCCTCCGAGCCTTTGAGAAGGATCGCTTTC 
hEC 4           CCGCCGTCACCGGATCCCAGACCGCCCTGCTCCTCCGAGCCTTTGAGAAGGATCGCTTTC 
hEC 7           CCGCCGTCACCGGATCCCAGACCGCCCTGCTCCTCCGAGCCTTTGAGAAGGATCGCTTTC 
hEC 13          CCGCCGTCACCGGATCCCAGACCGCCCTGCTCCTCCGAGCCTTTGAGAAGGATCGCTTTC 
hEC 12          CCGCCGTCACCGGATCCCAGACCGCCCTGCTCCTCCGAGCCTTTGAGAAGGATCGCTTTC 
hEC 11          CCGCCGTCACCGGATCCCAGACCGCCCTGCTCCTCCGAGCCTTTGAGAAGGATCGCTTTC 
hEC 8           CCGCCGTCACCGGATCCCAGACCGCCCTGCTCCTCCGAGCCTTTGAGAAGGATCGCTTTC 
hEC 6           CCGCCGTCACCGGATCCCAGACCGCCCTGCTCCTCCGAGCCTTTGAGAAGGATCGCTTTC 
hEC 9           CCGCCGTCACCGGATCCCAGACCGCCCTGCTCCTCCGAGCCTTTGAGAAGGATCGCTTTC 
hEC 10          CCGCCGTCACCGGATCCCAGACCGCCCTGCTCCTCCGAGCCTTTGAGAAGGATCGCTTTC 
hEC 5           CCGCCGTCACCGGATCCCAGACCGCCCTGCTCCTCCGAGCCTTTGAGAAGGATCGCTTTC 
                  A  V  T  G  S  Q  T  A  L  L  L  R  A  F  E  K  D  R  F  P 
                             
 
FJ439133 6361   CAGGCATCGCCGCCCGGGAGGAGCTGGCCAGAGAGACGGGCCTCCCGGAGTCCAGGATTC 
hEC 3           CAGGCATCGCCGCCCGGGAGGAGCTGGCCAGAGAGACGGGCCTCCCGGAGTCCAGGATTC 
hEC 4           CAGGCATCGCCGCCCGGGAGGAGCTGGCCAGAGAGACGGGCCTCCCGGAGTCCAGGATTC 
hEC 7           CAGGCATCGCCGCCCGGGAGGAGCTGGCCAGAGAGACGGGCCTCCCGGAGTCCAGGATTC 
hEC 13          CAGGCATCGCCGCCCGGGAGGAGCTGGCCAGAGAGACGGGCCTCCCGGAGTCCAGGATTC 
hEC 12          CAGGCATCGCCGCCCGGGAGGAGCTGGCCAGAGAGACGGGCCTCCCGGAGTCCAGGATTC 
hEC 11          CAGGCATCGCCGCCCGGGAGGAGCTGGCCAGAGAGACGGGCCTCCCGGAGTCCAGGATTC 
hEC 8           CAGGCATCGCCGCCCGGGAGGAGCTGGCCAGAGAGACGGGCCTCCCGGAGTCCAGGATTC 
hEC 6           CAGGCATCGCCGCCCGGGAGGAGCTGGCCAGAGAGACGGGCCTCCCGGAGTCCAGGATTC 
hEC 9           CAGGCATCGCCGCCCGGGAGGAGCTGGCCAGAGAGACGGGCCTCCCGGAGTCCAGGATTC 
hEC 10          CAGGCATCGCCGCCCGGGAGGAGCTGGCCAGAGAGACGGGCCTCCCGGAGCCCAGGATTC 
hEC 5           CAGGCATCGCCGCCCGGGAGGAGCTGGCCAGAGAGACGGGCCTCCCGGAGTCCAGGATTC 
                  G  I  A  A  R  E  E  L  A  R  E  T  G  L  P  E  S  R  I  Q 
                                                                  *          
 
FJ439133 6421   AGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGGACAGGGTGGCAGGGCGCCCGCGC 
hEC 3           AGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGGACAGGG 
hEC 4           AGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGGACAGGGT 
hEC 7           AGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGGACAGGGT 
hEC 13          AGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGGACAGGGT 
hEC 12          AGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGGACAGGGT 
hEC 11          AGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGGACAGGGT 
hEC 8           AGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGGACAGGGT 
hEC 6           AGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGGACAGGGT 
hEC 9           AGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGGACAGGGT 
hEC 10          AGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGGACAGGGT 
hEC 5           AGATCTGGTTTCAGAATCGAAGGGCCAGGCACCCGGGACAGGGT 
                  I  W  F  Q  N  R  R  A  R  H  P  G  Q  G  G  R  A  P  A  Q 
                             
 
 
Figure 4.11 Alignment of the RT-PCR products using the primer pair 1797/2235 
 
DNA sequences were edited manually to correct base-calling errors. Primer sequences were 
trimmer and the sequences aligned using Clustal. Sequences are compared to the equivalent 
region of the most distal D4Z4 repeat unit in the FJ439133 (GenBank) reference sequence. 
The homeobox sequences are highlighted in green. Three sequences have a single base 
change from FJ439133, these are highlighted with an asterisk.   
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4.2.8 Transcription outside of the DUX4 ORF 
In order investigate whether transcription was restricted to the predicted ORF, primers 
were designed to amplify fragments upstream of the ORF but within the repeat unit (Figure 
4.12a). Using a Onestep RT-PCR on hEC RNA a transcript was amplified with the 4q7 primer 
pair at the 5 end of the repeat (Figure 4.12b), but not with the 4q8 primer pair immediately 
upstream of the ORF. The 4q7 fragment was cloned and sequenced to confirm it originated 
from the repeat. No transcripts were amplified from myoblast or myotube RNA (Figure 
4.12b).  
Although some potential promoter regions upstream of the D4Z4 array have been 
suggested, the region has not been thoroughly investigated for control sequences. The TACAA 
promoter region identified by Dixit et al. (2007) is 5822bp downstream of this probe region 
however it is possible that there is a promoter sequence near to the probe region which could 
account for this transcription. 
4.2.9 Amplification of transcripts from the most distal D4Z4 repeat 
Snider et al. used a nested RT-PCR to amplify full-length DUX4 transcripts that originated 
from the most distal D4Z4 repeat using RNA from testis and FSHD muscle biopsies. They also 
identified a smaller transcript (DUX4-s, Figure 4.1b) in some of the FSHD muscle samples and 
in all of the control muscle samples. Thus, these nested conditions were used on RNA 
extracted from the three cultured myoblast cell lines established in this laboratory, primer 
positions are shown in Figure 4.13a. 
No full length (DUX4-fl, Figure 4.13b, c) transcripts were amplified from the myoblast cell 
lines, in either proliferating or differentiated states. Smaller products were amplified from 
RNA extracted from the GM17869 (Figure 4.13b) and GM17940 (Figure 4.13c) cell lines after 
differentiation into myotubes. However, these products appear to be too small to represent 
the DUX4-s transcripts. Despite a number of attempts, cloning the fragments was 
unsuccessful and therefore it was not possible to confirm their origin. No amplification was 
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seen when the nested RT-PCRs were repeated on RNA that was extracted from the hEC cell 
line (Figure 4.13d). 
As Snider et al. had noted expression from two germ cell tumour lines (Snider et al., 2010); 
the nested RT-PCR was repeated on RNA extracted from the germ cell tumour line GCT27 
(donated by Dr. Paul Scotting). Both the nested RT-PCR and the haplotyping of this cell line 
were performed by Amy Prosser.  
In muscle cells, Snider et al. had been able to amplify the full length transcript in 
myoblasts only from those that contained a 4qA allele, however, they were able to amplify 
transcripts from 4qA, 4qB and 10q alleles from testis RNA. They did not provide information 
on the chromosomal origin of transcripts from the germ cell tumour lines (Snider et al., 2010). 
Using the SSLP genotyping reaction described in Section 4.2.2.i, two 161 size alleles, one 159 
size allele and one 166 size allele were detected in the GCT27 cell line. Thus, the two alleles 
on chromosome 4 are likely to be 4qA159 and 4qA161. The nested RT-PCR reaction on the 
GCT27 cell line was performed using primers 14A and 174 for the primary reaction and 15A 
and 175 for the secondary reaction. A product of a similar size to the DUX4-fl transcript was 
amplified (Figure 4.14a); this was cloned and sequenced to confirm its origin.  
A summary of the RT-PCRs performed on the D4Z4 array is provided in Table 4.6. 
 
4.2.10 Analysis of DUX4 transcripts from the GCT27 cell line 
The product amplified from the GCT27 cell line was cloned into pGEM-T Easy and 16 
clones were sequenced. Of these, 8 were sequenced across the full length of the transcript. 
These sequences were compared with GenBank sequence FJ439133 and base changes from 
this consensus are shown in Figure 4.14b. Variants that only appear in a single clone have not 
been included in the analysis as it cannot be excluded that these are PCR errors.  
On the basis of the changes identified, 11 of the sequences can be split into 3 groups 
(Figure 4.14b). The remaining 5 have failed to sequence through the whole of the product and 
are missing sequence information at the variant positions used to group the previous 11 
sequences. A 10bp deletion of the sequence GTACCAGCAG was identified in 6 of the clones. 
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This deletion is located immediately proximal to the start of the second intron (See Figure 
4.14c), so is likely to be variation in splice site usage. Of the clones with sequence data in this 
region, all those that did not have the 10bp deletion contained a C-G change at position 7322 
within the first intron, which is also present on the 4qB163 allele in the HHW419 cell line. 
Thus, none of these sequences were identical to the FJ439133 sequence, which is from a 
4qA161 allele and are therefore likely to originate from one of the other GCT27 alleles. It is 
possible that the remaining 5 sequences that could not be grouped match the FJ439133 
4qA161 sequence, these will require re-sequencing. 
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Figure 4.12 Expression from outside of the DUX4 ORF  
a) Position of primers to amplify within the D4Z4 repeat, outside of the ORF. The ORF is 
shown in pale blue with the homeodomains highlighted in dark blue. pLAM is shown in green. 
b) Amplification of 4q7 transcripts by RT-PCR from RNA extracted from 17869 myoblast, 
myotube and hEC cell lines. 
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Figure 4.13 Attempts to amplify transcripts from the most distal D4Z4 repeat  
a) The DUX4 ORF is shown in pale blue with homeodomains highlighted in dark blue. The pLAM region is shown in green. The positions of primers used in the final round of 
the nested PCR are shown underneath. RT-PCR results are shown for the primer pair 15A and 175, which amplify either a 1263bp fragment (both introns spliced out) or a 
1399bp fragment (only intron 2 is spliced out). Results for the primer pair 16A and 175 were similar. b) Nested RT-PCR on RNA extracted from GM17869 at both 
proliferating and differentiated (myotube) stages. c) Nested RT-PCR on RNA extracted from GM17940 at both proliferating and differentiated (myotube) stages. d) Nested 
RT-PCR on RNA extracted from the hEC cell line. 
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   FJ439133  1541  GCCCAGGTACCAGCAGGTGGGCCGCCTACTGCGCACGCGCGGGTTTGCGGGCAGCCGCCT 
   GCT27 16        GCCCAGGTACCAGCAG:::::::::::::::::::::::::::::::::::::::::::: 
   GCT27 5         GCCCAG:::::::::::::::::::::::::::::::::::::::::::::::::::::: 
                    P  G  T  S  R  W  A  A  Y  C  A  R  A  G  L  R  A  A  A  W 
 
 
 
Figure 4.14 Analysis of GCT27 transcripts  
a) Nested RT-PCR of RNA extracted from the GCT27 cell line (performed by Amy Prosser). b) 
Table to show base changes from the FJ439133 consensus sequence (highlighted in orange). 
Sequences are split into three groups based on these changes. nd = no data. Sequences 
without data at the variant positions could not be grouped. c) Sequence alignment  of GCT27 
16 (without 10bp deletion) and GCT27 5 (with 10bp deletion). FJ439133 exon sequence is 
highlighted in blue and the intron sequence is highlighted in green. Both sequences end with 
the splice donor signal, AG, so the deletion is likely due to a variation in splice site usage. 
 
a b
c
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Table 4.6 RT-PCRs for amplification of DUX4 
A positive amplification is indicated by a ݱ and a negative amplification is indicated with an x. Orange boxes show where amplification from a cell line/primer pair 
combination was successful and blue boxes indicate unsuccessful amplification attempts. Where there was no amplification attempt boxes are left blank. Fskm = Fetal 
skeletal muscle. ABr = Adult Brain. 
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4.2.11 Protein expression from DUX4 
Proteins were extracted from the patient myoblast cell lines in order to test for DUX4 
expression as previously reported by Dixit et al. (2007). Western blotting was carried out on 
these protein extracts using the 9A12 antibody created by Dixit et al. (kindly provided by Prof 
Alexandra Belayew). As a control for antibody binding, TE671 cells were transfected with a 
construct overexpressing DUX4. The DUX4 protein runs at approximately 60KDa, in contrast 
to published data which shows the protein at 52kDa (Dixit et al., 2007). 
No bands of the same size as the DUX4 protein seen in the transfected cells were seen in 
any of the myoblast cell lines (Figure 4.15). A number of other bands are seen which are likely 
due to non-specific binding on the 9A12 antibody. As the antibody does not seem to be 
specific to DUX4 it is possible that the protein band identified by Dixit et al. is also due to 
nonspecific binding, especially since the DUX4 protein in the transfected cells appears to run 
at a different size to that reported by Dixit et al. Proteomic analysis of proteins identified by 
this antibody will be important in order to confirm they are bone fide DUX4 proteins. 
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Figure 4.15 Western Blot of myoblast cell lines 
Western blotting of TE671 cells transfected with a construct overexpressing DUX4 (lane 1) 
and myoblast cell lines (lines 3, 4 and 5) using the 9A12 antibody (Dixit et al., 2007) (1:1000 
dilution) followed by a Goat anti-Rabbit IgG (1:100000 dilution). The DUX4 protein in the 
transfected cells is indicated at around 60kDa, there is a smaller, strong band at around 35kD 
which is likely to be due to protein degradation. Additional bands are likely due to non-
specific binding of the 9A12 antibody.  No DUX4 protein was identified in the three myoblast 
cell lines (GM17731, GM17869 and GM17940).  
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4.2.12 Expression of gene loci proximal to the D4Z4 array 
A number of studies have compared expression of sequences upstream of the D4Z4 array 
in FSHD and control cells (for a summary see Table 1.1). The data produced is conflicting. In 
order to investigate expression from this region in the cell lines established in this lab, RT-PCR 
was performed with primers that amplify the DUX4C and FRG2 ORFs. If this region has a more 
open chromatin structure in FSHD and germ-line cells then there could potentially be non-
coding transcription in the region. In order to test for transcription from regions that do not 
contain a functional ORF, primers for the p13E-11 probe region were also used for RT-PCR. 
Primer positions and sequences are shown in Figure 4.16a and Table 2.5 respectively.  RNA 
extracted from hEC cells and myoblast cell lines in both their proliferating and differentiated 
(myotube) stages, was used for RT-PCR, as described in Section 2.4.1. 
A summary of the RT-PCRs performed on sequences upstream of the D4Z4 array is 
provided in Table 4.7. 
 
4.2.12.i p13E-11 
Using primers for the p13E-11 probe region, transcripts were amplified from hEC RNA 
using the OneStep kit (Figure 4.16d) but were not detected when using a two-step RT-PCR. No 
amplification for this locus was seen from RNA extracted from any of the myoblast cell lines.   
Although some potential promoter regions upstream of the D4Z4 array have been 
suggested, the region has not been thoroughly investigated for control sequences and so its 
possible there is a promoter sequence near to the probe region which could account for this 
transcription. The hEC cell line is thought to recapitulate many of the events that occur early 
in embryogenesis, when chromatin is more open and expression from CpG promoters is more 
likely to occur (Almstrup et al., 2004; Andrews et al., 2005; Schwartz et al., 2005). 
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4.2.12.ii DUX4C 
It has been reported that low levels of DUX4C expression can be detected in both control 
and FSHD myoblasts, in both proliferating and differentiated stages (Ansseau et al., 2009). 
However, no expression of DUX4C was detected in RNA extracted from any of the cell lines 
tested, despite following the published reaction conditions (Figure 4.16b). If transcription 
from DUX4C does occur in these cell lines, the difficulty in amplifying the transcripts suggests 
that they have a low abundance, or are degraded rapidly after production. 
 
4.2.12.iii FRG2 
Rijkers et al. amplified FRG2 mRNA from differentiating myoblast cultures and these 
transcripts were sequenced and shown to originate predominantly from chromosome 10 
(Rijkers et al., 2004). Expression of FRG2 sequences has also been detected in some non-FSHD 
myopathies; however, these were derived from either chromosomes 3 or 22 (Rijkers et al., 
2004), which have identical sequences over this region. 
For this study, reverse transcription was carried out using the Superscript III reverse 
transcriptase with oligo dT primers and then amplified using Biotaq polymerase and PCR 
primers EX2BF and SSC8 (according to Rijkers et al., 2004). Expression of FRG2 was detected 
in RNA from all cell lines investigated (Figure 4.16c) 
The RT-PCR products from the GM17731 myoblast RNA were cloned and sequenced. To 
determine the chromosome of origin, these sequences were then compared with FRG2 mRNA 
sequences in GenBank (Chromosome 3 or 22, NM_001124759.1; Chromosome 4, AY714545.1 
and Chromosome 10, NM_001080998.1). Of the 18 transcripts sequenced, 8 originated from 
chromosome 10, 7 from chromosomes 3 or 22 and 3 from chromosome 4 (Figure 4.17) . In 
agreement with published data, a higher number of transcripts originated from chromosome 
10 than chromosome 4. However, Rijkers et al. only identified transcripts from chromosomes 
3 or 22 in patients with a non-FSHD myopathy, while this study amplified these sequences 
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from FSHD myoblast cells. As most of the transcripts originated from chromosomes other 
than 4, it is unlikely these play a causative role in FSHD.  
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Figure 4.16 Expression of sequences proximal to D4Z4  
a) Schematic representation of the products expected by RT-PCRs of loci upstream of the D4Z4 array. DUX4 repeats are indicated with blue arrows and DUX4C is 
represented by an inverted arrow upstream of the array. The p13E-11 probe region is shown by a purple block. The FRG2 gene is shown in orange with the arrowhead 
indicating the direction of transcription. Primer sequences are provided in table 2.5. b) RT-PCR of the DUX4C ORF on RNA extracted from the hEC cells. c) RT-PCR of the 
FRG2 ORF in RNA extracted from hEC cells and from the myoblast cell line (GM17731) in both its proliferating and differentiated myotube form. d) RT-PCR of the p13E-11 
region from RNA extracted from hEC cells. 
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Table 4.7 RT-PCRs for amplification of upstream sequences  
A positive amplification is indicated by a ݱ and a negative amplification is indicated with an 
x. Orange boxes show where amplification from a cell line/primer pair combination was 
successful and blue boxes indicate unsuccessful amplification attempts. Fskm = Fetal skeletal 
muscle. ABr = Adult Brain. 
  
Myoblasts Myotubes 
 
 
hEC 17731 17869 17940 17731 17869 17940 Fskm 
P13E11                 
Plat Taq x               
Onestep ݱݱ xx         x   
Dux4C   
   
        
Biomix x 
   
        
Plat Taq x 
   
x x x   
Onestep                 
FRG2                 
Plat Taq                 
Superscript/kapa   x             
Superscript/biotaq ݱxݱ xݱݱݱ ݱݱ ݱ xݱ ݱݱ ݱ xxx 
Onestep                 
FRG1                 
Abgene   ݱ ݱ ݱ         
Biomix       ݱ ݱ       
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AH550    ATCTGCTGTGCCCACACCTGGGCTAGGTCTTGATAAACAGCCTCCGACATAGCTCGCACA 60 
AH552    ATCTGCTGTGCCCACACCTGGGCTAGGTCTTGATAAACAGCCTCCGACATAGCTCGCACA 60 
AH583    ATCTGCTGTGCCCACACCTGGGCTAGGTCTTGATAAACAGCCTCCGACATAGCTCGCACA 60 
AH590    ATCTGCTGTGCCCACACCTGGGCTAGGTCTTGATAAACAGCCTCCGACATAGCTCGCACA 60 
AH526    ------------------TGGGCTAGGTCTTGATAAACAGCCTCCGACATAGCTCGCACA 42 
AH587    ATCTGCTGTGCCCACACCTGGGCTAGGTCTTGATAAACAGCCTCTGACATAGCTCGCACA 60 
AH555    ATCTGCTGTGCCCACACCTGGGCTAGGTCTTGATAAACAGCCTCTGACATAGCTCGCACA 60 
AH591    ATCTGCTGTGCCCACACCTGGGCTAGGTCTTGATAAACAGCCTCTGACATAGCTCGCACA 60 
AH589    ATCTGCTGTGCCCACACCTGGGCTAGGTCTTGATAAACAGCCTCTGACATAGCTCGCACA 60 
AH586    ATCTGCTGTGCCCACACCTGGGCTAGGTCTTGATAAACAGCCTCTGACATAGCTCGCACA 60 
AH580    ATCTGCTGTGCCCACACCTGGGCTAGGTCTTGATAAACAGCCTCTGACATAGCTCGCACA 60 
AH551    ATCTGCTGTGCCCACACCTGGGCTAGGTCTTGATAAACAGCCTCTGACATAGCTCGCACA 60 
AH582    ATCTGCTGTGCCCACACCTGGGCTAGGTCTTGATAAACAGCCTCTGACATAGCTCGCACA 60 
AH581    ATCTGCTGTGCCCACACCTGGGCTAGGTCTTGATAAACAGCCTCTGACATAGCTCGCACA 60 
AH553    ATCTGCTGTGCCCACACCTGGGCTAGGTCTTGATAAACAGCCTCTGACATAGCTCGCACA 60 
AH588    ATCTGCTGTGCCCACACCTGGGCTAGGTCTTGATAAACAGCCTCTGACATAGCTCGCACA 60 
AH584    ATCTGCTGTGCCCACACCTGGGCTAGGTCTTGATAAACAGCTTCCGACATAGCTCGCACA 60 
AH585    ATCTGCTGTGCCCACACCTGGGCTAGGTCTTGATAAACAGCTTCCGACATAGCTCGCACA 60 
                                                  *  * 
 
AH550    GAGGTCACCAAGCTTTTTCGAAGTGACGGTGTTTGGACTTCTAGGGCCCGAGACCTATGC 120 
AH552    GAGGTCACCAAGCCTTTTCGAAGTGACGGTGTTTGGACTTCTAGGGCCCGAGACCTATGC 120 
AH583    GAGGTCACCAAGCTTTTTCGAAGTGACGGTGTTTGGACTTCTAGGGCCCGAGACCTATGC 120 
AH590    GAGGTCACCAAGCTTTTTCGAAGTGACGGTGTTTGGACTTCTAGGGCCCGAGACCTATGC 120 
AH526    GAGGTCACCAAGCTTTTTCGAAGTGACGGTGTTTGGACTTCTAGGGCCCGAGACCTATGC 102 
AH587    GAGGTCGCCAAGCTTTTTCGAATTGACGGTGTTTGGACTCCTAGGGCCCGAGACCTATGC 120 
AH555    GAGGTCACCAAGCTTTTTCGAATTGACGGTGTTTGGACTCCTAGGGCCCGAGACCTATGC 120 
AH591    GAGGTCACCAAGCTTTTTCGAATTGACGGTGTTTGGACTCCTAGGGCCCGAGACCTATGC 120 
AH589    GAGGTCACCAAGCTTTTTCGAATTGACGGTGTTTGGACTCCTAGGGCCCGAGACCTATGC 120 
AH586    GAGGTCACCAAGCTTTTTCGAATTGACGGTGTTTGGACTCCTAGGGCCCGAGACCTATGC 120 
AH580    GAGGTCACCAAGCTTTTTCGAATTGACGGTGTTTGGACTCCTAGGGCCCGAGACCTATGC 120 
AH551    GAGGTCACCAAGCTTTTTCGAATTGACGGTGTTTGGACTCCTAGGGCCCGAGACCTATGC 120 
AH582    GAGGTCACCAAGCTTTTTCGAATTGACGGTGTTTGGACTCCTAGGGCCCGAGACCTATGC 120 
AH581    GAAGTCACCAAGCTTTTTCGAATTGACGGTGTTTGGACTCCTAGGGCCCGAGACCTATGC 120 
AH553    GAAGTCACCAAGCTTTTTCGAATTGACGGTGTTTGGACTCCTAGGGCCCGAGACCTATGC 120 
AH588    GAAGTCACCAAGCTTTTTCGGATTGACGGTGTTTGGACTCCTAGGGCCCGAGACCTATGC 120 
AH584    GAGGTCACCAAGCTTTTTCGAAGTGACGGTGTTTGGACTCCTAGAGCCTGAGACT-ATGC 119 
AH585    GAGGTCACCAAGCTTTTTCGAAGTGACGGTGTTTGGACTCCTAGAGCCTGAGACC-ATGC 119 
           *   *      *      * *                *    *   *     **     
 
AH550    CGCTTGCTGCGCCCAGTGCAAGCCCTGGAACTTCCCCTATGGTGGACATCACAGGTCTCC 180 
AH552    CGCTTGCTGCGCCCAGTGCAAGCCCTGGAACTTCCCCTATGGTGGGCATCACAGGTCTCC 180 
AH583    CGCTTGCTGCGCCCAGTGCAAGCCCTGGAACTTCCCCTATGGTGGGCATCACAGGTCTCC 180 
AH590    CGCTTGCTGCGCCCAGTGCAAGCCCTGGAACTTCCCCTATGGTGGGCATCACAGGTCTCC 180 
AH526    CGCTTGCTGCGCCCAGTGCAAGCCCTGGAACTTCCCCTATGGTGGGCATCACAGGTCTCC 162 
AH587    CGCCTGCTGCGCCCAGTGCAAGCCCTGGAACGTCCCCTATGGTGGGCATCACAGGTCTCC 180 
AH555    CGCTTGCTGCGCCCAGTGCAAGCCCCGGAACGTCCCCTATGGTGGGCATCACAGGTCTCC 180 
AH591    CGCTTGCTGCGCCCAGTGCAAGCCCTGGAACGTCCCCTATGGTGGGCATCACAGGTCTCC 180 
AH589    CGCTTGCTGCGCCCAGTGCAAGCCCTGGAACGTCCCCTATGGTGGGCATCACAGGTCTCC 180 
AH586    CGCTTGCTGCGCCCAGTGCAAGCCCTGGAACGTCCCCTATGGTGGGCATCACAGGTCTCC 180 
AH580    CGCTTGCTGCGCCCAGTGCAAGCCCTGGAACGTCCCCTATGGTGGGCATCACAGGTCTCC 180 
AH551    CGCTTGCTGCGCCCAGTGCAAGCCCTGGAACGTCCCCTATGGTGGGCATCACAGGTCTCC 180 
AH582    CGCTTGCTGCGCCCAGTGCAAGCCCTGGAACGTCCCCTATGGTGGGCATCACAGGTCTCC 180 
AH581    CGCTTGCTGTGCCCAGTGCAAGCCCTGGAATGTCCCCTATGGTGGGCATCACAGGTCTCC 180 
AH553    CGCTTGCTGTGCCCAGTGCAAGCCCTGGAATGTCCCCTATGGTGGGCATCACAGGTCTCC 180 
AH588    CGCTTGCTGTGCCCAGTGCAAGCCCTGGAATGTCCCCTATGGTGGGCATCACAGGTCTCC 180 
AH584    TGCTTGCTGCACCCAGTGCAAGCCCTGGAACGTCCCCTATGGTGGGCACCACAGGTCTCC 179 
AH585    TGCTTGCTGCACCCAGTGCAAGCCCTGGAACGTCCCCTATGGTGGGCACCACAGGTCTCC 179 
         *  *     **              *    **             *  *            
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AH550    TGGATTTCACTGTTGTGCACAGCAGTGGAGGATCTTGATTTTTTATTCAACGTCAAGTTG 240 
AH552    TGGATTTCACTGTTGTGCACAGCAGTGGAGGATCTTGATTTTTTATTCAACGTCAAGTTG 240 
AH583    TGGATTTCACTGTTGTGCACAGCAGTGGAGGATCTTGATTTTTTATTCAACGTCAAGTTG 240 
AH590    TGGATTTCACTGTTGTGCACAGCAGTGGAGGATCTTGATTTTTTATTCAACGTCAAGTTG 240 
AH526    TGGATTTCACTGTTGTGCACAGCAGTGGAGGATCTTGATTTTTTATTCAACGTCAAGTTG 222 
AH587    TGGATTTCGCTGTTGTGCACAGGAGTGGAGGATCTTGATTTTTTATTCAATGACAAGCTG 240 
AH555    TGGATTTCATTGTTGTGCACAGGAGTGGAGGATCTTGATTTTTTATTCAATGACAAGCTG 240 
AH591    TGGATTTCACTGTTGTGCACAGGAGTGGAGGATCTTGATTTTTTATTCAATGACAAGCTG 240 
AH589    TGGATTTCACTGTTGTGCACAGGAGTGGAGGATCTTGATTTTTTATTCAATGACAAGCTG 240 
AH586    TGGATTTCACTGTTGTGCACAGGAGTGGAGGATCTTGATTTTTTATTCAATGACAAGCTG 240 
AH580    TGGATTTCACTGTTGTGCACAGGAGTGGAGGATCTTGATTTTTTATTCAATGACAAGCTG 240 
AH551    TGGATTTCACTGTTGTGCACAGGAGTGGAGGATCTTGATTTTTTATTCAATGACAAGCCG 240 
AH582    TGGATTTCACTGTTGTGCACAGGAGTGGAGGATCTTGATTTTTTATTCAATGACAAGCTG 240 
AH581    TGGATTTCACTGTTGTGCACAGCAGTGGAGGATCTTGATTTTTTATTCAATGACAAGCTG 240 
AH553    TGGATTTCACTGTTGTGCACAGCAGTGGAGGATCTTGATTTTTTATTCAATGACAAGCTG 240 
AH588    TGGATTTCACTGTTGTGCACAGCAGTGGAGGATCTTGATTTTTTATTCAATGACAAGCTG 240 
AH584    TGGATCTCACTGTTGTGCACAGCAGTGGAGGATCTTGATTTTTTATTCAAAGTCAAGCTG 239 
AH585    TGGATTTCACTGTTGTGCACAGCAGTGGAGGATCTTGATTTTTTATTCAAAGTCAAGCTG 239 
              *  **            *                           * *    **  
 
AH550    CACTCCTCTTCTGGACAGTTCCCTGCTCTGTCTTGGCAGATATCCTTGGAACTGATTTTT 300 
AH552    CACTCCTCTTCTGGACAGTTCCCTGCTCTGTCTTGGCAGATATCCTTGGAACTGATTTTT 300 
AH583    CACTCCTCTTCTGGACAGTTCCCTGCTCTGTCTTGGCAGATATCCTTGGAACTGATTTTT 300 
AH590    CACTCCTCTTCTGGACAGTTCCCTGCTCTGTCTTGGCAGATATCCTTGGAACTGATTTTT 300 
AH526    CACTCCTCTTC------------------------------------------------- 233 
AH587    CACTCCTTTTCTGGACAGTTCCCTGCTGTGTCTTGGCAGCTGTCCTTGGAACTCATTTTT 300 
AH555    CACTCCTTTTCTGGACAGTTCCCTGCTGTGTCTTGGCAGCTGTCCTTGGAACTCATTTTT 300 
AH591    CACTCCTTTTCTGGACAGTTCCCTGCTGTGTCTTGGCAGCTGTCCTTGGAACTCATTTTT 300 
AH589    CACTCCTTTTCTGGACAGTTCCCTGCTGTGTCTTGGCAGCTGTCCTTGGAACTCATTTTT 300 
AH586    CACTCCTTTTCTGGACAGTTCCCTGCTGTGTCTTGGCAGCTGTCCTTGGAACTCATTTTT 300 
AH580    CACTCCTTTTCTGGACAGTTCCCTGCTGTGTCTTGGCAGCTGTCCTTGGAACTCATTTTT 300 
AH551    CACTCCTTTTCTGGACAGTTCCCCGCTGTGTCTTGGCAGCTGTCCTTGGAACTCATTTTT 300 
AH582    CACTCCTTTTCTGGACAGTTCCCTGCTGTGTCTTGGCAGCTGTCCTTGGAACTCATTTTT 300 
AH581    CACTCCTTTTCTGGACAGTTCCCTGCTGTGTCTTGGCAGCTGTCCTTGGAACTCATTTTT 300 
AH553    CACTCCTTTTCTGGACAGTTCCCTGCTGTGTCTTGGCAGCTGTCCTTGGAACTCATTTTT 300 
AH588    CACTCCTTTTCTGGACAGTCCCCTGCTGTGTCTTGGCAGCTGTCCTTGGAACTCATTTTT 300 
AH584    CACTCCTCTTCTGGACAGTTCCCTGCTCTGTCTTGGCAGCTATCCTTGGAACTGATTTTT 299 
AH585    CACTCCTCTTCTGGACAGTTCCCTGCTCTGCCTTGGCAGCTATCCTTGGAACTGATTTTT 299 
                *                   *  *          *           *       
 
AH550    CTTTTCCTGCAGTTTTCC- 318 
AH552    CTTTTCCTGCAGTTTTCC- 318 
AH583    CTTTTCCTGCAGTTTTCC- 318 
AH590    CTTTTCCTGCAGTTTTCCC 319 
AH526    ------------------- 
AH587    CTTTTCCTGCAGTTTTCC- 318 
AH555    CTTTTCCTGCAGTTTTCC- 318 
AH591    CTTTTCCTGCAGTTTTCC- 318 
AH589    CTTTTCCTGCAGTTTTCC- 318 
AH586    CTTTTCCTGCAGTTTTCCC 319 
AH580    CTTTTCCTGCAGTTTTCCC 319 
AH551    CTTTTCCTGCAGTTTTCC- 318 
AH582    CCTTTCCTGCAGTTTTCCC 319 
AH581    CTTTTCCTGCAGTTTTCCC 319 
AH553    CTTTTCCTGCAGTTTTCC- 318 
AH588    CTTTTCCTGCAGTTTTCCC 319 
AH584    CTTTTTCTGCAGTTTTCC- 317 
AH585    CTTTTTCTGCAGTTTTCC- 317  
          *   * 
 
Figure 4.17 Clustal alignment of FRG2 sequences 
Clustal alignment of FRG2 sequences. Identical bases are highlighted with an asterisk. 
Sequence positions are indicated on the right hand side. Chromosome 3 or 22 sequences are 
highlighted in blue. Chromosome 10 sequences are highlighted in red. Chromosome 4 
sequences are highlighted in green. 
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4.3 Discussion 
Despite the identification of transcription from the distal D4Z4 repeat unit, there has been 
no detailed information about whether internal repeats are expressed. The work described 
here provides evidence that multiple repeats are expressed from a human embryonal 
carcinoma cell line. In addition, this data supports the hypothesis of a role for normal 
transcription from the D4Z4 array in the germ-cell lineage.  
 
4.3.1 Analysis of myoblast cell lines 
Patient myoblast cell lines (GM17731, GM17869 and G17940) were established in the 
laboratory and expression of myoblast/myotube specific markers was used to verify the 
cultures. It was confirmed that at early passages, the cultures consist almost entirely of 
myoblast cells (determined by their expression of desmin) and so further analyses using these 
cell lines (see chapter 4) were carried out on cultures with a passage number of 5 or below. If 
these cells were to be used at later passages it would be necessary to repeat the analyses and 
determine if the percentage of myoblasts in the culture was still sufficient. 
On differentiation of the patient cell lines, the fusion index was calculated after 6 days in 
differentiation media and ranged from 46%-83%, depending on the cell line. When analysing 
the results of further studies using the differentiated cells (see chapter 4), it will be important 
to consider the fact that the data will originate from a mixture of myoblasts and myotubes. 
The three patient cell lines were haplotyped in order to confirm that they carry the 
permissive 4q161 allele that was identified by Lemmers et al. The GM17869 and GM17940 
cell lines were haplotyped using sequence information from the P13E-11 and SSLP regions. 
With this technique, PCR and cloning bias may have meant that the complete set of 
haplotypes was not sampled. It is also possible that polymerase slippage during amplification 
of the microsatellite repeat at the SSLP region could also have caused a variation in copy 
number. Any variation in this region would have resulted in the incorrect assignment of a 
haplotype. The GM17731 cell line was analysed using the SSLP genotyping reaction described 
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in Lemmers et al. (2010). The results show two allele sizes, of 161 and 166, and suggest that 
there is an equal number of each size in the cell line. 4A161 is the most prevalent 
chromosome 4 allele in most populations (38% Europe, 40% CEU, YRT 20%) (Lemmers et al., 
2010b) while 10A166 is the most prevalent chromosome 10 allele in all populations that have 
been studied so far (Europe 86%, CEU 86%, YRT 77%) (Lemmers et al., 2010b). The data would 
therefore predict that the GM17731 cell line contains two 4A161 and two 10A166 alleles. The 
finding that all of the cell lines carried a 4A161 allele was to be expected as it has previously 
been shown that at least one copy of this allele is required for FSHD pathogenicity.  
 
4.3.2 Expression of upstream sequences 
A number of studies have looked at expression of candidate genes upstream of the D4Z4 
array and the results have been conflicting (see Table 1.1). In order to investigate expression 
of upstream sequences in the cell lines established in this lab, primers were designed to 
amplify from the p13E-11, FRG2 and DUX4c regions.  
Two previous studies had been unable to amplify DUX4C transcripts (Alexiadis et al., 2007; 
Osborne et al., 2007). In 2009, Ansseau et al. identified low levels of mRNA expression of 
DUX4C in both patients and control cells and saw an increase in DUX4C protein in FSHD cells 
by western blot. In the work described here, the primers and conditions described by Ansseau 
et al. were repeated. However, no transcripts were amplified from RNA extracted from the 
three myoblast cell lines, or from the hEC cell line. If transcription from DUX4C does occur in 
these cell lines, the difficulty in amplifying the transcripts suggests that they have a low 
abundance, or are degraded rapidly after production. Some FSHD patients have been 
identified that have a deletion including the DUX4C repeat, which makes its involvement in 
the disease unlikely.  
An increase in FRG2 expression in FSHD cells compared with control cells was seen by both 
Gabellini et al. (2002) and Rijkers et al. (2004). However, in 2007 a microarray study by 
Osbourne et al. saw no significant change. In this work, expression of FRG2 mRNA was 
detected in all of the three myoblast cell lines and in the hEC cell line. As the study was 
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restricted to FSHD myoblasts no interpretations about level of expression can be made. As 
FRG2 has homologous copies on many other chromosomes, the amplified transcripts from 
GM17731 were sequenced to confirm their origin. Of the transcripts amplified, 44% 
originated from chromosome 10, 39% from chromosomes 3/22 and only 17% from 
chromosome 4. The region around FRG2 is known to be deleted in some FSHD patients, and 
as the majority of expression comes from chromosomes other than 4, it is unlikely that these 
transcripts play a causative role in FSHD. It remains possible; however, that contraction of the 
array on chromosome 4 may have trans-acting effects on the expression of FRG2 on these 
other chromosomes. 
In this work, primers used to amplify the p13E-11 probe region were used in an RT-PCR on 
RNA extracted from hEC cells, and the myoblast cell lines. No transcripts were amplified from 
the myoblast cell lines, however expression from this region was detected in the hEC cell line. 
The hEC cell line is thought to recapitulate many of the events that occur early in 
embryogenesis, when chromatin is more open and CpG promoters are thought to be active 
(Almstrup et al., 2004; Andrews et al., 2005; Schwartz et al., 2005). It is possible that the 
region proximal to the D4Z4 array has an open chromatin structure at this time, and that 
(presumably) non-coding transcription can occur. While the work described here was being 
carried out, genomic D4Z4 sequences incorporating this proximal region were amplified from 
FSHD and control alleles and sequenced by Joanne Pollington. Comparison of disease 
permissive and non-permissive alleles did not identify any polymorphisms that were specific 
to the FSHD permissive alleles so it seems unlikely that any transcription from this region 
plays an important role in the FSHD pathology. 
As it seemed unlikely that any of these regions had a causative role in the FSHD 
phenotype, and as more expression data from DUX4 was being published, no further studies 
of expression from the upstream regions were performed. 
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4.3.3 Expression from the D4Z4 array in myoblast cell lines 
While the work in this chapter was being carried out, transcription from the final repeat of 
the D4Z4 array was confirmed and an explanation for the haplotype specific nature of the 
disease was published. Lemmers et al. (2010a) identified a polymorphism in the pLAM region 
that creates a functional polyadenylation signal on disease permissive chromosomes. Non-
permissive haplotypes have polymorphisms that deem this signal non-functional. The pLAM 
region is absent on 4qB chromosomes, which explains why these haplotypes are non-
permissive. The group hypothesised that the polyA signal stabilises transcripts from the last 
repeat and that expression of these transcripts causes the FSHD phenotype. 
 In order to confirm their hypothesis, a functional polyA signal was added to non-
permissive haplotypes and vice versa, the resulting constructs were transfected into C2C12 
cells and the stability of the transcript was assessed by northern blot. Transcripts were only 
detected from haplotypes which contained a functional polyA signal; the use of the signal was 
confirmed with 3RACE (Lemmers et al., 2010a). 
Lemmers et al. (2010a) also analysed a number of FSHD families with non-standard 
chromosomes. One of these families had the permissive polyA end on a chromosome 10 
background, which shows that it is not the chromosome background which affects the 
permissiveness of the haplotype, but the sequence at the distal end of the array. This finding 
confirms the role of DUX4 transcripts in FSHD and provides further evidence that the 
upstream candidate genes do not play a causative role in the disease. 
Snider et al. (2010) were able to amplify full length DUX4 transcripts from this final repeat 
in cell lines with alleles carrying the functional polyA signal. In cell lines with non-permissive 
alleles only smaller fragments could be amplified. In order to amplify transcripts, the group 
had to use a nested RT-PCR protocol which indicates a very low abundance of transcripts in 
the cell lines. 
In this work, a variety of reverse transcription and amplification reagents and conditions 
have been used on RNA extracted from the FSHD myoblast cell lines, including a repeat of the 
nested RT-PCR conditions described in the Snider et al. (2010) paper. No amplification from 
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the myoblast cell lines was seen. The difficulty in amplifying transcripts from D4Z4 suggests 
that expression levels are very low. It is possible that the myoblast culturing conditions may 
have affected expression of DUX4 and this could explain the differences between data from 
the cell lines established in this lab and those from the published expression studies.  
 
4.3.4 Expression from the D4Z4 array in hEC cell lines 
All of the RT-PCRs were repeated on RNA extracted from the hEC cell line. This cell line has 
been shown to have a global gene expression profile similar to that of undifferentiated 
human embryonic stem cells (Schwartz et al., 2005) and recapitulates many of the events that 
occur early in embryogenesis (Almstrup et al., 2004; Andrews et al., 2005; Schwartz et al., 
2005). 
Similar to the myoblast cell lines, full length mRNA transcripts could not be amplified from 
the hEC cells. It was possible, however, to amplify smaller fragments that covered the 
majority of the ORF (1161 out of 1275 bases). In the nested RT-PCR described by Snider et al. 
(2010) the reverse primer falls within the pLAM region, as this is not present in the 4qB163 
alleles found in the hEC cells, it would not be expected to amplify a product from this cell line. 
The largest of the amplified fragments covered 812bp from within the second 
homeodomain to 114bp short of the stop codon. Sequencing of these fragments identified 10 
variant positions and a 6bp indel that allowed the sequences to be divided into 17 different 
variant groups. This data indicates that multiple repeats are expressed in the hEC cell line 
studied. The TSPY and USP17 genes are other examples of protein coding genes that are 
organised in a tandem array, and it has been shown that multiple copies of these repeats are 
also expressed (Manz et al., 1993; Saitoh et al., 2000). 
Of the 14 variants identified in this 812bp product, 6 resulted in coding changes, none of 
which fell within the homeodomain. RT-PCR products amplified using the primer pair 
1797/2235 (from Snider et al. 2009) cover both of the homeobox sequences, 11 of these 
products were sequenced and no variant positions were identified. As the homeoboxes code 
for DNA binding domains, there is likely to be strong selection against variation in these 
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sequences. Single base pair changes that occurred in only one of the sequences were not 
included in the analysis. This means that the variants identified are likely to be bone fide base 
changes, rather than PCR errors.  It should be noted that the primers used were based on the 
consensus sequence for DUX4 and could therefore be selecting for specific sequences, which 
may have led to a bias in amplification. 
Strand-specific RT-PCR identified transcripts from both strands of the DUX4 sequence. 
There did not appear to be a preference for expression from either strand although the 
number of transcripts sequenced may be too small to identify any bias. Antisense transcripts 
are thought to control the expression of their sense counterparts (Katayama et al., 2005; Xu 
et al., 2011). As the sense and antisense transcripts overlap, it is possible that the antisense 
transcript binds to the sense copy and prevents protein binding. This may act as a mechanism 
for repression of the D4Z4 array, controlling expression from the repeats and preventing 
translation of the sense mRNA into a functional protein. 
The hEC cell line was haplotyped and shown to contain two 4qB163 alleles at the D4Z4 
locus. As these cells do not contain any FSHD permissive alleles, the sequence data from this 
cell line cannot provide information about variants that may be involved in the FSHD 
phenotype. However, amplification of RT-PCR products from this cell line shows that 
transcription can occur from these non-permissive alleles, and as multiple D4Z4 alleles have 
been conserved, the sequences would be expected to have a normal function outside of their 
role in FSHD. Therefore, data from this cell line can provide information on the repeat 
variants that are expressed during this normal role. Snider et al. have reported expression of 
DUX4 transcripts in both testis and germ-cell tumour lines, the hEC cell and GCT27 cell data 
described in this chapter supports the hypothesis that transcription from D4Z4 occurs in the 
germ-line lineage. 
Data from the expressed hEC cell transcripts was compared with genomic sequence data 
from the HHW419 cell line. This somatic cell hybrid line had previously been haplotyped and 
shown to contain a 4qB163 allele. Despite the sequences coming from different genomes, 
they share the same D4Z4 haplotype and so the sequences would be expected to be highly 
similar.  
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Of the 17 variant groups identified in the RT-PCR products, only 4 matched genomic 
sequences, and there were 17 genomic sequences without an equivalent expressed 
transcript. The lack of coverage of these genomic sequences in the hEC products may be due 
to variation in sequence between the two genomes. Alternatively, the sequenced hEC 
transcripts may not cover the full range of the expressed repeats. It is also possible that not 
all of the D4Z4 repeats in the array are expressed, or that some are degraded more rapidly 
than others.  
RT-PCR of the polyadenylated fraction of hEC RNA also amplified the HDUX4 product. 
Although the internal repeats do not appear to have a functional poly (A) signal, the presence 
of transcripts in this poly (A) fraction warrants further investigation. In order to confirm that 
the transcripts identified in this fraction are polyadenylated an oligo dT primer will need to be 
used for the RT-PCR step, however this was not possible with the OneStep RT-PCR kit used for 
amplification of these products. Further investigation into the poly (A) signals used in this cell 
line by 3 RACE would give more information about the normal expression of sequences from 
the D4Z4 arrays on a B-type chromosome. 
Not only could expression from the ORF be identified in the hEC cells, but expression 
upstream of the ORF, within each repeat, could also be identified. There are currently no 
recognised promoter sequences which could explain this expression, however, as the repeat 
sequences have not yet been fully characterised it is not possible to rule out the possibility of 
control sequences in some of the repeats that could account for these transcripts. 
  
4.3.5 Expression of the DUX4 protein 
Western blotting of protein extract from the myoblast cell lines did not identify any DUX4 
protein. As there were a number of other bands in these myoblast lines, likely due to 
nonspecific binding, the antibody was not used for any further investigations. The DUX4 
protein in transfected cells ran at around 60KDa, while published data shows a mass of 
52KDa. As the antibody is not specific to DUX4 it will be important to perform proteomic 
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analysis of any proteins identified by this antibody in order to confirm they are bone fide 
DUX4 proteins. 
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Chapter 5. Analysis of mouse Dux 
expression  
5.1 Introduction 
In 2007, Clapp et al. identified an homologous Dux array in the murine lineages. In 
contrast to primates, the mouse array is not located at a telomere and the flanking genes are 
different to the human array. Thus, although they are unlikely to be true orthologues, this is 
the only DUX gene array in the mouse and so may be functionally equivalent to D4Z4.   
Work in Jane Hewitts laboratory has been sequencing this region in the mouse. In 
C57BL/6J mice, there are approximately 40 repeats that are split into 3 separate Dux clusters 
(Figure 5.1a). Pulse Field Gel Electrophoresis (PFGE) using a probe to the repeat shows a 
similar organisation for other inbred strains of mice, however, outbred CD1 mice show a more 
complex pattern (Clapp et al., 2007; Figure 5.1b). The mouse repeat unit is 4899bp long, with 
an ORF of 2025bp. The double homeodomain region has 45% amino acid identity between 
the human and mouse, and 31% identity at the C-terminal domain (Figure 5.2). The difference 
in length of the ORF between the two species can be accounted for by a repeated 276bp 
region within the C-terminal region which is present in a single copy in humans while there 
are 5 copies in the mouse repeat (Figure 5.3). There is less sequence conservation between 
the mouse and human repeats outside of the ORF. 
Clapp et al. published evidence for expression of at least some copies of the mouse Dux 
gene. Although they were unable to amplify the full ORF, overlapping primers were used to 
show that the whole ORF is transcribed (Figure 5.4a) and this was confirmed using RNA-FISH 
and in situ hybridisation. This difficulty in amplifying full length transcripts can also be seen in 
at the human D4Z4 array, however work described in the previous chapter has shown it is 
possible to amplify smaller fragments from hEC cell RNA that cover 1161/1275bp of the ORF. 
Clapp and colleagues were also able to amplify both sense and antisense transcripts from the 
Dux array by RT-PCR. However, in contrast to the apparently limited expression of DUX4 
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shown in human cell lines, expression in the mouse was identified in a number of different 
tissues, particularly the CNS (Figure 5.4b). Since the expression patterns seem to differ 
between species it will be important to establish whether human DUX4 and the mouse Dux 
genes have equivalent functions.  
Overexpression of DUX4 in cultured cells has been shown to have toxic effects (Gabriels et 
al., 1999; Kowaljow et al., 2007; Wallace et al., 2011). In 2009, Bosnakovski et al. generated 
mouse Dux inducible C2C12 cell lines and used them to evaluate the toxicity of the mouse 
Dux protein. They found that 44% of cells were dead 24h after induction of Dux expression 
while another 30% showed characteristics of apoptosis (Bosnakovski et al., 2009), and suggest 
that mouse Dux expression has a toxic effect on myoblasts similar to that seen with 
overexpression of DUX4 in TE671 cells (Kowaljow et al., 2007). The group also showed that 
Xenopus embryos injected with mouse Dux at the 16 cell stage developed tail defects. 
D4Z4 is GC-rich with a high frequency of CpG dinucleotides, around 290 in each repeat 
unit. In 2001, Tsien et al. used Southern blot analysis with several CpG methylation sensitive 
restriction enzymes to show that these sites are mostly methylated in the D4Z4 repeats in 
brain, lung, liver, heart and spleen. In 2003, Overveld et al. examined two methylation 
sensitive sites in the first proximal unit of the array and showed significant hypomethylation 
of D4Z4 in individuals with FSHD on the disease chromosome. Non-penetrant gene carriers 
were also hypomethylated on their contracted alleles (van Overveld et al., 2003). In 2009, de 
Greef et al. used a CpoI digest to interrogate D4Z4 methylation on internal and proximal 
repeat units on 4q and 10q separately. They showed that hypomethylation of the repeats is 
observed below a threshold number of repeats, irrespective of the haplotype, and that a 
sharp increase in methylation levels is seen between 7 and 14 units. The level of 
hypomethylation on FSHD alleles was lower on the internal repeats (de Greef et al., 2009). 
In order to establish whether the mouse repeats have a similar methylation pattern to the 
human array, methylation sensitive restriction enzymes were used to investigate the 
methylation status of the mouse repeats. 
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Figure 5.1 Mouse Dux array organisation 
a) Schematic representation of the mouse Dux clusters and flanking genes. Flanking genes are 
shown in orange. There are three clusters of Dux repeats, which are indicated with a blue 
arrowhead. A representation of a single Dux repeat is shown underneath. There is a dispersed 
repeat upstream of the ORF, which is not found in the human repeat. The ORF is shown in 
pale blue with the homeodomains highlighted in dark blue.  b) PFGE analysis of EcoRV-
digested genomic DNA. The filter was hybridized with a 
32
P-labeled Dux probe, was washed 
under high-stringency conditions, and was exposed for 6 h (Clapp et al. 2007). 
  
a
. 
b
. 
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MouseHD1        RRHRKTVWQAWQEQALLSTFKKKRYLSFKERKELAKRMGVSDCRIRVWFQNRRNRSGEEG 
HumanHD1        GRRRRLVWTPSQSEALRACFERNPYPGIATRERLAQAIGIPEPRVQIWFQNERSRQLRQH 
 
MouseHD2        GRRPRTRLTSLQLRILGQAFERNPRPGFATREELARDTGLPEDTIHIWFQNRRARRRHRR 
HumanHD2        GRRKRTAVTGSQTALLLRAFEKDRFPGIAAREELARETGLPESRIQIWFQNRRARHPGQG 
 
 
MouseCTerm       FLDQLLTEVQLEEQGPAPVNVEETWEQ-----MDTTPDLPLTSEEYQTLLDML   
HumanCTerm       LLDELLASPEFLQQAQPLLETEAPGELEASEEAASLEA-PLSEEEYRALLEEL 
 
 
 
Figure 5.2 Clustal alignment of the mouse Dux and human DUX4 conserved regions 
a) Alignment of the two homeodomain regions. The alignment shows several invariant or 
highly conserved amino acids. Identical residues are highlighted in red, amino acids with 
similar properties are highlighted in green and those with weakly similar properties in blue. b) 
Alignment of the C-terminal regions of mouse Dux and human DUX4 proteins. All sequences 
are in the 5-3 orientation 
 
 
 
 
 
 
 
 
 
 
 
 
a
. 
b
. 
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MouseDux2      PGGRVHEGSQESFWPQE-EAGSTGMDTSSPSDSNSFCRESQPSQVAQPCGAGQEDARTQ  
MouseDux4      PGGRVHEGSWESFWPQE-EAGSTGLDTSSPSDSNSFCRESQPSQVAQRRGAGQEDARTQ  
MouseDux1      PEGREREGAQENLLPQE-EAGSTGMDTSSPSDLPSFCGESQPFQVAQPRGAGQQEAPTQ  
MouseDux3      PGSREHEGSQDSLLPLE-EAVNSGMDTSIPSIWPTFCRESQPPQVAQPSGPGQAQAPTQ  
MouseDux5      PGSMEHEGSQDSLLPLE-EAANSGRDTSIPSIWPAFCRKSQPPQVAQPSGPGQAQAPIQ  
HumanDUX4      GVRGGWGRGGPQVAGAAWEPQAGAAPPPQPAPPDASASARQG-QMQGIPAPSQALQEPA  
                                 *          *          *  *        * 
MouseDux2      ADSTGPLELLLLDQLLDEVQ-KEEHVPVPLDWGRN 92 
MouseDux4      ADSTGPLELLLFDQLLDEVQ-KEEHVPAPLDWGRN 92 
MouseDux1      AGNAGSLEP-LLDQLLDEVQ-VEEPAPAPLNLDGD 91 
MouseDux3      GGNTDPLE-LFLYQLLDEVQ-VEEHAPAPLNWDVD 91 
MouseDux5      GGNTDPLE-LFLDQLLTEVQ-LEEQGPAPVNVEET 91 
HumanDUX4      PWSALP-CGLLLDELLASPEFLQQAQPLLETEAPG 92 
                             **          * 
 
 
Figure 5.3 The mouse Dux ORF contains five copies of a repeat unit in the C-
terminal region 
a) Schematic representation of the five copies of the C-terminal repeated domains found in 
the mouse ORF. The ORF is shown in pale blue with the homeodomains highlighted in dark 
blue. The 5 repeats are indicated underneath. b) ClustalW alignment of the 5 mouse repeats 
and the single copy present in human DUX4. Sequences were edited manually to align the 
conserved LDQLL domain (highlighted). Invariant positions are indicated with an asterisk. All 
sequences are in the 5-3 orientation   
a
. 
b
. 
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Figure 5.4 Evidence of transcription from the mouse Dux array. Taken from Clapp et 
al. (2007) 
a) RT-PCR analysis of the mouse Dux repeat. Representative agarose gels of RT-PCR and 
genomic PCR products. M = molecular-weight ladder; -ve = no template; -RT = RNA added 
after inactivation of reverse transcriptase; +RT = RNA present throughout the OneStep 
reaction; G = genomic DNA template. The ORF is indicated by the gray rectangle, and the 
homeobox sequences by the black boxes. The putative polyA addition site is indicated by the 
black triangle. b) RT-PCR of mouse tissues by use of primers Dux_2f and Dux_2r, which should 
give a product of 400 bp. RT indicates a control reaction, where RNA was added after 
inactivation of the reverse transcriptase. dpc = days post coitum; C2C12 = mouse myoblast 
cell line. Dux transcripts were amplified from a range of tissues and embryonic stages. 
Detection of amplification was robust in the brain. In muscle cells (both in vivo and in vitro), 
amplification was weak but consistent. Sequencing of the products confirmed that they 
originated from the array. -ve = no template; -RT = control reaction where RNA was added 
after inactivation of the reverse transcriptase. +RT = RNA present throughout the OneStep 
reaction. (From Clapp et al. 2007.)  
a 
b. 
 160 
The main aim of this chapter was to investigate whether the sequence variation and 
expression pattern is similar between the mouse and human repeats. Sequence data has 
been gathered from the mouse repeat by RT-PCR and compared with genomic sequence data 
gathered by others in Jane Hewitts laboratory to establish from which regions of the array 
the transcripts originate. In addition, to establish whether the mouse array resides in the 
same environment and has the same epigenetic markers as the human array, the methylation 
status of the repeats has been investigated. 
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5.2 Results 
5.2.1 Amplification of mouse Dux transcripts 
Mouse embryo RNA (Ambion) was treated with DnaseI and amplification was performed 
using the OneStep Reverse Transcription kit, as described in Section 2.13.2. Initial attempts to 
amplify across the full length of the ORF were unsuccessful. However, it was possible to 
amplify smaller fragments from the beginning (mATG primers) and end (mD4Z42 and mTGA 
primers) of the ORF, as well as a central region 25bp downstream of the second 
homeodomain (mDux10 primers; Figure 5.5a,b). Thogether, these cover 881bp of the Dux 
ORF as well as a further 63bp 5 and 470bp 3. RT-PCR products were cloned into the pSMART 
vector and sequenced; analysis of the sequences is described in Section 5.2.2.  
Evidence of production of antisense transcripts had been shown previously by Clapp et al. 
(2007). In order to confirm this and test whether antisense transcription occurred from the 
regions amplified in this study, a modified OneStep reaction was performed as described in 
Section 4.2.4. Antisense transcription was seen only with the mATG primer pair, not the 
mD4Z42 (Figure 5.6). 
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Figure 5.5 Amplification of mDux transcripts 
a) Schematic representation of the mouse Dux fragments amplified by RT-PCR. b) Results of 
RT-PCR amplification using mATG, mDux10, mD4Z42 and mTGA primer pairs. The additional 
band in the mDux10 reaction was likely due to the primers annealing at multiple sites, the 
correct size band was extracted from the gel for sequencing   
a 
b. 
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Figure 5.6 Strand-specific amplification of transcripts from the mDux array 
Results of RT-PCR amplification using mATG and mD4Z4 primer pairs. In order to identify 
sense or antisense transcription only one of the primers was included in the reverse 
transcription step. Thus, for amplification of antisense transcripts, only the forward primer 
was included in the RT reaction. The p- controls did not have the second primer added. 
Additional bands in the mATG reactions were likely due to primers annealing at multiple sites, 
the correct size band was extracted from the gel for sequencing.  
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5.2.2 Sequence analysis of mouse Dux transcripts 
As described in section 5.1, three closely linked but distinct Dux clusters had previously 
been identified in mice. The smallest of these clusters contains 2 full repeat units and 4 partial 
repeats, and is present in the fully sequenced BAC clone 142C15 (GenBank Accession number 
AC146701 Figure 5.7). Repeat units from the two larger clusters of the mouse Dux array had 
been amplified by PCR and sequenced by others in Jane Hewitts laboratory and a consensus 
sequence had been compiled from these genomic sequences. The genomic sequence data 
and the 142C15 BAC clone contain sequence information from C57/Bl6 mice. The RNA used in 
this expression study was derived from Swiss Webster mice. 
Initially, the clones containing the four RT-PCR products amplified during this work were 
compared to the genomic consensus sequence and any variant positions identified. 
Sequences that showed high similarity to the genomic consensus are included in Figure 5.8. 
For each primer pair there were several clones that had a significant number of variants 
compared to this consensus and showed much higher similarity to the repeats within the 
142C15 BAC clone. Analysis of these sequences is described below.  
 
5.2.2.i  Sequence analysis of the mATG RT-PCR products 
The mATG RT-PCR product covers 233bp around the predicted ATG start codon and 
includes 83bp at the start of the first homeobox. A total of 22 clones were sequenced and 
compared to the genomic consensus (Table 5.1). Five clones were identical to the consensus 
sequence and a further 11 clones contained only one or two substitutions and are likely to 
originate from the main Dux clusters. Four clones carry the same G>A transition resulting in 
an amino acid substation (S11N), while another six have the same R15L substitution. Neither 
of these substitution fall within the homeodomain. 
Six of the clones contained the same 6 base changes from the consensus and when 
aligned with the BAC clone 142C15 were found to be identical to the first full repeat (repeat 3, 
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Figure 5.7) but all have a single nucleotide change from the other full repeat in this BAC. None 
of the variants identified in this RT-PCR product were present in the genomic sequences. 
Therefore, these clones are likely to represent transcripts from this genomic region. 
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Figure 5.7 Schematic representation of the BAC clone 142C15 
a) A schematic representation of the region of BAC clone 142C15 that contains mouse Dux 
repeats, indicated in orange. Regions 1 and 6 are partial; 3 and 5 are full length and contain 
complete Dux ORFs. However, repeats 2 and 4 lack full ORFs and are truncated to 4100bp and 
2495bp respectively. b) A Sequencher alignment of the Dux repeats in the 142C15 BAC. Below 
the alignment is a schematic representation of the three coding frames, a green flag indicates 
a possible start codon and a red line indicates a stop codon. There is a full length ORF within 
repeats 3 and 5 (highlighted).  
a 
b. 
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       1 CTTGACCCACATTGGAAGGAGACGGTATGTTTACCATTCTACAATGATCGACAATTCTAC 
      61 AGAGAGCCTTATGGCAGGCCAGCAGGACAAAACAATCTCTCATTTGCTGGCCGTCACCTC 
     121 AGGACTACTTATTTGAAGTGTCTCCAGTGTTCAAGGCTAACTCCAGAGATCTAAGAGCAC 
     181 AGAACATACCGCCAGCTAACACAGCACATGCAGGAAGATGATCAACTCTTTTCTTCAACC 
     241 TGCTCCATCGAAAGTGCACAACCTACTGGTGTCTCAAGCTTCCAGGCTCCTTTTCATACA 
     301 GTCTGTGAAAGAAACACCTTGTGAGGTGTCTCCATCTCTCTCTGTCTCTGTCTATCTGTC 
     361 TGTCTGTCTCTGTCTCTCTCTCTCTCCCTCCATTCCTCTTTTGCTCCCCCTCCCATTTCC 
     421 CTCCTTGCCTCCATTTCACCATCTCTTCCACTCTCTGTCTCCATCCCCATCCTTCTACCC 
     481 TCCCATATTCACTCCCCCCATCCACTTTCTACCTCCCTACTTCCCTATCTCTCTCTATCC 
     541 ATTCTTCCCTTCCTTCTGCACTCTGTCACTCTCTCCCTACCACCCTCCACCCTCTGTCCC 
     601 TAAATCCCTTCCCCCCTTCTCTCCACATCTGTGTTTGTCTCTCTCTTCGTGTCTTCCTCT 
     661 GCCCCTAACCCCACCCATGGTCGTGACTTTATCTTCCCTTAGGATATTTGTGAGCATGAT 
     721 GTGTGTGTGTTTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTTTGTGCTTGTGTGTGCCC 
     781 GCATGTGTGCACGTGTTTGTGTGTGCGTGTGTGCGTGCATGCATGCAAATGTGTGTATGT 
     841 GTGTGTTTGGTCTGAGGGTGTGCCTGTTCACAATTGTCTCTGTGTGTTGCTGCCAGGTGC 
     901 CTAGGGGCTGTTTGGATTTTCATTTAATCTCAGTACAGGTGATGTTCCCTCTTGTCCTCA 
     961 TAGCACAGTCAGACTTGGAAAGTCAAGGAAGGGGGTCTGAAACACTCTAGAGATAGGATG 
    1021 GAGGTGGTGATGTCTTTGGATCTCAGACCATGATGTTGGGATCGTCAGTGTGTGGTCTTG 
    1081 TCTTTGTAAGCTGATTGAATCCGGATGGGATGAACTGAGCATGGCTTCCATAGGGCTTGG 
    1141 GATTCCTGGAAGGCTGAGTCCAATTCCCCAAGCTTTACTGAAGACTGCTCCCCTTCTCAT 
    1201 AGGTGTCCTGGTACCTGTGCCACCTGCCAGTCAATGAATGATTTGGCTGATGGGAATGGC 
    1261 GAGTCCTCTGACTCTTGTGTGCTCCCTGGGTGTGGGTCTAGACTGGCGACCCCGTGGCTT 
    1321 GCCAGGGATGAGGAGCCTTTGGGGAGATTTTGCTGAGTGTCAGAGGACGCTTGAGGTCCG 
    1381 CCTCCTGGTGCCCTGATGTCAGGTGCCAGGCGTGGCAGGCGTGGCGCTTCTTGGCGGCAC 
    1441 CGCGAGGAAGGGGTAGGCATGTTCTGTAGCGCCTAACTGGTAGGTAGTGGGCGGGACTAC 
    1501 CTGAGCAGAGGCAGAGGTATTTAAGGGGCAGTGGTCACAGCCACTCTGCTGGCAGTTGCT 
 mATG 1                                         GCCACTCTGCTGGCAGTTGCT 
 mATG 2                                         GCCACTCTGCTGGCAGTTGCT 
 mATG 3                                         GCCACTCTGCTGGCAGTTGCT 
 mATG 4                                         GCCACTCTGCTGGCAGTTGCT 
 mATG 5                                         GCCACTCTGCTGGCAGTTGCT 
 mATG 6                                         GCCACTCTGCTGGCAGTTGCT 
 mATG 7                                         GCCACTCTGCTGGCAGTTGCT 
 mATG 8                                         GCCACTCTGCTGGCAGTTGCT 
 mATG 9                                         GCCACTCTGCTGGCAGTTGCT 
mATG 10                                         GCCACTCTGCTGGCAGTTGCT 
mATG 11                                         GCCACTCTGCTGGCAGTTGCT 
mATG 12                                         GCCACTCTGCTGGCAGTTGCT 
   mATG 13                                         GCCACTCTGCTGGCAGTTGCT 
mATG 14                                         GCCACTCTGCTGGCAGTTGCT 
mATG 15                                         GCCACTCTGCTGGCAGTTGCT 
 
    1561 GCAGCTTGTGCTTGTTCTGAAGCTGTCCTGAGTCGATTCTCCCAAGGTGAGGACTCCTGG 
 mATG 1  GCAGCTTGTGCTTGTTCTGAAGCTGTCCTGAGTCGATTCTCCCAAGGTGAGGACTCCTGG 
 mATG 2  GCAGCTTGTGCTTGTTCTGAAGCTGTCCTGAGTCGATTCTCCCAAGGTGAGGACTCCTGG 
 mATG 3  GCAGCTTGTGCTTGTTCTGAAGCTGTCCTGAGTCGATTCTCCCAAGGTGAGGACTCCTGG 
 mATG 4  GCAGCTTGTGCTTGTTCTGAAGCTGTCCTGAGTCGATTCTCCCAAGGTGAGGACTCCTGG 
 mATG 5  GCAGCTTGTGCTTGTTCTGAAGCTGTCCTGAGTCGATTCTCCCAAGGTGAGGACTCCTGG 
 mATG 6  GCAGCTTGTGCTTGTTCTGAAGCTGTCCTGAGTCGATTCTCCCAAGGTGAGGACTCCTGG 
 mATG 7  GCAGCTTGTGCTTGTTCTGAAGCTGTCCTGAGTCGATTCTCCCAAGGTGAGGACTCCTGG 
 mATG 8  GCAGCTTGTGCTTGTTCTGAAGCTGTCCTGAGTCGATTCTCCCAAGGTGAGGACTCCTGG 
 mATG 9  GCAGCTTGTGCTTGTTCTGAAGCTGTCCTGAGTCGATTCTCCCAAGGTGAGGACTCCTGG 
mATG 10  GCAGCTTGTGCTTGTTCTGAAGCTGTCCTGAGTCGATTCTCCCAAGGTGAGGACTCCTGG 
mATG 11  GCAGCTTGTGCTTGTTCTGAAGCTGTCCTGAGTCGATTCTCCCAAGGTGAGGACTCCTGG 
mATG 12  GCAGCTTGTGCTTGTTCTGAAGCTGTCCTGAGTCGATTCTCCCAAGGTGAGGACTCCTGG 
mATG 13  GCAGCTTGTGCTTGTTCTGAAGCTGTCCTGAGTCGATTCTCCCAAGGTGAGGACTCCTGG 
mATG 14  GCAGCTTGTGCTTGTTCTGAAGCTGTCCTGAGTCGATTCTCCCAAGGTGAGGACTCCTGG 
mATG 15  GCAGCTTGTGCTTGTTCTGAAGCTGTCCTGAGTCGATTCTCCCAAGGTGAGGACTCCTGG 
mATG 16                 TCTGAAGCTGTCCTGAGTCGAGTCTCCCAAGGTAAGGACTCCTGG 
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    1621 GAGGCCGTCATTGGCACCATGGCAGAAGCTGGCAGCCCTGTTGGTGGCAGTGGTGTGGCA  
 mATG 1  GAGGCCGTCATTGGCACCATGGCAGAAGCTGGCAGCCCCGTTGGTGGCAGTGGTGTGGCA 
 mATG 2  GAGGCCGTCATTGGCACCATGGCAGAAGCTGGCAGCCCTGTTGGTGGCAGTGGTGTGGCA 
 mATG 3  GAGGCCGTCATTGGCACCATGGCAGAAGCTGGCAGCCCTGTTGGTGGCAGTGGTGTGGCA 
 mATG 4  GAGGCCGTCATTGGCACCATGGCAGAAGCTGGCAGCCCTGTTGGTGGCAATGGTGTGGCA 
 mATG 5  GGGGCCGTCATTGGCACCATGGCAGAAGCTGGCAGCCCTGTTGGTGGCAATGGTGTGGCA 
 mATG 6  GAGGCCGTCATTGGCACCATGGCAGAAGCTGGCAGCCCTGTTGGTGGCAGTGGTGTGGCA 
 mATG 7  GAGGCCGTCATTGGCACCATGGCAGAAGCTGGCAGCCCTGTTGGTGGCAGTGGTGTGGCA 
 mATG 8  GAGGCCGTCATTGGCACCATGGCAGAAGCTGGCAGCCCTGTTGGTGGCAATGGTGTGGCA 
 mATG 9  GAGGCCGTCATTGGCACCATGGCAGAAGCTGGCAGCCCTGTTGGTGGCAGTGGTGTGGCA 
mATG 10  GAGGCCGTCATTGGCACCATGGCAGAAGCTGGCAGCCCTGTTGGTGGCAGTGGTGTGGCA 
mATG 11  GAGGCCGTCATTGGCACCATGGCAGAAGCTGGCAGCCCTGTTGGTGGCAATGGTGTGGCA 
mATG 12  GAGGCCGTCATTGGCACCATGGCAGAAGCTGGCAGCCCTGTTGGTGGCAGTGGTGTGGCA 
mATG 13  GAGGCCGTCATTGGCACCATGGCAGAAGCTGGCAGCCCTGTTGGTGGCAGTGGTGTGGCA 
mATG 14  GAGGCCGTCATTGGCACCATGGCAGAAGCTGGCAGCCCTGTTGGTGGCAGTGGTGTGGCA 
mATG 15  GAGGCCGTCATTGGCACCATGGCAGAAGCTGGCAGCCCTGTTGGTGGCAATGGTGTGGCA 
mATG 16  GAGGCCGTCATTGGCACCATGGCAGAAGCTGGCAGCCCTGTTGGTGGCAGTGGTGTGGCA 
                           M  A  E  A  G  S  P  V  G  G  S  G  V  A   
          *                                    *          *            
    1681 CGGGAATCCCGGCGGCGCAGGAAGACGGTTTGGCAGGCCTGGCAAGAGCAGGCCCTGCTA 
 mATG 1  CTAGAATCCCGGCGGCG                                                
 mATG 2  CTGGAATCCCGGCGGCGCAGGAAGACGGTTTGGCAGGCCTGGCAAGAGCAGGCCCTGCTA 
 mATG 3  CTGGAATCCCGGCGGCGCAGGAAGACGGTTTGGCAGGCCTGGCAAGAGCAGGCCCTGCTA 
 mATG 4  CGGGAATCCCGGCGGCGCAGGAAGACGGTTTGGCAGGCCTGGCAAGAGCAGGCCCTGCTA 
 mATG 5  CGGGAATCCCGGCGGCGCAGGAAGACGGTTTGGCAGGCCTGGCAAGAGCAGGCCCTGCTA 
 mATG 6  CTGGAATCCCGGCGGCGCAGGAAGACGGTTTGGCAGGCCTGGCAAGAGCAGGCCCTGCTA 
 mATG 7  CTGGAATCCCGGCGGCGCAGGAAGACGGTTTGGCAGGCCTGGCAAGAGCAGGCCCTGCTA 
 mATG 8  CGGGAATCCCGGCGGCGCAGGAAGACGGTTTGGCAGGCCTGGCAAGAGCAGGCCCTGCTA 
 mATG 9  CGGGAATCCCGGCGGCGCAGGAAGACGGTTTGGCAGGCCTGGCAAGAGCAGGCCCTGCTA 
mATG 10  CGGGAATCCCGGCGGCGCAGGAAGACGGTTTGGCAGGCCTGGCAAGAGCAGGCCCTGCTA 
mATG 11  CGGGAATCCCGGCGGCGCAGGAAGACGGTTTGGCAGGCCTGGCAAGAGCAGGCCCTGCTA 
mATG 12  CGGGAATCCCGGCGGCGCAGGAAGACGGTTTGGCAGGCCTGGCAAGAGCAGGCCCTGCTA 
mATG 13  CTGGAATCCCGGCGGCGCAGGAAGACGGTTTGGCAGGCCTGGCAAGAGCAGGCCCTGCTA 
mATG 14  CGGGAATCCCGGCGGCGCAGGAAGACGGTTTGGCAGGCCTGGCAAGAGCAGGCCCTGCTA 
mATG 15  CGGGAATCCCGGCGGCGCAGGAAGACGGTTTGGCAGGCCTGGCAAGAGCAGGCCCTGCTA 
mATG 16  CGGGAATCCCGGCGGCGCAGGAAGACGGTTTGGCAGGCCTGGCAAGAGCAGGCCCTGCTA 
         R  E  S  R  R  R  R  K  T  V  W  Q  A  W  Q  E  Q  A  L  L   
          **                                                               
 
    1741 TCAACTTTCAAGAAGAAGAGATACCTGAGCTTCAAGGAGAGGAAGGAGCTGGCCAAGCGA 
 mATG 2  TCAACTTTCAAGAAGAAGAGATACCTGAGCTT                               
 mATG 3  TCAACTTTCAAGAAGAAGAGATACCTGAGCTT                               
 mATG 4  TCAACTTTCAAGAAGAAGAGATACCTGAGCTT                               
 mATG 5  TCAACTTTCAAGAAGAAGAGATACCTGAGCTT                               
 mATG 6  TCAACTTTCAAGAAGAAGAGATACCTGAGCTT                               
 mATG 7  TCAACTTTCAAGAAGAAGAGATACCTGAGCTT                               
 mATG 8  TCAACTTTCAAGAAGAAGAGATACCTGAGCTT                               
 mATG 9  TCAACTTTCAAGAAGAAGAGATACCTGAGCTT                               
mATG 10  TCAACTTTCAAGAAGAAGAGATACCTGAGCTT                               
mATG 11  TCAACTTTCAAGAAGAAGAGATACCTGAGCTT                               
mATG 12  TCAACTTTCAAGAAGAAGAGATACCTGAGCTT                               
mATG 13  TCAACTTTCAAGAAGAAGAGATACCTGAGCTT                               
mATG 14  TCAACTTTCAAGAAGAAGAGATACCTGAGCTT                               
mATG 15  TCAACTTTCAAGAAGAAGAGATACCTGAGCTT                               
mATG 16  TCAACTTTCAAGAAGAAGAGATACCTGAGCTT                               
         S  T  F  K  K  K  R  Y  L  S  F  K  E  R  K  E  L  A  K  R   
                                                                                                     
   1801  ATGGGGGTCTCAGATTGCCGCATCCGCGTGTGGTTTCAGAACCGCAGGAATCGCAGTGGA 
         M  G  V  S  D  C  R  I  R  V  W  F  Q  N  R  R  N  R  S  G 
   
   1861  GAGGAGGGGCATGCCTCAAAGAGGTCCATCAGAGGCTCCAGGCGGCTAGCCTCGCCACAG 
         E  E  G  H  A  S  K  R  S  I  R  G  S  R  R  L  A  S  P  Q 
   
   1921  CTCCAGGAAGAGCTTGGATCCAGGCCACAGGGTAGAGGCATGCGCTCATCTGGCAGAAGG 
         L  Q  E  E  L  G  S  R  P  Q  G  R  G  M  R  S  S  G  R  R 
   
   1981  CCTCGCACTCGACTCACCTCGCTACAGCTCAGGATCCTAGGGCAAGCCTTTGAGAGGAAC 
         P  R  T  R  L  T  S  L  Q  L  R  I  L  G  Q  A  F  E  R  N  
  
   2041  CCACGACCAGGCTTTGCTACCAGGGAGGAGCTGGCGCGTGACACAGGGTTGCCCGAGGAC 
         P  R  P  G  F  A  T  R  E  E  L  A  R  D  T  G  L  P  E  D  
  
   2101  ACGATCCACATATGGTTTCAAAACCGAAGAGCTCGGCGGCGCCACAGGAGGGGCAGGCCC 
         T  I  H  I  W  F  Q  N  R  R  A  R  R  R  H  R  R  G  R  P   
                                                                                                     
   2161 ACAGCTCAAGATCAAGACTTGCTGGCGTCACAAGGGTCGGATGGGGCCCCTGCAGGTCCG 
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 Dux10 1                 ACTTGCTGGCGTCACAAGGGTCGGATGGGGCCCCTGCAGGTCCG 
 Dux10 2                 ACTTGCTGGCGTCACAAGGGTCGGATGGGGCCCCTGCAGGTCCG 
 Dux10 3                 ACTTGCTGGCGTCACAAGGGTCGGATGGGGCCCCTGCAGGTCCG 
 Dux10 4                 ACTTGCTGGCGTCACAAGGGTCGGATGGGGCCCCTGCAGGTCCG 
 Dux10 5                 ACTTGCTGGCGTCACAAGGGTCGGATGGGGCCCCTGCAGGTCCG 
 Dux10 6                 ACTTGCTGGCGTCACAAGGGTCGGATGGGGCCCCTGCAGGTCCG 
 Dux10 7                 ACTTGCTGGCGTCACAAGGGTCGGATGGGGCCCCTGCAGGTCCG 
 Dux10 8                 ACTTGCTGGCGTCACAAGGGTGGGATGGGGCCCCTGCAGGTCCG 
 Dux10 9                 ACTTGCTGGCGTCACAAGGGTCGGATGGGGCCCCTGCAGGTCCG 
Dux10 10                 ACTTGCTGGCGTCACAAGGGTCGGATGGGGCCCCTGCAGGTCCG 
Dux10 11                 ACTTGCTGGCGTCACAAGGGTCGGATGGGGCCCCTGCAGGTCCG 
Dux10 12                 ACTTGCTGGCGTCACAAGGGTCGGATGGGGCCCCTACAGGTCCG 
Dux10 13                 ACTTGCTGGCGTCACAAGGGTCGGATGGGGCCCCTGCAGGTCCG 
Dux10 14                 ACTTGCTGGCATCACAAGGGTCAGATGGGGCCCCTGCAGGTCCG 
Dux10 15                 ACTTGCTGGCGTCACAAGGGTCGGATGGGGCCCCTGCAGGTCCG 
Dux10 16                 ACTTGCTGGCATCACAAGGGTCGGATGGGGCCCCTGCAGGTCCG 
Dux10 17                 ACTTGCTGGCGTCACAAGGGTCGGATGGGGCCCCTACAGGTCCG 
Dux10 18                 ACTTGCTGGCGTCACAAGGGTCGGATGGGGCCCCTACAGGTCCG 
Dux10 19                 ACTTGCTGGCGTCACAAGGGTCGGATGGGGCCCCTACAGGTCCG 
         T  A  Q  D  Q  D  L  L  A  S  Q  G  S  D  G  A  P  A  G  P   
                                   *          **            *         
 
    2221 GAAGGCAGAGAGCGTGAAGGTGCCCAGGAGAACTTGTTGCCACAGGAAGAAGCAGGAAGT 
 Dux10 1 GAAGGCAGAGAGCGTGAAGGTGCCCAGGAGAACTTGTTGCCACAGGAAGAAGCAGGAAGT 
 Dux10 2 GAAGGCAGAGAGCGTGAAGGTGCCCAGGAGAACTTGTTGCCACAGGAAGAAGCAGGAAGT 
 Dux10 3 GAAGGCAGAGAGCGTGAAGGTGCCCAGGAGAACTTGTTGCCACAGGAAGAAGCAGGAAGT 
 Dux10 4 GAAGGCAGAGAGCGTGAAGGTGCCCAGGAGAACTTGTTGCCACAGGAAGAAGCAGGAAGT 
 Dux10 5 GAAGGCAGAGAGCGTGAAGGTGCCCAGGAGAACTTGTTGCCACAGGAAGAAGCAGGAAGT 
 Dux10 6 GAAGGCAGAGAGCGTGAAGGTGCCCAGGAGAACTTGTTGCCACAGGAAGGAGCAGGAAGT 
 Dux10 7 GAAGGCAGAGAGCGTGAAGGTGCCCAGGAGAACTTGTTGCCACAGGAAGAAGCAGGAAGT 
 Dux10 8 GAAGGCAGAGAGCGTGAAGGTGCCCAGGAGAACTTGTTGCCACAGGAAGAAGCAGGAAGT 
 Dux10 9 GAAGGCAGAGAGCGTGAAGGTGCCCAGGAGAACTTGTTGCCACAGGAAGAAGCAGGAAGT 
Dux10 10 GAAGGCAGAGAGCGTGAAGGTGCCCAGGAGAACTTGTTGCCACAGGAAGAAGCAGGAAGT 
Dux10 11 GAAGGCAGAGAGCGTGAAGGTGCCCAGGAGAACTTGTTGCCACAGGAAGAAGCAGGAAGT 
Dux10 12 GAAGGCAGAGAGCGTGAAGGTGCCCAGGAGAGCTTGTTGCCACAGGAAGAAGCAGGAAGT 
Dux10 13 GAAGGCAGAGAGCGTGAAGGTGCCCAGGAGAACTTGTTGCCACAGGAAGAAGCAGGAAGT 
Dux10 14 GAAGGCAGAGAGCGTGAAGGTGCCCAGGAGAACTTGTTGCCACAGGAAGAAGCAGGAAGT 
Dux10 15 GAAGGCAGAGAGCGTGAAGGTGCCCAGGAGAACTTGTTGCCACAGGAAGAAGCAGGAAGT 
Dux10 16 GAAGGCAGAGAGCGTGAAGGTGCCCAGGAGAACTTGTTGCCACAGGAAGAAGCAGGAAGT 
Dux10 17 GAAGGCAGAGAGCGTGAAGGTGCCCAGGAGAGCTTGTTGCCACAGGAAGAAGCAGGAAGT 
Dux10 18 GAAGGCAGAGAGCGTGAAGGTGCCCAGGAGAGCTTGTTGCCACAGGAAGAAGCAGGAAGT 
Dux10 19 GAAGGCAGAGAGCGTGAAGGTGCCCAGGAGAGCTTGTTGCCACAGGAAGAAGCAGGAAGT 
         E  G  R  E  R  E  G  A  Q  E  N  L  L  P  Q  E  E  A  G  S   
                                     *                 *            
 
   2281  ACGGGCATGGATACCTCGAGCCCTAGCGACTTGCCCTCCTTCTGCGGAGAGTCCCAGCCT 
 Dux10 1 ACGGGCATGGATACCTCGAGCCCTAGCGACTTGCCCTCCTTCTGCGGAGAGTCCCAGCCT 
 Dux10 2 ACGGGCATGGATACCTCGAGCCCTAGCGACTTGCCCTCCTTCTGCGGAGAATCCCAGCCT 
 Dux10 3 ACGGGCATGGATACCTCGAGCCCTAGCGACTTGCCCTCCTTCTGCGGAGAGTCCCAGCCT 
 Dux10 4 ACGGGCATGGATACCTCGAGCCCTAGCGACTTGCCCTCCTTCTGCGGAGAGTCCCAGCCT 
 Dux10 5 ACGGGCATGGATACCTCGAGCCCTAGCGACTTGCCCTCCTTCTGCGGAGAGTCCCAGCCT 
 Dux10 6 ACGGGCATGGATACCTCGAGCCCTAGCGACTTGCCCTCCTTCTGCGGAGAGTCCCAGCCT 
 Dux10 7 ACGGGCATGGATACCTCGAGCCCTAGCGACTTGCCCTCCTTCTGCGGAGGGTCCCAGCCT 
 Dux10 8 ACGGGCATGGATACCTCGAGCCCTAGCGACTTGCCCTCCTTCTGCGGAGAGTCCCAGCCT 
 Dux10 9 ACGGGCATGGATACCTCGAGCCCTAGCGACTTGCCCTCCTTCTGCGGAGAGTCCCAGCCT 
Dux10 10 ACGGGCATGGATACCTCGAGCCCTAGCGACTTGCCCTCCTTCTGCGGAGAGTCCCAGCCT 
Dux10 11 ACGGGCATGGATACCTCGAGCCCTAGCGACTTGCCCTCCTTCTGCGGAGAGTCCCAGCCT 
Dux10 12 ACGGGCATGGATACCTCGAGCCCTAGCGACTTGCCCTCCTTCTGCAGAGAGTCCCAGCCT 
Dux10 13 ACGGGCATGGATACCTCGAGCCCTAGCGACTTGCCCTCCTTCTGCGGAGAATCCCAGCCT 
Dux10 14 ACGGGGATGGATACCTCGAGCCCTAGCGACTTGCCCTCCTTCTGCGGAGAGTCCCAGCCT 
Dux10 15 ACGGGCATGGATACCTCGAGCCCTAGCGACTTGCCCTCCTTCTGCGGAGAGTCCCAGCCT 
Dux10 16 ACGGGGATGGATACCTCGAGCCCTAGCGACTTGCCCTCCTTCTGTGGAGAGTCCCAGCCT 
Dux10 17 ACGGGCATGGATACCTCGAGCCCTAGCGACTTGCCCTCCTTCTGCAGAGAGTCCCAGCCT 
Dux10 18 ACGGGCATGGATACCTCGAGCCCTAGCGACTTGCCCTCCTTCTGCAGAGAGTCCCAGCCT 
Dux10 19 ACGGGCATGGATACCTCGAGCCCTAGCGACTTGCCCTCCTTCTGCAGAGAGTCCCAGCCT 
         T  G  M  D  T  S  S  P  S  D  L  P  S  F  C  G  E  S  Q  P   
                 *                                      **   **       
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2341  TTCCAAGTGGCACAGCCCCGTGGAGCAGGCCAACAAGAGGCCCCCACTCAAGCAGGCAAC 
 Dux10 1 TTCCAAGTGGCACAGCCCCGTGGAGCAGGCCAACAAGAGGCCCCCACTCGAGCAGGCAAC 
 Dux10 2 TTCCAAGTGGCACAGCCCCGTGGAGCAGGCCAACAAGAGGCCCCCACTCAAGCAGGCAAC 
 Dux10 3 TTCCAAGTGGCACAGCCCCGTGGAGCAGGCCAACAAGAGGCCCCCACTCGAGCAGGCAAC 
 Dux10 4 TTCCAAGTGGCACAGCCCCGTGGAGCAGGCCAACAAGAGGCCCCCACTCGAGCAGGCAAC 
 Dux10 5 TTCCAAGTGGCACAGCCCCGTGGAGCAGGCCAACAAGAGGCCCCCACTCGAGCAGGCAAC 
 Dux10 6 TTCCAAGTGGCACAGCCCCGTGGAGCAGGCCAACAAGAGGCCCCCACTCGAGCAGGCAAC 
 Dux10 7 TTCCAGGTGGCACAGCCCCGTGGAGCAGGCCAACAAGAGGCCCCCACTCGAGCAGGCAAC 
 Dux10 8 TTCCAAGTGGCACAGCCCCGTGGAGCAGGCCAACAAGAGGTCCCCACTCGAGCAGGCAAC 
 Dux10 9 TTCCAAGTGGCACAGCCCCGTGGAGCAGGCCGACAAGAGGCCCCCACTCGAGCAGGCAAC 
Dux10 10 TTCCAAGTGGCACAGCCCCGTGGAGCAGGCCAACAAGAGGCCCCCACTCGAGCAGGCAAC 
Dux10 11 TTCCAAGTGGCACAGCCCCGTGGAGCAGGCCAACAAGAGGCCCCCACTCGAGCAGGCAAC 
Dux10 12 TTCCAAGTGGCACAGCCCCGTGGGGCAGGCCAACAAGAGGCCCCCACTCAAGCAGGCAAC 
Dux10 13 TTCCAAGTGGCACAGCCCCGTGGAGCAGGCCAACAAGAGGCCCCCACTCGAGCAGGCAAC 
Dux10 14 TTCCAAGTGGCACAGCCCCGTGGAGCAGGCCAACAAGAGGCCCCCACTCAAGCAGGCAAC 
Dux10 15 TTCCAAGTGGCACAGCCCCGTGGAGCAGGCCAACAAGAGGCCCCCACTCGAGCAGGCAAC 
Dux10 16 TTCCAAGTGGCACAGCCCCGTGGAGCAGGCCAACAAGAGGCCCCCACTCAAGCAGGCAAC 
Dux10 17 TTCCAAGTGGCACAGCCCCGTGGAGCAGGCCAACAAGAGGCCCCCACTCAAGCAGGCAAC 
Dux10 18 TTCCAAGTGGCACAGCCCCGTGGAGCAGGCCAACAAGAGGCCCCCACTCAAGCAGGCAAC 
Dux10 19 TTCCAAGTGGCACAGCCCCGTGGAGCAGGCCAACAAGAGGCCCCCACTCAAGCAGGCAAC 
         F  Q  V  A  Q  P  R  G  A  G  Q  Q  E  A  P  T  R  A  G  N   
              *                 *       *        *        *            
 
   2401  GCAGGCTCTCTGGAACCCCTCCTTGATCAGCTGCTGGATGAAGTCCAAGTAGAAGAGCCT 
 Dux10 1 GCAGGCT                                        
 Dux10 2 GCAGGCT                                    
 Dux10 3 GCAGGCT                                          
 Dux10 4 GCAGGCT                                        
 Dux10 5 GCAGGCT                                        
 Dux10 6 GCAGGCT                                               
 Dux10 7 GCAGGCT                                                
 Dux10 8 GCAGGCT                                          
 Dux10 9 GCAGGCT                                              
Dux10 10 GCAGGCT                                            
Dux10 11 GCAGGCT                                               
Dux10 12 GCAGGCT                                                  
Dux10 13 GCAGGCT                                                
Dux10 14 GCAGGCT                                               
Dux10 15 GCAGGCT                                             
Dux10 16 GCAGGCT                                               
Dux10 17 GCAGGCT                                                 
Dux10 18 GCAGGCT                                                  
Dux10 19 GCAGGCT                                                
      A  G  S  L  E  P  L  L  D  Q  L  L  D  E  V  Q  V  E  E  P   
                                                                                                     
 
   2461  GCTCCAGCCCCTCTGAATTTGGATGGAGACCCTGGTGGCAGGGTGCATGAAGGTTCCCAG 
         A  P  A  P  L  N  L  D  G  D  P  G  G  R  V  H  E  G  S  Q    
 
   2521  GAGAGCTTTTGGCCACAGGAAGAAGCAGGAAGTACAGGCATGGATACTTCTAGCCCCAGC 
         E  S  F  W  P  Q  E  E  A  G  S  T  G  M  D  T  S S  P  S   
 
   2581  GACTCAAACTCCTTCTGCAGAGAGTCCCAGCCTTCCCAAGTGGCACAGCCCTGTGGAGCG 
         D  S  N  S  F  C  R  E  S  Q  P  S  Q  V  A  Q  P  C  G  A  
  
   2641  GGCCAAGAAGATGCCCGCACTCAAGCAGACAGCACAGGCCCTCTGGAACTCCTCCTCCTT 
         G  Q  E  D  A  R  T  Q  A  D  S  T  G  P  L  E  L  L  L  L 
   
   2701  GATCAACTGCTGGACGAAGTCCAAAAGGAAGAGCATGTGCCAGTCCCACTGGATTGGGGT 
         D  Q  L  L  D  E  V  Q  K  E  E  H  V  P  V  P  L  D  W  G  
  
   2761  AGAAATCCTGGCAGCAGGGAGCATGAAGGTTCCCAGGACAGCTTACTGCCCCTGGAGGAA 
         R  N  P  G  S  R  E  H  E  G  S  Q  D  S  L  L  P  L  E  E   
 
   2821  GCAGTAAATTCGGGCATGGATACCTCGATCCCTAGCATCTGGCCAACCTTCTGCAGAGAA 
         A  V  N  S  G  M  D  T  S  I  P  S  I  W  P  T  F  C  R  E   
 
   2881  TCCCAGCCTCCCCAAGTGGCACAGCCCTCTGGACCAGGCCAAGCACAGGCCCCCACTCAA 
         S  Q  P  P  Q  V  A  Q  P  S  G  P  G  Q  A  Q  A  P  T  Q  
  
   2941  GGTGGGAACACGGACCCCCTGGAGCTCTTCCTCTATCAACTGTTGGATGAAGTCCAAGTA 
         G  G  N  T  D  P  L  E  L  F  L  Y  Q  L  L  D  E  V  Q  V  
  
   3001  GAAGAGCATGCTCCAGCCCCTCTGAATTGGGATGTAGATCCTGGTGGCAGGGTGCATGAA 
         E  E  H  A  P  A  P  L  N  W  D  V  D  P  G  G  R  V  H  E   
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   3061  GGTTCGTGGGAGAGCTTTTGGCCACAGGAAGAAGCAGGAAGTACAGGCCTGGATACTTCA 
         G  S  W  E  S  F  W  P  Q  E  E  A  G  S  T  G  L  D  T  S  
  
   3121  AGCCCCAGCGACTCAAACTCCTTCTTCAGAGAGTCCAAGCCTTCCCAAGTGGCACAGCGC 
         S  P  S  D  S  N  S  F  F  R  E  S  K  P  S  Q  V  A  Q  R   
 
   3181  CGTGGAGCGGGCCAAGAAGATGCCCGCACTCAAGCAGACAGCACAGGCCCTCTGGAACTC 
MD4Z4 1                                               GGCCCTCTGGAACTC 
MD4Z4 2                                               GGCCCTCTGGAACTC 
         R  G  A  G  Q  E  D  A  R  T  Q  A  D  S  T  G  P  L  E  L   
                                                                                                     
 
   3241  CTCCTCTTTGATCAACTGCTGGACGAAGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTG 
MD4Z4 1  CTCCTCTTTGATCAACTGCTGGACGAAGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTG 
MD4Z4 2  CTCCTCTTTGATCAACTGCTGGGCGAAGTCCAAAAG:AAGAGCATGTGCCAGCCCCACTG 
         L  L  F  D  Q  L  L  D  E  V  Q  K  E  E  H  V  P  A  P  L   
                              *             *    
                       
   3301  GATTGGGGTAGAAATCCTGGCAGCATGGAGCATGAAGGTTCCCAGGACAGCTTACTGCCC 
MD4Z4 1  GATTGGGGTAGAAATCCTGGCAGCATGGAGCATGAAGGTTCCCAGGACAGCTTACTGCCC 
MD4Z4 2  GATTGGGGTAGAAATCCTGGCAGCATGGAGCATGAAGGTTCCCAGGACAGCTTACTGCCC 
         D  W  G  R  N  P  G  S  M  E  H  E  G  S  Q  D  S  L  L  P   
                                                                                                     
 
   3361  CTGGAGGAAGCAGCAAATTCGGGCAGGGATACCTCGATCCCTAGCATCTGGCCAGCCTTC 
MD4Z4 1  CTGGAGAAAGCAGCAAATTCGGGCAGGGATACCTCGATCCCTAGCATCTGGCCAGCCTTC 
MD4Z4 2  CTGGAGGAAGCAGCAAATTCGGGCAGGGATACCTCGATCCCTAGCATCTGGCCAGCCTTC 
         L  E  E  A  A  N  S  G  R  D  T  S  I  P  S  I  W  P  A  F   
              *                                                           
 
   3421  TGCAGAAAATCCCAGCCTCCCCAAGTGGCACAGCCCTCTGGACCAGGCCAAGCACAGGCC 
MD4Z4 1  TGCAGAAAATCCCAGCCTCCCCAAGTGGCACAGCCCTCTGGACCAGGCCAAGCACAGGCC 
MD4Z4 2  TGCAGAAAATCCCAGCCTCCCCAAGTGGCACAGCCCTCTGGACCAGGCCAAGCACAGGCC 
         C  R  K  S  Q  P  P  Q  V  A  Q  P  S  G  P  G  Q  A  Q  A   
 
 
3481     CCCATTCAAGGTGGGAACACGGACCCCCTGGAGCTCTTCCTTGATCAACTGCTGACCGAA 
MD4Z4 1  CCCATTCAAGGTGGGAACACGGACCCCCTGGAGCTCTTCCTTGATCAACTGCTGACCGAA 
MD4Z4 2  CCCATTCAAAGTGGGAACACGGACCCCCTGGAGCTCTTCCTTGATCAACTGCTGACCGAA 
         P  I  Q  G  G  N  T  D  P  L  E  L  F  L  D  Q  L  L  T  E   
                  *                                                        
 
   3541  GTCCAACTTGAGGAGCAGGGGCCTGCCCCTGTGAATGTGGAGGAAACATGGGAGCAAATG 
mD4Z4 1  GTCCAACTTGAGGAGCAGGGGCCTGCCCCTGTGGATGTGGAGGAA                 
mD4Z4 2  GTCCAACTTGAGGAGCAGGGGCCTGCCTCTGTGAATGTGGAGGAA                 
mTGA 1       CTTGAGGAGCAGGGGCCTGCCCCTGTGAATGTGGAGGAAACATGGGAGCAAATG 
mTGA 2       CTTGAGGAGCAGGGGCCTGCCCCTGTGAATGTGGAGGAAACATGGGAGCAAATG 
mTGA 3       CTTGAGGAGCAGGGGCCTGCCCCTGTGAATGTGGAGGAAACATGGGAGCAAATG 
mTGA 4       CTTGAGGAGCAGGGGCCTGCCCCTGTGAATGTGGAGGAAACATGGGAGCAAATG 
mTGA 5       CTTGAGGAGCAGGGGCCTGCCCCTGTGAATGTGGAGGAAACATGGGAGCAAATG 
mTGA 6       CTTGAGGAGCAGGGGCCTGCCCCTGTGAATGTGGAGGAAACATGGGAGCAAATG 
mTGA 7       CTTGAGGAGCAGGGGCCTGCCCCTGTGAATGTGGAGGAAACATGGGAGCAAATG 
mTGA 8       CTTGAGGAGCAGGGGCCTGCCCCTGTGAATGTGGAGGAAACATGGGAGCAAATG 
mTGA 9       CTTGAGGAGCAGGGGCCTGCCCCTGTGAATGTGGAGGAAACATGGGAGCAAATG 
      V  Q  L  E  E  Q  G  P  A  P  V  N  V  E  E  T  W  E  Q  M   
                                    *     *                             
 
 3601  GACACAACACCTGATCTGCCTCTCACTTCAGAAGAATATCAGACTCTTCTAGATATGCTC 
mTGA 1 GACACAACACCTGATCTGCCTCTCACTTCAGAAGAATATCAGACTCTTCTAGATATGCTC 
mTGA 2 GACACAACACCTGATCTGCCTCTCACTTCAGAAGAATATCAGACTCTTCTAGATATGCTC 
mTGA 3 GACACAACACCTGATCTGCCTCTCACTTCAGAAGAATATCAGACTCTTCTAGATATGCTC 
mTGA 4 GACACAACACCTGATCTGCCTCTCACTTCAGAAGAATATCAGACTCTTCTAGATATGCTC 
mTGA 5 GACACAACACCTGATCTGCCTCTCACTTCAGAAGAATATCAGACTCTTCTAGATATGCTC 
mTGA 6 GACACAACACCTGATCTGCCTCTCACTTCAGAAGAATATCAGACTCTTCTAGATATGCTC 
mTGA 7 GACACAACATCTGATCTGCCTCTCACTTCAGAAGAATATCAGACTCTTCTAGATATGCTC 
mTGA 8 GACACAACACCTGATCTGCCTCTCACTTCAGAAGAATATCAGACTCTTCTAGATATGCTC 
mTGA 9 GACACAACATCTGATCTGCCTCTCACTTCAGAAGAATATCAGACTCTTCTAGATATGCTC 
      D  T  T  P  D  L  P  L  T  S  E  E  Y  Q  T  L  L  D  M  L   
                *                                                        
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 3661  TGACTCCCCGACAGTACCCCTTGCTTCTAGAAACCCGAGAGGCCAAAGTCCTGAAGAGAC 
mTGA 1 TGACTCCCCGACAGTACCCCTTGCTTCTAGAAACCCGAGAGGCCAAAGTCCTGAAGAGAC 
mTGA 2 TGACTCCCCGACAGTACCCCTTGCTTCTAGAAACCCGAGAGGCCAAAGTCCTGAAGAGAC 
mTGA 3 TGACCCCCCGACAGTACCCCTTGCTTCTAGAAACCCGAGAGGCCAAAGTCCTGAAGAGAC 
mTGA 4 TGACTCCCCGACAGTACCCCTTGCTTCTAGAAACCCGAGAGGCCAAAGTCCTGAAGAGAC 
mTGA 5 TGACTCCCCGACAGTACCCCTTGCTTCTAGAAACCCGAGAGGCCAAAGTCCTGAAGAGAC 
mTGA 6 TGACTCCCCGACAGTACCCCTTGCTTCTAGAAACCCGAGAGGCCAAAGTCCTGAAGAGAC 
mTGA 7 TGACTCCCCGACAGTACCCCTTGCTTCTAGAAACCCGAGAGGCCAAAGTCCTGAAGAGAC 
mTGA 8 TGACTCCCCGACAGTACCCCTTGCTTCTAGAAACCCGAGAGGCCAAAGTCCTGAAGAGAC 
mTGA 9 TGACTCCCCGACGGTACCCCTTGCTTCTAGAAACCCGAGAGGCCAAAGTCCTGAAGAGAC 
           *       * 
 3721  CCGATTTGGAACTGGAGAAGGGACCCATCCCAGCAAGGATGTGCATCAAAAACCCAACTC 
mTGA 1 CCGATTTGGAACTGGAGAAGGGACCCATCCCAGCAAGGATGTGCATCAAAAACCCAACTC 
mTGA 2 CCGATTTGGAACTGGAGAAGGGACCCATCCCAGCAAGGATGTGCATCAAAAACCCAACTC 
mTGA 3 CCGATTTGGAACTGGAGAAGGGACCCATCCCAGCAAGGATGTGCATCAAAAACCCAACTC 
mTGA 4 CCGATTTGGAACTGGAGAAGGGACCCATCCCAGCAAGGATGTGCATCAAAAACCCAACTC 
mTGA 5 CCGATTTGGAACTGGAGAAGGGACCCATCCCAGCAAGGATGTGCATCAAAAACCCAACTC 
mTGA 6 CCGATTTGGAACTGGAGAAGGGACCCATCCCAGCAAGGATGTGCATCAAAAACCCAACTC 
mTGA 7 CCGATTTGGAACTGGAGAAGGGACCCATCCCAGCAAGGATGTGCATCAAAAACCCAACTC 
mTGA 8 CCGATTTGGAACTGGAGAAGGGACCCATCCCAGCAAGGATGTGCATCAAAAACCCAACTC 
mTGA 9 CCGATTTGGAACTGGAGAAGGGACCCATCCCAGCAAGGATGTGCATCAAAAACCCAACTC 
 
 3781  CAGTGACTTCCCGAAATGCAAGGTGTCTCGCTAACTATAAGGATTGATTGCAGGTGGGGA 
mTGA 1 CAGTGACTTCCCGAAATGCAAGGTGTCTCGCCAACTATAAGGATTGATTGCAGGTGGGGA 
mTGA 2 CAGTGACTTCCCGAAATGCAAGGTGTCTCGCTAACTATAAGGATTGATTGCAGGTGGGGA 
mTGA 3 CAGTGACTTCCCGAAATGCAAGGTGTCTCGCTAACTATAAGGATTGATTGCAGGTGGGGA 
mTGA 4 CAGTGACTTCCCGAAATGCAAGGTGTCTCGCTAACTATAAGGATTGATTGCAGGTGGGGA 
mTGA 5 CAGTGACTTCCCGAAATCCAAGGTGTCTCCCCAACTATAAGGATTGATTGCAGGTGGGGA 
mTGA 6 CAGTGACTTCCCGAAATGCAAGGTGTCTCGCCAACTATAAGGATTGATTGCAGGTGGGGA 
mTGA 7 CAGTGACTTCCCGAAATGCAAGGTGTCTCGCTAACTATAAGGATTGATCGCAGGTGGGGA 
mTGA 8 CAGTGACTTCCCGAAATGCAAGGTGTCTCGCTAACTATAAGGATTGATTGCAGGTGGGGA 
mTGA 9 CAGTGACTTCCCGAAATACAAGGTGTCTCGCTAACTATAAGGATTAATTGCAGGTGGGGA 
                        *           * *             *  *                 
 
 3841  TAATAATGAAGTGCCTTCTCCAGGGCCCGGGGATTAGGAAATCAGCCCTGAAAGTGAGAG 
mTGA 1 TAATAATGAAGTGCCTTCTCCAGGGCCCGGGGATTAGGAAATCAGCCCTGAAAGTGAGAG 
mTGA 2 TAATAATGAAGTGCCTTCTCCAGGGCCCGGGGATTAGGAAATCAGCCCTGAAAGTGAGAG 
mTGA 3 TAATAATGAAGTGCCTTCTCCAGGGCCCGGGGATTAGGAAATCAGCCCTGAAAGTGAGAG 
mTGA 4 TAATAATGAAGTGCCTTCTCCAGGGCCCGGGGATTAGGAAATCAGCCCTGAAAGAGAGAG 
mTGA 5 TAATAATGAAGTGCCTTCTCCAGGGCCCGGGGATTAGGAAATCAGCCCTGAAAGTGAGAG 
mTGA 6 TAATAATGAAGTGCCTTCTCCAGGGCCCGGGGATTAGGAAATCAGCCCTGAAAGTGAGAG 
mTGA 7 TAATAATGAAGTGCCTTCTCCAGGGCCCGGGGATTAGGAAATCAGCCCTGAAAGTGAGAG 
mTGA 8 TAATAATGAAGTGCCTTCTCCAGGGCCCGGGGATTAGGAAATCAGCCCTGAAAGTGAGAG 
mTGA 9 TAATAATGAAGTGCCTTCTCCAGGGCCCGGGGATTAGGAAATCAGCCCTGAAAGTGAGAG 
                                                             *      
 
 3901  AGAGACTCTGCTACAGGGACAGATGGAGAGGCCAATAGTGACTCCTCAACAACAAGGAGC 
mTGA 1 AGAGACTCTGCTACAGGGACAGATGGAGAGGCCAATAGTGACTCCTCAACAACAAGGAGC 
mTGA 2 AGAGACTCTGCTACAGGGACAGATGGAGAGGCCAATAGTGACTCCTCAACAACAAGGAGC 
mTGA 3 AGTGACTCTGCTACAGGGACAGGTGGAGAGGCCAATAGTGACTCCTCAACAACAAGGAGC 
mTGA 4 AGAGACTCTGCTACAGGGACAGATGGAGAGGCCAATAGTGACTCCTCAACAACAAGGAGC 
mTGA 5 AGAGACTCTGCTACAGGGACAGATGGAGAGGCCAATAGTGACTCCTCAACAACAAGGAGC 
mTGA 6 AGAGACTCTACTACAGGGACAGATGGAGAGGCCAATAGTGACTCCTCAACAACAAGGAGC 
mTGA 7 AGAGACTCTGCTACAGGGACAGATGGAGAGGCCAATAGTGACTCCTCAACAACAAGGAGC 
mTGA 8 AGAGACTCTGCTACAGGGACAGATGGAGAGGCCAATAGTGACTCCTCGACAACAAGGAGC 
mTGA 9 AGAGACTCTGCTACAGGGACAGATGGAGAGGCCAATAGTGACTCCTCAACAACAAGGAGC 
         *      *            *                        * 
 
 3961  CTAAAGATAACCCCAAAAGAAGGGCCACACCAAGTGACTGGCTCCAGTGGACCCCAGGAA 
mTGA 1 CTAAAGATAACCCCAAAAGAAGGGCCACACCAAGTGACCGGCTCCAGTGGACCCCAGGAA 
mTGA 2 CTAAAGATAACCCCAAAAGAAGGGCCACACCAAGTGACTGGCTCCAGTGGACCCCAGGAA 
mTGA 3 CTAAAGATAACCCCAAAAGAAGGGCCACACCAAGTGACTGGCTCCAGTGGACCCCAGGAA 
mTGA 4 CTAAAGATAACCCCAAAAGAAGGGCCACACCAAGTGACTGGCTCCAGTGGACCCCAGGAA 
mTGA 5 CTAAAGATAACCCCAAAAGAAGGGCCACACCAAGTGACTGGCTCCAGTGGACCCCAGGAA 
mTGA 6 CTAAAGATAACCCCAAAAGAAGGGCCACACCAAGTGACTGGCTCCAGTGGACCCCAGGAA 
mTGA 7 CTAAAGATAATCCCAAAAGAAGGGCCACACCAAGTGACTGGCTCCAGTGGACCCCAGGAA 
mTGA 8 CTAAAGATAACCCCAAAAGAAGGGCCACACCAAGTGACTGGCTCCAGTGGACCCCAGGAA 
mTGA 9 CTAAAGATAACCCCAAAAGAAGGGCCACACCAAGTGACTGGCTCCAGTGGACCCCAGGAA 
*                        * 
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 4021  ATCACACGGGACACTAGGACTAGGCTTCACTACAGAGGACACACACTCCCTGAGGGCAAT 
mTGA 1 ATCGCACGGGACACTAGGACTAGGCTTCACTACAGAGGACACACACTCCCTGAGGGCAAT 
mTGA 2 ATCACACGGGACACTAGGACTAGGCTTCACTACAGAGGACACACACTCCCTGAGGGCAAT 
mTGA 3 ATCACACGGGACACTAGGACTAGGCTTCACTACAGAGGACACACACTCCCTGAGGGCAAT 
mTGA 3 ATCACACGGGACACTAGGACTAGGCTTCACTACAGAGGACACACACTCCCTGAGGGCAAT 
mTGA 5 ATCGCACGGGACACTAGGACTAGGCTTCACTACAGAGGACACACACTCCCTGAGGGCAAT 
mTGA 6 ATCACACGGGACACTAGGACTAGGCTTCACTACAGAGGACACACACTCCCTGAGGGCAAT 
mTGA 7 ATCACACGGGACACTAGGACTAGGCTTCACTACAGAGGACACACACTCCCTGAGGGCAAT 
mTGA 8 ATCACACGGGACACTAGGACTAGGCTTCACTACAGAGGACACACACTCCCTGAGGGCAAT 
mTGA 9 ATCACACGGGACACTAGGACTAGGCTTCACTACAGAGGACACACACTCCCTGAGGGCAAT 
          * 
 
 4081  GGGGAGAGTGGACTCCTTCCCTGGCTTATATGGACTGCTGTTATCCTTACAGATGCTTCA 
mTGA 1 GGGGAGAGTGGACTCCTTCCCTGGCTTATATGGACTGCTGTTATCCTTACAG         
mTGA 2 GGGGAGAGTGGACTCCTTCCCTGGCTTATATGGACTGCTGTTATCCTTACAG         
mTGA 4 GGGGAGAGTGGACTCCTTCCCTGGCTTATATGGACTGCTGTTATCCTTACAG         
mTGA 3 GGGGAGAGTGGACTCCTTCCCTGGCTTATATGGACTGCTGTTATCCTTACAG         
mTGA 5 GGGGAGAGTGGACTCCTTCCCTGGCTTATATGGACTGCTGTTATCCTTACAG         
mTGA 6 GGGGAGAGTGGACTCCTTCCCTGGCTTATATGGACTGCTGTTATCCTTACAG         
mTGA 7 GGGGAGAGTGGACTCCTTCCCTGGCTTATATGGACTGCTGTTATCCTTACAG         
mTGA 8 GGGGAGAGTGGACTCCTTCCCTGGCTTATATGGACTGCTGTTATCCTTACAG         
mTGA 9 GGGGAGAGTGGACTCCTTCCCTGGCTTATATGGACTGCTGTTATCCTTACAG      
    
 
4141  TGCAGAGCTGTGCAAGGTTTTACAGGCCAGTCTTTTAATATCTACTACCCATAGGTCTTT 
4201  TGTTTGTTTTCTTTTTCTTTTTCACTTTCTTTTTCATTTTTTTTTCTTTTTCTTTTTTTT 
4261  AGGGGTGGGTTGGCTTTGTTGGGTTTGGTTTGGTTTTGTGTAGTTTGTTTCCATTGCTTT 
4321  CAATAAACTTTATTGATTTTAACAAAATTTGTTCGTGTGTTTGTGTGCTGTTTTGTGGGA 
4381  TGAGGGGTGGGTTGAATAGGCTGTTTTGTTCTACCCGGAGAAAGTGCATGAGAATTCCAT 
4441  TTAAAGGGATTCAAGACATAGGAAGGTATTCAGGAGGGATGCAGAGAGGCCAGGTAGAAA 
4501  AGGGCAGAGAACAAGGAAGGCTGGGCTATGTCCAGTGGAGAGACGGGCTTGCTTGATCTA 
4561  GTAACAAGCAGGTGGAATGTCAACTGAAAGAAGAATGTGTGTAAGGCATAACCTTGTCAA 
4621  GAAAGATCATCTTGGGAATACAGTGCAGCTAGGTGTGAACATCTTATTCCAAGCTTGAAA 
4681  CACAGCCATCAGTCTATTCTTCATCCATCCATCCATCCATCCATCCATCCATCCATCCAT 
4741  CCATCCATCCATCTATCCATCCTTGCATCCATTCATCCATGCATGCCTAAATCAATCTGT 
4801  AGATCTTTCAATCCTATTGGGATTAATCCCCAGCACCCTCCCTAATCCCTCTTTTGATCT 
4861  TGAGATTCCCAGGTGTTCAAGGTCATGCTGTTTATATGGAGCTCCAAGTTGATCCTTGAC 
 
Figure 5.8 Alignment of RT-PCR clone sequences with the Dux repeat consensus 
The sequences of the RT-PCR were aligned to the Dux consensus sequence using Sequencher. 
The predicted amino acid sequence of the ORF is shown underneath. Nucleotide changes 
from the consensus are highlighted in red and potential coding changes are indicated with an 
asterisk.  
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Table 5.1 Summary of nucleotide variants in mATG clones 
Sequence variants are shown in orange, blue blocks are the same base as the genomic 
consensus sequence. The number of clones containing each set of variants is shown. Three 
variants fall within the homeodomain sequence. Coding changes are shown underneath.  
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5.2.2.ii Sequence analysis of the mDux10 RT-PCR products 
The mDux10 RT-PCR product covers 231bp, beginning 25bp downstream of the second 
homeodomain (Figure 5.8). Twenty six  mDux10 clones were sequenced and compared with 
the genomic consensus (Table 5.2). Seven of the variants identified in this RT-PCR product 
were also seen in the genomic sequences. None of the clones were identical to the consensus 
sequence, 19 sequences had between 1 and 3 variations from the consensus and 4 of these 
variant positions result in a coding change.  
There were 7 highly variant clones, which contained 31 base changes from the consensus. 
These sequences were aligned to the BAC clone 142C15 and were almost identical to repeat 
two, which is a truncated repeat lacking an ORF (Figure 5.7). The sequences did not match any 
of the other repeats in the BAC clone. 
  
5.2.2.iii mD4Z42 
The mD4Z4 RT-PCR product is 360bp long and ends 78bp upstream of the stop codon 
(Figure 5.8). Twenty eight clones were sequenced and compared with the genomic consensus 
(Table 5.3). One clone was identical to the consensus sequence, while 1 sequence had only a 
single base change. Five clones had a T-C change at position 3247 that was also seen in 19 of 
the 69 genomic sequences. In addition, these 5 sequences all had a further 7 or 8 base 
changes from the consensus that were not present in the genomic sequence data, this 
suggests it is unlikely that these 5 clones originated from these particular repeats. Of the 11 
variant positions identified in these 5 clones, 9 result in coding changes.  
The final 21 sequences had 31 or 32 base changes from the consensus sequence as well as 
two deletions of 3bp and 2bp respectively. These highly variant sequences were aligned with 
the BAC clone 142C15. 19 of the sequences were identical to the final repeat except for 7 
single base pair changes that were present in only one of the sequences and are likely to be 
PCR or cloning errors. A further 2 sequences had a single T-C change at position 103679, 
causing a phenylalanine to serine substitution. These sequences aligned with repeat one, the 
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first partial repeat. This data suggests that most of the RT-PCR products using these primers 
originate from repeats represented in the BAC clone 142C15. 
Finally, the 5 sequences that had 6-9 changes from the genomic consensus were aligned 
with the BAC sequence. Two of the clones varied at 2 positions from this sequence (aligned 
with repeat 3) and a single base change each which is likely due to PCR or sequencing error. 
One sequence aligned with repeat 4, this had 3 changes from the sequence. The remaining 2 
sequences were highly variable compared with this BAC clone. It is likely that at least the last 
3 sequences come from genomic repeats that have not yet been sampled. 
 
5.2.2.iv mTGA 
The mTGA RT-PCR product is 581bp long, including the final 117bp of the ORF and a 
further 464bp downstream of the stop codon. 31 clones were sequenced and compared with 
the consensus (Table 5.4). Four clones were identical to the consensus sequence, while a 
further 5 clones had only one or two base changes. 22 clones contained a 4bp deletion of 
GAGA at position 1496, 8 of these clones had a further 8-10 base changes from the consensus 
as well as a single base pair deletion at position 3895 in 2 of the clones and position 3960 in 
the other 6. The remaining 14 clones contained 24 base changes from the consensus 
sequence as well as two single base pair deletions. None of the variants identified in these RT-
PCR products are present in the genomic sequences. 
The 14 highly variant clones were compared with the BAC clone 142C15 and all were 
found to be identical to repeat 2 apart from 15 single base pair changes that were present in 
only one of the sequences and are likely to be PCR or cloning errors. Of the remaining 8 
clones, 6 aligned with repeat number 5 of the BAC clone with 2 variants present in all 
sequences and a further 6 single base pair changes in individual sequences. The final 2 clones 
aligned at repeat number 6 and contained 8 variants compared with the BAC clone. These 8 
sequences are likely to originate from repeats that have not yet been sequenced. 
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Table 5.2 Variants in mDux10 clones 
Sequence variants are shown in orange or green, blue blocks are the same base as the genomic consensus sequence. The number of clones with each set of variants is 
shown. Coding changes are shown underneath. The number of genomic sequences amplified by other members of Jane Hewitts group that contain each variant is 
indicated. (A) indicates a base change in the genomic sequences at the same position, but a different base.  
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Table 5.3 Variants in mD4Z42 clones 
Sequence variants are shown in orange or green, blue blocks are the same base as the genomic consensus sequence. The number of clones with each set of variants is 
shown. Coding changes are shown underneath. The number of genomic sequences amplified by other members of Jane Hewitts group that contain each variant is 
indicated.  
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Table 5.4 Variants in mD4Z42 clones 
Sequence variants are shown in orange, blue blocks are the same base as the genomic consensus sequence. The number of clones with each set of variants is shown. 
Coding changes are shown underneath. The number of genomic sequences amplified by other members of Jane Hewitts group that contain each variant is indicated. 
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5.2.3 BAC clone repeats 
For each of the regions amplified by RT-PCR, a large number of sequences matched the 
BAC clone 142C15 (Figure 5.9a)), with a total of 43% of clones apparently originating from this 
region. As this smaller Dux cluster contains only two full repeats it is perhaps surprising that 
so many clones align here. However, as the mouse embryo RNA comes from a different 
mouse strain to the one amplified for the genomic sequences, it is possible the Swiss-Webster 
mice have a larger number of repeats in this Dux cluster. It is also possible that the large 
number of amplification products from this region is due to amplification or cloning bias 
Surprisingly, the sequences which matched the BAC clone did not appear to come from 
the same repeats, nor were they all expressed from full length repeats (Figure 5.7) (Figure 5.8 
Sequence alignment). Each sequence was manually aligned with the other repeats in order to 
confirm it was identical to only one of the regions, this was confirmed in all cases.  
Six mATG sequences and 2 mD4Z42 sequences aligned with the third repeat, which 
contains a full length Dux ORF (Figure 5.7). As transcripts have been identified from the 
beginning and end of this repeat it is likely that this ORF is transcribed. Transcripts have also 
been identified from the first two partial repeats, even though these regions do not appear to 
contain a functional ORF (Figure 5.7). The organisation of this region may vary in Swiss 
Webster mice, resulting in functional ORFs that could account for this expression. 
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Figure 5.9 mDux RT-PCR products which appear to originate from BAC 142C15 
a) Summary of the mDux products that originate from the BAC clone 142C15 b) Schematic 
representation of the region of BAC clone 142C15 which contains mouse Dux repeats is 
shown. Repeats are indicated in orange. Repeats 3 and 5 are full length repeats, repeats 1, 2 
and 4 are partial repeats. The positions of mATG, mDux10, mD4Z42 and mTGA RT-PCR 
products are indicated in purple. 
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 1    AGGTCTATGCTAATGTTCACAGGACACTACCTGAGGGAAGGGGCAGGGAAGATTATTCCA 
 61   TGGGTTTAATGGACTGCTTATATTCTTACCAATGCTTGGTGCTGAACTGTGCAATGATTT 
 121  ATAAGCCAGTCCTTGCAAATTTACTACTCATAGAACGTTGGTTTTGTTTTGTTTTGATTG 
 181  TTTCCATTGTTTTCAATAAAGTTTATTACTTTCAACAAATTTTGTTTGTTTGTGTGTTGT 
 241  TTTTGAGTCTGGGGGTTAAATAGGCTCTTTTGATCTAACCGGGGAATGTGTATGAGCTTT 
 301  CCAATTAAAAGGGATAAAAGACATAGGAAGGTAATCAGGAGGGATGCAGAGAGGCCAGGT 
 361  AGGAAGGGGAGAGAACAAGGAAGGCTGGGCTCTGTCCAATGGAGAGATGGGCTTGGTTGC 
 421  TCTAGTAACAAGCCAGTGGAATGTCAATTGAAAGAAGAATGTGTGTAAGGCATAACCATG 
 481  TAAAGAAAGATCATGCTGGGAATACAGTGCAGCCATGCGGGAACATCTTATTCCAAGCTT 
 541  GACACACAGTTCATCCTTCCATCCACCCATGCATTGATCTGGAGTTCTTGCTACTCCTAT 
 601  TGGTTTTAATCCCCAACACCCACCCTTATTCCTCTTTTGATCTTAAGATCCCCAAGTCTC 
 661  CAAGGTCATAATGTTTACTTGGAGCTCCAAGTTGAACCTTGACAAACATGGAAAGAATGT 
 721  GTTTATCATTCTACAATGGCCTATAATTTTACAAAGAACATTTTGGCATGCCAGCAGGAT 
 781  AAAACAATATCTCACCTGCTGGTCATCAGCTCAGGGAATCCTCCTTGAGGTGTCTCCAGT 
 841  GTACAAGGCTAACTCCAGAGATCTAACAGTACAGGCCATACCCTTAGAAAACAGCACTAT 
 901  GCAAAAGATGATCAACACTTTTCTTCACACTGCTCAATAGAAAATGAACAATTTAATGAT 
 961  ATCTCAAGCTTCCAGGCTCCTTATCATACTGTCTGTGAAAGAAACAAATGGGAAGGTCCC 
 1021 TCTCCTTCTCCCTCTCCCTCTCCCTCTCCCTCTCCCTCTCCCTCTCCCTCTCCCTCTCCC 
 1081 TCTCCCTCTCCCTCTCCCTCTCCCTCTCCCTCTCCCCCTCCCCCTCTCCCTCCCCCTCTC 
 1141 CCTCCCCATCTCCCTCCCCATCTCCCTCCCCATCTCCCTCCCCATCTCCCTCCCCTTCTT 
 1201 TTCTCACACCCCCTCTTTCTCTTACTTGCTATTGCTCTCTTAATCTCTATCTCTCTCTCC 
 1261 CTCCCTCCATTCCTTCTTTGATCCCCCTCCCTTTTCTGTCCATGCCTCACTTTCACCATC 
 1321 TCTTCCACTCTCTCTCCACATCCTTTCTCCCTCCCTTCTGCACTCGCTCCCTCCCCTCCA 
 1381 CTTTCTCCCTTCCTACATAATTCCTTCTCTCTATCGATCCTTCCCTCCCTTCTGCACTCC 
 1441 CTCACCCAATCCTCTCCTCACTCTGTCCCTCAATCCCTTCCCACTCTCTTACTCTCTCTC 
 1501 TCTCTCTTCCAGTCTGTCTGTCTGTTTGTCTCTTCCTGTTTTACTTTGCCATGGAACCCC 
 1561 ATCCATAGTCCTGCCATTCACATTCCTCAGGATTGTGTGTGTGTGTGTGAGAGAGAGTGT 
 1621 GGTCTGAGGGTGTGCCTGTTCACAATTGACTCAGTGTGTTGTTGCTAAGGGCTTGGGGGC 
 1681 AGTTTGGGGTTGCATTTTTGATCCCAGTACAGGTGAAGTTCGGTCTTGTCCTCATAGCAC 
 1741 AGCCAGATTTGGAAAGCCAAGGAAGGGGGTCTGAAACACTCTAGAGATAGGAAGGAGAAG 
 1801 GGGATGTCTAGAACTCCTTCTTGATCAACTGCTGGATGACGTCCAAATAGAAAAGTATGC 
 1861 TCCAGCCCCTCTGGATTTGGATGGAGACCCTGGTGGCCGGGTGCATGAAGGTTCCCGGGA 
 1921 CAGCTTTTTGCCACAGGAAGAAACAGGAAGTACAGGCATGGATACTTCAAGCCCTAGAAA 
 1981 AACACTCTAGTTCTGCAAAGAGTCCCAGCATTCCCAAATCACAGCCCTGTGGAGCAGGAT 
 2041 AGCAGCCTTCCATATAACCCAGGGAAGGAGTCCACTCTCCCACTTCCCCTCAGGTAGTGT 
 2101 CTGTACTATTTAGTGAAGCCGACCTAGTGTCCCATCTGAATTCCCGGGGTCGACTGGAGC 
 2161 CAGTTACTTGGTGTGGCCCACAGCTCAAGATCAAGACTTGCTGGCGTCACAAGGGTCGGA 
 2221 TGGGGCCCCTACAGGTCTGGAAGGCAGAGAGCATGAAGGTGCCCAGGAGAGCTTGTTGCC 
 2281 AGAGGAAGAAGCAGGAAGTACGGGAAAGGATACTTTGAGCTCTAGCGATTCACCCTCCTT 
 2341 CTGAAGAGAGTCCCAGACTTCCCAAAAGGCACAGCCCTGTGGAGCGGGCCAAAAAGATAC 
 2401 CCGGAATCAAGCAGACAGCACAGGCCCTCTGGAAATTCTCCCTGATCAACTGCAGGGCAA 
AH134                       GGCCCTCTGGAAATTCTCCCTGATCAACTGCAGGGCAA 
   AH440                       GGCCCTCTGGAAATTCTCCCTGATCAACTGCAGGGCAA 
   AH443                       GGCCCTCTGGAAATTCTCCCTGATCAACTGCAGGGCAA 
   AH136                       GGCCCTCTGGAAATTCTCCCTGATCAACTGCAGGGCAA 
   AH147                       GGCCCTCTGGAAATTCTCCCTGATCAACTGCAGGGCAA 
   AH140                       GGCCCTCTGGAAATTCTCCCTGATCAACTGCAGGGCAA 
   AH438                       GGCCCTCTGGAAATTCTCCCTGATCAACTGCAGGGCAA 
   AH135                       GGCCCTCTGGAAATTCTCCCTGATCAACTGCAGGGCAA 
   AH436                       GGCCCTCTGGAAATTCTCCCTGATCAACTGCAGGGCAA  
AH126                       GGCCCTCTGGAAATTCTCCCTGATCAACTGCAGGGCAA 
   AH123                       GGCCCTCTGGAAATTCTCCCTGATCAACTGCAGGGCAA 
   AH127                       GGCCCTCTGGAAATTCTCCCTGATCAACTGCAGGGCAA 
   AH132                       GGCCCTCTGGGAATTCTCCCTGATCAACTGCAGGGCAA 
   AH130                       GGCCCTCTGGAAATTCTCCCTGATCAACTGCAGGGCAA 
   AH118                       GGCCCTCTGGAAATTCTCCCTGATCAACTGCAGGGCAA 
   AH439                       GGCCCTCTGGAAATTCTCCCTGATCAACTGCAGGGCAA 
   AH144                       GGCCCTCTGGAAATTCTCCCTGATCAACTGCAGGGCAA 
   AH117                       GGCCCTCTGGAAATTCTCCCTGATCAACTGCAGGGCAA 
   AH122                       GGCCCTCTGGAAATTCTCCCTGATCAACTGCGGGGCGA 
   AH143                       GGCCCTCTGGAAATTCTCCCTGATCAACTGCAGGGCAA 
   AH137                       GGCCCTCTGGAAATTCTCCCTGATCAACTGCAGGGCAA 
  
 2461 AGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTGGATTGGGGTAGAAATCCTGGCAGCAG 
   AH134 AGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTGGATTGGGGTAGAAATCCTGGCAGCAG 
   AH440 AGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTGGATTGGGGTAGAAATCCTGGCAGCAG 
   AH443 AGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTGGATTGGGGTAGAAATCCTGGCAGCAG 
   AH136 AGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTGGATTGGGGTAGAAATCCTGGCAGCAG 
   AH147 AGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTGGATTGGGGTAGAAATCCTGGCAGCAG 
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   AH140 AGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTGGATTGGGGTAGAAATCCTGGCAGCAG 
   AH438 AGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTGGATTGGGGTAGAAATCCTGGCAGCAG 
   AH135 AGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTGGATTGGGGTAGAAATCCTGGCAGCAG 
   AH436 AGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTGGATTGGGGTAGAAATCCTGGCAGCAG 
   AH126 AGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTGGATTGGGGTAGAAATCCTGGCAGCAG 
   AH123 AGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTGGATTGGGGTAGAAATCCTGGCAGCAG 
   AH127 AGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTGGATTGGGGTAGAAATCCTGGCAGCAG 
   AH132 AGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTGGATTGGGGTAGAAATCCTGGCAGCAG 
   AH130 AGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTGGATTGGGGTAGAAATCCTGGCAGCAG 
   AH118 AGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTGGATTGGGGTAGAAATCCTGGCAGCAG 
   AH439 AGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTGGATTGGGGTAGAAATCCTGGCAGCAG 
   AH144 AGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTGGATTGGGGTAGAAATCCTGGCAGCAG 
   AH117 AGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTGGATTGGGGTAGAAATCCTGGCAGCAG 
   AH122 AGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTGGATTGGGGTAGAAATCCTGGCAGCAG 
   AH143 AGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTGGATTGGGGTAGAAATCCTGGCAGCAG 
   AH137 AGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTGGATTGGGGTAGAAATCCTGGCAGCAG 
     
    2521 GGAGCATGAAGGTTCCCAGGACAGCTTACTGCGCCTGGATGAAGCAGCAAATTCGGGCAT 
   AH134 GGAGCATGAAGGTTCCCAGGACAGCTTACTGCGCCTGGATGAAGCAGCAAATTCGGGCAT 
   AH440 GGAGCATGAAGGTTCCCAGGACAGCTTACTGCGCCTGGATGAAGCAGCAAATTCGGGCAT 
   AH443 GGAGCATGAAGGTTCCCAGGACAGCTTACTGCGCCTGGATGAAGCAGCAAATTCGGGCAT 
   AH136 GGAGCATGAAGGTTCCCAGGACAGCTTACTGCGCCTGGATGAAGCAGCAAATTCGGGCAT 
   AH147 GGAGCATGAAGGTTCCCAGGACAGCTTACTGCGCCTGGATGAAGCAGCAAATTCGGGCAT 
   AH140 GGAGCATGAAGGTTCCCAGGACAGCTTACTGCGCCTGGATGAAGCAGCAAATTCGGGCAT 
   AH438 GGAGCATGAAGGTTCCCAGGACAGCTTACTGCGCCTGGATGAAGCAGCAAATTCGGGCAT 
   AH135 GGAGCATGAAGGTTCCCAGGACAGCTTACTGCGCCTGGATGAAGCAGCAAATTCGGGCAT 
   AH436 GGAGCATGAAGGTTCCCAGGACAGCTTACTGCGCCTGGATGAAGCAGCAAATTCGGGCAT 
   AH126 GGAGCATGAAGGTTCCCAGGACAGCTTACTGCGCCTGGATGAAGCAGCAAATTCGGGCAT 
   AH123 GGAGCATGAAGGTTCCCAGGACAGCTTACTGCGCCTGGATGAAGCAGCAAATTCGGGCAT 
   AH127 GGAGCATGAAGGTTCCCAGGACAGCTTACTGCGCCTGGATGAAGCAGCAAATTCGGGCAT 
   AH132 GGAGCATGAAGGTTCCCAGGACAGCTTACTGCGCCTGGATGAAGCAGCAAATTCGGGCAT 
   AH130 GGAGCATGAAGGTTCCCAGGACAGCTTACTGCGCCTGGATGAAGCAGCAAATTCGGGCAT 
   AH118 GGAGCATGAAGGTTCCCAGGACAGCTTACTGCGCCTGGATGAAGCAGCAAATTCGGGCAT 
   AH439 GGAGCATGAAGGTTCCCAGGACAGCTTACTGCGCCTGGATGAAGCAGCAAATTCGGGCAT 
   AH144 GGAGCATGAAGGTTCCCAGGACAGCTTACTGCGCCTGGATGAAGCAGCAAATTCGGGCAT 
   AH117 GGAGCATGAAGGTTCCCAGGACAGCTTACTGCGCCTGGATGAAGCAGCAAATTCGGGCAT 
   AH122 GGAGCATGAAGGTTCCCAGGACAGCTTACTGCGCCTGGATGAAGCAGCAAATTCGGGCAT 
   AH143 GGAGCATGAAGGTTCCCAGGACAGCTTACTGCGCCTGGATGAAGCAGCAAATTCGGGCAT 
   AH137 GGAGCATGAAGGTTCCCAGGACAGCTTACTGCGCCTGGATGAAGCAGCAAATTCGGGCAT 
 
 2581 GGATACCTTGATCACTAGCATTTGACCAACCTTGTGCAGAGTTGCAGCCTCCCCAGGTGG 
   AH134 GGATACCTTGATCACTAGCATTTGACCAACCTTGTGCAGAGTTGCAGCCTCCCCAGGTGG 
   AH440 GGATACCTTGATCACTAGCATTTGACCAACCTTGTGCAGAGTTGCAGCCTCCCCAGGTGG 
   AH443 GGATACCTTGATCACTAGCATTTGACCAACCTTGTGCAGAGTTGCAGCCTCCCCAGGTGG 
   AH136 GGATACCTTGATCACTAGCATTTGACCAACCTTGTGCAGAGTTGCAGCCTCCCCAGGTGG 
   AH147 GGATACCTTGATCACTAGCATTTGACCAACCTTGTGCAGAGTTGCAGCCTCCCCAGGTGG 
   AH140 GGATACCTTGATCACTAGCATTTGACCAACCTTGTGCAGAGTTGCAGCCTCCCCAGGTGG 
   AH438 GGATACCTTGATCACTAGCATTTGACCAACCTTGTGCAGAGTTGCAGCCTCCCCAGGTGG 
   AH135 GGATACCTTGATCACTAGCATTTGACCAACCTTGTGCAGGGTTGCAGCCTCCCCAGGTGG 
   AH436 GGATACCTTGATCACTAGCATTTGACCAACCTTGTGCAGAGTTGCAGCCTCCCCAGGTGG 
   AH126 GGATACCTTGATCACTAGCATTTGACCAACCTTGTGCAGAGTTGCAGCCTCCCCAGGTGG 
   AH123 GGATACCTTGATCACTAGCATTTGACCAACCTTGTGCAGAGTTGCAGCCTCCCCAGGTGG 
   AH127 GGATACCTTGATCACTAGCATTTGACCAACCTTGTGCAGAGTTGCAGCCTCCCCAGGTGG 
   AH132 GGGTACCTTGATCACTAGCATTTGACCAACCTTGTGCAGAGTTGCAGCCTCCCCAGGTGG 
   AH130 GGATACCTTGATCACTAGCATTTGACCAACCTTGTGCAGAGTTGCAGCCTCCCCAGGTGG 
   AH118 GGATACCTTGATCACTAGCATTTGACCAACCTTGTGCAGAGTTGCAGCCTCCCCAGGTGG 
   AH439 GGATACCTTGATCACTAGCATTTGACCAACCTTGTGCAGAGTTGCAGCCTCCCCAGGTGG 
   AH144 GGATACCTTGATCACTAGCATTTGACCAACCTTGTGCAGAGTTGCAGCCTCCCCAGGTGG 
   AH117 GGATACCTTGATCACTAGCATTTGACCAACCTTGTGCAGAGTTGCAGCCTCCCCAGGTGG 
   AH122 GGATACCTTGATCACTAGCATTTGACCAACCTTGTGCAGAGTTGCAGCCTCCCCAGGTGG 
   AH143 GGATACCTTGATCACTAGCATTTGACCAACCTTGTGCAGAGTTGCAGCCTCCCCAGGTGG 
   AH137 GGATACCTTGATCACTAGCATTTGACCAACCTTGTGCAGAGTTGCAGCCTCCCCAGGTGG 
  
 2641 CACAGCCATCTGGACCAGGCCAAGCACAGGCCCCCACTCAGAGTGGGTTCATAGACTCTC 
   AH134 CACAGCCATCTGGACCAGGCCAAGCACAGGCCCCCACTCAGAGTGGGTTCATAGACTCTC 
   AH440 CACAGCCATCTGGACCAGGCCAAGCACAGGCCCCCACTCAGAGTGGGTTCATAGACTCTC 
   AH443 CACAGCCATCTGGACCAGGCCAAGCACAGGCCCCCACTCAGAGTGGGTTCATAGACTCTC 
   AH136 CACAGCCATCTGGACCAGGCCAAGCACAGGCCCCCACTCAGAGTGGGTTCATAGACTCTC 
   AH147 CACAGCCATCTGGACCAGGCCAAGCACAGGCCCCCACTCAGAGTGGGTTCATAGACTCTC 
   AH140 CACAGCCATCTGGACCAGGCCAAGCACAGGCCCCCACTCAGAGTGGGTTCATAGACTCTC 
   AH438 CACAGCCATCTGGACCAGGCCAAGCACAGGCCCCCACTCAGAGTGGGTTCATAGACTCTC 
   AH135 CACAGCCATCTGGACCAGGCCAAGCACAGGCCCCCACTCAGAGTGGGTTCATAGACTCTC 
   AH436 CACAGCCATCTGGACCAGGCCAAGCACAGGCCCCCACTCAGAGTGGGTTCATAGACTCTC 
   AH126 CACAGCCATCTGGACCAGGCCAAGCACAGGCCCCCACTCAGAGTGGGTTCATAGACTCTC 
   AH123 CACAGCCATCTGGACCAGGCCAAGCACAGGCCCCCACTCAGAGTGGGTTCATAGACTCTC 
   AH127 CACAGCCATCTGGACCAGGCCAAGCACAGGCCCCCACTCAGAGTGGGTTCATAGACTCTC 
   AH132 CACAGCCATCTGGACCAGGCCAAGCACAGGCCCCCACTCAGAGTGGGTTCATAGACTCTC 
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   AH130 CACAGCCATCTGGACCAGGCCAAGCACAGGCCCCCACTCAGAGTGGGTTCATAGACTCTC 
   AH118 CACAGCCATCTGGACCAGGCCAAGCACAGGCCCCCACTCAGAGTGGGTTCATAGACTCTC 
   AH439 CACAGCCATCTGGACCAGGCCAAGCACAGGCCCCCACTCAGAGTGGGTTCATAGACTCTC 
   AH144 CACAGCCATCTGGACCAGGCCAAGCACAGGCCCCCACTCAGAGTGGGTTCATAGACTCTC 
   AH117 CACAGCCATCTGGACCAGGCCAAGCACAGGCCCCCACTCAGAGTGGGTTCATAGACTCTC 
   AH122 CACAGCCATCTGGACCAGGCCAAGCACAGGCCCCCACTCAGAGTGGGTTCATAGACTCTC 
   AH143 CACAGCCATCTGGACCAGGCCAAGCACAGGCCCCCACTCAGAGTGGGTTCATAGACTCTC 
   AH137 CACAGCCATCTGGACCAGGCCAAGCACAGGCCCCCACTCAGAATGGGTTCATAGACTCTC  
 
 2701 TGGAGCTCTTCCTTGATCAACTGCTGACCGAAGTCCAACTTGAGGAGCAGGGGCCTGCCC 
   AH440 TGGAGCTCTTCCTTGATCAACTGCTGACCGAAGTCCAACTTGAGGAGCAGGAGCCTGCCC 
   AH443 TGGAGCTCTTCCTTGATCAACTGCTGACCGAAGTCCAACTTGAGGAGCAGGGGCCTGCCC 
   AH136 TGGAGCTCTTCCTTGATCAACTGCTGACCGAAGTCCAACTTGAGGAGCAGGGGCCTGCCC 
   AH147 TGGAGCTCTTCCTTGATCAACTGCTGACCGAAGTCCAACTTGAGGAGCAGGGGCCTGCCC 
   AH140 TGGAGCTCTTCCTTGATCAACTGCTGACCGAAGTCCAACTTGAGGAGCAGGGGCCTGCCC 
   AH438 TGGAGCTCTTCCTTGATCAACTGCTGACCGAAGTCCAACTTGAGGAGCAGGGGCCTGCCC 
   AH135 TGGAGCTCTTCCTTGATCAACTGCTGACCGAAGTCCAACTTGAGGAGCAGGGGCCTGCCC 
   AH436 TGGAGCTCTTCCTTGATCAACTGCTGACCGAAGTCCAACTTGAGGAGCAGGGGCCTGCCC 
   AH126 TGGAGCTCTTCCTTGATCAACTGCTGACCGAAGTCCAACTTGAGGAGCAGGGGCCTGCCC 
   AH123 TGGAGCTCTTCCTTGATCAACTGCTGACCGAAGTCCAACTTGAGGAGCAGGGGCCTGCCC 
   AH127 TGGAGCTCTTCCTTGATCAACTGCTGACCGAAGTCCAACTTGAGGAGCAGGGGCCTGCCC 
   AH132 TGGAGCTCTCCCTTGATCAACTGCTGACCGAAGTCCAACTTGAGGAGCAGGGGCCTGCCC 
   AH130 TGGAGCTCTTCCTTGATCAACTGCTGACCGAAGTCCAACTTGAGGAGCAGGGGCCTGCCC 
   AH118 TGGAGCTCTTCCTTGATCAACTGCTGACCGAAGTCCAACTTGAGGAGCAGGGGCCTGCCC 
   AH439 TGGAGCTCTTCCTTGATCAACTGCTGACCGAAGTCCAACTTGAGGAGCAGGGGCCTGCCC 
   AH144 TGGAGCTCTTCCTTGATCAACTGCTGACCGAAGTCCAACTTGAGGAGCAGGGGCGTGCCC 
   AH117 TGGAGCTCTTCCTTGATCAACTGCTGACCGAAGTCCAACTTGAGGAGCAGGGGCCTGCCC 
   AH122 TGGAGCTCTCCCTTGATCAACTGCTGACCGAAGTCCAACTTGAGGAGCAGGGGCCTGCCC 
   AH143 TGGAGCTCTTCCTTGATCAACTGCTGACCGAAGTCCAACTTGAGGAGCAGGGGCCTGCCC 
   AH137 TGGAGCTCTTCCTTGATCAACTGCTGACCGAAGTCCAACTTGAGGAGCAGGGGCCTGCCC  
 
 2761 CTGTGAATGTGGAGGAAACATGGGAGCAAATGGACACAACACCTGATCTGCCTCTCACTC 
   AH134 CTGTGAATGTGGAGGAA   
   AH440 CTGTGAATGTGGAGGAA   
   AH443 CTGTGAATGTGGAGGAA   
   AH136 CTGTGAATGTGGAGGAA   
   AH147 CTGTGAATGTGGAGGAA   
   AH140 CTGTGAATGTGGAGGAA   
   AH438 CTGTGAATGTGGAGGAA   
   AH135 CTGTGAATGTGGAGGAA   
   AH436 CTGTGAATGTGGAGGAA   
   AH126 CTGTGAATGTGGAGGAA   
   AH123 CTGTGAATGTGGAGGAA   
   AH127 CTGTGAATGTGGAGGAA   
   AH132 CTGTGAATGTGGAGGAA   
   AH130 CTGTGAATGTGGAGGAA   
   AH118 CTGTGAATGTGGAGGAA   
   AH439 CTGTGAATGTGGAGGAA   
   AH144 CTGTGAATGTGGAGGAA   
   AH117 CTGTGAATGTGGAGGAA   
   AH122 CTGTGAACGTGGAGGAA   
   AH143 CTGTGAATGTGGAGGAA  
AH137 CTGTGAATGTGGAGGAA 
 
 2821 CAGAAGAATATCAGACTCTTCTAGATATGCTCTGACTCCCTGACAGTACCCCTTGCTTCT 
 2881 AGAAACCCGAGAGGCCAAAGTCCTGAAGAGACCCGATTTGGAACTGGAGAAGGGACCCAT 
 2941 CCCAGCAAGGATGTGCATCAAAAACCCAACTCCAGTGACTTCCCGAAATGCAAGGTGTCT 
 3001 CGCTAACTATAAGGATTGATTGCAGGTGGGGATAATAATGAAGTGCCTTCTCCAGGGCCC 
 3061 GGGGATTAGGAAATCAGCCCTGAAAGTGAGAGACTCTGCTACAGGGACAGATGGAGAGGC 
 3121 CAATAGTGACTCCTCAACAACAAGGACCCTAAAGGTAACCCCAAAAGAAGGGCCACACCA 
 3181 AGTGACTGGCTCCAGTGGACCCCAGGAAATCACACGGGACACTAGGACTAGGCTTCACTA 
 3241 CAGAGGACACACACTCCCTGAGGGCAATGGGGAGAGTGGACTCCTTCCCTGGGTTATATG 
 3301 GACTGCTGTTATCCTTACAGATGCTTCGTGCAGAGCTGTGCAAGGTTTTACAGGCCAGTC 
 3361 TTGTAATATCTACTACCCATAGGTCTTTTGTTTGTTTTCTTTTTCTTTTTCACTTTCTTT 
 3421 TTCATTTTTTTTCTTTTTCTTTTTTTTAGGGGTGGGTTGTCTTTGCTGGGTTTGGTTTGG 
 3481 TTTTGTGTAGTTTGTTTCCATTGCTTTCAATAAAGTTTATTGATTTTAACAAAATTTGTT 
 3541 TGTGTGTTTGTGTGCTGTTTTGTGGGATGCGGGGTGGGTTGAATAGGCTGTTTTGTTCTA 
 3601 CCCGGAGAACGTGCATGAGAATTCCATTTAAAGGGATGAAAGACATAGGAAGGTATTCAG 
 3661 GAGGGATGCAGAGAAGCCAGGTAGAAAAGGGGAGAGAACAAGGAAGGCTGGGCTGTGTCC 
 3721 AGTGGAGAGACGGGCTTGCTTGATCTAGTAACAAGCAGGTGGAATGTCAACTGAAAGAAG 
 3781 AATGTGTGTAAGGCATAACCTTGTCAAGAAAGATCATCTTGGGAATACAGTGCAGCTAGG 
 3841 TGTGAACATCTTATTCCAAGCTGAAACACAGCCATCAGTCTATTCTTCATCCATCCATCC 
 3901 ATCCATCCATCTATCCATCCTTGCATCCATTCATCCATGCATGCCTAAATCAATCTGTAG 
 3961 ATCTTTCAATCCTATTGGGATTAATCCCCAGCACCCTCCCTTATCCCTCTTTTGATCTTG 
 4021 AGATTCCCAGGTGTTCAAGGTCATGCTGTTTATATGGAGCTCCAAGTTGATCTTTGACCC 
 4081 ACATTGGAAGGAGACGGTATGTTTACCATTCTACAATGACCGACAATTCTACAGAGAGCC 
 4141 TTATGGCATGCCAGCAGGACAAAACAATCTCTCATTTGCTGGCCATCACCTCAGGACAAC 
 185 
 4201 TTATTTGAAGTGTCTCCAGTGTTCAAGGCTAACTCCAGAGATCTAAGAGCACAGAACATA 
 4261 CTGCCAGCAAACACAGCACATGCAAGAAGACGATCAACTCTTTTCCTCACCCTGCTCCAT 
 4321 AGAAAGTGCACAACCTACTGGTGTCTCCAGCTTCCAGGCTCCTTTTCATACAGTCTGTGA 
 4381 AAGAAACACCTTGTGAGGTGTCTCCCTCTCTCTCTGTCTCTCTCTGTCTGTCTGTCTGTC 
 4441 TCTATCTCTCTCTCTCTCCCTTCATTCCTCTTTTGCTCCCCCTCCCATTTCCCCACTTGC 
 4501 CTCCATTTCACCATCTCTTCCACTCTCTGTCTCCATCCCCATACTTCTATCCTCCCATCT 
 4561 TCACTCCCCCATCCACAATCTACCTCCCTACTTCCCTATCTCTCTCTATCCATTCTTCCC 
 4621 TTCCTTCTGCACTCTGTCACTCTCTCCCTACCACCCTCCACCCTCTGTCCCTAAATCCCT 
 4681 CCCCCCTTCTCTTTACATCTGTGTTTGCCTCTCTCTTTGTGTCTTCCTCTGCCCCTAACC 
 4741 CCACCAATGGTCGTGACTTTATCCTCCCTTAGGATATTTGTGAGCATGATGTGTGTGTGT 
 4801 GTGTATGTGTGTGTTTGTGCTTGTGTGTGCCCGCATGTGTGCATGTGTTTGTGTGTGCAT 
 4861 GCGTGCGTGCATGCATGCAAATGTGTGTAAGTGTGTGTGTGGTCTGAGGGTGTGCCTGTT 
 4921 CACAATTGTCTCTGTGTGTTGCTGCCAGGTGCCTAGGGGCTGTTTGGACTTTCATTTTGA 
 4981 TCTCAGTACAGGTGATGTTCCCTCTTGTCCTCATAGCACAGTCAGACTTGGAAAGTCAAG 
 5041 GAAGGGGGTCTGAAACACTCTAGAGATAGGATGGAGGTGGTGATGTCTTTGGATCTCAGA 
 5101 CCATGATGTTGGGATGGTCAGTGGGAGGTCTTGTCTTTGTAAGCTGATTGAATCCGGATG 
 5161 GGATGAACTGAGCATGGCTTCCATAGGGCTTGGGATTCGGGGAAGGCTGAGTCCAATTCC 
 5221 CCAAGCTTTACTGAAGACTGCTCTCCTTCTCATAGGTGTCCTGGTACCTGTGCCACCTGC 
 5281 CAGTCAATGAATGACATGGCTGATGGGAATGGCGAGTCCTCTGACTCTTGTGTGCTCCCT 
 5341 GAGTGTGGGTCTAGACTGGCGACCCCGTGGCTTGCCAGGGATGAGGAGCCTTTGGGGAGA 
 5401 TTTTGCTGAGTGTCAGAGGACGTTTGAGGTCCCCCTCCTGGTGCCCTGACGTCAGGTGCC 
 5461 AGGCGTGGCAGGCATGGCAAGGATGCTGGAGGTCTGCCTCCTGGTGCCCTGATGTCAGGT 
 5521 GCCAGGCGTGGCAGGTGTGGTGCTTCTTGGAAGCACCGCGAGGAAGGGGTAGGCATGTTC 
 5581 TGTAGCCCAAGGCGCCTAACTGGTAGGTAGTGGGTGGGACTACCTGAGCAGAGGCAGAGA 
 5641 TATTTAAGGGGTAGTGGTCACAGCCACTCTGCTGGCAGTTGCTGCAGCTTGTGTTTGTTC 
 5701 TGAAGCTGTCCTGAGTCGATTCTCCCAAGGTGAGTACTTCTGGCAGGCCGTCATTGGCAC 
 5761 CATGGCAGAAGCTGGCAGCCCTGTTGGTGGCTGTGGTGTGGCACAGGAATCCCGGCAGCG 
 5821 CAGGAAGACGGTTTGGCAGGACTTGCAAGAGGAGGCCCTATCAGCTTTCAACTAGAAGAG 
 5881 ATACCTGTACTTTTAGGTGCTGGCCAGGCAAATGGGGATCCCAGATTGCTGAATTTGGGT 
 5941 GTGGTTTCTGAATTGCAGGAAATCGCACTGGAGGGGGAGGGGCATGCCTCAAAGAGGTTC 
 6001 ACCTGAGGCTCCAACCAAATAGCCTCACCACAGCTCCAGGAAGAACTAGGCTCCAGGGTA 
 6061 CAGGGTGGAGGCATGCGCTCATCCAGCAGAAGGCCTCACACTGGACTCACTTTGTCACAG 
 6121 CGCAGGATCCTAGCACAAGCATTTGAGAGGAACCCACGACCAGGCTGTGCTACCAGGGAG 
 6181 GAGCTGGCACTTGAGACAGGGTTGCCCGAGGACATGATCCACACATGGTTGAAAAACAAA 
 
 6241 AGAGCTCGGCGCCACAGGAGGGGCAGGCCCACAGCTCAAGATCAAGACTTGCTGGCCTCA 
   AH432                                               ACTTGCTGGCCTCA 
   AH435                                               ACTTGCTGGCCTCA 
   AH408                                               ACTTGCTGGCCTCA 
   AH411                                               ACTTGCTGGCCTCA 
   AH421                                               ACTTGCTGGCCTCA 
   AH415                                               ACTTGCTGGCCTCA 
   AH418                                               ACTTGCTGGCCTCA 
     
    6301 CAAGTGTCCGGTGGGGCCCCTGCAGGTCCGGTAGGCAGGGGCCATGAAGTTGCACAGGAG 
   AH432 CAAGTGTCCGGTGGGGCCCCTGCAGGTCCGGTAGGCAGGGGCCATGAAGTTGCACAGGAG 
   AH435 CAAGTGTCCGGTGGGGCCCCTGCAGGTCCGGTAGGCAGGGGCCATGAAGTTGCACAGGAG 
   AH408 CAAGTGTCCGGTGGGGCCCCTGCAGGTCCGGTAGGCAGGGGCCATGAAGTTGCACAGGAG 
   AH411 CAAGTGTCCGGTGGGGCCCCTGCAGGTCCGGTAGGCAGGGGCCATGAAGTTGCACAGGAG 
   AH421 CAAGTGTCCGGTGGGGCCCCTGCAGGTCCGGTAGGCAGGGGCCATGAAGTTGCACAGGAG 
   AH415 CAAGTGTCCGGTGGGGCCCCTGCAGGTCCGGTAGGCAGGGGCCATGAAGTTGCACAGGAG 
   AH418 CAAGTGTCCGGTGGGGCCCCTGCAGGTCCGGTAGGCAGGGGCCATGAAGTTGCACAGGAG 
     
    6361 AGCTCATTGCCACAGGAAGAAGCAGGAAGTACGGGCATGGATACTACAAGCACCAGCTAC 
   AH432 AGCTCATTGCCACAGGAAGAAGCAGGAAGTACGGGCATGGATACTACAAGCACCAGCTAC 
   AH435 AGCTCATTGCCACAGGAAGAAGCAGGAAGTACGGGCATGGATACTACAAGCACCAGCTAC 
   AH408 AGCTCATTGCCACAGGAAGAAGCAGGAAGTACGGGCATGGATACTACAAGCACCAGCTAC 
   AH411 AGCTCATTGCCACAGGAAGAGGCAGGAAGTACGGGCATGGATACTACAAGCACCAGCTAC 
   AH421 AGCTCATTGCCACAGGAAGAAGCAGGAAGTACGGGCATGGATACTACAAGCACCAGCTAC 
   AH415 AGCTCATTGCCACAGGAAGAAGCAGGAAGTACGGGCATGGATACTACAAGCACCAGCTAC 
   AH418 AGCTCATTGCCACAGGAAGAAGCAGGAAGTACGGGCATGGATACTACAAGCACCAGCTAC 
 
 6421 TCGCCCTCTTTCTGCAGAGAGTCCCAACTTTCCCAAGTGTCACAGCCCCGTGGAGCAGGC 
   AH432 TCGCCCTCTTTCTGCAGAGAGTCCCAACTTTCCCAAGTGTCACAGCCCCGTGGAGTAGGC 
   AH435 TCGCCCTCTTTCTGCAGAGAGTCCCAACTTTCCCAAGTGTCACAGCCCCGTGGAGCAGGC 
   AH408 TCGCCCTCTTTCTGCAGAGAGTCCCAACTTTCCCAAGTGTCACAGCCCCGTGGAGCAGGC 
   AH411 TCGCCCTCTTTCTGCAGAGAGTCCCAACTTTCCCAAGTGTCACAGCCCCGTGGAGCAGGC 
   AH421 TCGCCCTCTTTCTGCAGAGAGTCCCAACTTTCCCAAGTGGCACAGCCCCGTGGAGCAGGC 
   AH415 TCGCCCTCTTTCTGCAGAGAGTCCCAACTTTCCCAAGTGTCACAGCCCCGTGGAGCAGGC 
   AH418 TCGCCCTCTTTCTGCAGAGAGTCCCAACTTTCCCAAGTGTCACAGCCCCGTGGAGCAGGC 
 
 6481 CAAAAAGAGGTCCCCACTCAAGCAGGCAACGTAGGCCCTCTGGAACTTCTCCTTGATGAA 
   AH432 CAAAAAGAGGTCCCCACTCAAGCAGGCAACGTAGGCC   
   AH435 CAAAAAGAGGTCCCCACTCAAGCAGGCAACGTAGGCC   
   AH408 CAAAAAGAGGTCCCCACTCAAGCAGGCAACGTAGGCC   
   AH411 CAAAAAGAGGTCCCCACTCAAGCAGGCAACGTAGGCC   
   AH421 CAACAAGAGGCCCCCACTCAAGCAGGCAACGCAGGCT   
 186 
   AH415 CAAAAAGAGGTCCCCACTCAAGCAGGCAACGTAGGCC   
   AH418 CAAAAAGAGGTCCCCACTCAAGCAGGCAACGTAGGCC   
 
 6541 CTGCAGGACGAAGTACAGGTGAAAGAGCATGTGCCAGACCCTTTGGATTTGGGTAGTGAT 
 6601 CCTGGCGCCAGGGAGCCTGAAGGTTCCCAGGACAGCTTACAGAGCCTGGATGAAGCAGCA 
 6661 AATTCAGGCTGGCATACCTCGGTCCCGAGCATCTCGTCAACCTTGTGCAGAGAGTCCCAG 
 6721 CCTTCCCAAGTGGCACAGCCCTCTGGACCAGGACAAGCACAGGCCCCCACTCAAAGTGGG 
 
 6781 TTCATAGACCCTCTGGAGCTCTTTCTCGATGAACTGCTGACTGAAGTCCAACTTGAGGAG 
   AH99                                                     CTTGAGGAG 
   AH173                                                    CTTGAGGAG 
   AH190                                                    CTTGAGGAG 
   AH187                                                    CTTGAGGAG 
   AH110                                                    CTTGAGGAG 
   AH100                                                    CTTGAGGAG 
   AH189                                                    CTTGAGGAG 
   AH170                                                    CTTGAGGAG 
   AH194                                                    CTTGAGGAG 
   AH108                                                    CTTGAGGAG 
   AH188                                                    CTTGAGGAG 
   AH105                                                    CTTGAGGAG 
   AH106                                                    CTTGAGGAG 
   AH107                                                    CTTGAGGAG   
 
    6841 CAGGGGCCTGCCCCTGTGAATGTGGAGGAAACAGGGGAGCAAATGGACACAACACCTGAG 
   AH99  CAGGGGCCTGCCCCTGTGAATGTGGAGGAAACAGGGGAGCAAATGGACACAACGCCTGAG 
   AH173 CAGGGGCCTGCCCCTGTGAATGTGGAGGAAACAGGGGAGCAAATGGACACAACACCTGAG 
   AH190 CAGGGGCCTGCCCCTGTGAATGTGGAGGAAACAGGGGAGCAAATGGACACAACACCTGAG 
   AH187 CAGGGGCCTGCCCCTGTGAATGTGGAGGAAACAGGGGAGCAAATGGACACAACACCTGAG 
   AH110 CAGGGGCCTGCCCCTGTGAATGTGGAGGAAACAGGGGAGCAAATGGACACAACACCTGAG 
   AH100 CAGGGGCCTGCCCCCGTGAATGTGGAGGAAACAGGGGAGCAAATGGACACAACACCCGAG 
   AH189 CAGGGGCCTGCCCCTGTGAATGTGGAGGAAACAGGGGAGCAAATGGACACAACACCTGAG 
   AH170 CAGGGGCCTGCCCCTGTGAATGTGGAGGAAACAGGGGAGCAAATGGACACAACACCTGAG 
   AH194 CAGGGGCCTGCCCCTGTGAATGTGGAGGAAACAGGGGAGCAAATGGACACAACACCTGAG 
   AH108 CAGGGGCCTGCCCCTGTGAATGTGGAGGAAACAGGGGAGCAAATGGACACAACACCTGAG 
   AH188 CAGGGGCCTGCCCCTGTGAATGTGGAGGAAACAGGGGAGCAAATGGACACAACACCTGAG 
   AH105 CAGGGGCCTGCCCCTGTGAATGTGGAGGAAACAGGGGAGCAAATGGACACAACACCTGAG 
   AH106 CAGGGGCCTGCCCCTGTGAATGTGGAGGAAACAGGGGAGCAAATGGACACAACACCTGAG 
   AH107 CAGGGGCCTGCCCCTGTGAATGTGGAGGAAACAGGGGAGCAAATGGACACAACACCTGAG 
  
 6901 CTGCCTCTCACCCCAGAAGAATATCAGACTCTTCTAGATATGCTCTGACTCCCTGACAGT 
   AH99  CTGCCTCTCACCCCAGAAGAATATCAGACTCTTCTAGATATGCTCTGACTCCCTGACAGT 
   AH173 CTGCCTCTCACCCCAGAAGAATATCAGACTCTTCTAGATATGCTCTGACTCCCTGACAGT 
   AH190 CTGCCTCTCACCCCAGAAGAATATCAGACTCTTCTAGATATGCTCTGACTCCCTGACAGT 
   AH187 CTGCCTCTCACCCCAGAAGAATATCAGACTCTTCTAGATATGCTCTGACTCCCTGACAGT 
   AH110 CTGCCTCTCACCCCAGAAGAATATCAGACTCTTCTAGATATGCTCTGACTCCCTGACAGT 
   AH100 CTGCCTCTCACCCCAGAAGAATATCAGACTCTTCTAGATATGCTCTGACTCCCTGACAGT 
   AH189 CTGCCTCTCACCCCAGAAGAATATCAGACTCTTCTAGATATGCTCTGACTCCCTGACAGT 
   AH170 CTGCCTCTCACCCCAGAAGAATATCAGACTCTTCTAGATATGCTCTGACTCCCTGACAGT 
   AH194 CTGCCTCTCACCCCAGAAGAATATCAGACTCTTCTAGATATGCTCTGACTCCCTGACAGT 
   AH108 CTGCCTCTCACCCCAGAAGAATATCAGACTCTTCTAGATATGCTCTGACTCCCTGACAGT 
   AH188 CTGCCTCTCACCCCAGAAGAATATCAGACTCTTCTAGATATGCTCTGACTCCCTGACAGT 
   AH105 CTGCCTCTCACCCCAGAAGAATATCAGACTCTTCTAGATATGCTCTGACTCCCTGACAGT 
   AH106 CTGCCTCTCACCCCAGAAGAATATCAGACTCTTCTAGATATGCTCTGACTCCCTGACAGT 
   AH107 CTGCCTCTCACCCCAGAAGAATATCAGACTCTTCTAGATATGCTCTGACTCCCTGACAGT 
     
    6961 ACCCCTTGCATCTAGACACCCGCGAGGCCAAATCCTAAAGAGACCCAATTTGGAACTGGA 
   AH99  ACCCCTTGCATCTAGACACCCGCGAGGCCAAATCCTAAAGAGACCCAATTTGGAACTGGA 
   AH173 ACCCCTTGCATCTAGACACCCGCGAGGCCAAATCCTAAAGAGACCCAATTTGGAACTGGA 
   AH190 ACCCCTTGCATCTAGACACCCGCGAGGCCAAATCCTAAAGAGACCCAATTTGGAACTGGA 
   AH187 ACCCCTTGCATCTAGACACCCGCGAGGCCAAATCCTAAAGAGACCCAATTTGGAACTGGA 
   AH110 ACCCCTTGCATCTAGACACCCGCGAGGCCAAATCCTAAAGAGACCCAATTTGGAACTGGA 
   AH100 ACCCCTTGCATCTAGACACCCGCGAGGCCAAATCCTAAAGAGACCCAATTTGGAACTGGA 
   AH189 ACCCCTTGCATCTAGACACCCGCGAGGCCAAATCCTAAAGAGACCCAATTTGGAACTGGA 
   AH170 ACCCCTTGCATCTAGACACCCGCGAGGCCAAATCCTAAAGAGACCCAATTTGGAACTGGA 
   AH194 ACCCCTTGCATCTAGACACCCGCGAGGCCAAATCCTAAAGAGACCCAATTTGGAACTGGA 
   AH108 ACCCCTTGCATCTAGACACCCGCGAGGCCAAATCCTAAAGAGACCCAATTTGGAACTGGA 
   AH188 ACCCCTTGCATCTAGACACCCGCGAGGCCAAATCCTAAAGAGACCCAATTTGGAACTGGA 
   AH105 ACCCCTTGCATCTAGACACCCGCGAGGCCAAATCCTAAAGAGACCCAATTTGGAACTGGA 
   AH106 ACCCCTTGCATCTAGACACCCGCGAGGCCAAATCCTAAAGAGACCCAATTTGGAACTGGA 
   AH107 ACCCCTTGCATCTAGACACCCGCGAGGCCAAATCCTAAAGAGACCCAATTTGGAACTGGA 
  
7021 GAAGGTACCCATTTCAGCAAGGATGTGCACAAAAACGCAACTCCAGTGACTTCCCGAAAT 
   AH99  GAAGGTACCCATTTCAGCAAGGATGTGCACAAAAACGCAACTCCAGTGACTTCCCGAAAT 
   AH173 GAAGGTACCCATTTCAGCAAGGATGTGCACAAAAACGCAACTCCAGTGACTTCCCGAAAT 
   AH190 GAAGGTACCCATTTCAGCAAGGATGTGCACGAAAACGCAACTCCAGTAACTTCCCGAAAT 
   AH187 GAAGGTACCCATTTCAGCAAGGATGTGCACAAAAACGCAACTCCAGTGACTTCCCGAAAT 
 187 
   AH110 GAAGGTACCCATTTCAGCAAGGATGTGCACAAAAACGCAACTCCAGTGACTTCTCGAAAT 
   AH100 GAAGGTACCCATTTCAGCAAGGATGTGCACAAAAACGCAACTCCAGTGACTTCCCGAAAT 
   AH189 GAAGGTACCCATTTCAGCAAGGATGTGCACAAAAACGCAACTCCAGTGACTTCCCGAAAT 
   AH170 GAAGGTACCCATTTCAGCAAGGATGTGCACAAAAACGCAACTCCAGTGACTTCCCGAAAT 
   AH194 GAAGGTACCCATTTCAGCAAGGATGTGCACAAAAACGCAACTCCAGTGACTTCCCGAAAT 
   AH108 GAAGGTACCCATTTCAGCAAGGATGTGCACAAAAACGCAACTCCAGTGACTTCCCGAAAT 
   AH188 GAAGGTACCCATTTCAGCAAGGATGTGCACAAAAACGCAACTCCAGTGACTTCCCGAAAT 
   AH105 GAAGGTACCCATTTCAGCAAGGATGTGCACAAAAACGCAACTCCAGTGACTTCCCGAAAT 
   AH106 GAAGGTACCCATTTCAGCAAGGATGTGCACAAAAACGCAACTCCAGTGACTTCCCGAAAT 
   AH107 GAAGGTACCCATTTCAGCAAGGATGTGCACAAAAACGCAACTCCAGTGACTTCCCGAAAT 
  
7081  GCAAGGTGTCTTGCTAACTATAAGGATGGATTGCAGGTGGGGATAATAATGAAGTGCCTT 
   AH99  GCAAGGTGTCTTGCTAACTATAAGGATGGATTGCAGGTGGGGATAATAATGAAGTGCCTT 
   AH173 GCAAGGTGTCTTGCTAACTATAAGGATGGATTGCAGGTGGGGATAATAATGAAGTGCCTT 
   AH190 GCAAGGTGTCTTGCTAACTATAAGGATGGATTGCAGGTGGGGATAATAATGAAGTGCCTT 
   AH187 GCAAGGTGTCTTGCTAACTATAAGGATGGATTGCAGGTGGGGATAATAATGAAGTGCCTT 
   AH110 GCAAGGTGTCTTGCTAGCTATAAGGATGGATTGCAGGTGGGGATAATAATGAAGTGCCTT 
   AH100 GCAAGGTGTCTTGCTAACTATAAGGATGGATTGCAGGTGGGGATAATAATGAAGTGCCTT 
   AH189 GCAAGGTGTCTTGCTAACTATAAGGATGGATTGCAGGTGGGGATAATAATGAAGTGCCTT 
   AH170 GCAAGGTGTCTTGCTAACTATAAGGATGGATTGCAGGTGGGGATAATAATGAAGTGCCTT 
   AH194 GCAAGGTGTCTTGCTAACTATAAGGATGGATTGCAGGTGGGGATAATAATGAAGTGCCTT 
   AH108 GCAAGGTGTCTTGCTAACTATAAGAATGGATTGCAGGTGGGGATAATAATGAAGTGCCTT 
   AH188 GCAAGGTGTCTTGCTAACTATAAGGATGGATTGCAGGTGGGGATAATAATGAAGTGCCTT 
   AH105 GCAAGGTGTCTTGCTAACTATAAGGATGGATTGCAGGTGGGGATAATAATGAAGTGCCTT 
   AH106 GCAAGGTGTCTTGCTAACTATAAGGATGGATTGCAGGTGGGGATAATAATGAAGTGCCTT 
   AH107 GCAAGGTGTCTTGCTAACTATAAGGATGGATTGCAGGTGGGGATAATAATGAAGTGCCTT 
 
7141  CTGCAGCGCCCAGGGATTAGGAAATCAGCCCTGAAAGTGAGAGACTCTGCTACAGGGACA 
   AH99  CTGCAGCGCCCAGGGATTAGGAAATCAGCCCTGAAAGTGAGAGACTCTGCTACAGGGACA 
   AH173 CTGCAGCGCCCAGGGATTAGGAAATCAGCCCTGAAAGTGAGAGACTCTGCTACAGGGACA 
   AH190 CTGCAGCGCCCAGGGATTAGGAAATCAGCCCTGAAAGTGAGAGACTCTGCTACAGGGACA 
   AH187 CTGCAGCGCCCAGGGATTAGGAAATCAGCCCTGAAAGTGAGAGACTCTGCTACAGGGACA 
   AH110 CTGCAGCGCCCAGGGATTAGGAAATCAGCCCTGAAAGTGAGAGACTCTGCTACAGGGACA 
   AH100 CTGCAGCGCCCAGGGATTAGGAAATCAGCCCTGAAAGTGAGAGACTCTGCTACAGGGACA 
   AH189 CTGCAGCGCCCAGGGATTAGGAAATCAGCCCTGAAAGTGAGAGACTCTGCTACAGGGACA 
   AH170 CTGCAGCGCCCAGGGATTAGGAAATCAGCCCTGAAAGTGAGAGACTCTGCTACAGGGACA 
   AH194 CTGCAGCGCCCAGGGATTAGGAAATCAGCCCTGAAAGTGAGAGACTCTGCTACAGGGACA 
   AH108 CTGCAGCGCCCAGGGATTAGGAAATCAGCCCTGAAAGTGAGAGACTCTGCTACAGGGACA 
   AH188 CTGCAGCGCCCAGGGATTAGGAAATCAGCCCTGAAAGTGAGAGACTCTGCTACAGGGACA 
   AH105 CTGCAGCGCCCAGGGATTAGGAAATCAGCCCTGAAAGTGAGAGACTCTGCTACAGGGACA 
   AH106 CTGCAGCGCCCAGGGATTAGGAAATCAGCCCTGAAAGTGAGAGACTCTGCTACAGGGACA 
   AH107 CTGTAGCGCCCAGGGATTA  
 
 7201 GATGGAGAGGCCAATAGTGACTCCTCAACAACAAGGAGCCTAAAGATAACCCCAAAAGAA 
   AH99  GATGGAGAGGCCAATAGTGACTCCTCAACAACAAGGAGCCTAAAGATAACCCCAAAAGAA 
   AH173 GATGGAGAGGCCAATAGTGACTCCTCAACAACAAGGAGCCTAAAGATAACCCCAAAAGAA 
   AH190 GATGGAGAGGCCAATAGTGACTCCTCAACAACAAGGAGCCTAAAAATAACCCCAAAAGAA 
   AH187 GATGGAGAGGCCAATAGTGACTCCTCAACAACAAGGAGCCTAAAGATAACCCCAAAAGAA 
   AH110 GATGGAGAGGCCAATAGTGACTCCTCAACAACAAGGAGCCTAAAGATAACCCCAAAAGAA 
   AH100 GATGGAGAGGCCAATAGTGACTCCTCAACAACAAGGAGCCTAAAGATAACCCCAAAAGAA 
   AH189 GATGGAGAGGCCAATAGTGACTCCTCAACAACAAGGAGCCTAAAGATAACCCCAAAAGAA 
   AH170 GATGGAGAGGCCAATAGTGACTCCTCAACAACAAGGAGCCTAAAGATAACCCCAAAAGAA 
   AH194 GATGGAGAGGCCAATAGTGACTCCTCAACAACAAGGAGCCTAAAGATAACCCCAAAAGAA 
   AH108 GATGGAGAGGCCAATAGTGACTCCTCAACAACAAGGAGCCTAAAGATAACCCCAAAAGAA 
   AH188 GATGGAGAGGCCAATAGTGACTCCTCAACAACAAGGAGCCTAAAGATAACCCCAAAAGAA 
   AH105 GATGGAGAGGCCAATAGTGACTCCTCAACAACAAGGAGCCTAAAGATAACCCCAAAAGAA 
   AH106 GATGGAGAGGCCAATAGTGACTCCCCAACAACAAGGAGCCTAAAGATAACCCCAAAAGAA 
 
 7261 GGGCCACACCAAGTGACTGGCTCCAGTGGACCCCAGGAAATCACACGGGACACTAGGACT 
   AH99  GGGCCACACCAAGTGACTGGCTCCAGTGGACCCCAGGAAATCACACGGGACACTAGGACT 
   AH173 GGGCCACACCAAGTGACTGGCTCCAGTGGACCCCAGGAAATCACACGGGACACTAGGACT 
   AH190 GGGCCACACCAAGTGACTGGCTCCAGTGGACCCCAGGAAATCACACGGGACACTAGGACT 
   AH187 GGGCCACACCAAGTGACTGGCTCCAGTGGACCCCAGGAAATCACACGGGACACTAGGACT 
   AH110 GGGCCACACCAAGTGACTGGCTCCAGTGGACCCCAGGAAATCACACGGGACACTAGGACT 
   AH100 GGGCCACACCAAGTGACTGGCTCCAGTGGACCCCAGGAAATCACACGGGACACTAGGACT 
   AH189 GGGCCACACCAAGTGACTGGCTCCAGTGGACCCCAGGAAATCACACGGGACACTAGGACT 
   AH170 GGGCCACACCAAGTGACTGGCTCCAGTGGACCCCAGGAAATCACACGGGACACTAGGACT 
   AH194 GGGCCACACCAAGTGACTGGCTCCAGTGGACCCCAGGAAATCACACGGGACACTAGGACT 
   AH108 GGGCCACACCAAGTGACTGGCTCCAGTGGACCCCAGGAAATCACACGGGACACTAGGACT 
   AH188 GGGCCACACCAAGTGACTGGCTCCAGTGGACCCCAGGAAATCACACGGGACACTAGGACT 
   AH105 GGGCCACACCAAGTGACTGGCTCCAGTGGACCCCAGGAAATCACACGGGACACTAGGACT 
   AH106 GGGCCACACCAAGTGACTGGCTCCAGTGGACCCCAGGAAATCACACGGGACACTAGGACT 
     
  
 7321 AGGCTTCACTACAGAGGACACACACTCCCTGAGGGCAATCGGGAGAGTGGACTCCTTCCC 
   AH99  AGGCTTCACTACAGAGGACACACACTCCCTGAGGGCAATCGGGAGAGTGGACTCCTTCCC 
   AH173 AGGCTTCACTACAGAGGACACACACTCCCTGAGGGCAATCGGAAGAGTGGACTCCTTCCC 
 188 
   AH190 AGGCTTCACTACAGAGGACACACACTCCCTGAGGGCAATCGGGAGAGTGGACTCCTTCCC 
   AH187 AGGCTTCACTACAGAGGACACACACTCCCTGAGGGCAATCGGGAGAGTGGACTCCTTCCC 
   AH110 AGGCTTCACTACAGAGGACACACACTCCCTGAGGGCAATCGGGAGAGTGGACTCCTTCCC 
   AH100 AGGCTTCACTACAGAGGACACACACTCCCTGAGGGCAATCGGGAGAGTGGACTCCTTCCC 
   AH189 AGGCTTCACTACAGAGGACACACACTCCCTGAGGGCAATCGGGAGAGTGGACTCCTTCCC 
   AH170 AGGCTTCACTACAGAGGACACACACTCCCTGAGGGCAATCGGGAGAGTGGACTCCTTCCC 
   AH194 AGGCTTCACTACAGGGGACACACACTCCCTGAGGGCAATCGGGAGAGTGGACTCCTTCCC 
   AH108 AGGCTTCACTACAGAGGACACACACTCCCTGAGGGCAATCGGGAGAGTGGACTCCTTCCC 
   AH188 AGGCTTCACTACAGAGGACACACACTCCCTGAGGGCAATCGGGAGAGTGGACTCCTTCCC 
   AH105 AGGCTTCACTACAGAGGACACACACTCCCTGAGGGCAATCGGGAGAGTGGACTCCTTCCC 
   AH106 AGGCTTCACTACAGGGGACACACACTCCCTGAGGGCAATCGGGAGAGTGGACTCCTTCCC 
  
 7381 TGGGTTGTATGGACTGCTGCTATTCTTACAGATGCTTCGTGCAGAGCTGTGCAAGGTTTT 
   AH99  TGGGTTGTATGGACTGCTGCTATTCTTACAG      
   AH173 TGGGTTGTATGGACTGCTGCTATTCTTACAG      
   AH190 TGGGTTGTATGGACTGCTGCTATTCTTACAG      
   AH187 TGGGTTGTATGGACTGCTGCTATTCTTACAG      
   AH110 TGGGTTGTATGGACTGCTGCTATTCTTACAG      
   AH100 TGGGTTGTATGGACTGCTGCTATTCTTACAG      
   AH189 TGGGTTGTATGGACTGCTGCTATTCTTACAG      
   AH170 TGGGTTGTATGGACTGCTGCTATTCTTACAG      
   AH194 TGGGTTGTATGGACTGCTGCTATTCTTACAG      
   AH108 TGGGTTGTATGGACTGCTGCTATTCTTACAG      
   AH188 TGGATTGTATGGACTGCTGCTATTCTTACAG      
   AH105 TGGGTTGTATGGACTGCTGCTATTCTTACAG      
   AH106 TGGGTTGTATGGACTGCTGCTATCCTTACAG      
 
 7441 ACAGGCCAGTCTTTTAATATCTACTACCCATAGGTCTTTTGTTTGTTTTCTTTTTCTTTT 
 7501 TCACTTTCTTTTTCATTTTTTTTTCTTTATTTTTTTGGGTGGGTTGTCTTTGCTGGGTTT 
 7561 GGTTTGGTTCTGTGTAGTTTGTTTCCATTGCTTTCAATAAAGTTTATTGATTTTGACAAA 
 7621 ATTTGTTTGTGTGTTTGTGTACTGTGTTGTGGGATGAGGGGTGGGTTGAAGAGGCTGTTT 
 7681 TGTTCTACCCGGAGAATGTGCATGAGAATTCCATTTAAAGGGATGAAAGACATAGGAAGG 
 7741 TATTCAGGAGGGATGCAGAGAGGCCAGGTAGAAAAGGGGAGAGAACAAGGAAGGCTGGGC 
 7801 TGTGTCCAGTGGAGAGACGGGCTTGCTTGATCTAGTAACAAGCAGGTGGAATGTCAACTG 
 7861 AAAGAAGAATGTGTGTAAGGCATAACCTTGTCAAGAAAGATCATCTTGGGAATACAGTGC 
 7921 AGCTAGGTGTGAACATCTTATTCCAAGCTTGAAACACAGCCATCAGTCTATTCTTCATCC 
 7981 ATCCATCCATCTATCCATTCTTGCATCCATTCATCCATGCATGCCTAAATAATCTGGAGG 
 8041 TCTTTCAATCCTTTTGGGATTAATCCCCAGCACCCTCCCTTATCCTTCTTTTGATCTTGA 
 8101 GATTCCCAGGTGTTCAAGGTCATGCTGTTTACATGGAGCTCCAAGTTGATCCTTGACCCA 
 8161 CATTGGAAGGACTCGGTATGTTTAATATTCTACAATGACCGACAATTCTACAGAGAGCCT 
 8221 TATGGCATGCCAGCAGGACAAAACAATCTCTCATTTGCTGGCCATCACCTCAGGACAACT 
 8281 TATTTGAAGTGTCTCCAGTGTTCAAGGCTAACTCCAGAGATCTAAGAGCACAGAACATAC 
 8341 CGCCAGCAAACACAGCACATGCAAGAAGATGATCAACTCTTTTCTTCACCCTTCTCCATA 
 8401 GAAAGTGCAAAACCTACTGGTGTCTCAAGCTTCCAGGCTCCTTTTCATACAGTCTGTGAA 
 8461 AGAAACACCTTGTGAGGTGTCTCCCTCTCTCTCTGTCTCTGTCTGTCTGTCTGTCTCTGT 
 8521 CTCTCTCTCTCTCCCTCCATTCCTCTTTTGCTCCCCCTCCCATTTCCCTCCTTGCCTCCA 
 8581 TTTCACCATCTCTTCCACTCTCTGTCTCCATCCCCATCCTTCTACCCTCCCATATTCACT 
 8641 CCCCCCATCCACTTTCTACCTCCCTACTTCCCTATCTCTCTCTATGGATTCTTCCCTTCC 
 8701 TTCTGCACTCTGTCACTCTCTCCCTACCACCCTCCACCCTCTGTCCCTAAATCCCTTCCC 
 8761 CCCTTCTCTCCACATCTGTGTTTGTCTCTCTCTTCGTGTCTTCCTCTGCCCCTAACCCCA 
 8821 CCCATGGTCGTGACTTTATCTTCCCTTAGGATATTTGTGAGCATGATGTGTGTGTGTTTG 
 8881 TGTGTGTGTGTGTGTTTGTGCTTGTGTGTGCCCGCATGTGTGTACGTGTTTGTGTGTGCG 
 8941 TGTGTGCGTGTGTGCGTGCATGCATGCAAATGTGTGTATGTGTGTGTGTGGTCTGAGGGT 
 9001 GTGCCTGTTCACAATTGTCTCTGTGTGTTGCTGCCAGGTGCCTAGGGGCTGTTTGGACTT 
 9061 TCATTTTGATCTCAGTACAGGTGATGTTCCCTCTTGTCCTCATAGCACAGTCAGACTTGG 
 9121 AAAGTCAAGGAAGGGGGTCTGAAACACTCTAGAGATAGGATGGAGGTGGTGATGTCTTTG 
 9181 GATCTCAGACCATGATGTTGGGATCGTCAGTGGGTGGTCTTGTCTTTGTAAGCTGATTGA 
 9241 ATCCGGATGGGATGAACTGAGCATGGCTTCCATAGGGCTTGGGATTCCTGGAAGGCTGAG 
 9301 TCCAATTCCCCAAGCTTTACTGAAGACTGCTCCCCTTCTCATAGGTGTCCTGGTACCTGT 
 9361 GCCACCTGCCAGTCAATGAATGACATGGCTGATGGGAATGGCGAGTCCTCTGACTCTTGT 
 9421 GTGCTCCCTGGGTGTGGGTCTAGACTGGCGACCCCGTGGCTTGCCAGGGATGAGGAGCCT 
 9481 TTGGGGAGATTTTGCTGAGTGTCAGAGGATGCTTGAGGTCCGCCTCCTGGTGCCCTGATG 
 9541 TCAGGTGCCAGGCGTGGCAGGCTTGGCGCTTCTTGGGGGCAATGCGAGAAAGGGGTAGGC 
 9601 ATGTTCTGTAGCCCAAGGCGCCTAACTGGTAGGTAGTGGGCGGGACTACCTGAGCAGAGG 
     
    9661 CAGAGGTATTTAAGGGGCAGTGGTCACAGCCACTCTGCTGGCAGTTGCTGCAGCTTGTGT 
   AH379                             GCCACTCTGCTGGCAGTTGCTGCAGCTTGTGT 
   AH377                             GCCACTCTGCTGGCAGTTGCTGCAGCTTGTGT 
   AH384                             GCCACTCTGCTGGCAGTTGCTGCAGCTTGTGT 
   AH378                             GCCACTCTGCTGGCAGTTGCTGCAGCTTGTGT 
   AH381                             GCCACTCTGCTGGCAGTTGCTGCAGCTTGTGT 
   AH383                                                         GTGT 
  
 9721 TTGTTCTGAAGCTGTCCTGAGTCGAGTCTCCCAAGGTAAGGACTCCTGGGAGGCCGTCAT 
   AH379 TTGTTCTGAAGCTGTCCTGAGTCGAGTCTCCCAAGGTAAGGACTCCTGGGAGGCCGTCAT 
   AH377 TTGTTCTGAAGCTGTCCTGAGTCGAGTCTCCCAAGGTAAGGACTCCTGGGAGGCCGTCAT 
   AH384 TTGTTCTGAAGCTGTCCTGAGTCGAGTCTCCCAAGGTAAGGACTCCTGGGAGGCCGTCAT 
 189 
   AH378 TTGTTCTGAAGCTGTCCTGAGTCGAGTCTCCCAAGGTAAGGACTCCTGGGAGGCCGTCAT 
   AH381 TTGTTCTGAAGCTGTCCTGAGTCGAGTCTCCCAAGGTAAGGACTCCTGGGAGGCCGTCAT 
   AH383 TTGTTCTGAAGCTGTCCTGAGTCGAGTCTCCCAAGGTAAGGACTCCTGGGAGGCCGTCAT 
     
    9781 TGGCACCATGGCAGAAGCTGGCAGCCCTGTTGGTGGCAGTGGTGTGGCACGGGAATCCCG 
   AH379 TGGCACCATGGCAGAAGCTGGCAGCCCTGTTGGTGGCAGTGGTGTGGCACGGGAATCCCG 
   AH377 TGGCACCATGGCAGAAGCTGGCAGCCCTGTTGGTGGCAGTGGTGTGGCACGGGAATCCCG 
   AH384 TGGCACCATGGCAGAAGCTGGCAGCCCTGTTGGTGGCAGTGGTGTGGCACGGGAATCCCG 
   AH378 TGGCACCATGGCAGAAGCTGGCAGCCCTGTTGGTGGCAGTGGTGTGGCACGGGAATCCCG 
   AH381 TGGCACCATGGCAGAAGCTGGCAGCCCTGTTGGTGGCAGTGGTGTGGCACGGGAATCCCG 
   AH383 TGGCACCATGGCAGAAGCTGGCAGCCCTGTTGGTGGCAGTGGTGTGGCACGGGAATCCCG 
             M  A  E  A  G  S  P  V  G  G  S  G  V  A  R  E  S  R  
     
    9841 GCGGCGCAGGAAGATGGTTTGGCAGGCCTGGCAAGAGCAGGCCCTGCTATCAACTTTTAA 
   AH379 GCGGCGCAGGAAGATGGTTTGGCAGGCCTGGCAAGAGCAGGCCCTGCTATCAACTTTTAA 
   AH377 GCGGCGCAGGAAGATGGTTTGGCAGGCCTGGCAAGAGCAGGCCCTGCTATCAACTTTTAA 
   AH384 GCGGCGCAGGAAGATGGTTTGGCAGGCCTGGCAAGAGCAGGCCCTGCTATCAACTTTTAA 
   AH378 GCGGCGCAGGAAGATGGTTTGGCAGGCCTGGCAAGAGCAGGCCCTGCTATCAACTTTTAA 
   AH381 GCGGCGCAGGAAGATGGTTTGGCAGGCCTGGCAAGAGCAGGCCCTGCTATCAACTTTTAA 
   AH383 GCGGCGCAGGAAGATGGTTTGGCAGGCCTGGCAAGAGCAGGCCCTGCTATCAACTTTTAA 
       R  R  R  K  M  V  W  Q  A  W  Q  E  Q  A  L  L  S  T  F  K  
     
    9901 GGAGAAGAGATACCTGAGCTTCAAGGAGAGGAAGGAGCTGGCCAAGCGAATGGGGGTCTC 
   AH379 GGAGAAGAGATACCTGAGCTT 
AH377 GGAGAAGAGATACCTGAGCTT 
AH384 GGAGAAGAGATACCTGAGCTT 
AH378 GGAGAAGAGATACCTGAGCTT 
AH381 GGAGAAGAGATACCTGAGCTT 
AH383 GGAGAAGAGATACCTGAGCTT 
       E  K  R  Y  L  S  F  K  E  R  K  E  L  A  K  R  M  G  V  S  
     
 9961 AGATTGCCGCATCCGCGTGTGGTTTCAGAACCGCAGGAATCGCAGTGGAGAGGAGGGGCA 
       D  C  R  I  R  V  W  F  Q  N  R  R  N  R  S  G  E  E  G  H  
     
10021 TGCCTCAAAGAGGTCCATCAGAGGCTCCAGGCGGCTAGCCTCGCCACAGCTCCAGGAAGA 
       A  S  K  R  S  I  R  G  S  R  R  L  A  S  P  Q  L  Q  E  E  
     
10081 GCTTGGATCCAGGCCACAGGGTAGAGGCCTGCGCTCATCTGGCAGAAGGCCTCGCACTCG 
       L  G  S  R  P  Q  G  R  G  L  R  S  S  G  R  R  P  R  T  R  
     
10141 ACTCACCTCGCTACAGCGCAGGATCCTAGGGCAAGCCTTTGAGAGGAACCCACGACCAGG 
       L  T  S  L  Q  R  R  I  L  G  Q  A  F  E  R  N  P  R  P  G  
 
10201 CTTTGCTACCAGGGAGGAGCTGGCGCGTGACACAGGGTTGCCCGAGGACACGATCCACAT 
       F  A  T  R  E  E  L  A  R  D  T  G  L  P  E  D  T  I  H  I  
     
10261 ATGGTTTCAAAACCGAAGAGCTCGGCGGCGCCACAGGAGGGGCAGGCCCACAGCTCAAGA 
       W  F  Q  N  R  R  A  R  R  R  H  R  R  G  R  P  T  A  Q  D  
     
10321 TCAAGACTTGCTGGCGTCACAAGGGTCGGATGGGGCCCCTACAGGTCCGGAAGGCAGAGA 
       Q  D  L  L  A  S  Q  G  S  D  G  A  P  T  G  P  E  G  R  E  
     
10381 GCGTGAAGGTGCCCAGGAGAGCTTGTTGCCACAGGAAGAAGCAGGAAGTACGGGCATGGA 
       R  E  G  A  Q  E  S  L  L  P  Q  E  E  A  G  S  T  G  M  D  
     
10441 TACCTCGAGCCCTAGCGACTTGCCCTCCTTCTGCAGAGAGTCCCAGCCTTTCCAAGTGGC 
       T  S  S  P  S  D  L  P  S  F  C  R  E  S  Q  P  F  Q  V  A  
     
10501 ACAGCCCCGTGGAGCAGGCCAACAAGAGGCCCCCACTCAAGCAGGCAACGCAGGCTCTCT 
       Q  P  R  G  A  G  Q  Q  E  A  P  T  Q  A  G  N  A  G  S  L  
     
10561 GGAACCCCTCCTTGATCAGCTGCTGGATGAAGTCCAAGTAGAAGAGCCTGCTCCAGCCCC 
       E  P  L  L  D  Q  L  L  D  E  V  Q  V  E  E  P  A  P  A  P  
     
10621 TCTGAATTTGGATGGAGACCCTGGTGGCAGGGTGCATGAAGGTTCCCAGAAGAGCTTTTG 
       L  N  L  D  G  D  P  G  G  R  V  H  E  G  S  Q  K  S  F  W  
      
10681 GCCACAGGAAGAAGCAGGAAGTACAGGCATGGATACTTCAAGCCCCAGCGACTCAAACTC 
       P  Q  E  E  A  G  S  T  G  M  D  T  S  S  P  S  D  S  N  S  
     
10741 CTTCTGCAGAGAGTCCTTTCCTTCCCAAGTGGCACAGCCCTGTGGATCGGGCCAAGAAGA 
       F  C  R  E  S  F  P  S  Q  V  A  Q  P  C  G  S  G  Q  E  D  
     
10801 TGCCCGCACTCAAGCAGACAGCACAGGCCCTCTGGAACTCCTCCTCCTTGATCAACTGCT 
       A  R  T  Q  A  D  S  T  G  P  L  E  L  L  L  L  D  Q  L  L  
      
10861 GGACGAAGTCCAAAAGGAAGAGCATGTGCCAGTCCCACTGGATTGGGGTAGAAATCCTGG 
 190 
       D  E  V  Q  K  E  E  H  V  P  V  P  L  D  W  G  R  N  P  G  
     
10921 CAGCAGGGAGCATGAAGGTTCCCAGGACAGCTTACTGCCCCTGGAGGAAGCAGCAAATTC 
       S  R  E  H  E  G  S  Q  D  S  L  L  P  L  E  E  A  A  N  S  
  
10981 GGGCATGGATACCTCGATCCCTAGCATCTGGCCAACCTTCTGCAGAGAATCCCAGCCTCC 
       G  M  D  T  S  I  P  S  I  W  P  T  F  C  R  E  S  Q  P  P  
     
11041 CCAAGTGGCACAGCCCTCTGGACCAGGCCAAGCACAGGCCCCCACTCAAGGTGGGAACAC 
       Q  V  A  Q  P  S  G  P  G  Q  A  Q  A  P  T  Q  G  G  N  T  
     
11101 GGACCCCCTGGAGCTCTTGCTCTATCAACTGTTGGATGAAGTCCAAGTAGAAGAGCATGC 
       D  P  L  E  L  L  L  Y  Q  L  L  D  E  V  Q  V  E  E  H  A  
     
11161 TCCAGCCCCTCTGAATTGGGATGTAGATCCTGGTGGCAGGGTGCATGAAGGTTCGTGGGA 
       P  A  P  L  N  W  D  V  D  P  G  G  R  V  H  E  G  S  W  E  
     
11221 GAGCTTTTGGCCACAGAGAGAAGCAGGAAGTACAGGCCTGGATACTTCAAGCCCCAGCGA 
       S  F  W  P  Q  R  E  A  G  S  T  G  L  D  T  S  S  P  S  D  
     
11281 CTCAAACTCCTTCTGCAGAGAGTCCCAGACTTCCCAAGTGGCACAGCCCTGTGGATCGGG 
       S  N  S  F  C  R  E  S  Q  T  S  Q  V  A  Q  P  C  G  S  G  
     
11341 CCAAGAAGATGCCCGCACTCAAGCAAACAGCACAGGCCCTCTGGAACTCCTCCTCCTTGA 
AH442                                   GGCCCTCTGGAACTCCTCCTCCTTGA 
AH441                                   GGCCCTCTGGAACTCCTCCTCCTTGA 
       Q  E  D  A  R  T  Q  A  N  S  T  G  P  L  E  L  L  L  L  D  
     
11401 TCAACTGCTGGACGAAGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTGGATTGGGGTAG 
AH442 TCAACTGCTGGACGAAGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTGGATTGGGGTAG 
AH441 TCAACTGCTGGACGAAGTCCAAAAGGAAGAGCATGTGCCAGCCCCACTGGATTGGGGTAG 
       Q  L  L  D  E  V  Q  K  E  E  H  V  P  A  P  L  D  W  G  R  
     
11461 AAATCCTGGCAGCAGGGAGCATGAAGGTTCCCAGGACAGCTTACTGCCCCTGGAGGAAGC 
AH442 AAATCCTGGCAGCAGGGAGCATGAAGGTTCCCAGGACAGCTTACTGCCCCTGGAGGAAGC 
AH441 AAATCCTGGCAGCAGGGAGCATGAAGGTTCCCAGGACAGCTTACTGCCCCTGGAGGAAGC 
       N  P  G  S  R  E  H  E  G  S  Q  D  S  L  L  P  L  E  E  A  
     
11521 AGCAAATTCGGGCATGGATACCTCGATCCCTAGCATCTGGCCAACCTTCTGCAGAGAATC 
AH442 AGCAAATTCGGGCATGGATACCTCGATCCCTAGCATCTGGCCAACCTTCTGCAGAGAATC 
AH441 AGCAAATTCGGGCATGGATACCTTGATCCCTAGCATCTGGCCAACCTTCTGCAGAGAATC 
       A  N  S  G  M  D  T  S  I  P  S  I  W  P  T  F  C  R  E  S  
 
11581 CCAGCCTCCCCAAGTGGCACAGCCCTCTGGACCAGGCAAAGCACAGGCCCCGACTCAAGG 
AH442 CCAGCCTCCCCAAGTGGCACTGCCCTCTGGACCAGGCCAAGCACAGGCCCCGACTCAAGG 
AH441 CCAGCCTCCCCAAGTGGCACAGCCCTCTGGACCAGGCCAAGCACAGGCCCCGACTCAAGG 
       Q  P  P  Q  V  A  Q  P  S  G  P  G  Q  A  Q  A  P  T  Q  G  
 
11641 TGGGAACACGGACCCTCTGGAGCTCTTCCTTGATCAACTGCTGACCGAAGTCCAACTTGA 
AH442 TGGGAACACGGACCCTCTGGAGCTCTTCCTTGATCAACTGCTGACCGAAGTCCAACTTGA 
AH441 TGGGAACACGGACCCTCTGGAGCTCTTCCTTGATCAACTGCTGACCGAAGTCCAACTTGA 
AH177                                                        CTTGA 
AH193                                                        CTTGA 
       G  N  T  D  P  L  E  L  F  L  D  Q  L  L  T  E  V  Q  L  E  
     
11701 GGAGCAGGGGCCTTCCCCTGTGAATGTGGAGGAAACATGGGAGCAAATGGACACAACACC 
AH442 GGAGCAGGGGCCTGCCCCTGTGAATGTGGAGGAA   
AH441 GGAGCAGGGGCCTGCCCCTGTGAATGTGGAGGAA 
AH177 GGAGCAGGGGCCTGCCCCTGTGAATGTGGAGGAAACATGGGAGCAAATGGACACAACACC 
AH193 GGAGCAGGGGCCTGCCCCTGTGAATGTGGAGGAAACATGGGAGCAAATGGACACAACACC 
       E  Q  G  P  A  P  V  N  V  E  E  T  W  E  Q  M  D  T  T  P  
 
11761 TGATCTGCCTCTCACTCCAGAAGAATATCAGACTCTTCTAGATATGCTCTGACTCCCTGA 
AH177 TGATCTGCCTCTCACTCCAGAAGAATATCAGACTCTTCTAGATATGCTCTGACTCCCTGA 
AH193 TGATCTGCCTCTCACTCCAGAAGAATATCAGACTCTTCTAGATATGCTCTGACTCCCTGA 
       D  L  P  L  T  P  E  E  Y  Q  T  L  L  D  M  L  .    
     
11821 CAGTACCTCTTGCTTCTAGAAACCGGAAAGGCCAAAGTCCTGAAGAGACCCGATTTGGAA 
AH177 CAGTACCTCTTGCTTCTAGAAACCCGAAAGGCCAAAGTCCTGAAGAGACCCGATTTGGAA 
AH193 CAGTACCTCTTGCTTCTAGAAACCCGAAAGGCCAAAGTCCTGAAGAGACCCGATTTGGAA 
 
11881 CTGGAGAAGTGACCCATCCCAGCAAGGATGTGCATCAAAAACCCAACTCCAGTGACTTCC 
AH177 CTGGAGAAGTGACCCATCCCAGCAAGGATGTGCATCAAAAACCCAACTCCAGTGACTTCC 
AH193 CTGGAGAAGTGACCCATCCCAGCAAGGATGTGCATCAAAAACCCAACTCCAGTGACTTCC 
     
 
 191 
11941 CGAAATGCAAGGTGTCTCGCTAACTATAAGGATTGATTGCAGGTGGGGATAATAATGAAG 
AH177 CGAAATGCAAGGTGTCTCGCTAACTATAAGGATTGATTGCAGGTGGGGATAATAATGAAG 
AH193 CGAAATGCAAGGTGTCTCGCTAACTATAAGGATTGATTGCAGGTGGGGATAATAATGAAG 
     
12001 TGCCTTCTCCAGGGCCCGGGGATTAGGAAATCAGCCCTGAAAGTGAGAGACTCTGCTACA 
AH177 TGCCTTCTCCAGGGCCCGGGGATTAGGAAATCAGCCCTGAAAGTGAGAGACTCTGCTACA 
AH193 TGCCTTCTCCAGGGCCCGGGGATTAGGAAATCAGCCCTGAAAGTGAGAGACTCTGCTACA 
     
12061 GGGACAGATGGAGAGGCCAATAGTGACTCCTCAACAACAAGGAGCCTAAAGATAACGCCA 
AH177 GGGACAGATGGAGAGGCCAATAGTGACTCCTCAACAACGCGGAGC:TAAAGATAACGCCA 
AH193 GGGACAGATGGAGAGGCCAATAGTGACTCCTCAACAACACGGAGC:TAAAGATAACGCCA 
 
12121 AAAGAAGGGCTACACCAAGTGACTGGCTCCAGTGGACCCCAGGAAATCACACGGGACACT 
AH177 AAAGAAGGGCTACACCAAGTGACTGGCTCCAGTGGACCCCAGGAAATCACACGGGACACT 
AH193 AAAGAAGGGCTACACCAAGTGACTGGCTCCAGTGGACCCCAGGAAATCACACGGGACACT 
     
12181 AGGACTAGGCTTCACTACAGAGGACACACACTCCCTGAGGGCAATGGGGAGAGTGGACTC 
AH177 AGGACTAGGCTTCACTACAGAGGACACACACTCCCTGAGGGCAATGGGGAGAGTGGACTC 
AH193 AGGACTAGGCTTCACTACAGAGGACACACACTCCCTGAGGGCAATGGGGAGAGTGGACTC 
     
12241 CTTCCTTGGCTTATATGGACTGCTGTTATCCTTACAGATGCTTCGTGCAGAGCTGTGCAA 
AH177 CTTCCTTGGCTTATATGGACTGCTGTTATCCTTACAG   
AH193 CTTCCTTGGCTTATATGGACTGCTGTTATCCTTACAG   
     
12301 GGTTTTACAGGCCAGTCTTTTAATATCTACTACCCATAGGTCTTTTGTTTGTTTTCTTTT 
12361 TCTTTTTCACTTTCTTTTTCATTTTTTTTCTTTTTCTTCTTTTAAGGGGTGGGTTGGCTT 
12421 TGTTGGGTTTGGTTTGGTTTTGTGTAGTTTGTTTCCATTGCTTTCAATAAAGTTTATTGA 
12481 TTTTAACAAAATTTGTTTGTGTGTTTGTGTGCTGTTTTGTGTGATGAGGGGTGGGTTGAA 
12541 TAGGCTGTTTTGTTCTACCCGGAGAACGTGCATGAGAATTCCATTTAAAGGGATTAAAGA 
12601 CATAGGAAGGTATTCAGGAGGGATGCAGAGAGGCCAGGTAGAAAAGGGGAGAGAACAAGG 
12661 AAGGCTGGGCTATGTCCAGTGGAGAGACGGGCTTGCTTGATCTAGTAACAAGCAGGTGGA 
12721 ATGTCAACTGAAAGAAGAATGTGTGTAAGGCATAACCTTGTCAAGAAAGATCATCTTGGG 
12781 AATACAGTGCAGCTAGGTGTGAACATCTTATTCCAAGCTTGAAACACAGCCATCAGTCTA 
12841 TTCTTCATCCATCCATCCATCCATCCATCCATCCATGCCTAAATCAATCTGTAGATCTTT 
12901 CAATCCTATTGGGATTAATCCCCAGCACCCTCCCTAATCCCTCTTTTGATCTTGAGATTC 
12961 CCAGGTGTTCAAGGTCATACTGTTTATATGGAGCTCCAAGTTGATCCTTGACCCACATTG 
13021 GAAGGAGACGGTATGTTTACCATTCTACAATGACCGACAATTCTTTTTTTTTTTTTTTTT 
13081 TTTTTCGTTTTCAGCTTTTTATTTTTTTATGACCGACAATTCTACAGAGAGCCTTAAAGC 
13141 ATGCCAGCAGGACAAAACAATCTCTCATTTGCTGGCCATCACTTCAGGACAACTTATTTG 
13201 AAGTGTCTCCAGTGTTCAAGGCTAACTCCAGAGATCTAAGAGCACAGAACATACCGCCAG 
13261 CAAACACAGCACATGCAAGAAGACGATCAACTCTTTTCTTCAACCTGCTCCATAGAAAGT 
13321 GCACAACCTACTGGTGTCTCAAGCTTCCAGGCTCCTTTTTATACAGTCTGTGAAAGAAAC 
13381 ACCTTGTGAGGTGTCTCCCTCTCTCTCTGTCTCTGTCTGTCTGTCTGTCTCTGTCTGTCT 
13441 GTCTGTCTCTGTCTGTCTCTCTCTCCCTCCATTCCTCTTTTGCTCCCCCTCCATTTCCCT 
13501 CCCTGCCTCCATTTCACCATCTCTTCCCCTCTCTGTCTCCATCCCCATTCTTCTACCCTC 
13561 CCATATTCACTCCCCCCCATCCACTTTCTACCTCCCTACTTCCCTATCTCTCTGTATCGA 
13621 TTCTTCCCTTCCTTCTGCACTCTGTCACTCTCTCCTTACCACCCTCCACCCTCTGTCCCT 
13681 AAATCCCTTCCCCCCTTCTCTCCACATCTGTGTTTGTCTCTCTCTTCGTGTCTTCCTCTG 
13741 CCCCTAACCCCAACCATGGTCGTGACTTTATCTTCACTGGAGTTGGGTTTTTGATGCACA 
13801 TCTGGCCAACCTTCTGCAGAGAATACCAGCCTCCCCAAGTGGCACAGCCCTCTGGACCAG 
13861 GCCAAGCACAGGCCCCCACTCAAGGTGGGAACACGGACCCCCTGGAGCTCTTGCTCTATC 
13921 AACTGTTGGATGAAGTCCAAGTAGAAGAGCATGCTCCAGCCCGTCAGAATTGGGATGTAG 
13981 ATCCTGGTGGCAGGGTGCATGAAGGTTCGTGGGAGAGCTTTTGGCCACAGGAAGAAGCAG 
14041 GAAGTACAGGCCTGGATACTTCAAGCCCCAGCGACTCAAACTCCTTCTGCAGAGAGTCCC 
14101 AGACTTCCCAAGTGGCACAGCCCTGTGGATCGGGCCAAGAAGATGCCCGCACTCAAGCAG 
 
14161 ACAGCACAGGCCCTCTGGAACTCCTCCTCCTTGATCAACTGCTGGACGAAGTCCAAAAGG 
AH145         GGCCCTCTGGAACTCCTCCTCCTTGCTCTNCTGCTGGACGAAGTCCAAAAGG 
 
14221 AAGAGCATGTGCCAGTCCCACTGGATTGGGGTAGAAATCCTGGCAGCAGGGAGCATGAAG 
AH145 AAGAGCATGTGCCAGTCCCACTGGATTGGGGTAGAAATCCTGGCAGCAGGGAGCATGAAG 
     
14281 GTTCCCAGGACAGCTTACTGCCCCTGGAGGAAGCAGCAAATTCGGGCATGGATACCTCGA 
AH145 GTTCCCAGGACAGCTTACTGCCCCTGGAGGAAGCAGCAAATTCGGGCATGGATACCTCGA 
     
14341 TCCCTAGCATCTGGCCAACCTTCTGCAGAGAATCCCAGCCTCCCCAAGTGGCACAGCCCT 
AH145 TCCCTAGCATCTGGCCAACCTTCTGCAGAGAATCCCAGCCTCCCCAAGTGGCACAGCCCT 
 
 
14401 CTGGACCAGGCCAAGCACAGGCCCCCACTCAAGGTGGGAACACGGACCCTCTGGAGCTCT 
AH145 CTGGACCAGGCCAAGCACAGGCCCCCACTAAAGGTGGGAACACGGACCATCTGGAGCTCT 
 
14461 TCCTTGATCAACTGCTGACCGAAGTCCAACTTGAGGAGCAGGGGCCTGCCCCTGTGAATG 
AH145 TCCTTGATCAACTGCTGACCGAAGTCCAACTTGAGGAGCAGGGGCCTGCCCCTGTGAATG 
AH174                              CTTGAGGAGCAGGGGCCTGCCCCTGTGAATG 
AH98                               CTTGAGGAGCAGGGGCCTGCCCCTGTGAATG 
AH172                              CTTGAGGAGCAGGGGCCTGCCCCTGTGAATG 
 192 
AH112                              CTTGAGGAGCAGGGGCCTGCCCCTGTGAATG 
AH175                              CTTGAGGAGCAGGGGCCTGCCCCTGTGAATG 
AH103                              CTTGAGGAGCAGGGGCCTGCCCCTGTGAATG 
     
14521 TGGAGGAAACATGGGAGCAAATGGACACAACACCTGATCTGCCTCTCACTCCAGAAGAAT 
AH145 TGGAGGAA  
AH174 TGGAGGAAACATGGGAGCAAATGGACACAACACCTGATCTGCCTCTCACTCCAGAAGAAT 
AH98  TGGAGGAAACATGGGAGCAAATGGACACAACACCTGATCTGCCTCTCACTCCAGAAGGAT 
AH172 TGGAGGAAACATGGGAGCAAATGGACACAACACCTGATCTGCCTCTCACTCCAGAAGAAT 
AH112 TGGAGGAAACATGGGAGCAAATGGACACAACACCTGATCTGCCTCTCACTCCAGAAGAAT 
AH175 TGGAGGAAACATGGGAGCAAATGGACACAACACCTGATCTGCCTCTCACTCCAGAAGAAT 
AH103 TGGAGGAAACATGGGAGCAAATGGACACAACACCTGATCTGCCTCTCACTCCAGAAGAAT 
 
14581 ATCAGACTCTTCTAGATATGCTCTGACTCCCCGACAGTACCTCTTGCTTCTAGAAACCCG 
AH174 ATCAGACTCTTCTAGATATGCTCTGACTCCCCGACTGTACCTCTTGCTTCTAGAAACCCG 
AH98  ATCAGACTCTTCTAGATATGCTCTGACTCCCCGACTGTACCTCTTGCTTCTAGAAACCCG 
AH172 ATCAGACTCTTCTAGATATGCTCTGACTCCCCGACTGTACCTCTTGCTTCTAGAAACCCG 
AH112 ATCAGACTCTTCTAGATATGCTCTGACTCCCCGACTGTACCTCTTGCTTCTAGAAACCCG 
AH175 ATCAGACTCTTCTAGATATGCTCTGACTCCCCGACTGTACCTCTTGCTTCTAGAAACCCG 
AH103 ATCAGACTCTTCTAGATATGCTCTGACTCCCCGACTGTACCTCTTGCTTCTAGAAACCCG 
 
14641 AGAGGCCAAAGTCCTGAAGAGACCCGATTTGGAACTGGAGAAGTGACCCATCCCAGCAAG 
AH174 AGAGGCCAAAGTCCTGAAGAGACCCGATTTGGAACTGGAGAAGTGACCCATCCCAGCAAG 
AH98  AGAGGCCAAAGTCCTGAAGAGACCCGATTTGGAACTGGAGAAGTGACCCATCCCAGCAAG 
AH172 AGAGGCCAAAGTCCTGAAGAGACCCGATTTGGAACTGGAGAAGTGACCCATCCCAGCAAG 
AH112 AGAGGCCAAAGTCCTGAAGAGACCCGATTTGGAACTGGAGAAGTGACCCATCCCAGCAAG 
AH175 AGAGGCCAAAGTCCTGAAGAGACCCGATTTGGAACTGGAGAAGTGACCCATCCCAGCAAG 
AH103 AGAGGCCAAAGTCCTGAAGAGACCCGATTTGGAACTGGAGAAGTGACCCATCCCAGCAAG 
     
14701 GATGTGCATCAAAAACCCAACTCCAGTGACTTCCCGAAATGCAAGGTGTCTCGCTAACTA 
AH174 GATGTGCATCAAAAACCCAACTCCAGTGACTTCCCGAAATGCAAGGCGTCTCCCTAACTA 
AH98  GATGTGCATCAAAAACCCAACTCCAGTGACTTCCCGAAATGCAAGGTGTCTCCCTAACTA 
AH172 GATGTGCATCAAAAACCCAACTCCAGTGACTTCCCGAAATGCAAGGTGTCTCCCTAACTA 
AH112 GATGTGCATCAAAAACCCAACTCCAGTGACTTCCCGAAATGCAAGGTGTCTCCCTAACTA 
AH175 GATGTGCATCAAGAACCCAACTCCAGTGACTTCCCGAAATGCAAGGTGTCTCCCTAACTA 
AH103 GATGTGCATCAAAAACCCAACTCCAGTGACTTCCCGAAATGCAAGGTGTCTCCCTAACTA 
 
14761 TAAGGATTGATTGCAGGTGGGGATAATAATGAAGTGCCTTCTCCAGGGCCCGGGGATTAG 
AH174 TAAGGATTGATTGCAGGTGGGGATAATAATGAAGTGCCTTCTCCAGGGCCCGGGGATTAG 
AH98  TAAGGATTGATTGCAGGTGGGGATAATAATGAAGTGCCTTCTCCAGGGCCCGGGGATTAG 
AH172 TAAGGATTGATTGCAGGTGGGGATAATAATGAAGTGCCTTCTCCAGGGCCCGGGGATTAG 
AH112 TAAGGATTGATTGCAGGTGGGGATAATAATGAAGTGCCTTCTCCAGGGCCCGGGGATTAG 
AH175 TAAGGATTGATTGCAGGTGGGGATAATAATGAAGTGCCTTCTCCAGGGCCCGGGGATTAG 
AH103 TAAGGATTGATTGCAGGTGGGGATAATAATGAAGTGCCTTCTCCAGGGCCCGGGGATTAG 
     
14821 GAAATCAGCCCTGAAAGTCGAGACTCTGCTACAGGGACAGATGGAGAGGCCAATAGTGAC 
AH174 GAAATCAGCCCTGAAAGTCGAGACTCTGCTACAGGGACAGATGGAGAGGCCAATAGTGAC 
AH98  GAAATCAGCCCTGAAAGTCGAGACTCTGCTACAGGGACAGATGGAGAGGCCAATAGTGAC 
AH172 GAAATCAGCCCTGAAAGTCGAGACTCTGCTACAGGGACAGATGGAGAGGCCAATAGTGAC 
AH112 GAAATCAGCCCTGAAAGTCGAGACTCTGCTACAGGGACAGATGGAGAGGCCAATAGTGAC 
AH175 GAAATCAGCCCTGAAAGTCGAGACTCTGCTACAGGGACAGATGGAGAGGCCAATAGTGAC 
AH103 GAAATCAGCCCTGAAAGTCGAGACTCTGCTACAGGGACAGATGGAGAGGCCAATAGTGAC 
     
14881 TCCTCAACAACAAGGAGCCTAAAGATAACCCCAAAAGAAGGGCCACACCAAGTGACTGGC 
AH174 TCCTCAACAACAAGGAGTCTAAAGATAACCCCAAAAGAAGGGCCACACCAAGTGACTGGC 
AH98  TCCTCAACAACAAGGAGCCTAAAGATAACCCCAAAAGAAGGGCCACACCAAGTGACTGGC 
AH172 TCCTCAACAACAAGGAGCCTAAAGATAACCCCAAAAGAAGGGCCACACCAAGTGACTGGC 
AH112 TCCTCAACAACAAGGAGCCTAAAGATAACCCCAAAAGAAGGGCCACACCAAGTGACTGGC 
AH175 TCCTCAACAACAAGGAGCCTAAAGATAACCCCAAAAGAAGGGCCACACCAAGTGACTGGC 
AH103 TCCTCAACAACAAGGAGCCTAAAGATAACCCCAAAAGAAGGGCCACACCAAGTGACTGGC 
 
14941 TCCAGTGGACCCCAGGAAATCACACAGGACACTAGGACTAGGCTTCACTACAGAGGACAC 
AH174 TCCAGTGGACCCCAGGAAGTCACACAGGACACTAGGACTAGGCTTCACTACAGAGGACAC 
AH98  TCCAGTGGACCCCAGGAAATCACACAGGACACTAGGACTAGGCTTCACTACAGAGGACAC 
AH172 TCCAGTGGACCCCAGGAAATCACACAGGACACTAGGACTAGGCTTCACTACAGAGGACAC 
AH112 TCCAGTGGACCCCAGGAAATCACACAGGACACTAGGACTAGGCTTCACTACAGAGGACAC 
AH175 TCCAGTGGACCCCAGGAAATCACACAGGACACTAGGACTAGGCTTCACTACAGAGGACAC 
AH103 TCCAGTGGACCCCAGGAAATCACACAGGACACTAGGACTAGGCTTCACTACAGAGGACAC 
 
15001 ACACTCCCTGAGGGCAATGGGGAGAGTGGACGCCTTCCTTGGCTTATATGGACTGCTGTT 
AH174 ACACTCCCTGAGGGCAATGGGGAGAGTGGACGCCTTCCTTGGCTTATATGGACTGCTGTT 
AH98  ACACTCCCTGAGGGCAATGGGGAGAGTGGACGCCTTCCTTGGCTTATATGGACTGCTGTT 
AH172 ACACTCCCTGAGGGCAATGGGGAGTGTGGACGCCTTCCTTGGCTTATATGGACTGCTGTT 
AH112 ACACTCCCTGAGGGCAATGGGGAGAGTGGACGCCTTCCTTGGCTTATATGGACTGCTGTT 
AH175 ACACTCCCTGAGGGCAATGGGGAGAGTGGACGCCTTCCTTGGCTTATATGGACTGCTGTT 
AH103 ACACTCCCTGAGGGCAATGGGGAGAGTGGACGCCTTCCTTGGCTTATATGGACTGCTGTT 
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15061 ATCCTTACAGATGCTTCGTGCAGAGCTGTGCAAGGTTTTACAGGCCAGTCTTTTAATATC 
AH174 ATCCTTACAG      
AH98  ATCCTTACAG      
AH172 ATCCTTACAG      
AH112 ATCCTTACAG      
AH175 ATCCTTACAG      
AH103 ATCCTTACAG      
     
15121 TACTACCCATAGGTCTTTTGTTTGTTTTCTTTTTCTTTTTCACTTTCTTTTTCATTTTTT 
     
 
 
 
 
 
 
 
 
 
Figure 5.10 Alignment of RT-PCR clones matching BAC 142C15 
The sequences of the RT-PCR were aligned to the BAC clone 142C15 using Sequencher. The 
predicted amino acid sequence of the ORF is shown underneath. Nucleotide changes from the 
consensus are highlighted in red.  
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5.2.4 Nested RT-PCR on mouse testis RNA 
During the work described in this chapter, amplification of full length transcripts from the 
human array was achieved from human testis RNA using a nested RT-PCR reaction (Snider et 
al., 2010). Therefore, nested primers were designed to amplify a 2143bp product from the 
mouse array, to determine whether full length Dux transcripts are expressed in mouse testis. 
Mouse testis RNA was treated with DnaseI as described previously and RT-PCR was carried 
out using Superscript III and BioTaq polymerase. The nested RT-PCR reaction was also 
performed with mouse midterm embryo RNA and RNA extracted from ES cells that were 
kindly provided by Dr Paul Scotting. RNA extraction was carried out as previously described 
(section 2.4.1). Nested primers are shown in Figure 5.11a. 
Amplification of a fragment of around 2000bp was seen from testis RNA (Figure 5.11b). If 
this product represented Dux it would be the largest transcript identified in mouse this far. 
The RT-PCR product was cloned into pSMART and sequenced. Sequencing from one end of 
the clone failed and so sequence data from only half the length of these PCR products could 
be analysed (approximately 1000bp).  
AH648 and AH642 were aligned with the BAC clone 142C15 and had 33 and 26 variants 
respectively so were unlikely to originate from here. They were then aligned with the 
genomic consensus sequence and had 14 and 5 variants respectively (Table 5.6). The number 
of genomic sequences in which each variant is found is indicated in Table 5.6. Of the 14 
variants identified in AH648, 12 of them were also present in a single genomic clone which is 
highly variant compared with the other genomic sequences. 
The three sequences, AH635, AH631 and AH634 were also aligned with the genomic 
consensus. The first 556bp of these sequences aligned with the consensus sequence between 
positions 3584 and 4137, with 31 base changes and a 4p deletion. The other half of the 
sequence aligned with the genomic consensus between positions 1628 and 2141, with 73 
changes from the consensus. The two halves of these sequences (section 1 and section 2) 
were then aligned with the BAC clone. The first 556 base pairs (section 1) aligned with repeat 
number 2 of the BAC clone, AH634 was identical to the BAC sequence, AH635 had one variant 
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position and AH631 had 2 variant positions. The final 497bp (section 2) aligned with repeat 2; 
however it aligns 615bp upstream of the first half of the sequence (Figure 5.12). AH631 had 1 
variant position, AH634 had 3 variant positions and AH635 had 5 variant positions. This data 
suggests that these three RT-PCR products originate from a recombinant repeat sequence 
which has not yet been identified in genomic sequencing of the region. The sequence was 
used in a BLAST search of the mouse genome and aligned with 99% identity with the mouse 
chromosome 10 contig (NT 039500.7) across the whole length of the sequence, confirming 
the presence of a recombinant repeat sequence in the mouse genome. 
 
  
 196 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11 Amplification of full length mouse Dux transcripts by nested RT-PCR 
a) Schematic representation of the mouse Dux array with nested RT-PCR primers indicated. b) 
RT-PCR of mouse RNA from testis and midterm embryo (Ambion) and from RNA extracted 
from mouse ES cells (kindly provided by Dr Paul Scotting). Amplification of the correct full 
length product was only seen from Testis RNA. 
 
 
 
 
 
 
a 
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Table 5.5 Variants in the mDux sequences AH648 and AH642  
Sequence variants are shown in orange, blue blocks are the same base as the genomic 
consensus sequence. Coding changes are shown underneath. The number of genomic 
sequences amplified by other members of Jane Hewitts group that contain each variant is 
indicated. 
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Figure 5.12 Schematic representation of the alignment of AH631, AH634 and AH635 
with BAC clone 142C15 
The region of BAC clone 142C15 which contains mouse Dux repeats is shown. Repeats are 
indicated in orange. Repeats 3 and 5 are full length repeats, repeats 1, 2, 4and 6 are partial 
repeats. The positions of sections 1 and 2 of the clones AH631, AH634 and AH635 are 
indicated in purple. 
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106621            TAGTGGTCACAGCCACTCTGCTGGCAGTTGCTGCAGCTTGTGTTTGTTCTGAAGCTGTCC 
         
106681            TGAGTCGATTCTCCCAAGGTGAGTACTTCTGGCAGGCCGTCATTGGCACCATGGCAGAAG 
AH634 Section 2                                          TCATTGGCACCATGGCAGAAG 
AH631 Section 2                                          TCATTGGCACCATGGCAGAAG 
         
106741            CTGGCAGCCCTGTTGGTGGCTGTGGTGTGGCACAGGAATCCCGGCAGCGCAGGAAGACGG 
AH634 Section 2   CTGGCAGCCCTGTTGGTGGCTGTGGTGTGGCACAGAAATCCCGGCAGCGCAGGAAGACGG 
AH635 Section 2                                                      AGAAGACGG 
AH631 Section 2   CTGGCAGCCCTGTTGGTGGCTGTGGTGTGGCACAGGAATCCCGGCAGCGCAGGAAGACGG 
 
106801            TTTGGCAGGACTTGCAAGAGGAGGCCCTATCAGCTTTCAACTAGAAGAGATACCTGTACT 
AH634 Section 2   TTTGGCAGGACTTGCAAGAAGAGGCCCTATCAGCTTTCAACTAGAAGAGATACCTGTACT 
AH635 Section 2   TTTGGCAGGACTTGCAAGAAGAGGCCCTATCAGCTTTCAACTAGAAGAGATACCTGTACT 
AH631 Section 2   TTTGGCAGGACTTGCAAGAGGAGGCCCTATCAGCTTTCAACTAGAAGAGATACCTGTACT 
 
106861            TTTAGGTGCTGGCCAGGCAAATGGGGATCCCAGATTGCTGAATTTGGGTGTGGTTTCTGA 
AH634 Section 2   TTTAGGTGCTGGCCAGGCAAATGGGGATCCCAGATTGCTGAATTTGGGTGTGGTTTCTGA 
AH635 Section 2   TTTAGGTGCTGGCCAGGCAAAAGGGGATCCCAGATTGCTGAATTTGGGTGTGGTTTCTGA 
AH631 Section 2   TTTAGGTGCTGGCCAGGCAAATGGGGATCCCAGATTGCTGAATTTGGGTGTGGTTTCTGA 
 
106921            ATTGCAGGAAATCGCACTGGAGGGGGAGGGGCATGCCTCAAAGAGGTTCACCTGAGGCTC 
AH634 Section 2   ATTGCAGGAAATCGCACTGGAGGGGGAGGGGCATGCCTCAAAGAGGTTCACCTGAGGCTC 
AH635 Section 2   ATTGCAGGAAATCGCACGGGAGGGGGAGGGGCATGCCTCAAAGAGGTTCACCTGAGGCTC 
AH631 Section 2   ATTGCAGGAAATCGCACTGGAGGGGGAGGGGCATGCCTCAAAGAGGTTCACCTGAGGCTC 
 
106981            CAACCAAATAGCCTCACCACAGCTCCAGGAAGAACTAGGCTCCAGGGTACAGGGTGGAGG 
AH634 Section 2   CAACCAAATAGCCTCACCACAGCTCCAGGAAGAACTAGGCTCCAGGGTACAGGGTGGAGG 
AH635 Section 2   CAACCAAATAGCCTCACCACAGCTCCAGGAAGAACTAGGCTCCAGGGTACAGGGTGGAGG 
AH631 Section 2   CAACCAAATAGCCTCACCACAGCTCCAGGAAGAACTAGGCTCCAGGGTACAGGGTGGAGG 
         
107041            CATGCGCTCATCCAGCAGAAGGCCTCACACTGGACTCACTTTGTCACAGCGCAGGATCCT 
AH634 Section 2   CATGCGCTCATCCAGCAGAAGGCCTCACACTGGACTCACTTTGTCACAGCGCAGGATCCT 
AH635 Section 2   CATGCGCTCATCCAGCAGAAGGCCTCACACTGGACTCACTTTGTCACAGCGCAGGATCCT 
AH631 Section 2   CATGCGCTCATCCAGCAGAAGGCCTCACACTGGACTCGCTTTGTCACAGCGCAGGATCCT 
 
107101            AGCACAAGCATTTGAGAGGAACCCACGACCAGGCTGTGCTACCAGGGAGGAGCTGGCACT 
AH634 Section 2   AGCACAAGCATTTGAGAGGAACCCACGACCAGGCTGTGCTACCAGGGAGGAGCTGGCACT 
AH635 Section 2   AGCACAAGCATTTGAGAGGAACCCACGACCAGGCTGTGCTACCAGGGAGGAGCTGGCACT 
AH631 Section 2   AGCACAAGCATTTGAGAGGAACCCACGACCAGGCTGTGCTACCAGGGAGGAGCTGGCACT 
         
107161            TGAGACAGGGTTGCCCGAGGACATGATCCACACATGGTTGAAAAACAAAAGAGCTCGGCG 
AH634 Section 2   TGAGACAGGGTTGCCCGAGGACATGATCCACACATGGTTGAAAAGCAAAAGAGCTCGG 
AH635 Section 2   TGAGACAGGGTTGCCCGAGGACATGATCCACACATGGTTGAAAAGCAAAAGAGCTCG 
AH631 Section 2   TGAGACAGGGTTGCCCGAGGACATGATCCACACATGGTTGAAAAACAAAAGAGCTC 
                                                             
107221            CCACAGGAGGGGCAGGCCCACAGCTCAAGATCAAGACTTGCTGGCCTCACAAGTGTCCGG 
107281            TGGGGCCCCTGCAGGTCCGGTAGGCAGGGGCCATGAAGTTGCACAGGAGAGCTCATTGCC 
107341            ACAGGAAGAAGCAGGAAGTACGGGCATGGATACTACAAGCACCAGCTACTCGCCCTCTTT 
107401            CTGCAGAGAGTCCCAACTTTCCCAAGTGTCACAGCCCCGTGGAGCAGGCCAAAAAGAGGT 
107461            CCCCACTCAAGCAGGCAACGTAGGCCCTCTGGAACTTCTCCTTGATGAACTGCAGGACGA 
107521            AGTACAGGTGAAAGAGCATGTGCCAGACCCTTTGGATTTGGGTAGTGATCCTGGCGCCAG 
107581            GGAGCCTGAAGGTTCCCAGGACAGCTTACAGAGCCTGGATGAAGCAGCAAATTCAGGCTG 
107641            GCATACCTCGGTCCCGAGCATCTCGTCAACCTTGTGCAGAGAGTCCCAGCCTTCCCAAGT 
107701            GGCACAGCCCTCTGGACCAGGACAAGCACAGGCCCCCACTCAAAGTGGGTTCATAGACCC 
107761            TCTGGAGCTCTTTCTCGATGAACTGCTGACTGAAGTCCAACTTGAGGAGCAGGGGCCTGC 
107821            CCCTGTGAATGTGGAGGAAACAGGGGAGCAAATGGACACAACACCTGAGCTGCCTCTCAC 
AH634 Section 1               GGAGGAAACAGGGGAGCAAATGGACACAACACCTGAGCTGCCTCTCAC 
AH631 Section 1               GGAGGAAACAGGGGAGCAAATGGACACAACACCTGAGCTGCCTCTCAC 
AH635 Section 1               GGAGGAAACAGGGGAGCAAATGGACACAACACCTGAGCTGCCTCTCAC 
         
107881            CCCAGAAGAATATCAGACTCTTCTAGATATGCTCTGACTCCCTGACAGTACCCCTTGCAT 
AH634 Section 1   CCCAGAAGAATATCAGACTCTTCTAGATATGCTCTGACTCCCTGACAGTACCCCTTGCAT 
AH631 Section 1   CCCAGAAGAATATCAGACTCTTCTAGATATGCTCTGACTCCCTGACAGTACCCCTTGCAT 
AH635 Section 1   CCCAGAAGAATATCAGACTCTTCTAGATATGCTCTGACTCCCTGACAGTACCCCTTGCAT 
         
107941            CTAGACACCCGCGAGGCCAAATCCTAAAGAGACCCAATTTGGAACTGGAGAAGGTACCCA 
AH634 Section 1   CTAGACACCCGCGAGGCCAAATCCTAAAGAGACCCAATTTGGAACTGGAGAAGGTACCCA 
AH631 Section 1   CTAGACACCCGCGAGGCCAAATCCTAAAGAGACCCAATTTGGAACTGGAGAAGGTACCCA 
AH635 Section 1   CTAGACACCCGCGAGGCCAAATCCTAAAGAGACCCAATTTGGAACTGGAGAAGGTACCCA 
        
 
108001            TTTCAGCAAGGATGTGCACAAAAATGCAACTCCAGTGACTTCCCGAAATGCAAGGTGTCT 
AH634 Section 1   TTTCAGCAAGGATGTGCACAAAAATGCAACTCCAGTGACTTCCCGAAATGCAAGGTGTCT 
AH631 Section 1   TTTCAGCAAGGATGTGCACAAAAATGCAACTCCAGTGACTTCCCGAAATGCAAGGTGTCT 
AH635 Section 1   TTTCAGCAAGGATGTGCACAAAAATGCAACTCCAGTGACTTCCCGAAATGCAAGGTGTCT 
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     108061       TGCTAACTATAAGGATGGATTGCAGGTGGGGATAATAATGAAGTGCCTTCTGCAGCGCCC 
AH634 Section 1   TGCTAACTATAAGGATGGATTGCAGGTGGGGATAATAATGAAGTGCCTTCTGCAGCGCCC 
AH631 Section 1   TGCTAACTATAAGGATGGATTGCAGGTGGGGATAATAATGAAGTGCCTTCTGCAGCGCCC 
AH635 Section 1   TGCTAACTATAAGGATGGATTGCAGGTGGGGATAATAATGAAGTGCCTTCTGCAGCGCCC 
         
108121            AGGGATTAGGAAATCAGCCCTGAAAGTGAGAGACTCTGCTACAGGGACAGATGGAGAGGC 
AH634 Section 1   AGGGATTAGGAAATCAGCCCTGAAAGTGAGAGACTCTGCTACAGGGACAGATGGAGAGGC 
AH631 Section 1   AGGGATTATGAAATCAGCCCTGAAAGTGAGAGACTCTGCTACAGGGACAGATGGAGAGGC 
AH635 Section 1   AGGGATTAGGAAATCAGCCCTGAAAGTGAGAGACTCTGCTACAGGGACAGATGGAGAGGC 
 
108181            CAATAGTGACTCCTCAACAACAAGGAGCCTAAAGATAACCCCAAAAGAAGGGCCACACCA 
AH634 Section 1   CAATAGTGACTCCTCAACAACAAGGAGCCTAAAGATAACCCCAAAAGAAGGGCCACACCA 
AH631 Section 1   CAATAGTGACTCCTCAACAACAAGGAGCCTAAAGATAACCCCAAAAGAAGGGCCACACCA 
AH635 Section 1   CAATAGTGACTCCTCAACAACAAGGAGCCTAAAGATAACCCCAAAAGAAGGGCCACACCA 
         
108241            AGTGACTGGCTCCAGTGGACCCCAGGAAATCACACGGGACACTAGGACTAGGCTTCACTA 
AH634 Section 1   AGTGACTGGCTCCAGTGGACCCCAGGAAATCACACGGGACACTAGGACTAGGCTTCACTA 
AH631 Section 1   AGTGACTGGCTCCAGTGGACCCCAGGAAATCACACGGGACACTAGGACTAGGCTTCACTA 
AH635 Section 1   AGTGACTGGCTCCAGTGGACCCCAGGAAATCACACGGGACACTAGGACTAGGCTTCACTA 
         
108301            CAGAGGACACACACTCCCTGAGGGCAATCGGGAGAGTGGACTCCTTCCCTGGGTTGTATG 
AH634 Section 1   CAGAGGACACACACTCCCTGAGGGCAATCGGGAGAGTGGACTCCTTCCCTGGGTTGTATG 
AH631 Section 1   CCGAGGACACACACTCCCTGAGGGCAATCGGGAGAGTGGACTCCTTCCCTGGGTTGTATG 
AH635 Section 1   CAGAGGACGCACACTCCCTGAGGGCAATCGGGAGAGTGGACTCCTTCCCTGGGTTGTATG 
 
108361            GACTGCTGCTATTCTTACAGATGCTTCGTGCAGAGCTGTGCAAGGTTTTACAGGCCAGTC 
AH634 Section 1   GACTGCTGCTATTCTTACAG 
AH631 Section 1   GACTGCTGCTATTCTTACAG 
AH635 Section 1   GACTGCTGCTATTCTTACAG 
 
 
 
Figure 5.13 Alignment of AH631, AH634 and AH635 with BAC clone 142C15 
The sequences of the RT-PCR products were aligned to the BAC clone 142C15 using 
Sequencher. The predicted amino acid sequence of the ORF is shown underneath. Nucleotide 
changes from the consensus are highlighted in red.  
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5.2.5 Does the mouse array have the same DNA methylation pattern 
as the human repeats? 
In humans, individuals unaffected with FSHD have high levels of methylation at the D4Z4 
array (Tsien et al., 2001). The array is hypomethylated on the disease allele of FSHD1 patients, 
and on both 4q and 10q alleles in FSHD2 patients. The methylation status of the mouse array 
was investigated to see whether it has the same methylation.  
Liver and testis tissues were harvested from C57/BL6 mice by Jane Hewitt, and DNA was 
extracted as described in section 2.6.1. The DNA was then digested with MspI or HpaII 
restriction enzymes. These enzymes are isoschizomers which cleave the sequence CCGG and 
have different sensitivities to methylation. HpaII is sensitive to methylation of either C in the 
sequence. MspI is able to cut methylated CpG dinucleotides, however, it may be also be 
sensitive to CpNpG methylation. 
There are 5 MspI/HpaII restriction sites in the mouse Dux array and primers were 
designed to flank these sites (Figure 5.14a). If the site is unmethylated, both enzymes will be 
able to cleave the DNA and no product will be amplified from DNA digested with either 
enzyme. However, if there is methylation at the CpG dinucleotide, the HpaII enzymes activity 
will be blocked and a product will be amplified from DNA digested with this enzyme. The MspI 
enzyme would be unaffected by this methylation and so no product would be amplified from 
DNA digested with MspI (Figure 5.14b). As a control for DNA quality, primers that amplify a 
product between the MspI/HpaII sites were also used, these reactions should be positive 
when using DNA digested with either enzyme. 
In order to be sure that the DNA had been fully digested, primers were designed that flank 
a MspI/HpaII site in the pgk-1 gene. This gene is known to be methylated only on the inactive 
X chromosomes in mice (Singer-Sam et al., 1990) and so a product should only be amplified in 
DNA from female mice. Because this site is methylated in females and unmethylated in males 
it could be used as both a positive and negative control. In addition, an MspI/HpaII site in the 
DHFR gene has been shown to be unmethylated at every stage in development (Kafri et al., 
1992), this acts as a good digestion control as no product should be amplified in any digested 
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samples. Finally, amplification of the Igfr2 gene acts as a positive control to show that the 
enzyme is unable to cut methylated DNA (primers M114 and M115, Table 2.4).  This 
imprinted gene is known to be methylated only in the maternal oocytes of mice. The 
amplicon contains 3 MspI sites, these will be methylated on the maternal chromosome and so 
the product is expected to be produced only with the HpaII digests. (Figure 5.15a) 
When the PCRs were performed on the sites within the Dux array, products were 
amplified from DNA digested with both enzymes, although the intensity of the bands in the 
MspI digested DNA were lower (Figure 5.15b). Although the controls suggested that the DNA 
was digested, the control genes are not in the same region as the Dux array, so its possible 
that some of the repeats remain intact. In addition, it has been suggested that the MspI 
enzyme may be sensitive to methylation of the second C in the recognition sequence, if this is 
the case then methylation at this position would prevent cleavage of the site and a product 
would be seen. 
 
 
  
 203 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14 Location of MspI/HpaII sites in the mouse Dux repeat 
a) Schematic representation of a single Dux repeat unit (5  3 orientation) with the 5 
MspI/HpaII indicated. Primers flanking the sites are shown underneath in purple with their 
amplification product in orange. The control primer pair does not have an MspI/HpaII site 
within the product so should be amplified in DNA digested with either enzyme. b) Diagram to 
illustrate the expected results, dependent on methylation state and enzyme used for 
digestion. Purple arrows indicate primers. The restriction enzyme site is indicated. The CH3 
highlights the methylated site.  
a 
b 
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Figure 5.15 Confirmation of complete digestion of mouse DNA 
a) Table to show expected results from control PCRs if digestion is complete b) PCR using 
mspCtrl primers which are within the array but do not contain a MspI/HpaII restriction site. c) 
PCR using Pgk1 primers. d) PCR using Igf2R primers. e) PCR using DHFR primers. 
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Figure 5.16 Methylation sensitive PCRs on MspI/HpaII digested DNA 
Methylation sensitive PCRs on MspI or HpaII digested DNA. Primer sequences are shown in 
Table 2.4 a) Primer pair Msp1 b) Primer pair Msp2 c) Primer pair Msp3 d) Primer pair Msp4 e) 
Primer pair Msp5 
 
 
 
a b 
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e 
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5.3 Discussion 
The main aim of the work in this chapter was to investigate expression from the mouse 
Dux array. Although no complete full length ORFs have been identified, smaller fragments 
from along the array have been amplified and sequenced and their variants compared with 
genomic sequence data from Jane Hewitts laboratory. 
Of the 107 RT-PCR products that were successfully cloned and sequenced, 46 aligned with 
the BAC clone 142C15. Two full length repeat units, and a further 4 partial repeats were 
identified in the sequence of the BAC. Only the first full repeat (repeat 3) appears to have a 
functional ORF. Thus, it was surprising to find that not all of the RT-PCR products that appear 
to originate from this BAC region aligned to repeat 3. In fact, only 17% of sequences aligned 
to this functional ORF. As discussed previously, the mouse strain from which the BAC clone 
originates is a C57/Bl6 mouse, while the RNA used for RT-PCR in this study is from Swiss-
Webster mice. The outbred CD1 mouse was shown to have a more complex pattern of 
repeats (Clapp et al., 2007), so it is possible that the outbred Swiss Webster mice also contain 
variations in repeat structure. If this is the case, the sequences which align to partial repeats 
without ORFs in this clone, may well come from repeats which remain functional in the Swiss 
Webster mice. Alternatively, these smaller fragments may represent regulatory RNAs such as 
those recently suggested for the human array (Snider et al., 2009).  
The majority of the remaining sequences, 50 out of 61, aligned with the genomic 
consensus sequence that had been compiled from genomic sequences amplified by others in 
Jane Hewitts laboratory. Within these sequences, 14 variant positions were identified and 10 
of these resulted in coding changes within the ORF. None of the variants occurred within the 
86bp of homeodomain sequence in the mATG RT-PCR product of the conserved C-Terminal 
domain region in the mTGA product. 6 of the variant positions were also identified in the 
genomic sequences. It is surprising that so many of the variants resulted in coding changes, 
71% of variants in these mouse RT-PCR products result in coding changes, while in the human 
RT-PCR products only 42% of variants result in a coding change (Table 4.1). None of the 
changes occurred in the conserved homeodomain and C-terminal domain sequences, so its 
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possible that the sequence outside of these regions is less constrained. The levels of sequence 
variation between the sequences that match this consensus and the expressed sequences 
amplified from the hEC transcripts (table 4.2) are very similar, based on this sequence data a 
variant occurs, on average, every 63 base pairs in the mouse sequences and every 58 base 
pairs in the human sequences. However, the sequence of the repeats in the 142C15 region 
varies considerably compared to genomic sequences from the other Dux clusters, the repeats 
in this region may be less constrained, however, as a large proportion of transcripts appear to 
originate from here the region is likely to be transcribed. It is possible this 142C15 region has 
a different function to the other Dux clusters. 
Finally, 11 sequences did not appear to originate from either the genomic sequences or 
the 142C15 BAC clone. It is likely that these sequences come from repeats which have not yet 
been fully sequenced. 
No full length clones were able to be sequenced from the nested RT-PCR, however 
transcripts of around 1000bp were sequenced. Two of the 5 sequences aligned with the 
genomic consensus. One of these sequences, AH648, had 14 variant positions compared with 
the consensus, however a single genomic sequence has 12 of these changes so it is likely 
there are other variant repeats in mouse Dux region. 
The other three sequences were found to be rearranged, as the two halves of the 
sequence aligned with the 142C15 sequence separately, with a 615bp gap in the middle. This 
is unlikely to be as a result of splicing of the transcript as a BLAST search of the full RT-PCR 
product aligns with the chromosome 10 contig with 99% identity. No rearranged sequences 
have yet been identified from the genomic mDux sequences. 
The second aim of the work in this section was to investigate the methylation status of the 
mDux repeats. Five MspI/HpaII sites were identified in each repeat unit and amplification of 
PCR products surrounding these sites was investigated. The results of this analysis could not 
be linked with individual repeat units so this work would give a view of methylation state 
across the whole of the array. 
There were initial problem with confirming complete digestion of the mouse DNA, 
however 4 control PCRs were included to overcome these. Once the control PCRs confirmed 
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complete digestion the MspI PCRs were performed on the DNA. For each of the 5 sites, 
amplification was seen from DNA digested with both MspI and HpaII enzymes, however there 
appeared to be less amplification from the MspI digested DNA.  
As the control PCRs used to confirm complete digestion are located in different parts of 
the genome to the mouse Dux repeats, its possible that although these regions have been 
fully digested the mouse array region has not. If the repeat units are compacted into 
heterchromatin, its possible that the enzymes could not easily access their restriction sites. 
Although it has been confirmed that the HpaII enzyme is sensitive to methylation on either C 
of the recognition sequence, it has also been suggested that the MspI enzyme is sensitive to 
methylation of the external c of the sequence. If this external C is sometimes methylated, and 
the MspI enzyme is sensitive to this methylation, this could explain the amplification of 
products from the MspI digested DNA. 
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Chapter 6. General Discussion 
This chapter gives an overview of advances in FSHD research that developed during the 
work described in this thesis. When the work described here began, the data showing 
expression from D4Z4 was new and most research was still focussed on a position effect 
mechanism on neighbouring genes. Over the last few years there have been a number of 
significant publications confirming expression from the D4Z4 array and providing an 
explanation for the haplotype specific pathogenicity. 
In 2009, Snider et al. reported amplification of smaller fragments at the 3 and 5 ends of 
the ORF, in most cases their transcripts matched the final repeat of the array, although 
variant bases in some of the transcripts were suggestive of transcription from internal D4Z4 
repeats. The group were also able to confirm the presence of the two splice forms reported 
by Dixit et al. (2007). In 2010, this group were able to report expression of two transcripts 
(DUX4-fl and DUX4-s) from the final repeat of the array, as they used a primer in the pLAM 
region their approach would not have amplified transcripts from internal repeats. The DUX4-fl 
transcript was amplified from 5/10 FSHD myoblast cell cultures, as well as testis and germ cell 
tumour RNA, while the DUX4-s transcript was present in all skeletal muscle controls and some 
of the FSHD samples. It is interesting that the full length transcripts were not identified in all 
of the FSHD samples. This would suggest that either the full length transcript is not required 
for the disease, or that it is expressed at a low abundance so that it is not always possible to 
detect. The requirement for a nested RT-PCR protocol in order to detect amplification is also 
consistent with a low abundance of DUX4 mRNA. 
This explanation for the difficulty in amplification of DUX4 mRNA was confirmed by Snider 
et al. (2010) reporting that only a small percentage of nuclei show DUX4 expression. Using RT-
PCR on limiting dilutions of myoblast cells along with immunostaining of cells with 
monoclonal antibodies to DUX4, the group were able to show that only 0.1% of FSHD muscle 
nuclei express DUX4. This observation could also help to explain why the RT-PCR results vary 
between reactions; the success of amplification will be dependent on the number of DUX4 
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expressing cells in the sample used, which is likely to vary. Snider and colleagues reported 
that muscle cells which show expression of the DUX4-fl transcript contain nuclear foci, which 
are characteristic of DUX4-induced apoptosis. It is possible that the culturing conditions of the 
myoblast cells affect the number of DUX4 positive cells in a sample; for example, apoptotic 
cells may no longer attach to the culture flasks and be lost on passaging or collection.  
Expression from the testis and germ cell tumour RNA was detected at levels 100 fold 
higher than in FSHD muscle cells. The data described in this thesis support the finding as the 
hEC cell line used was isolated from a teratocarcinoma, a tumour derived from germ cells. In 
contrast to the myoblast data, identification of transcripts from this cell line did not require a 
nested RT-PCR and results were easily repeatable across reactions.  
In 2010, Lemmers et al. reported that FSHD patients carry specific variants in the 
chromosome 4 region, distal to the last repeat of the array, which create a poly adenylation 
signal for transcripts derived from D4Z4. 4qB chromsomes lack this region, including the poly 
A site, while chromosome 10q carries the sequence ATCAAA which is not known to be a poly 
A signal. On FSHD permissive alleles, a polymorphism creates the signal ATTAAA, a commonly 
used poly A signal in humans. Lemmers and colleagues transfected C2C12 cells with 
constructs where the poly A signal of permissive chromosomes was replaced with a signal 
from a non-permissive chromosome and vice versa. They were able to show that constructs 
with the permissive poly A signal produced stable DUX4 constructs, while no transcript was 
detected from those with a non-permissive signal. In the mouse array, the most commonly 
used poly A signal, AATAAA, is present within the individual repeat unit, perhaps explaining 
why expression from the mouse array is more robust.  
Lemmers et al. studied FSHD patients with unusual hybrid structures that contain both 
Bln
+
 and Bln
-
 repeat units. They identified a patient whose FSHD allele resides on 
chromosome 10 rather than chromosome 4. This array starts with two and a half Bln
+
 repeats 
and ends with one and a half Bln
-
 repeat units. The permissive distal end of the chromosome 
4 had been transferred to chromosome 10 and importantly, none of the FSHD candidate 
genes that reside proximal to the D4Z4 array on chromosome 4 were transferred (Lemmers et 
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al., 2010a). This data provides strong evidence that the genes proximal to the array do not 
have a key role in FSHD pathogenesis. 
Together, these data support a model for FSHD whereby expression from the D4Z4 array 
in differentiated tissues is repressed due to increased H3K9me3, possibly facilitated by the 
repetitive nature of the array. On contraction of this array, the chromatin in the region is 
relaxed and transcription of a full length transcript occurs from the most distal repeat; only if 
that allele contains a polymorphism creating a functional poly A signal is the transcript stable. 
Snider et al. (2010) also suggested that the DUX4-s transcript is produced as a mechanism to 
control transcripts that escape repression, but that this mechanism is disrupted on 
contraction of the array. Expression of the DUX4-fl transcript is thought to be toxic to cells, 
and might therefore induce the muscle damage seen in FSHD patients. 
While expression of DUX4 in differentiated muscle cells appears to be the cause of this 
disease, there is an increasing amount of data that supports a normal role of the DUX4 gene 
during development. Firstly, the DUX gene has been conserved for >100mya, strongly 
suggesting a protein coding function for the gene (Clapp et al., 2007). Secondly, expression of 
DUX4 transcripts has been identified in the germ-line lineage by Snider et al. (2010) and by 
the work described in this thesis. Importantly, this expression is not restricted to FSHD 
permissive alleles, Snider et al. reported expression from both 4q and 10q alleles from testis 
RNA, while the work described here amplified transcripts from a hEC cell line containing only 
4qB163 and 10qA166 alleles.  
Analysis of the RT-PCR products amplified during this work has provided information on 
the variation seen between repeats of the D4Z4 array. Neither the sequence of, or expression 
from the internal repeat units has previously been examined. The transcripts contained a 
number of variant sites indicating that expression occurs from multiple units of the repeat 
array. 
In order to investigate the normal function of the DUX4 protein, binding sites and partners 
for the protein will need to be investigated which could be achieved by chromatin 
immunoprecipitation assays. Although it has been reported that the DUX4 protein binds to 
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the promoter region of PITX1 causing its upregulation, work described in this thesis was 
unable to confirm that overexpression of DUX4 induces PITX1 expression.  
An animal model for FSHD would be useful to investigate the function of the DUX genes. 
To date, DUX4 has been overexpressed in both Xenopus and Zebrafish (Snider et al., 2009; 
Wuebbles et al., 2010; Wallace et al., 2011) embryos, resulting in developmental 
malformations and heart defects. However, as these species genomes do not contain any 
homologous DUX genes they are unlikely to provide a useful model for FSHD (Leidenroth and 
Hewitt, 2010). DUX4 has also been overexpressed in adult mouse by injection into muscle 
(Wallace et al., 2011),
 
which produced muscle degeneration consistent with FSHD. However, 
there is currently no mouse model stably expressing DUX4 at the levels seen in FSHD patients. 
If the mouse Dux array was shown to be functionally equivalent to the D4Z4 array in humans, 
a mouse model of FSHD could potentially be developed by deletion of part of the mouse Dux 
array. In addition, if the Dux and DUX4 genes do carry out equivalent functions, further 
studies of the mouse gene may be helpful in elucidating the normal role of DUX4 during 
development. 
Work described in this thesis has contributed to the understanding of the mouse Dux 
array. Firstly, analysis of the methylation status of the repeats indicates that the mouse array 
is methylated, as seen in humans unaffected with FSHD. Secondly, amplification and 
sequencing of transcripts from the mouse array has given an insight into sequence variation 
between repeats, and the genomic origins of mouse Dux transcripts.  
Analysis of transcripts amplified from mouse RNA has shown that a large proportion of the 
RT-PCR products originated from a small cluster of Dux repeats, some of which do not appear 
to contain functional ORFs. Transcripts originating from these partial repeats may be non-
functional and it is currently unclear what role these may have. There have been reports of 
small mRNA transcripts in humans and it has been suggested that these may have a 
regulatory role, controlling transcription from the array. Alternatively, these fragments may 
originate from full repeats that have not yet been identified in the mouse genome. During this 
work, three longer transcripts were identified which showed a rearrangement compared with 
genomic transcripts, supporting the suggestion that there are variant genomic repeats within 
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the mouse genome which have not yet been identified in genomic sequencing studies. It is 
possible that these variant repeats are not present in the inbred mouse strain used for the 
genomic sequencing, if there is significant variation at this region between inbred and 
outbred strains then comparison of the organisation of and expression from the arrays in 
multiple strains may provide helpful information about the function of the arrays in the mice. 
 
 
 
 
  
 214 
Chapter 7. References 
Agresti, A., Rainaldi, G., Lobbiani, A., Magnani, I., Dilernia, R., Meneveri, R., Siccardi, A.G., and 
Ginelli, E. (1987). Chromosomal location by in situ hybridization of the human SAU3A family of 
DNA repeats. Human Genetics 75, 326-332. 
 
Alexiadis, V., Ballestas, M.E., Sanchez, C., Winokur, S., Vedanarayanan, V., Warren, M., and 
Ehrlich, M. (2007). RNAPol-ChIP analysis of transcription from FSHD-linked tandem repeats 
and satellite DNA. Biochimica Et Biophysica Acta-Gene Structure and Expression 1769, 29-40. 
 
Almstrup, K., Hoei-Hansen, C.E., Wirkner, U., Blake, J., Schwager, C., Ansorge, W., Nielsen, J.E., 
Skakkebaek, N.E., Meyts, E.R.D., and Leffers, H. (2004). Embryonic stem cell-like features of 
testicular carcinoma in situ revealed by genome-wide gene expression profiling. Cancer 
Research 64, 4736-4743. 
 
Altherr, M.R., Bengtsson, U., Markovich, R.P., and Winokur, S.T. (1995). Efforts toward 
understanding the molecular-basis of facioscapulohumeral muscular-dystrophy. Muscle & 
Nerve Suppl 2, S32-S38. 
 
Alvarado, D.M., McCall, K., Aferol, H., Silva, M.J., Garbow, J.R., Spees, W.M., Patel, T., Siegel, 
M., Dobbs, M.B., and Gurnett, C.A. (2011). Pitx1 haploinsufficiency causes clubfoot in humans 
and a clubfoot-like phenotype in mice. Human Molecular Genetics 20, 3943-3952. 
 
Andrews, P.W., Matin, M.M., Bahrami, A.R., Damjanov, I., Gokhale, P., and Draper, J.S. (2005). 
Embryonic stem (es) cells and embryonal carcinoma (ec) cells: Opposite sides of the same 
coin. Biochemical Society Transactions 33, 1526-1530. 
 
Ansseau, E., Laoudj-Chenivesse, D., Marcowycz, A., Tassin, A., Vanderplanck, C., Sauvage, S., 
Barro, M., Mahieu, I., Leroy, A., Leclercq, I., Mainfroid, V., Figlewicz, D., Mouly, V., Butler-
Browne, G., Belayew, A., and Coppee, F. (2009). Dux4c is up-regulated in FSHD. It induces the 
myf5 protein and human myoblast proliferation. PLoS ONE 4. 
 
Bakker, E., Wijmenga, C., Vossen, R., Padberg, G.W., Hewitt, J., Vanderwielen, M., Rasmussen, 
K., and Frants, R.R. (1995). The FSHD-linked locus D4F104S1 (p13E-11) on 4q35 has a homolog 
on 10qter. Muscle & Nerve Suppl 2, S39-S44. 
 
Barro, M., Carnac, G., Flavier, S., Mercier, J., Vassetzky, Y., and Laoudj-Chenivesse, D. (2010). 
Myoblasts from affected and non affected FSHD muscles exhibit morphological differentiation 
defects. Journal of Cellular and Molecular Medicine 14, 275-289. 
 
Bastress, K.L., Stajich, J.M., Speer, M.C., and Gilbert, J.R. (2005). The genes encoding for D4Z4 
binding proteins HMGB2, YY1, NCL, and MYOD1 are excluded as candidate genes for FSHD1B. 
Neuromuscular Disorders 15, 316-320. 
 
Beckers, M.-C., Gabriels, J., van der Maarel, S., De Vriese, A., Frants, R.R., Collen, D., and 
Belayew, A. (2001). Active genes in junk DNA? Characterization of DUX genes embedded 
within 3.3 kb repeated elements. Gene 264, 51-57. 
 
Bodega, B., Ramirez, G.D.C., Grasser, F., Cheli, S., Brunelli, S., Mora, M., Meneveri, R., Marozzi, 
A., Mueller, S., Battaglioli, E., and Ginelli, E. (2009). Remodeling of the chromatin structure of 
the facioscapulohumeral muscular dystrophy (FSHD) locus and upregulation of FSHD-related 
gene 1 (FRG1) expression during human myogenic differentiation. BMC Biology 7, 41. 
 
 215 
Booth, H.A.F., and Holland, P.W.H. (2007). Annotation, nomenclature and evolution of four 
novel homeobox genes expressed in the human germ line. Gene 387, 7-14. 
 
Bosnakovski, D., Daughters, R.S., Xu, Z.H.H., Slack, J.M.W., and Kyba, M. (2009). Biphasic 
myopathic phenotype of mouse DUX, an orf within conserved FSHD-related repeats. PLoS 
ONE 4. 
 
Boulikas, T. (1993). Nature of DNA-sequences at the attachment regions of genes to the 
nuclear matrix. Journal of Cellular Biochemistry 52, 14-22. 
 
Boulikas, T. (1995). Chromatin domains and prediction of MAR sequences. International 
Review of Cytology 162A, 279-388. 
 
Brouwer, O.F., Padberg, G.W., Bakker, E., Wijmenga, C., and Frants, R.R. (1995). Early-onset 
facioscapulohumeral muscular-dystrophy. Muscle & Nerve Suppl 2, S67-S72. 
 
Buzhov, B.T., Lemmers, R., Tournev, I., Dikova, C., Kremensky, I., Petrova, J., Frants, R.R., and 
van der Maarel, S.M. (2005). Genetic confirmation of facioscapulohumeral muscular 
dystrophy in a case with complex D4Z4 rearrangments. Human Genetics 116, 262-266. 
 
Cacurri, S., Piazzo, N., Deidda, G., Vigneti, E., Galluzzi, G., Colantoni, L., Merico, B., Ricci, E., 
and Felicetti, L. (1998). Sequence homology between 4qter and 10qter loci facilitates the 
instability of subtelomeric KpnI repeat units implicated in facioscapulohumeral muscular 
dystrophy. American Journal of Human Genetics 63, 181-190. 
 
Carter, D., Chakalova, L., Osborne, C.S., Dai, Y.-F., and Fraser, P. (2002). Long-range chromatin 
regulatory interactions in vivo. Nature Genetics 32, 623-626. 
 
Celegato, B., Capitanio, D., Pescatori, M., Romualdi, C., Pacchioni, B., Cagnin, S., Vigano, A., 
Colantoni, L., Begum, S., Ricci, E., Wait, R., Lanfranchi, G., and Gelfi, C. (2006). Parallel protein 
and transcript profiles of FSHD patient muscles correlate to the D4Z4 arrangement and reveal 
a common impairment of slow to fast fibre differentiation and a general deregulation of 
MyoD-dependent genes. Proteomics 6, 5303-5321. 
 
Chen, Y.-W., Zhao, P., Borup, R., and Hoffman, E.P. (2000). Expression profiling in the 
muscular dystrophies: Identification of novel aspects of molecular pathophysiology. Journal of 
Cell Biology 151, 1321-1336. 
 
Clapp, J., Mitchell, L.M., Bolland, D.J., Fantes, J., Corcoran, A.E., Scotting, P.J., Armour, J.A.L., 
and Hewitt, J.E. (2007). Evolutionary conservation of a coding function for D4Z4, the tandem 
DNA repeat mutated in facioscapulohumeral muscular dystrophy. American Journal of Human 
Genetics 81, 264-279. 
 
Clark, L.N., Koehler, U., Ward, D.C., Wienberg, J., and Hewitt, J.E. (1996). Analysis of the 
organisation and localisation of the FSHD-associated tandem array in primates: Implications 
for the origin and evolution of the 3.3 kb repeat family. Chromosoma 105, 180-189. 
 
Cockell, M., and Gasser, S.M. (1999). Nuclear compartments and gene regulation. Current 
Opinion in Genetics & Development 9, 199-205. 
 
Coulon, V., L'Honore, A., Ouimette, J.F., Dumontier, E., van den Munckhof, P., and Drouin, J. 
(2007). A muscle-specific promoter directs Pitx3 gene expression in skeletal muscle cells. 
Journal of Biological Chemistry 282, 33192-33200. 
 
Drner, A., and Schultheiss, H.-P. (2007). Adenine nucleotide translocase in the focus of 
cardiovascular diseases. Trends in Cardiovascular Medicine 17, 284-290. 
 
 216 
Davie, J.R. (1995). The nuclear matrix and the regulation of chromatin organization and 
function. International Review of Cytology, Vol 162a 162A, 191-250. 
 
de Greef, J.C., Lemmers, R., Camano, P., Day, J.W., Sacconi, S., Dunand, M., van Engelen, 
B.G.M., Kiuru-Enari, S., Padberg, G.W., Rosa, A.L., Desnuelle, C., Spuler, S., Tarnopolsky, M., 
Venance, S.L., Frants, R.R., van der Maarel, S.M., and Tawil, R. (2010). Clinical features of 
facioscapulohumeral muscular dystrophy 2. Neurology 75, 1548-1554. 
 
de Greef, J.C., Lemmers, R.J.L.F., van Engelen, B.G.M., Sacconi, S., Venance, S.L., Frants, R.R., 
Tawil, R., and van der Maarel, S.M. (2009). Common epigenetic changes of D4Z4 in 
contraction-dependent and contraction-independent FSHD. Human Mutation 30, 1449-1459. 
 
Deak, K.L., Lemmers, R., Stajich, J.M., Klooster, R., Tawil, R., Frants, R.R., Speer, M.C., van der 
Maarel, S.M., and Gilbert, J.R. (2007). Genotype-phenotype study in an FSHD family with a 
proximal deletion encompassing p13E-11 and D4Z4. Neurology 68, 578-582. 
 
Deidda, G., Cacurri, S., Piazzo, N., and Felicetti, L. (1996). Direct detection of 4q35 
rearrangements implicated in facioscapulohumeral muscular dystrophy (FSHD). Journal of 
Medical Genetics 33, 361-365. 
 
DeLaurier, A., Schweitzer, R., and Logan, M. (2006). Pitx1 determines the morphology of 
muscle, tendon, and bones of the hindlimb. Developmental Biology 299, 22-34. 
 
Dickson, M.C. (1998). Characterisation of the subtelomeric region of human chromosome 4q, 
PhD Thesis, (University of Manchester) 
 
Ding, H., Beckers, M.C., Plaisance, S., Marynen, P., Collen, D., and Belayew, A. (1998). 
Characterization of a double homeodomain protein (DUX1) encoded by a cDNA homologous 
to 3.3 kb dispersed repeated elements. Human Molecular Genetics 7, 1681-1694. 
 
Dixit, M., Ansseau, E., Tassin, A., Winokur, S., Shi, R., Qian, H., Sauvage, S., Mattotti, C., van 
Acker, A.M., Leo, O., Figiewicz, D., Barro, M., Laoudj-Chenivesse, D., Belayew, A., Coppee, F., 
and Chen, Y.W. (2007). DUX4, a candidate gene of facioscapulohumeral muscular dystrophy, 
encodes a transcriptional activator of PITX1. Proceedings of the National Academy of Sciences, 
USA 104, 18157-18162. 
 
Doerner, A., Pauschinger, M., Badorff, A., Noutsias, M., Giessen, S., Schulze, K., Bilger, J., 
Rauch, U., and Schultheiss, H.P. (1997). Tissue-specific transcription pattern of the adenine 
nucleotide translocase isoforms in humans. Febs Letters 414, 258-262. 
 
Fischbeck, K.H., and Garbern, J.Y. (1992). Facioscapulohumeral muscular dystrophy defect 
identified. Nature Genetics 2, 3-4. 
 
Forlani, G., Giarda, E., Ala, U., Di Cunto, F., Salani, M., Tupler, R., Kilstrup-Nielsen, C., and 
Landsberger, N. (2010). The MeCP2/YY1 interaction regulates ANT1 expression at 4q35: Novel 
hints for Rett syndrome pathogenesis. Human Molecular Genetics 19, 3114-3123. 
 
Funakoshi, M., Goto, K., and Arahata, K. (1998). Epilepsy and mental retardation in a subset of 
early onset 4q35-facioscapulohumeral muscular dystrophy. Neurology 50, 1791-1794. 
 
Gabellini, D., D'Antona, G., Moggio, M., Prelle, A., Zecca, C., Adami, R., Angeletti, B., Ciscato, 
P., Pellegrino, M.A., Bottinelli, R., Green, M.R., and Tupler, R. (2006). Facioscapulohumeral 
muscular dystrophy in mice overexpressing FRG1. Nature 439, 973-977. 
 
Gabellini, D., Green, M.R., and Tupler, R. (2002). Inappropriate gene activation in FSHD: A 
repressor complex binds a chromosomal repeat deleted in dystrophic muscle. Cell 110, 339-
348. 
 
 217 
Gabriels, J., Beckers, M.C., Ding, H., De Vriese, A., Plaisance, S., van der Maarel, S.M., Padberg, 
G.W., Frants, R.R., Hewitt, J.E., Collen, D., and Belayew, A. (1999). Nucleotide sequence of the 
partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 
kb element. Gene 236, 25-32. 
 
Garrick, D., Fiering, S., Martin, D.I.K., and Whitelaw, E. (1998). Repeat-induced gene silencing 
in mammals. Nature Genetics 18, 56-59. 
 
GibsonBrown, J.J., Agulnik, S.I., Chapman, D.L., Alexiou, M., Garvey, N., Silver, L.M., and 
Papaioannou, V.E. (1996). Evidence of a role for T-box genes in the evolution of limb 
morphogenesis and the specification of forelimb/hindlimb identity. Mechanisms of 
Development 56, 93-101. 
 
Gilbert, J.R., Stajich, J.M., Speer, M.C., Vance, J.M., Stewart, C.S., Yamaoka, L.H., Samson, F., 
Fardeau, M., Potter, T.G., Roses, A.D., and et al. (1992). Linkage studies in 
facioscapulohumeral muscular dystrophy (FSHD). American Journal of Human Genetics 51, 
424-427. 
 
Gilbert, J.R., Stajich, J.M., Wall, S., Carter, S.C., Qiu, H., Vance, J.M., Stewart, C.S., Speer, M.C., 
Pufky, J., Yamaoka, L.H., Rozear, M., Samson, F., Fardeau, M., Roses, A.D., and Pericakvance, 
M.A. (1993). Evidence for heterogeneity in facioscapulohumeral muscular-dystrophy (FSHD). 
American Journal of Human Genetics 53, 401-408. 
 
Gottschling, D.E., Aparicio, O.M., Billington, B.L., and Zakian, V.A. (1990). Position effect at 
saccharomyces cerevisiae telomeres - reversible repression of pol-II transcription. Cell 63, 
751-762. 
 
Grewal, P.K., van Geel, M., Frants, R.R., de Jong, P., and Hewitt, J.E. (1999). Recent 
amplification of the human FRG1 gene during primate evolution. Gene 227, 79-88. 
 
Griggs, R.C., Tawil, R., Storvick, D., Mendell, J.R., and Altherr, M.R. (1993). Genetics of 
facioscapulohumeral muscular-dystrophy - new mutations in sporadic cases. Neurology 43, 
2369-2372. 
 
Gurnett, C.A., Alaee, F., Kruse, L.M., Desruisseau, D.M., Hecht, J.T., Wise, C.A., Bowcock, A.M., 
and Dobbs, M.B. (2008). Asymmetric lower-limb malformations in individuals with homeobox 
PITX1 gene mutation. American Journal of Human Genetics 83, 616-622. 
 
Hanakahi, L.A., Dempsey, L.A., Li, M.J., and Maizels, N. (1997). Nucleolin is one component of 
the B cell-specific transcription factor and switch region binding protein, lr1. Proceedings of 
the National Academy of Sciences, USA 94, 3605-3610. 
 
Hanel, M.L., Wuebbles, R.D., and Jones, P.L. (2009). Muscular dystrophy candidate gene FRG1 
is critical for muscle development. Developmental Dynamics 238, 1502-1512. 
 
Haslbeck, K.M., Bierhaus, A., Erwin, S., Kirchner, A., Nawroth, P., Schlotzer, U., Neundorfer, B., 
and Heuss, D. (2004). Receptor for advanced glycation endproduct (RAGE)-mediated nuclear 
factor-kappa B activation in vasculitic neuropathy. Muscle & Nerve 29, 853-860. 
 
Hewitt, J.E., Lyle, R., Clark, L.N., Valleley, E.M., Wright, T.J., Wijmenga, C., van Deutekom, 
J.C.T., Francis, F., Sharpe, P.T., Hofker, M., Frants, R.R., and Williamson, R. (1994). Analysis of 
the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystropothhy. 
Human Molecular Genetics 3, 1287-1295. 
 
Hirano, M., and DiMauro, S. (2001). ANT1, Twinkle, POLG, and TP: New genes open our eyes 
to ophthalmoplegia. Neurology 57, 2163-2165. 
 
 218 
Iqbal, Z., Roper, H., Pericak-Vance, M.A., Hung, W.Y., Delong, R., Cummings, W.J.K., and 
Siddique, T. (1992). Genetic heterogeneity in facioscapulohumeral disease. American Journal 
of Human Genetics 51, A191. 
 
Jardine, P., Jones, M., Tyfield, L., Upadhyaya, M., and Lunt, P. (1993). De-novo DNA 
rearrangement in atypical facioscapulohumeral muscular dystrophy. Clinical Genetics 44, 167-
167. 
 
Jiang, G.C., Yang, F., van Overveld, P.G.M., Vedanarayanan, V., van der Maarel, S., and Ehrlich, 
M. (2003). Testing the position-effect variegation hypothesis for facioscapulohumeral 
muscular dystrophy by analysis of histone modification and gene expression in subtelomeric 
4q. Human Molecular Genetics 12, 2909-2921. 
 
Jordens, E.Z., Palmieri, L., Huizing, M., Van Den Heuvel, L.P., Sengers, R.C.A., Drner Wim 
Ruitenbeek, A., Trijbels, F.J., Valsson, J., Sigfusson, G., Palmieri, F., and Smeitink, J.A.M. (2002). 
Adenine nucleotide translocator 1 deficiency associated with Sengers syndrome. Annals of 
Neurology 52, 95-99. 
 
Jurica, M.S., Licklider, L.J., Gygi, S.P., Grigorieff, N., and Moore, M.J. (2002). Purification and 
characterization of native spliceosomes suitable for three-dimensional structural analysis. 
RNA 8, 426-439. 
 
Kafri, T., Ariel, M., Brandeis, M., Shemer, R., Urven, L., McCarrey, J., Cedar, H., and Razin, A. 
(1992). Developmental pattern of gene-specific DNA methylation in the mouse embryo and 
germ line. Genes & Development 6, 705-714. 
 
Katayama, S., Tomaru, Y., Kasukawa, T., Waki, K., Nakanishi, M., Nakamura, M., Nishida, H., 
Yap, C.C., Suzuki, M., Kawai, J., Suzuki, H., Carninci, P., Hayashizaki, Y., Wells, C., Frith, M., 
Ravasi, T., Pang, K.C., Hallinan, J., Mattick, J., Hume, D.A., Lipovich, L., Batalov, S., Engstrom, 
P.G., Mizuno, Y., Faghihi, M.A., Sandelin, A., Chalk, A.M., Mottagui-Tabar, S., Liang, Z., 
Lenhard, B., Wahlestedt, C., Core, R.G.N.P., Genome Sci, G., and Consortium, F. (2005). 
Antisense transcription in the mammalian transcriptome. Science 309, 1564-1566. 
 
Kawamura-Saito, M., Yamazaki, Y., Kaneko, K., Kawaguchi, N., Kanda, H., Mukai, H., Gotoh, T., 
Motoi, T., Fukayama, M., Aburatani, H., Takizawa, T., and Nakamura, T. (2006). Fusion 
between CIC and DUX4 up-regulates PEA3 family genes in ewing-like sarcomas with 
t(4;19)(q35;q13) translocation. Human Molecular Genetics 15, 2125-2137. 
 
Kleinjan, D.J., and van Heyningen, V. (1998). Position effect in human genetic disease. Human 
Molecular Genetics 7, 1611-1618. 
 
Klinge, L., Eagle, M., Haggerty, I.D., Roberts, C.E., Straub, V., and Bushby, K.M. (2006). Severe 
phenotype in infantile facioscapulohumeral muscular dystrophy. Neuromuscular Disorders 16, 
553-558. 
 
Kohler, J., Rupilius, B., Otto, M., Bathke, K., and Koch, M.C. (1996). Germline mosaicism in 
4q35 facioscapulohumeral muscular dystrophy (FSHD1A) occurring predominantly in 
oogenesis. Human Genetics 98, 485-490. 
 
Kondo, T., Bobek, M.P., Kuick, R., Lamb, B., Zhu, X.X., Narayan, A., Bourc'his, D., Viegas-
Pequignot, E., Ehrlich, M., and Hanash, S.M. (2000). Whole-genome methylation scan in ICF 
syndrome: Hypomethylation of non-satellite DNA repeats D4Z4 and NBL2. Human Molecular 
Genetics 9, 597-604. 
 
Kosak, S.T., Skok, J.A., Medina, K.L., Riblet, R., Le Beau, M.M., Fisher, A.G., and Singh, H. 
(2002). Subnuclear compartmentalization of immunoglobulin loci during lymphocyte 
development. Science 296, 158-162. 
 
 219 
Kowaljow, V., Marcowycz, A., Ansseau, E., Conde, C.B., Sauvage, S., Mattotti, C., Arias, C., 
Corona, E.D., Nufiez, N.G., Leo, O., Wattiez, R., Iglewicz, D.F., Laoudj-Chenivesse, D., BelayeW, 
A., Coppe, F., and Rosa, A.L. (2007). The DUX4 gene at the FSHDIA locus encodes a pro-
apoptotic protein. Neuromuscular Disorders 17, 611-623. 
 
Lanctot, C., Lamolet, B., and Drouin, J. (1997). The bicoid-related homeoprotein ptx1 defines 
the most anterior domain of the embryo and differentiates posterior from anterior lateral 
mesoderm. Development 124, 2807-2817. 
 
Lanctot, C., Moreau, A., Chamberland, M., Tremblay, M.L., and Drouin, J. (1999). Hindlimb 
patterning and mandible development require the ptx1 gene. Development 126, 1805-1810. 
 
Laoudj-Chenivesse, D., Carnac, G., Bisbal, C., Hugon, G., Bouillot, S., Desnuelle, C., Vassetzky, 
Y., and Fernandez, A. (2005). Increased levels of adenine nucleotide translocator 1 protein 
and response to oxidative stress are early events in facioscapulohumeral muscular dystrophy 
muscle. Journal of Molecular Medicine 83, 216-224. 
 
Lapidot, M., and Pilpel, Y. (2006). Genome-wide natural antisense transcription: Coupling its 
regulation to its different regulatory mechanisms. Embo Reports 7, 1216-1222. 
 
Leidenroth, A., and Hewitt, J.E. (2010). A family history of DUX4: Phylogenetic analysis of 
DUXA, B, C and Duxbl reveals the ancestral DUX gene. BMC Evolutionary Biology 10. 
 
Lemmers, R., de Kievit, P., Sandkuijl, L., Padberg, G.W., van Ommen, G.J.B., Frants, R.R., and 
van der Maarel, S.M. (2002). Facioscapulohumeral muscular dystrophy is uniquely associated 
with one of the two variants of the 4q subtelomere. Nature Genetics 32, 235-236. 
 
Lemmers, R., Osborn, M., Haaf, T., Rogers, M., Frants, R.R., Padberg, G.W., Cooper, D.N., van 
der Maarel, S.M., and Upadhyaya, M. (2003). D4F104S1 deletion in facioscapulohumeral 
muscular dystrophy - phenotype, size, and detection. Neurology 61, 178-183. 
 
Lemmers, R., van der Maarel, S.M., van Deutekom, J.C.T., van der Wielen, M.J.R., Deidda, G., 
Dauwerse, H.G., Hewitt, J., Hofker, M., Bakker, E., Padberg, G.W., and Frants, R.R. (1998). 
Inter- and intrachromosomal sub-telomeric rearrangements on 4q35: Implications for 
facioscapulohumeral muscular dystrophy (FSHD) aetiology and diagnosis. Human Molecular 
Genetics 7, 1207-1214. 
 
Lemmers, R., van der Vliet, P.J., Klooster, R., Sacconi, S., Camano, P., Dauwerse, J.G., Snider, 
L., Straasheijm, K.R., van Ommen, G.J., Padberg, G.W., Miller, D.G., Tapscott, S.J., Tawil, R., 
Frants, R.R., and van der Maarel, S.M. (2010a). A unifying genetic model for 
facioscapulohumeral muscular dystrophy. Science 329, 1650-1653. 
 
Lemmers, R., van der Vliet, P.J., van der Gaag, K.J., Zuniga, S., Frants, R.R., de Knijff, P., and 
van der Maarel, S.M. (2010b). Worldwide population analysis of the 4q and 10q subtelomeres 
identifies only four discrete interchromosomal sequence transfers in human evolution. 
American Journal of Human Genetics 86, 364-377. 
 
Lemmers, R., van Overveld, P.G.M., Sandkuijl, L.A., Vrieling, H., Padberg, G.W., Frants, R.R., 
and van der Maarel, S.M. (2004a). Mechanism and timing of mitotic rearrangements in the 
subtelomeric D4Z4 repeat involved in facioscapulohumeral muscular dystrophy. American 
Journal of Human Genetics 75, 44-53. 
 
Lemmers, R., Wohlgemuth, M., Frants, R.R., Padberg, G.W., Morava, E., and van der Maarel, 
S.M. (2004b). Contractions of D4Z4 on 4qB subtelomeres do not cause facioscapulohumeral 
muscular dystrophy. American Journal of Human Genetics 75, 1124-1130. 
 
Lemmers, R., Wohlgemuth, M., van der Gaag, K.J., van der Vliet, P.J., van Teijlingen, C.M.M., 
de Knijff, P., Padberg, G.W., Frants, R.R., and van der Maarel, S.M. (2007). Specific sequence 
 220 
variations within the 4q35 region are associated with facioscapulohumeral muscular 
dystrophy. American Journal of Human Genetics 81, 884-894. 
 
Lemmers, R.J.L.F., Peggy De Kievit, Michel van Geel, Michiel J. R. van der Wielen, Egbert 
Bakker, George W. Padberg, Frants, R.R., and Maarel, S.M.V.D. (2001). Complete allele 
information in the diagnosis of facioscapulohumeral muscular dystrophy by triple DNA 
analysis. Annals of Neurology 50, 816-819. 
 
Levis, R., Hazelrigg, T., and Rubin, G.M. (1985). Effects of genomic position on the expression 
of transduced copies of the white gene of Drosophila. Science 229, 558-561. 
 
Lewis, E.B. (1950). The phenomenon of position effect. Advances in Genetics Incorporating 
Molecular Genetic Medicine 3, 73-115. 
 
Li, K., Warner, C.K., Hodge, J.A., Minoshima, S., Kudoh, J., Fukuyama, R., Maekawa, M., 
Shimizu, Y., Shimizu, N., and Wallace, D.C. (1989). A human-muscle adenine-nucleotide 
translocator gene has 4 exons, is located on chromosome-4, and is differentially expressed. 
Journal of Biological Chemistry 264, 13998-14004. 
 
Logan, M., and Tabin, C.J. (1999). Role of Pitx1 upstream of Tbx4 in specification of hindlimb 
identity. Science 283, 1736-1739. 
 
Lunt, P.W., Compston, D.A.S., and Harper, P.S. (1989). Estimation of age-dependent 
penetrance in facioscapulohumeral muscular-dystrophy by minimizing ascertainment bias. 
Journal of Medical Genetics 26, 755-760. 
 
Lunt, P.W., and Harper, P.S. (1991). Genetic-counseling in facioscapulohumeral muscular-
dystrophy. Journal of Medical Genetics 28, 655-664. 
 
Lunt, P.W., Jardine, P.E., Koch, M., Maynard, J., Osborn, M., Williams, M., Harper, P.S., and 
Upadhyaya, M. (1995a). Phenotypic genotypic correlation will assist genetic-counseling in 
4q35-facioscapulohumeral muscular-dystrophy. Muscle & Nerve Suppl 2, S103-S109. 
 
Lunt, P.W., Jardine, P.E., Koch, M.C., Maynard, J., Osborn, M., Williams, M., Harper, P.S., and 
Upadhyaya, M. (1995b). Correlation between fragment size at D4F104S1 and age at onset or 
at wheelchair use, with a possible generational-effect, accounts for much phenotypic 
variation in 4q35-facioscapulohumeral muscular dystrophy (FSHD). Human Molecular 
Genetics 4, 951-958. 
 
Lyle, R., Wright, T.J., Clark, L.N., and Hewitt, J.E. (1995). FSHD-associated repeat, D4Z4, is a 
member of a dispersed family of homeobox-containing repeats, subsets of which are 
clustered on the short arms of the acrocentric chromosomes. Genomics 28, 389-397. 
 
Macaione, V., Aguennouz, M., Rodolico, C., Mazzeo, A., Patti, A., Cannistraci, E., Colantone, L., 
Di Giorgio, R.M., De Luca, G., and Vita, G. (2007). RAGE-NF-kappa B pathway activation in 
response to oxidative stress in facioscapulohumeral muscular dystrophy. Acta Neurologica 
Scandinavica 115, 115-121. 
 
Manz, E., Schnieders, F., Brechlin, A.M., and Schmidtke, J. (1993). TSPY-related sequences 
represent A microheterogeneous gene family organized as constitutive elements in DYZ5 
tandem repeat units on the human y-chromosome. Genomics 17, 726-731. 
 
Marshall, W.F., Fung, J.C., and Sedat, J.W. (1997). Deconstructing the nucleus: Global 
architecture from local interactions. Current Opinion in Genetics & Development 7, 259-263. 
 
Masny, P.S., Bengtsson, U., Chung, S.A., Martin, J.H., van Engelen, B., van der Maarel, S.M., 
and Winokur, S.T. (2004). Localization of 4q35.2 to the nuclear periphery: Is FSHD a nuclear 
envelope disease? Human Molecular Genetics 13, 1857-1871. 
 221 
 
Masny, P.S., Chan, O.Y.A., de Greef, J.C., Bengtsson, U., Ehrlich, M., Tawil, R., Lock, L.F., 
Hewitt, J.E., Stocksdale, J., Martin, J.H., van der Maarel, S.M., and Winokur, S.T. (2010). 
Analysis of allele-specific RNA transcription in FSHD by RNA-DNA fish in single myonuclei. 
European Journal of Human Genetics 18, 448-456. 
 
Mathews, K.D., Mills, K.A., Bosch, E.P., Ionasescu, V.V., Wiles, K.R., Buetow, K.H., and Murray, 
J.C. (1992). Linkage localization of facioscapulohumeral muscular dystrophy (FSHD) in 4q35. 
American Journal of Human Genetics 51, 428-431. 
 
Meneveri, R., Agresti, A., Dellavalle, G., Talarico, D., Siccardi, A.G., and Ginelli, E. (1985). 
Identification of A human clustered G+C-rich DNA family of repeats (SAU3A family). Journal of 
Molecular Biology 186, 483-489. 
 
Meneveri, R., Agresti, A., Marozzi, A., Saccone, S., Rocchi, M., Archidiacono, N., Corneo, G., 
Dellavalle, G., and Ginelli, E. (1993). Molecular-organization and chromosomal location of 
human gc-rich heterochromatic blocks. Gene 123, 227-234. 
 
Mills, K.A., Buetow, K.H., Xu, Y., Ritty, T.M., Mathews, K.D., Bodrug, S.E., Wijmenga, C., Balazs, 
I., and Murray, J.C. (1992). Genetic and physical mapping on chromosome-4 narrows the 
localization of the gene for facioscapulohumeral muscular-dystrophy (FSHD). American 
Journal of Human Genetics 51, 432-439. 
 
Miura, K., Kumagai, T., Matsumoto, A., Iriyama, E., Watanabe, K., Goto, K., and Arahata, K. 
(1998). Two cases of chromosome 4q35-linked early onset facioscapulohumeral muscular 
dystrophy with mental retardation and epilepsy. Neuropediatrics 29, 239-241. 
 
Monici, M.C., Aguennouz, M., Mazzeo, A., Messina, C., and Vita, G. (2003). Activation of 
nuclear factor-kappa B in inflammatory myopathies and duchenne muscular dystrophy. 
Neurology 60, 993-997. 
 
Morosetti, R., Mirabella, M., Gliubizzi, C., Broccolini, A., Sancricca, C., Pescatori, M., Gidaro, T., 
Tasca, G., Frusciante, R., Tonali, P.A., Cossu, G., and Ricci, E. (2007). Isolation and 
characterization of mesoangioblasts from facioscapulohumeral muscular dystrophy muscle 
biopsies. Stem Cells 25, 3173-3182. 
 
Moylan, J.S., and Reid, M.B. (2007). Oxidative stress, chronic disease, and muscle wasting. 
Muscle & Nerve 35, 411-429. 
 
Nassif, N., Penney, J., Pal, S., Engels, W.R., and Gloor, G.B. (1994). Efficiant copying of 
nonhomologous sequences from ectopic sites via p-element-induced gap repair. Molecular 
and Cellular Biology 14, 1613-1625. 
 
Nguyen, C.T., Gonzales, F.A., and Jones, P.A. (2001). Altered chromatin structure associated 
with methylation-induced gene silencing in cancer cells: Correlation of accessibility, 
methylation, MeCP2 binding and acetylation. Nucleic Acids Research 29, 4598-4606. 
 
Osborne, R.J., Welle, S., Venance, S.L., Thornton, C.A., and Tawil, R. (2007). Expression profile 
of FSHD supports a link between retinal vasculopathy and muscular dystrophy. Neurology 68, 
569-577. 
 
Ostlund, C., Garcia-Carrasquillo, R.M., Belayew, A., and Worman, H.J. (2005). Intracellular 
trafficking and dynamics of double homeodomain proteins. Biochemistry 44, 2378-2384. 
 
Ottaviani, A., Rival-Gervier, S., Boussouar, A., Foerster, A.M., Rondier, D., Sacconi, S., 
Desnuelle, C., Gilson, E., and Magdinier, F. (2009). The D4Z4 macrosatellite repeat acts as a 
CTCF and A-type lamins-dependent insulator in facio-scapulo-humeral dystrophy. Plos 
Genetics 5. 
 222 
 
Ottaviani, A., Rival-Gervier, S., Forster, A., Gilson, E., and Magdinier, F. (2006). The D4Z4 
subtelomeric element behaves as a CTCF-dependent insulator and anchors telomeres to the 
nuclear periphery. Neuromuscular Disorders 16, 713-713. 
 
Padberg, G.W. (2004a). Facioscapulohumeral muscular dystrophy: A clinician's experience. In 
Facioscapulohumeral muscular dystrophy clinical medicine and molecular cell biology, M. 
Upadhyaya, and D.N. Cooper, eds. (Garland Science/BIOS Scientific Publishers), pp. 41-54. 
 
Padberg, G.W. (2004b). Facioscapulohumeral muscular dystrophy: A clinician's experience. In 
Facioscapulohumeral muscular dystrophy, D.N.C. M.Upadhyaya, ed. (Garland Science/BIOS 
Scientific Publishers), pp. 41-54. 
 
Padberg, G.W., Brouwer, O.F., Dekeizer, R.J.W., Dijkman, G., Wijmenga, C., Grote, J.J., and 
Frants, R.R. (1995). On the significance of retinal vascular-disease and hearing-loss in 
facioscapulohumeral muscular-dystrophy. Muscle & Nerve Suppl 2, S73-S80. 
 
Petrov, A., Allinne, J., Pirozhkova, I., Laoudj, D., Lipinski, M., and Vassetzky, Y.S. (2008). A 
nuclear matrix attachment site in the 4q35 locus has an enhancer-blocking activity in vivo: 
Implications for the facio-scapulo-humeral dystrophy. Genome Research 18, 39-45. 
 
Petrov, A., Pirozhkova, I., Carnac, G., Laoudj, D., Lipinski, M., and Vassetzky, Y.S. (2006). 
Chromatin loop domain organization within the 4q35 locus in facioscapulohumeral dystrophy 
patients versus normal human myoblasts. Proceedings of the National Academy of Sciences, 
USA 103, 6982-6987. 
 
Pirozhkova, I., Petrov, A., Dmitriev, P., Laoudj, D., Lipinski, M., and Vassetzky, Y. (2008). A 
functional role for 4qA/B in the structural rearrangement of the 4q35 region and in the 
regulation of FRG1 and ANT1 in facioscapulohumeral dystrophy. PLoS ONE 3, e3389. 
 
Rappsilber, J., Ryder, U., Lamond, A., and Mann, M. (2002). Large-scale proteomic analysis of 
the human spliceosome. Genome Research 12, 1231-1245. 
 
Rijkers, T., Deidda, G., van Koningsbruggen, S., van Geel, M., Lemmers, R., van Deutekom, 
J.C.T., Figlewicz, D., Hewitt, J.E., Padberg, G.W., Frants, R.R., and van der Maarel, S.M. (2004). 
FRG2, an FSHD candidate gene, is transcriptionally upregulated in differentiating primary 
myoblast cultures of FSHD patients. Journal of Medical Genetics 41, 826-836. 
 
Rossi, M., Ricci, E., Colantoni, L., Galluzzi, G., Frusciante, R., Tonali, P.A., and Felicetti, L. 
(2007). The facioscapulohumeral muscular dystrophy region on 4qter and the homologous 
locus on 10qter evolved independently under different evolutionary pressure. BMC Medical 
Genetics 8. 
 
Saito, A., Higuchi, I., Nakagawa, M., Saito, M., Uchida, Y., Inose, M., Kasai, T., Niiyama, T., 
Fukunaga, H., Arimura, K., and Osame, M. (2000). An overexpression of fibroblast growth 
factor (FGF) and FGF receptor 4 in a severe clinical phenotype of facioscapulohumeral 
muscular dystrophy. Muscle & Nerve 23, 490-497. 
 
Saitoh, Y., Miyamoto, N., Okada, T., Gondo, Y., Showguchi-Miyata, J., Hadano, S., and Ikeda, 
J.E. (2000). The RS447 human megasatellite tandem repetitive sequence encodes a novel 
deubiquitinating enzyme with a functional promoter. Genomics 67, 291-300. 
 
Sarfarazi, M., Upadhyaya, M., Padberg, G., Pericak-Vance, M., Siddique, T., Lucotte, G., and 
Lunt, P. (1989). An exclusion map for facioscapulohumeral (Landouzy-Dejerine) disease. 
Journal of Medical Genetics 26, 481-484. 
 
Sarfarazi, M., Wijmenga, C., Upadhyaya, M., Weiffenbach, B., Hyser, C., Mathews, K., Murray, 
J., Gilbert, J., Pericakvance, M., Lunt, P., Frants, R.R., Jacobsen, S., Harper, P.S., and Padberg, 
 223 
G.W. (1992). Regional mapping of facioscapulohumeral muscular-dystrophy gene on 4q35 - 
combined analysis of an international consortium. American Journal of Human Genetics 51, 
396-403. 
 
Schwartz, C.M., Spivak, C.E., Baker, S.C., McDaniel, T.K., Loring, J.F., Nguyen, C., Chrest, F.J., 
Wersto, R., Arenas, E., Zeng, X.M., Freed, W.J., and Rao, M.S. (2005). Ntera2: A model system 
to study dopaminergic differentiation of human embryonic stem cells. Stem Cells and 
Development 14, 517-534. 
 
Scofield, D.G., Hong, X., and Lynch, M. (2007). Position of the final intron in full-length 
transcripts: Determined by NMD? Molecular Biology and Evolution 24, 896-899. 
 
Shapiro, M.D., Bell, M.A., and Kingsley, D.M. (2006). Parallel genetic origins of pelvic reduction 
in vertebrates. Proceedings of the National Academy of Sciences, USA 103, 13753-13758. 
 
Shapiro, M.D., Marks, M.E., Peichel, C.L., Blackman, B.K., Nereng, K.S., Jonsson, B., Schluter, 
D., and Kingsley, D.M. (2004). Genetic and developmental basis of evolutionary pelvic 
reduction in threespine sticklebacks. Nature 428, 717-723. 
 
Singer-Sam, J., Grant, M., LeBon, J.M., Okuyama, K., Chapman, V., Monk, M., and Riggs, A.D. 
(1990). Use of a HpaII-polymerase chain reaction assay to study DNA methylation in the Pgk-1 
CpG island of mouse embryos at the time of X-chromosome inactivation. Mol Cell Biol 10, 
4987-4989. 
 
Snider, L., Asawachaicharn, A., Tyler, A.E., Geng, L.N., Petek, L.M., Maves, L., Miller, D.G., 
Lemmers, R., Winokur, S.T., Tawil, R., van der Maarel, S.M., Filippova, G.N., and Tapscott, S.J. 
(2009). RNA transcripts, miRNA-sized fragments and proteins produced from D4Z4 units: New 
candidates for the pathophysiology of facioscapulohumeral dystrophy. Human Molecular 
Genetics 18, 2414-2430. 
 
Snider, L., Geng, L.N., Lemmers, R., Kyba, M., Ware, C.B., Nelson, A.M., Tawil, R., Filippova, 
G.N., van der Maarel, S.M., Tapscott, S.J., and Miller, D.G. (2010). Facioscapulohumeral 
dystrophy: Incomplete suppression of a retrotransposed gene. Plos Genetics 6. 
 
Spaenkuch, B., and Strebhardt, K. (2005). RNA interference-based gene silencing in mice: The 
development of a novel therapeutical strategy. Current Pharmaceutical Design 11, 3405-3419. 
 
Stepien, G., Torroni, A., Chung, A.B., Hodge, J.A., and Wallace, D.C. (1992). Differential 
expression of adenine-nucleotide translocator isoforms in mammalian-tissues and during 
muscle-cell differentiation. Journal of Biological Chemistry 267, 14592-14597. 
 
Stratton, M.R., Reeves, B.R., and Cooper, C.S. (1989). Misidentified cell. Nature 337, 311-312. 
 
Sugimoto, A. (2004). High-throughput RNAi in Caenorhabditis elegans: Genome-wide screens 
and functional genomics. Differentiation 72, 81-91. 
 
Tam, R., Smith, K.P., and Lawrence, J.B. (2004). The 4q subtelomere harboring the FSHD locus 
is specifically anchored with peripheral heterochromatin unlike most human telomeres. 
Journal of Cell Biology 167, 269-279. 
 
Tawil, R., Forrester, J., Griggs, R.C., Mendell, J., Kissel, J., McDermott, M., King, W., 
Weiffenbach, B., Figlewicz, D., Cos, L., Langsam, A., Pandya, S., Martens, B., Brower, C., Herr, 
B., Downing, K., and Gorell, W.C. (1996). Evidence for anticipation and association of deletion 
size with severity in facioscapulohumeral muscular dystrophy. Annals of Neurology 39, 744-
748. 
 
Thomas, J.O., and Travers, A.A. (2001). HMG1 and 2, and related 'architectural' DNA-binding 
proteins. Trends in Biochemical Sciences 26, 167-174. 
 224 
 
Thomas, M.J., and Seto, E. (1999). Unlocking the mechanisms of transcription factor YY1: Are 
chromatin modifying enzymes the key? Gene 236, 197-208. 
 
Thomas, N.S.T., Wiseman, K., Spurlock, G., MacDonald, M., Ustek, D., and Upadhyaya, M. 
(2007). A large patient study confirming that facioscapulohumeral muscular dystrophy (FSHD) 
disease expression is almost exclusively associated with an FSHD locus located on a 4qA-
defined 4qter subtelomere. Journal of Medical Genetics 44, 215-218. 
 
Tonini, M.M.O., Lemmers, R., Pavanello, R.C.M., Cerqueira, A.M.P., Frants, R.R., van der 
Maarel, S.M., and Zatz, M. (2006). Equal proportions of affected cells in muscle and blood of a 
mosaic carrier of facioscapulohumeral muscular dystrophy. Human Genetics 119, 23-28. 
 
Tsien, F., Sun, B.D., Hopkins, N.E., Vedanarayanan, V., Figlewicz, D., Winokur, S., and Ehrlich, 
M. (2001). Methylation of the FSHD syndrome-linked subtelomeric repeat in normal and FSHD 
cell cultures and tissues. Molecular Genetics and Metabolism 74, 322-331. 
 
Tsumagari, K., Chang, S.-C., Lacey, M., Baribault, C., Chittur, S.V., Sowden, J., Tawil, R., 
Crawford, G.E., and Ehrlich, M. (2011). Gene expression during normal and FSHD myogenesis. 
BMC Medical Genomics 4. 
 
Tupler, R., Berardinelli, A., Barbierato, L., Frants, R., Hewitt, J.E., Lanzi, G., Maraschio, P., and 
Tiepolo, L. (1996). Monosomy of distal 4q does not cause facioscapulohumeral muscular 
dystrophy. Journal of Medical Genetics 33, 366-370. 
 
Tupler, R., Perini, G., Pellegrino, M.A., and Green, M.R. (1999). Profound misregulation of 
muscle-specific gene expression in facioscapulohumeral muscular dystrophy. Proceedings of 
the National Academy of Sciences, USA 96, 12650-12654. 
 
Upadhyaya, M., Jardine, P., Maynard, J., Farnham, J., Sarfarazi, M., Wijmenga, C., Hewitt, J.E., 
Frants, R., Harper, P.S., and Lunt, P.W. (1993). Molecular analysis of British 
facioscapulohumeral dystrophy families for 4q DNA rearrangements. Human Molecular 
Genetics 2, 981-987. 
 
Upadhyaya, M., Lunt, P., Sarfarazi, M., Broadhead, W., Farnham, J., and Harper, P.S. (1992). 
The mapping of chromosome 4q markers in relation to facioscapulohumeral muscular 
dystrophy (FSHD). American Journal of Human Genetics 51, 404-410. 
 
van der Maarel, S.M., Deidda, G., Lemmers, R., van Overveld, P.G.M., van der Wielen, M., 
Hewitt, J.E., Sandkuijl, L., Bakker, B., van Ommen, G.J.B., Padberg, G.W., and Frants, R.R. 
(2000). De novo facioscapulohumeral muscular dystrophy: Frequent somatic mosaicism, sex-
dependent phenotype, and the role of mitotic transchromosomal repeat interaction between 
chromosomes 4 and 10. American Journal of Human Genetics 66, 26-35. 
 
van Deutekom, J.C.T., Bakker, E., Lemmers, R., vanderWielen, M.J.R., Bik, E., Hofker, M.H., 
Padberg, G.W., and Frants, R.R. (1996a). Evidence for subtelomeric exchange of 3.3 kb 
tandemly repeated units between chromosomes 4q35 and 10q26: Implications for genetic 
counselling and etiology of FSHD1. Human Molecular Genetics 5, 1997-2003. 
 
van Deutekom, J.C.T., Lemmers, R., Grewal, P.K., vanGeel, M., Romberg, S., Dauwerse, H.G., 
Wright, T.J., Padberg, G.W., Hofker, M.H., Hewitt, J.E., and Frants, R.R. (1996b). Identification 
of the first gene (FRG1) from the FSHD region on human chromosome 4q35. Human 
Molecular Genetics 5, 581-590. 
 
Van Deutekom, J.C.T., Wijmenga, C., Vantienhoven, E.A.E., Gruter, A.M., Frants, R.R., Hewitt, 
J.E., Padberg, G.W., Vanommen, G.J.B., and Hofker, M.H. (1993a). FSHD associated DNA 
rearrangements are due to deletions of integral copies of A 3.2 kb tandemly repeated unit. 
Human Molecular Genetics 2, 2037-2042. 
 225 
 
van Deutekom, J.C.T., Wljmenga, C., Tlenhoven, E.A.E.V., Gruter, A.-M., Hewitt, J.E., Padberg, 
G.W., Ommen, G.-J.B.v., Hofker, M.H., and Fronts, R.R. (1993b). FSHD associated DNA 
rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. 
Human Molecular Genetics 2, 2037-2042. 
 
van Driel, R., Wansink, D.G., vanSteensel, B., Grande, M.A., Schul, W., and deJong, L. (1995). 
Nuclear domains and the nuclear matrix. International Review of Cytology 162A, 151-189. 
 
van Geel, M., Dickson, M.C., Beck, A.F., Bolland, D.J., Frants, R.R., van der Maarel, S.M., de 
Jong, P.J., and Hewitt, J.E. (2002). Genomic analysis of human chromosome 10q and 4q 
telomeres suggests a common origin. Genomics 79, 210-217. 
 
van Geel, M., Heather, L.J., Lyle, R., Hewitt, J.E., Frants, R.R., and de Jong, P.J. (1999). The 
FSHD region on human chromosome 4q35 contains potential coding regions among 
pseudogenes and a high density of repeat elements. Genomics 61, 55-65. 
 
van Koningsbruggen, S., Straasheijm, K.R., Sterrenburg, E., de Graaf, N., Dauwerse, H.G., 
Frants, R.R., and van der Maarel, S.M. (2007). FRG1P-mediated aggregation of proteins 
involved in pre-mRNA processing. Chromosoma 116, 53-64. 
 
van Overveld, P.G.M., Enthoven, L., Ricci, E., Rossi, M., Felicetti, L., Jeanpierre, M., Winokur, 
S.T., Frants, R.R., Padberg, G.W., and van der Maarel, S.M. (2005). Variable hypomethylation 
of D4Z4 in facioscapulohumeral muscular dystrophy. Annals of Neurology 58, 569-576. 
 
van Overveld, P.G.M., Lemmers, R., Deidda, G., Sandkuijl, L., Padberg, G.W., Frants, R.R., and 
van der Maarel, S.M. (2000). Interchromosomal repeat array interactions between 
chromosomes 4 and 10: A model for subtelomeric plasticity. Human Molecular Genetics 9, 
2879-2884. 
 
van Overveld, P.G.M., Lemmers, R., Sandkuijl, L.A., Enthoven, L., Winokur, S.T., Bakels, F., 
Padberg, G.W., van Ommen, G.J.B., Frants, R.R., and van der Maarel, S.M. (2003). 
Hypomethylation of D4Z4 in 4q-linked and non-4q-linked facioscapulohumeral muscular 
dystrophy. Nature Genetics 35, 315-317. 
 
Wallace, L.M., Garwick, S.E., Mei, W.Y., Belayew, A., Coppee, F., Ladner, K.J., Guttridge, D., 
Yang, J., and Harper, S.Q. (2011). DUX4, a candidate gene for facioscapulohumeral muscular 
dystrophy, causes p53-dependent myopathy in vivo. Annals of Neurology 69, 540-552. 
 
Weiffenbach, B., Bagley, R., Falls, K., Hyser, C., Storvick, D., Jacobsen, S.J., Schultz, P., Mendell, 
J., Willems van Dijk, K., Milner, E.C., and et al. (1992). Linkage analyses of five chromosome 4 
markers localizes the facioscapulohumeral muscular dystrophy (FSHD) gene to distal 4q35. 
American Journal of Human Genetics 51, 416-423. 
 
Weiffenbach, B., Dubois, J., Storvick, D., Tawil, R., Jacobsen, S.J., Gilbert, J., Wijmenga, C., 
Mendell, J.R., Winokur, S., Altherr, M.R., Schultz, P., Olandt, S., Frants, R.R., Pericakvance, M., 
and Griggs, R.C. (1993). Mapping the facioscapulohumeral muscular dystrophy gene is 
complicated by chromosome-4q35 recombination events. Nature Genetics 4, 165-169. 
 
Wijmenga, C., Brouwer, O.F., Padberg, G.W., and Frants, R.R. (1992a). Transmission of de-
novo mutation associated with facioscapulohumeral muscular-dystrophy. Lancet 340, 985-
986. 
 
Wijmenga, C., Frants, R.R., Brouwer, O.F., Moerer, P., Weber, J.L., and Padberg, G.W. (1990). 
Location of facioscapulohumeral muscular dystrophy gene on chromosome 4. Lancet 336, 
651-653. 
 
 226 
Wijmenga, C., Hewitt, J.E., Sandkuijl, L.A., Clark, L.N., Wright, T.J., Dauwerse, H.G., Gruter, A.-
M., Hofker, M.H., Moerer, P., Williamson, R., van Ommen, G.-J.B., Padberg, G.W., and Frants, 
R.R. (1992b). Chromosome 4q DNA rearrangements associated with facioscapulohumeral 
muscular dystrophy. Nature Genetics 2, 26-30. 
 
Wijmenga, C., Padberg, G.W., Moerer, P., Wiegant, J., Liem, L., Brouwer, O.F., Milner, E.C.B., 
Weber, J.L., Vanommen, G.B., Sandkuyl, L.A., and Frants, R.R. (1991). Mapping of 
facioscapulohumeral muscular dystrophy gene to chromosome 4q35-qter by multipoint 
linkage analysis and in situ hybridization. Genomics 9, 570-575. 
 
Wijmenga, C., Sandkuijl, L.A., Moerer, P., Vanderboorn, N., Bodrug, S.E., Ray, P.N., Brouwer, 
O.F., Murray, J.C., Vanommen, G.J.B., Padberg, G.W., and Frants, R.R. (1992c). Genetic-linkage 
map of facioscapulohumeral muscular-dystrophy and 5 polymorphic loci on chromosome 
4q35-qter. American Journal of Human Genetics 51, 411-415. 
 
Wijmenga, C., Winokur, S.T., Padberg, G.W., Skraastad, M.I., Altherr, M.R., Wasmuth, J.J., 
Murray, J.C., Hofker, M.H., and Frants, R.R. (1993). The human skeletal muscle adenine 
nucleotide translocator gene maps to chromosome 4q35 in the region of the 
facioscapulohumeral muscular dystrophy locus. Human Genetics 92, 198-203. 
 
Winokur, S.T., Barrett, K., Martin, J.H., Forrester, J.R., Simon, M., Tawil, R., Chung, S.A., 
Masny, P.S., and Figlewicz, D.A. (2003a). Facioscapulohumeral muscular dystrophy (FSHD) 
myoblasts demonstrate increased susceptibility to oxidative stress. Neuromuscular Disorders 
13, 322-333. 
 
Winokur, S.T., Bengtsson, U., Feddersen, J., Mathews, K.D., Weiffenbach, B., Bailey, H., 
Markovich, R.P., Murray, J.C., Wasmuth, J.J., and Altherr, M.R. (1994). The DNA 
rearrangement associated with facioscapulohumeral muscular dystrophy involves a 
heterochromatin-associated repetitive element: Implications for a role of chromatin structure 
in the pathogenesis of the disease. Chromosome Research 2, 225-234. 
 
Winokur, S.T., Bengtsson, U., Vargas, J.C., Wasmuth, J.J., and Altherr, M.R. (1996). The 
evolutionary distribution and structural organization of the homeobox-containing repeat 
D4Z4 indicates a functional role for the ancestral copy in the FSHD region. Human Molecular 
Genetics 5, 1567-1575. 
 
Winokur, S.T., Chen, Y.W., Masny, P.S., Martin, J.H., Ehmsen, J.T., Tapscott, S.J., van der 
Maarel, S.M., Hayashi, Y., and Flanigan, K.M. (2003b). Expression profiling of FSHD muscle 
supports a defect in specific stages of myogenic differentiation. Human Molecular Genetics 
12, 2895-2907. 
 
Winokur, S.T., Schutte, B., Weiffenbach, B., Washington, S.S., McElligott, D., Chakravarti, A., 
Wasmuth, J.H., and Altherr, M.R. (1993). A radiation hybrid map of 15-loci on the distal long 
arm of chromosome-4, the region containing the gene responsible for facioscapulohumeral 
muscular-dystrophy (FSHD). American Journal of Human Genetics 53, 874-880. 
 
Wuebbles, R.D., Hanel, M.L., and Jones, P.L. (2009). FSHD region gene 1 (FRG1) is crucial for 
angiogenesis linking FRG1 to facioscapulohumeral muscular dystrophy-associated 
vasculopathy. Disease Models & Mechanisms 2, 267-274. 
 
Wuebbles, R.D., Long, S.W., Hanel, M.L., and Jones, P.L. (2010). Testing the effects of FSHD 
candidate gene expression in vertebrate muscle development. Int J Clin Exp Pathol 3, 386-400. 
 
Xing, Y., Johnson, C.V., Moen, P.T., Jr., McNeil, J.A., and Lawrence, J. (1995). Nonrandom gene 
organization: Structural arrangements of specific pre-mRNA transcription and splicing with sc-
35 domains. J Cell Biol 131, 1635-1647. 
 
 227 
Xu, Z., Wei, W., Gagneur, J., Clauder-Muenster, S., Smolik, M., Huber, W., and Steinmetz, L.M. 
(2011). Antisense expression increases gene expression variability and locus interdependency. 
Molecular Systems Biology 7. 
 
Yamaoka, L., Speer, M.C., Stajich, J., Lewis, K., Clancy, R., Qiu, H., Kumar, A., Vance, J., Stewart, 
C., Rozear, M., Roses, A.D., Pericalvance, M.A., and Gilbert, J.R. (1995). Exclusion mapping of 
chromosomal regions which cross-hybridize to FSH1A associated markers in FSH1B. American 
Journal of Human Genetics 57, 1905-1905. 
 
Yip, D.J., and Picketts, D.J. (2003). Increasing D4Z4 repeat copy number compromises C2C12 
myoblast differentiation. Febs Letters 537, 133-138. 
 
Zatz, M., Marie, S.K., Passosbueno, M.R., Vainzof, M., Campiotto, S., Cerqueira, A., Wijmenga, 
C., Padberg, G., and Frants, R. (1995). High proportion of new mutations and possible 
anticipation in Brazilian facioscapulohumeral muscular-dystrophy families. American Journal 
of Human Genetics 56, 99-105. 
 
Zeng, W.H., de Greef, J.C., Chen, Y.Y., Chien, R., Kong, X.D., Gregson, H.C., Winokur, S.T., Pyle, 
A., Robertson, K.D., Schmiesing, J.A., Kimonis, V.E., Balog, J., Frants, R.R., Ball, A.R., Lock, L.F., 
Donovan, P.J., van der Maarel, S.M., and Yokomori, K. (2009). Specific loss of histone H3 lysine 
9 trimethylation and HP1 gamma/cohesin binding at D4Z4 repeats is associated with 
facioscapulohumeral dystrophy (FSHD). Plos Genetics 5. 
 
Zhang, X.Y., Loflin, P.T., Gehrke, C.W., Andrews, P.A., and Ehrlich, M. (1987). 
Hypermethylation of human DNA-sequences in embryonal carcinoma-cells and somatic 
tissues but not in sperm. Nucleic Acids Research 15, 9429-9449. 
 
Zhou, D.M., He, Q.C.S., Wang, C.Y., Zhang, J., and Wong-Staal, F. (2006). RNA interference and 
potential applications. Current Topics in Medicinal Chemistry 6, 901-911. 
 
 
 
